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Abstract 
 
Background: Scaphoid fractures account for 90% of all carpal fractures and occur 
predominantly in young men. Despite insufficient evidence of its effectiveness, there has 
been an increase in immediate surgical fixation of this fracture.  
 
Objective: To compare clinical and cost-effectiveness of surgical fixation with cast treatment 
and early fixation of those that fail to unite for scaphoid waist fractures in adults.  
 
Design: Multicentre, pragmatic, open-label, parallel two-arm randomised controlled trial 
using a remote randomisation service with an economic evaluation and nested qualitative 
study.  
 
Setting: Orthopaedic departments of 31 hospitals in England and Wales recruited from July 
2013 with final follow-up in September 2017.   
 
Participants: Adults (aged ≥ 16 years), presenting within two weeks of injury with a clear, 
unequivocal bicortical fracture of the scaphoid waist seen on (scaphoid series) plain 
radiographs. 
 
Interventions: Early surgical fixation using standard CE marked headless compression 
screws. Below elbow cast immobilisation for six to ten weeks, and urgent fixation of 
confirmed non-union.  
 
Main outcome measures: The primary outcome and end-point was the Patient Rated Wrist 
Evaluation (PRWE) total score at 52 weeks, with a clinically relevant difference of six points. 
Secondary outcomes included PRWE pain and function subscales, Short Form 12-item 
questionnaire (SF-12), bone union, range of movement and grip strength, complications and 
return to work and unpaid recreational activities. Resource use and the EuroQol (EQ-5D-3L) 
were collected for the health economic evaluation. 
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Results: The mean age of the 439 participants was 33 years, 363 were male (83%) and 269 
had an undisplaced fracture (61%). The primary analysis was on the 408 participants 
providing valid PRWE outcome data for at least one post-randomisation time-point (surgery 
n=203 of 219, 93%; cast n=205 of 220, 93%) using the principles of intention-to-treat 
(participants analysed in the group to which they were originally randomised regardless of 
non-adherence to their allocated treatment). There was no clinically relevant difference in the 
total PRWE at 52 weeks: cast group mean 14.0 [95% confidence interval (CI) 11.3 to 16.6] 
and surgery group mean 11.9 (95% CI 9.2 to 14.5); adjusted mean difference of -2.1 in favour 
of surgery (95% CI -5.8 to 1.6, p=0.27). Non-union rate was low in both groups (surgery 
group n=1, 0.5%; plaster cast group n=4, 1.8%) and 73 patients need to be offered surgery 
over cast, to prevent one extra non- union at 52 weeks.  Eight participants in the surgery 
group had 11 re-operations, and one participant in the cast group required a re-operation for 
non-union. The base-case economic analysis at 52 weeks showed that the cost of surgical 
intervention was £1,295 more per patient (95% CI £1,084 to £1,504) than that of cast 
treatment. Quality of life differences were not significant. The base-case analysis of a lifetime 
extrapolated model confirmed that the initial use of cast with immediate fixation of non-
unions was the most cost-effective option. The nested qualitative study identified patients 
desire to have a “sense of recovering” which surgeons should address at the outset. 
 
Limitation: The control treatment pathway was initial cast treatment with early confirmation 
of non-union and early fixation of un-united fractures. Of 17 participants who had surgery for 
confirmed non-union, 14 had it within six months from randomisation and three were treated 
after six months. Three of four participants in the plaster cast group, who had a non-union at 
52 weeks, had not been offered surgery. 
 
Conclusions: Adult patients with an undisplaced or minimally displaced scaphoid waist 
fracture should have the wrist immobilised in cast and all suspected non-unions immediately 
investigated and those confirmed urgently fixed.  
 
Future work: Patients will be followed-up at five years to include an investigation of the 
outcome of the partial union of the fracture and the consequences of degenerative arthritis, 
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malunion and screw problems on their quality of life. This long-term follow-up will further 
inform the areas of uncertainty in the extrapolated model.  
 
Trial registration: ISRCTN67901257 
 
Funding details: This project was funded by the National Institute for Health Research 
Health Technology Assessment (HTA) Programme (project number 11/36/37). 
 
Word count: 634 
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Plain English Summary  
 
Fracture of the scaphoid bone (one of eight small bones in the wrist) is common in young 
active people, caused by a fall on the hand or the hand being suddenly forced backward. The 
usual treatment is to rest the wrist in a plaster cast for six to ten weeks and allow the broken 
bone to heal. In one in ten cases treated in a plaster cast, the bone does not heal and an 
operation is needed. In the operation, the broken bone is held still with a screw. In the last 
few years, it has become more common to fix the broken bone with a screw in the first few 
days after injury, instead of resting the wrist in plaster cast. It is not clear if fixing the bone 
early with a screw compared with resting the wrist in a cast  gives better outcomes for 
patients and if one treatment gives more value for money to the National Health Service 
(NHS). 
  
In this study, 439 adult patients agreed to either have surgery to hold the broken scaphoid 
with a special screw or to have the wrist held still in a plaster cast (with surgery offered after 
six  weeks to those that are still not healed). The decision about which treatment to use was 
made using randomisation, which is similar to tossing a coin. Patients reported their own 
wrist pain and function at six, 12, 26 and 52 weeks. Information was also collected on general 
health, bone healing, grip strength and range of movement, complications from treatment and 
costs.  
 
No important differences were found in patients’ wrist pain and function at 52 weeks. The 
bone did not heal properly in four patients in the surgery group compared with nine patients 
in the plaster cast group at 52 weeks. For one of these patients in the surgery group and four 
in the plaster cast group, the bone did not join at all. There were eight patients in the surgery 
group who had further surgery following their initial operation to fix their wrist, and one 
patient in the cast group who required repeated surgery because their bone did not join at all. 
The overall cost of treating with a plaster cast was cheaper than early surgery. The preferred 
treatment, therefore, is to use plaster cast initially and immediately fix the bone with a screw 
if it doesn’t heal.  
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Scientific Summary  
 
Background 
Scaphoid fractures account for 90% of all carpal fractures, and occur predominantly in 
young, active men. Typically, the scaphoid fractures when the wrist is suddenly extended 
either when putting the hand out to break a fall or when the palm is struck forcibly by an 
object. Most fractures (64%) affect the waist of the scaphoid. Despite insufficient evidence, 
there is an increasing trend to immediately surgically fix this fracture rather than immobilise 
the wrist in a cast and then only fix those that fail to unite. 
 
Objectives 
The objective was to evaluate the clinical and cost-effectiveness of surgical fixation 
compared with cast treatment (with early fixation of those that fail to unite) of scaphoid waist 
fractures in adults. There was also a qualitative study to explore the patient experience of 
fracture and its treatment, and to investigate attitudes towards, and experiences of, 
participating in a surgical clinical trial. 
 
Design 
The Scaphoid Waist Internal Fixation for Fractures Trial (SWIFFT) was a multicentre, 
pragmatic, open-label, parallel two-arm randomised controlled trial (RCT) with an economic 
evaluation (within-trial and extrapolated analysis) and nested qualitative study. Patients were 
randomised on an equal basis to receive either of the two treatment options via a remote 
randomisation service. Randomisation was stratified by the presence or lack of displacement 
of the fracture. This was defined as a step or gap 1 to 2mm inclusive, as seen on any 
radiographic view. Random block sizes of six and twelve were used. Follow-up was at six, 
12, 26 and 52 weeks. Data collection included imaging [radiographs and Computed 
Tomography (CT) scan] at baseline, six, 12 and 52 weeks. Hospital forms and participant 
questionnaires were also used to collect data. There was no blinding of outcome assessment.  
 
The economic evaluation assessed the relative cost-effectiveness of surgical fixation 
compared with cast treatment using costs and outcomes collected over 52 weeks. The costs 
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and outcomes were extrapolated and modelled over the lifetimes of a patient cohort due to the 
potential long-term future burden of osteoarthritis and other adverse events. This model 
permitted the inclusion of additional treatment pathways and analyses of a number of relevant 
scenarios to explore the key drivers of cost-effectiveness that warrant extra focus and future 
research.   
 
The nested qualitative study used purposive sampling of those SWIFFT trial participants who 
indicated a willingness to be interviewed within six weeks of randomisation and at 52 weeks 
(n=30). Both men and women, experiencing different treatments, of different ages and 
occupations were purposively selected. Patients who declined to participate in the trial were 
also purposively selected to be interviewed (n=10). All interviews were semi-structured and 
where possible undertaken face-to-face at a time and location convenient to the participant. 
 
Setting 
Trial recruitment was undertaken from the orthopaedic departments of 30 National Health 
Service (NHS) hospitals in England and one hospital in Wales. Patients were recruited from 
fracture clinics from 23rd July 2013 until 26th July 2016. 
 
Participants 
Adults (aged ≥ 16 years), presenting at a participating site within two weeks of their injury, 
for which surgery could be undertaken within two weeks of presentation to the NHS, and 
with a clear, unequivocal bicortical fracture of the scaphoid waist seen on a scaphoid series of 
plain radiographs were considered for inclusion. Patients were excluded from the trial if: their 
fracture had >2mm displacement as these are likely to be unstable and require surgical 
intervention; they had a concurrent wrist fracture in the opposite limb; they had a trans-
scaphoid perilunate dislocation; they had multiple injuries in the same limb; they lacked 
mental capacity to comply with treatment or data collection; they were pregnant since 
radiation exposure would be contraindicated; or they were not resident in the trauma 
catchment area of a participating site to allow follow-up. 
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Interventions  
Early percutaneous or open surgical fixation using standard CE marked headless compression 
screws. The choice of implant was the surgeon’s decision. To avoid learning curve problems, 
surgeons used techniques with which they were fully familiar. The comparator was below 
elbow cast immobilisation for six to ten weeks, with or without inclusion of the thumb and 
urgent fixation performed when non-union was confirmed. All participants randomised into 
the two groups received standardised written physiotherapy advice, detailing the exercises 
they needed to perform for rehabilitation following their injury. 
 
Main outcome measures 
The primary outcome and end-point was the Patient Rated Wrist Evaluation (PRWE) total 
score (scale 0-100, with lower scores indicating a better outcome) at 52 weeks. It was also 
completed at six, 12 and 26 weeks. The trial was powered to detect a clinically relevant 
difference in the PRWE of six points assuming a standard deviation of 20 (equivalent to an 
effect size of 0.3) at 52 weeks.  
 
Secondary outcomes were the subscale scores of pain and function of the PRWE; Short Form 
12-item questionnaire (SF-12) physical and mental component summary scores (PCS and 
MCS); bone union; range of movement and grip strength; complications; return to work and 
unpaid recreational activities; and the resource use and the EuroQol (EQ-5D-3L) were 
collected, and a literature review performed, to inform the health economic evaluation.  
 
All patient-reported outcomes (i.e. PRWE, SF-12, EQ-5D-3L, return to work and unpaid 
recreational activities) were collected by post, in hospital clinic, or occasionally over the 
telephone, at six, 12, 26 and 52 weeks. Bone union was assessed on radiographs at six, 12 and 
52 weeks and CT scans at 52 weeks. The other outcomes (i.e. range of movement and grip 
strength and complications) were collected in routine hospital clinics at six and 12 weeks, and 
additionally at 52 weeks.  
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Statistical analysis 
Analyses were conducted using the principles of intention-to-treat (ITT), analysing 
participants in the groups to which they were originally randomised, using two-sided 
statistical tests assessed at the 5% significance level. 
 
The primary outcome (total PRWE scores) were compared between the two groups using a 
covariance pattern, mixed-effect linear regression model incorporating all post-randomisation 
time points.  Treatment group, time point, a treatment-by-time interaction, participant age at 
randomisation, baseline fracture displacement and dominance of injured hand were included 
as fixed effects, and participant as a random effect (to account for the repeated observations 
per participant).  This analysis included any participant with valid PRWE outcome data for at 
least one post-randomisation time point.  It therefore does not include the small number of 
participants who provided no post-randomisation PRWE data.  An estimate of the difference 
between treatment groups in total PRWE score was extracted for each time point, and overall, 
with a 95% confidence interval (CI) and p-value.  The treatment effect estimate for the 52 
week time point served as the primary outcome.  The treatment effects for the six, 12 and 26 
week time points, and the overall effect, served as secondary outcomes.  
 
Sensitivity analyses were specified a priori to explore the effect of the following: missing 
data (using multiple imputation by chained equations); handling multi-site data (including 
site as a random effect [within which participants were nested] in the model as described for 
the analyses of the primary outcome); timing of data collection by repeating the analysis of 
the primary outcome only including data collected within agreed timeframes around each 
time point; exploring the effect on the primary analysis of separately excluding participants 
who three raters agreed on the baseline images that (i) there was no fracture or  (ii) 
displacement of the fracture was greater than 2mm; and complier average causal effect 
(CACE) analysis to explore the effect of non-compliance. Current smoking status (yes/no) 
was included as a covariate in the primary analysis model in a post-hoc sensitivity check to 
adjust for a chance imbalance at baseline. In total, three subgroup analyses were undertaken: 
one exploring patient treatment preferences as expressed at baseline; and two exploring 
baseline fracture displacement.   
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The secondary outcomes of pain and function subscales of the PRWE; PCS and MCS of the 
SF-12; and grip strength were summarised descriptively for each time point by treatment 
group and overall, and were analysed using the same method as the primary outcome adjusting 
for the same covariates.  Extent of union was presented at six, 12 and 52 weeks by trial arm. 
Regression methods were used to analyse the union data only at 52 weeks dichotomising 
participants as ‘probably need surgery’ and ‘probably don’t need surgery’ and also using the 
repeated measures of dichotomised union at six, 12 and 52 weeks. Rates of malunion (based 
on ratio of the scaphoid height to length at thresholds of 0.6 and 0.7) were presented overall 
and for each treatment group at six, 12 and 52 weeks. Complications that were defined as 
medical, surgical or plaster cast were presented for each treatment group at six, 12 and 52 
weeks using only data collected at the hospital but not the data on complications identified 
elsewhere. Logistic regression that adjusted for age, hand dominance and fracture 
displacement was used to analyse the data for participants who had at least one of these 
complications over 52 weeks. This analysis did not address the severity of the complication 
nor all the complications identified elsewhere. All serious and non-serious adverse events and 
complications noted on review of imaging were summarised by treatment group. 
 
Economic analysis 
The perspective of the economic analysis was that of the United Kingdom (UK) NHS and 
Personal Social Services. For the within-trial-analysis, the EQ-5D-3L was collected from 
patient questionnaires to permit the estimation of quality-adjusted-life-years (QALYs) for 
each patient for the 52 weeks of the trial. The resource use data, collected from patient 
questionnaires and hospital forms, were used to estimate costs that were expressed in UK 
pounds sterling at 2017 prices. Differences in mean costs and QALYs at 52 weeks were used 
to estimate the incremental cost-effectiveness ratio (ICER) of surgery compared with cast for 
a “within-trial” analysis. Multiple imputation of missing data was used with an ITT analysis 
to estimate a base-case ICER, adjusting for the baseline quality of life. The extrapolated 
analysis used data from a literature review and from the trial to estimate the health and 
resource use implications beyond the timeframe of the trial for four treatment options: no 
treatment; cast immobilisation only; cast immobilisation followed by immediate surgery for 
confirmed non-union; and surgical fixation. This included estimating the ICER and net health 
benefit (NHB) for the four treatment options, estimating the probability of each strategy as 
being cost-effective at a given willingness-to-pay threshold using a cost-effectiveness 
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acceptability curve (CEAC), and a series of scenario analyses to explore the impact of 
structural uncertainty on the results. 
 
Qualitative analysis 
The discursive, exploratory and semi-structured nature of the data led to an inductive, 
thematic approach to the data analysis. A systematic and structured approach was used, 
including data familiarisation, theme identification and thematic model generation, to explore 
the data on its own terms and to prioritise the insight generated therein.  
 
Clinical effectiveness results 
Of the 1047 patients who met the inclusion criteria, there were 775 who were eligible, of 
whom 439 were randomised. The mean age of the trial participants was 33 years, 363 were 
male (83%) and 269 had an undisplaced fracture (61%). The independent review by three 
raters of baseline imaging confirmed that only one participant had no fracture. 
 
Of the 219 participants allocated to surgery, 188 (86%) received treatment as allocated. The 
main operating surgeon was most commonly a consultant (66%), and the consultant was also 
the most common assisting surgeon when a specialist trainee was the operating surgeon. Of 
the 220 participants allocated to plaster cast, only six (3%) immediately switched to surgery 
following randomisation. Of 17 participants in the plaster cast group who had surgery for 
early identified non-union in the plaster cast group, 14 had it within six months from 
randomisation and three were treated after six months. Three of the four participants in the 
plaster cast group who had identified non-union at 52 weeks had not been offered surgery 
during the 52 week follow-up. 
 
The primary analysis was on the 408 participants providing valid PRWE outcome data for at 
least one post-randomisation time-point (surgery n=203 of 219, 93%; cast n=205 of 220, 
93%) using the principles of intention-to-treat (participants analysed in the group to which 
they were originally randomised regardless of non-adherence to their allocated treatment). 
There was no clinically relevant difference in the total PRWE at 52 weeks: cast group mean 
14.0 (95% confidence interval [CI] 11.3 to 16.6) and surgery group mean 11.9 (95% CI 9.2 to 
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14.5); adjusted mean difference of -2.1 in favour of surgery (95% CI -5.8 to 1.6, p=0.27).  
CACE analysis, to take into account non-compliance, found at 52 weeks an increased 
difference in favour of surgery in the total PRWE of -3.1 (95% CI -7.3 to 1.1, p=0.15). The 
adjusted mean difference in total PRWE at 6 weeks in favour of surgery was -4.2 (95% CI -
8.5 to 0.1, p=0.06), at 12 weeks was -5.6 (95% CI -9.8 to -1.4, p=0.01), at 26 weeks was -0.3 
(95% CI -4.1 to 3.6, p=0.89) and overall was -3.0 (95% CI -6.3 to 0.3, p=0.07). The 
sensitivity analyses that have been described produced similar results on the total PRWE to 
the primary analysis. This included the post-hoc sensitivity analysis that adjusted for smoking 
status. No significant interaction was observed between randomised allocation and treatment 
preference nor fracture displacement on the total PRWE. 
 
For secondary outcomes, the adjusted mean difference at 52 weeks in favour of surgery in 
PRWE pain subscale was -1.1 (95% CI -3.3 to 1.0, p=0.31) and for the function subscale was 
-1.0 (95% CI -2.6 to 0.7, p=0.25). For the SF-12 MCS at 52 weeks, the adjusted mean 
difference was -1.2 points (95% CI -3.3 to 0.8, p=0.24) favouring the plaster cast group. In 
PCS was 1.6 (95% CI 0.2 to 3.1, p=0.03) favouring the surgery group, although there was no 
statistically significant difference at 6 or 26 weeks. There was little difference in range of 
movement at 52 weeks between the two groups, or in adjusted mean grip strength. The rate of 
non-union in both groups was low. Participants in the surgery group (4 of 219, 1.8%) 
compared with plaster cast (9 of 220, 4.1%), were less likely to have non- or only slight union 
of their fracture at 52 weeks (i.e. probably need surgery vs probably don’t need surgery), but 
this difference was not statistically significant. Based on these figures, 44 patients would 
need to be offered surgery over cast, to prevent one extra non or slight union at 52 weeks.  At 
52 weeks, using the 0.7 threshold of the ratio of scaphoid height to length, malunion 
increased between baseline and 52 weeks on CT scans and was similar (3.2%) in the two 
groups.  The rate of screws penetrating the neighbouring joint of 1 mm or more was 
unexpectedly high (36.2%, 68/188 who had initial surgery). There were eight participants in 
the surgery group who had 11 re-operations, and one participant in the cast group required a 
re-operation for a non-union. There were no intra-operative complications. Surgical 
complications occurred in 14.2% in the surgery group and 1.4% of the plaster cast group. 
Cast issues, usually minor, occurred in 2.7% and 20.5% respectively. There were 
inconsistencies in reporting complications between the complication and adverse event form. 
Plaster cast softening or breaking and symptoms of non-union were described as “adverse 
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events”. At least one non-serious “adverse event” was reported for 24 (11.0%) participants in 
the surgery group and 29 (13.2%) in the plaster cast group. All three serious adverse events 
were in the surgery group. Further complications were also identified on review of the 
imaging. One patient in the surgery group required partial wrist fusion for surgery related 
complications. 
 
Cost-effectiveness results 
The base-case economic analysis showed that, at 52 weeks, the cost of initial surgical 
intervention was, on average, £1,295 more per patient (95% CI £1,0084 to £1,504) than the 
cost of cast immobilisation with surgery for non-union. Surgery was slightly more beneficial 
in terms of utilities, but this difference was not significant. The cost per QALY for surgery 
compared to cast immobilisation with early fixation of confirmed non-union was £81,962.  
The economic evaluation base-case analysis of the extrapolated long-term model established 
that the initial use of cast with immediate fixation of confirmed non-union was the most cost-
effective option over the discounted lifetime of the patient, with a 61% probability of being 
cost-effective at the willingness-to-pay threshold of £20,000/QALY. The NHB at this 
threshold was also the highest at 19.02. This was followed by primary surgical fixation, the 
use of a cast without a surgical option, and finally no treatment.  
 
Qualitative study findings 
The nested qualitative study identified that how a patient understands their scaphoid fracture 
and perceives their own “sense of recovering” was important in their assessment of treatment 
success. Notably, the act of plaster cast removal was an important threshold in a patient’s 
sense of returning to normal. A broadly positive attitude towards surgery amongst those 
interviewed, reflected the finding at baseline that when consenting participants did have a 
preference for treatment it was predominantly in favour of surgery. This may have been a 
consequence of participants’ concerns about the duration of immobilisation in plaster cast and 
the uncertainty (however small) of the need for further treatment.  
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Conclusions 
Among adults with a waist scaphoid fracture that is undisplaced or minimally displaced, the 
clinical and cost-effective strategy is that patients should be immobilised in cast, all suspected 
non-unions immediately investigated and those confirmed urgently fixed. Surgeons should 
address, at the outset, patients’ desire to have a “sense of recovering”. 
 
Recommendation for future research 
The planned five-year follow-up of trial participants will help explore the outcomes of 
participants with a partial union of the scaphoid fracture, and the impact of the progression of 
degenerative arthritis, malunion and screw problems (mal-position and penetration within 
joints) on quality of life. This will further inform the areas of uncertainty in the extrapolated 
model.  
 
Trial registration 
ISRCTN67901257 
 
Funding details 
This project was funded by the National Institute for Health Research Health Technology 
Assessment (HTA) Programme (project number 11/36/37). 
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Chapter 1 Introduction 
Scaphoid fracture accounts for 90% of all carpal fractures1 and 2-7% of all fractures.2  It is an 
important public health problem as it predominantly affects young active individuals (mean 
age 29 years)3 in their most productive working years.  
 
The scaphoid fractures typically when the wrist is suddenly extended either when putting the 
hand out to break a fall or when the palm is struck forcibly by an object.  
 
Most fractures (64%) affect the waist of the scaphoid but 5% affect the proximal pole 
(proximal 20% of the scaphoid) and around 13.3 % involve the distal part of the scaphoid. 
The tuberosity fractures in 18.1%. Figure 1 illustrates this. 
 
 
 
 
 
Figure 1: Locations of scaphoid fractures 
This shows the location of the scaphoid fracture and the 
proportions reported.4 Non-tuberosity fractures account for 
81.9% of all scaphoid fractures and 78.2% of these involve the 
waist. 
 
The scaphoid, lunate and triquetrum form the proximal carpal row attached to each other by 
ligaments. These bones are subject to loads when the muscles whose tendons cross the wrist 
bones contract. This row acts together like a helix. When the scaphoid flexes under load, the 
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triquetrum extends so the middle section, the lunate, remains in a neutral and stable position.5, 
6  
 
A fracture of the scaphoid breaks this helix so now the two parts rotate; the distal scaphoid 
fragment flexing under load while the remainder of the proximal carpal helix extends. The 
proximal carpal row can no longer stabilise the distal carpal row, and hence the wrist. The 
resulting abnormal loading between the distal part of the broken scaphoid and the distal 
radius leads to cartilage degeneration and arthritis, while the proximal part extends causing 
carpal collapse. This pattern after failure of union is called the SNAC (Scaphoid Non-union 
Advanced Collapse) wrist.7 
 
Scaphoid fractures disrupt the proximal carpal row and alter the complex mechanics of this 
row thereby altering how the wrist is stabilised to permit the hand and digits to function 
efficiently. 
 
About 88-90% of these fractures unite when treated initially in a plaster cast. However, 10-
12% of the scaphoid fractures treated with plaster cast do not unite, with a higher incidence 
(14-50%) in displaced fractures.8-10 The retrograde intra-osseous circulation11 jeopardises the 
blood circulation, particularly in the proximal scaphoid and may explain the higher failure of 
union in proximal fractures.  Non-union if untreated almost inevitably leads to arthritis, 
especially in the radio-scaphoid joint, usually within five years.12, 13 This disables patients at a 
very young age. 
 
Diagnosis of the fracture is usually confirmed in emergency departments on radiographs of 
the scaphoid taken in different projections and it is usual to obtain a “scaphoid series of 
radiographs” which include a posterior-anterior, lateral and 45-degree supination and 
pronation views, as shown in Figure 2. In addition, an elongated view of the scaphoid is 
obtained to avoid missing fractures which may be obscured due to the palmar and radial 
inclination of the scaphoid. It is possible to have an incomplete fracture of the scaphoid and 
these usually heal un-eventfully14. However, clear and bicortical fractures cause clinical 
concern as these are more likely to be unstable. 
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Figure 2: Five radiographic views of the scaphoid 
Figure 2 shows the five radiographic views. A. Posterior 
anterior view – the fracture is just visible. B. Elongated 
scaphoid view. The fracture is “clear” and “bicortical”. 
Also, the gap could be over 1 mm and the radial margin 
shows a small step. C is the semi-supine oblique view. D. 
On the lateral view alignment can be assessed. E. The semi-
prone view also shows the fracture and suggests 
displacement. 
 
Treatments 
Getting the fracture to heal restores the integrity of the proximal carpal row and thereby the 
stability of the wrist. This stability restores hand function, reduces the feeling of weakness 
and significantly reduces the risk of carpal collapse and the resulting  arthritis15 (Scaphoid 
Non-union Advanced Collapse SNAC).  
 
The aim of treatment is to immobilise the fracture as the physiological processes of healing 
occur. The immobilisation of the fracture fragments relative to one another can be done in 
various ways. Movement between fracture fragments can be constrained by immobilising the 
injured wrist in a cast or by surgically introducing a screw across the fracture.  
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Fixation 
Immediate surgical fixation may avoid the need to immobilise the wrist in a cast and could 
accelerate return to function, work and sport16 but requires the person to have an operation 
and be exposed to surgical risks. The fracture is fixed with a standard CE marked headless 
screw generating compression at the fracture site but avoiding the pressure effects of the 
screw head on articular cartilage. This can be done either percutaneously or open.17-19 The 
surgical techniques are well described and are now standard.20-22 These screws have not 
changed during the recruitment period for this study. Some surgeons use splintage for the 
first few weeks after surgery. 
 
Cast treatment  
The usual treatment is immobilisation in a below elbow cast for 6-10 weeks, followed by 
mobilisation. The type of below elbow cast used does not affect union rate.8 The 10- 12% 
patients who develop non-union seen on radiographs and/or CT scan, usually have urgent 
surgical fixation. This is the current standard non-operative pathway.3 
 
Current evidence 
There are eight randomised controlled trials (RCTs)3, 18, 23-28 reporting on 463 participants 
with undisplaced or minimally displaced fractures of the scaphoid waist who had either of 
these two treatments. These RCTs had small sample sizes (range from 25 to 88) and have 
been systematically reviewed nine times29-37  and these reviews all commented on the low 
quality of evidence.   
 
Some studies reported that fracture fixation facilitated earlier restoration of function and 
return to previous activity level, especially if a cast or splint was not used after fixation, but 
patients had a higher rate of complications of between 9 and 22 percent although these were 
usually minor.3, 18, 25 
 
It is unclear whether patients who had surgical fixation of undisplaced or minimally displaced 
scaphoid fractures had better longer-term benefit than those treated in a cast. 
The rate of union was similar between surgical and cast treatment with early fixation of those 
fractures that failed to unite.3 Another study,28 reported similar outcomes at 10 years.  
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Displaced fractures 
A scaphoid fracture is considered displaced if there is a step or gap of 1mm or more.38 
Angulation and rotation between fragments are more difficult to assess. A systematic review 
reported that non-union occurs in around 18% of displaced fractures39  and  that when treated 
in a cast the relative risk  of non-union between undisplaced and displaced fractures is 4.4 
(95% confidence interval 2.3-8.7).39 At present the evidence of treatment of displaced 
fractures is weak and recommendations are based on case-series.40 When the displacement is 
>2mm clinicians consider the fracture so unstable that they usually recommend early 
reduction and fixation.   
 
Increase in surgical activity 
Despite insufficient evidence there is an increasing trend41 to immediately fix this fracture 
rather than immobilise in a  cast for 6 weeks and only fix those 10% to 12% that fail to unite.3 
This current trend to fix fractures may be attributed to short-term benefits, but concerns 
remain about the lack of evidence on long-term benefits and additional risks from surgery, 
such as malunion, infection, implant related problems and avascular necrosis (AVN). 
Hospital Episode Statistics (HES) for National Health Service (NHS) hospitals in England 
recorded a two thirds increase (1534, 1720 and 2582) of acute scaphoid fracture fixations for 
the years 2007/8, 2008/9 and 2009/10 before this study was commissioned. The rate of 
surgical fixation42 rose very slightly from 37% to 41% from 2007/8 to 2008/9 but then 
increased sharply to 62% in 2009/10. This trend of increasing intervention rate emphasized 
the need for this study. 
 
Economic aspects 
There is also poor information on the economic aspects43 of this injury and its treatment.  One 
study used a decision analytical model43 and utility scores were obtained from 50 medical 
students. This study concluded that early fixation provided more quality adjusted life years 
compared to cast treatment and consumed less economic resources. However a different 
view, from studies of both non-randomised (95 patients) and randomised evidence (52 
patients), is that cast treatment is economically less costly, has also been suggested44, 45 based 
on comparison of direct and indirect costs in patients who had their fracture treated in a cast 
or had it fixed. 
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What do patients feel and experience? 
There is little published on patient experiences and preferences after a scaphoid fracture.  
Understanding our patient’s priorities helps efficient patient-centred clinical decision making. 
We know little about the patient’s experience of their recovery and the impact of the injury 
and its treatment on them. We also have poor understanding of the issues pertinent to 
recruiting participants in surgical, clinical trials.46, 47   
 
Five-year review 
The long-term consequences of cast immobilisation and internal fixation have not been 
adequately determined in RCTs. The consolidation of partial union of the fracture has not 
been investigated, nor has progression of carpal mal-alignment or the development of 
arthritis. Although this report focusses on outcomes at 52 weeks the study will investigate 
function, impairment and arthritis at five years.48 
 
Null hypothesis 
There is no difference in the Patient Rated Wrist Evaluation (PRWE)49 score at  52 weeks 
follow-up between adults with a scaphoid waist fracture treated with screw fixation versus 
plaster cast immobilisation and fixation of only those fractures that fail to unite. 
 
Research question 
Our aim was to determine the effectiveness and cost-effectiveness of surgical fixation versus 
plaster cast treatment (with early fixation of 10-12% that fail to unite) of scaphoid waist 
fractures in adults in an adequately powered multi-centre pragmatic RCT (SWIFFT)48 and to 
qualitatively investigate patient experiences of their treatment and participation in the trial. 
 
Research objectives 
 
1 
Our primary objective was to determine the effectiveness of surgical 
fixation versus non-operative plaster cast treatment (with fixation of 
those that fail to unite, estimated as 10% to 12% of the total) of 
scaphoid waist fractures in adults. Outcome was assessed using the 
PRWE50 (a patient self-reported assessment of wrist pain and function) 
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at 52 weeks which was the primary end point. The PRWE was also 
completed at six, 12, 26 weeks and will be completed at five years. The 
power of the study permitted identification of a clinically meaningful 
difference of six points in the PRWE. 
 
Our secondary objectives were: 
2 To assess radiological union of the fracture at 52 weeks using 
radiographs and CT scans; recovery of wrist range and strength; return 
to work and unpaid recreational activities and; complications. 
3 To conduct an economic analysis to investigate the cost-effectiveness of 
surgical fixation versus initial immobilisation in a plaster cast. 
4 To qualitatively explore patient experiences of fracture and its 
treatment; and investigate attitudes towards, and experiences of, 
participating in a surgical, clinical research trial. 
5 To undertake a five-year clinical review of all trial participants to 
determine the long-term consequences of cast immobilisation and 
internal fixation. 
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Chapter 2 Trial design and methods 
This chapter describes the trial design and methods to address the objectives about the 
clinical effectiveness of the healthcare interventions being compared. The methods of the 
health economic evaluation and the nested qualitative study are described in their respective 
chapters. 
 
Trial design 
This was a multi-centre, stratified (displacement present or not, with equal allocation [1:1]), 
parallel-group design conducted in England and Wales of patients aged 16 years or over with 
a clear bi-cortical fracture of the scaphoid waist as seen on plain radiographs. Patients were 
randomly assigned to either immediate surgical fixation or initial non-operative wrist 
immobilisation in a below elbow cast with later surgical fixation of only those fractures that 
failed to unite. 
 
Participants 
The diagnosis of fracture was on standard radiographic views available at each hospital i.e. 
posterior-anterior, lateral, semi 45° prone, semi 45°supine and an elongated scaphoid view 
e.g. Ziter.51 If these radiographic views were not taken routinely at a participating site, we 
sought to obtain them after the patient had consented into the trial to confirm eligibility 
before randomisation.  
 
A research Computerised Tomogram (CT) scan was also taken at baseline to compare with 
the CT scan at 52 weeks for the bone union assessment. The baseline CT scan was taken 
within two weeks of the patient’s injury (i.e. before randomisation) or if that was not feasible, 
before surgery if the patient was allocated to surgery. It was decided that although eligibility 
assessment should be based on the radiographic views, because a baseline CT scan was 
available it was necessary for a member of the radiology team to confirm whether a fracture 
was visible or not. If the baseline CT scan was viewed before randomisation, and a member 
of the radiology team could not confirm to the participating site staff that there was a clear 
bicortical fracture of the scaphoid waist, the surgeon would decide whether to continue to 
recruit the patient. This was to prevent the potential for an immediate crossover to plaster cast 
if the surgeon thought there was a not a sufficiently visible fracture to operate on. If this 
happened after randomisation, the patient remained in the trial because there was a fracture 
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on the series of radiographic views. This could, however, influence the surgeon’s decision to 
continue to operate on the patient when allocated to surgery i.e. could lead to a cross-over.  
 
Inclusion criteria 
Patients were eligible for the trial if they:  
 were skeletally mature and aged 16 years or older  
 presented at a participating site within two weeks of their injury and within which 
time it was feasible to have surgery   
 had a clear, unequivocal bicortical fracture of the scaphoid waist seen on a series of 
plain radiographs of the scaphoid which: 
a) did not involve the proximal pole (proximal fifth of the scaphoid) and  
b) included minimally displaced fractures with less than or equal to 2mm step 
or gap on any radiographic view. 
 
Exclusion criteria 
Patients were excluded from the trial if:  
 their fracture had >2mm displacement as these are likely to be unstable and require 
surgical intervention 
 they had a concurrent wrist fracture in the opposite limb  
 they had a trans-scaphoid perilunate dislocation 
 they had multiple injuries in the same limb  
 they lacked mental capacity to comply with treatment or data collection  
 they were pregnant because radiation exposure would be contraindicated 
 they were not resident in the trauma catchment area of a participating site to allow 
follow-up. 
 
Setting 
The trial recruited from the orthopaedic departments of 30 National Health Service hospitals 
in England and one hospital in Wales. There were three additional hospitals in England that 
screened for patients but did not recruit to the trial. Recruitment started in July 2013 and final 
follow-up was in September 2017. All 34 participating Trusts have been listed (see Appendix 
1). 
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Interventions 
 
Cast treatment followed by surgical fixation if there is confirmed non-union   
Control treatment was non-operative with wrist immobilisation in a below elbow cast for six 
to ten weeks, followed by mobilisation. The below elbow cast could include the thumb or not 
as this does not affect union rate.8 Early CT was obtained if plain radiographs at six to twelve 
weeks raised the suspicion of non-union. If non-union was confirmed on radiographs and/or 
CT scan, urgent surgical fixation was expected to be performed and was encouraged by the 
trial team who monitored this with the completion of the Six and Twelve Week Treatment 
Confirmation Forms (see Supplementary File 1 and 2). The surgical procedure to treat a non-
union and post-operative care was similar to the surgical arm of this trial. Cast 
immobilisation, identification and confirmation of non-union at 6 to 12 weeks and immediate 
surgical fixation of confirmed non-union is the current standard non-operative pathway.3  
 
Surgical fixation 
Surgical treatment was by percutaneous or open surgical fixation depending on the surgeon’s 
preferred technique. Standard CE marked headless compression screws18, 52 were used to 
avoid the pressure effects of the screw head on articular cartilage. These are standard surgical 
techniques.20-22 The type of implant used was not restricted but the screw used was recorded 
(see Supplementary File 3). The surgical approach or the postoperative care was not specified 
but was left to clinical discretion, as it was expected that most surgeons would use some 
splintage for the first few weeks after surgery. The application of a plaster cast or splint 
following surgery and its duration was recorded. It was agreed at each recruiting site which 
surgeons would fix the scaphoid fractures and that surgeons would use techniques with which 
they were familiar to avoid learning curve problems. 
 
Rehabilitation 
All participants randomised into the two groups received standardised, written physiotherapy 
advice detailing the exercises they needed to perform for rehabilitation following their injury 
(see Supplementary File 4). All participants were advised to move their shoulder, elbow and 
finger joints fully within the limits of their comfort. Those participants treated in a cast, 
performed range-of-movement exercises at the wrist as soon as their plaster cast was 
removed at the six week follow-up appointment when there were no concerns regarding bone 
union. Those participants who had the fracture fixed began their wrist exercises as soon as 
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comfort permitted, if they did not have a plaster cast, or as soon as the cast was removed. 
Any other rehabilitation input beyond the written information sheet (including a formal 
referral to physiotherapy) was the decision of the treating clinicians. A record of any 
additional rehabilitation input (reason for referral and number of appointments) was recorded 
at the 52-week hospital visit.  
 
Outcomes 
The outcomes and the time points when various outcomes were assessed are described below.  
 
Primary outcome 
The primary outcome and end-point for the trial was the Patient Rated Wrist Evaluation 
(PRWE) total score at 52 weeks from randomisation. The PRWE was completed at 
baseline for the time before and after injury, and at six, 12, 26, 52 weeks and will be 
completed at five years after randomisation. The PRWE is a 15-item questionnaire that is 
completed by the participant. It is a brief, reliable and valid instrument for assessing wrist 
pain and disability.50, 53 Scoring for all the questions is on a ten-point ordered scale, ranging 
from ‘no pain’ or ‘no difficultly’ (0) to ‘worst ever pain’ or ‘unable to do’ (10). A total 
score can be computed on a scale of 0 to 100 (0 = no disability), as well as two non-
overlapping subscales (pain and function) which are weighted equally. PRWE was chosen 
as the primary outcome as patient reported functional outcomes are favoured for decision 
making and it allows assessment of both wrist pain and function.  
 
Two small RCTs3, 18 of patients with fractures of the scaphoid have demonstrated that there 
is little change in objective and subjective outcomes between 26 and 52 weeks. For the 10% 
to 12% of patients who are treated initially in cast but do not heal, surgery should be 
performed between six and twelve weeks from randomisation. Therefore, if assessed at 26 
weeks this would leave only 14 to 20 weeks for healing and recovery to take place. To 
allow all patients the time to heal from surgery and to stabilise from any complications, 52 
weeks was chosen as the primary end point.  
 
Secondary outcomes 
Secondary outcomes were: health-related quality of life; bone union; range of movement 
and grip strength; return to work and unpaid recreational activities; and complications. 
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Health related quality of life 
PRWE: The total scores at other time points (six, 12, and 26 weeks) as well as the PRWE 
subscale scores of pain and function were secondary outcomes. 
 
Short Form 12-Item Questionnaire (SF-12): The SF-12 is a 12 item generic patient-reported 
outcome measure of physical and mental health, the population norms of which have a mean 
of 50 and standard deviation of 10; higher scores indicate better health.54 The SF-12 was 
completed at six, 12, 26 and 52 weeks to measure the potential broader consequences of a 
scaphoid fracture on both the participants’ physical and mental health. 
 
EuroQol (EQ-5D-3L): The EQ-5D is a validated, generic patient-reported outcome measure 
covering five health domains (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) with three response options to each domain.55, 56 The use of this non-
fracture-specific instrument allows the assessment of health-related quality of life outcomes 
in the health economic analysis. The EQ-5D has high validity and reliability in proximal 
humerus fractures57 and hip fractures.58 It was completed at baseline, six, 12, 26 and 52 
weeks.        
 
Bone Union  
The secondary outcome of bone union59 was determined at 52 weeks (in line with the 
primary end point). A research CT scan was obtained and a series of plain radiographs 
undertaken comprising posterior-anterior, lateral, 45° semi-prone, 45° semi-supine views 
and an elongated scaphoid view e.g. Ziter type view. Routine radiographs were also 
collected for bone union assessment at six and 12 week hospital clinics. 
 
Union was defined as complete disappearance of the fracture line8 on radiographs and 
complete bridging on CT scans60, 61 from those taken at baseline. Partial union was based 
on the proportion of the fracture plane traversed by bridging trabeculae on true sagittal and 
coronal multiplanar reconstructions of the scaphoid on CT. CT was used to determine non-
union as there is only poor to moderate inter-observer agreement (range of Kappa from 
0.11 to 0.53) when determining the union of a scaphoid fracture on plain radiographs.62  
 
Scaphoid fracture displacement was assessed on radiographs and on a CT scan.63  
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Malunion was assessed on the 52 week CT scan,64 which was defined as the ratio of 
Scaphoid Height to Length ≥ 0.6 in the true sagittal axis of the scaphoid, to assess any 
humpback deformity.65  
 
A limitation of this assessment of bone union, however, was that the presence of the screw to 
fix the fracture would unblind the observer as to whether the participant had an operation or 
not. To minimise the potential for this to introduce bias, two consultant radiologists with a 
special interest in musculoskeletal radiology and a consultant orthopaedic surgeon (Chief 
Investigator), interpreted the plain radiographs and CTs independent of each other. All three 
met to discuss cases where there was discordance in line with rules defined in a Standard 
Operating Procedure (see Supplementary File 5). The two radiologists were both employed at 
participating hospital sites (Leicester and Birmingham). During the trial they did not report 
on plain radiographs or CTs of the scaphoid during clinical practice, in an attempt to maintain 
independence when reporting on imaging of trial participants.  
 
Range of movement and grip strength  
The range of movement of both wrists was measured using a goniometer66 and grip strength 
of both hands was measured using a calibrated Jamar dynamometer.67-70 Both were recorded 
at baseline, six, 12 and 52 weeks (see Supplementary File 6). The measurements were 
performed with the subject seated, arm by the side, elbow bent at 90 degrees and the wrist in 
neutral position for rotation.71 Staff were advised to use the second setting on the Jamar 
dynamometer except for participants with large hands where the third setting was used.72 The 
Beighton Joint Laxity Score (excluding the thumb count for the injured wrist) was recorded at 
baseline to measure hypermobility of joints.73 These assessments were standardised across 
participating sites using an instruction sheet (see Supplementary File 7). 
 
Return to work and unpaid recreational activities  
This was established through participant self-report on the number of days off work and 
ability to perform usual activities when at work and when performing unpaid recreational 
activities. This was recorded at six, 12, 26 and 52 week follow-up. 
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Complications  
Expected and unexpected complications were recorded at the six, 12 and 52 week hospital 
visits (see Supplementary File 8). The expected complications included: 
 Infection, defined as “Surgical Site Infection”.74  
 Delayed wound healing, defined as any wound that has not healed by two 
weeks.  
 Complex Regional Pain Syndrome (CRPS), defined as puffy painful swelling 
of the whole hand restricting full tuck of the fingers at two weeks.  
 Nerve events (hypoaesthesia or numbness in the territory of the palmar 
cutaneous branch of the median nerve, superficial division of the radial nerve 
or the median nerve).  
 Vessel events (large (>2 cm) haematoma in the line of the radial artery).  
 Screw related complications (protrusion of either end into the adjacent joint, 
fracture or bending of the screw, a radiolucent halo around any part of the 
screw >1mm, screw backing out or moving).  
 Degenerative change in the adjacent joints.75  
 Avascular necrosis76 of the proximal pole of the scaphoid. 
 
In addition, the three raters reviewed the imaging at each time-point for complications. This 
included assessing the presence or not of osteoarthritis, presence or not of screw penetration, 
screw lucency (none, <1mm, 1-2mm) and avascular necrosis (no radiodensity, just radio-
dense, marked radiodensity on 1 view or one MPR, marked radiodensity on >1 views or 
MPRs).  
 
Sample size 
For surgery to justify its increased costs and the exposure to risk, it must result in greater or 
quicker improvement in patients’ wrist symptoms and function compared with non-
operative management. A six point improvement in the PRWE in the surgery group 
(compared to the controls) was chosen to be a minimally clinical important difference. The 
standard deviation of PRWE at 52 weeks was taken to be 20 points from the PRWE User 
manual.49 This figure was reported for distal radius fracture rather than scaphoid fracture at 
six months. The only published evidence for scaphoid fracture implies a standard deviation 
in the range of eight to ten points;28 however, this estimate was at a median of ten years after 
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the patient’s injury. To be conservative, a standard deviation of 20 was chosen. This gives a 
standard effect size of 0.3 for the 6 point PRWE difference. A superiority design was used 
to observe an effect size of 0.3 at 80% power using a two-sided 5% significance level 
requiring 350 participants in total. After allowing for 20% attrition, the recruitment target 
was 438 participants (219 surgery and 219 plaster cast). The estimate of attrition was 
expected to be realistic given that four previous RCTs (three studies were single centre and 
one study had two centres) of the treatment of scaphoid fractures had reported response 
rates for completion of patient-reported functional outcomes to be between 77% and 
100%.31 
 
There were no planned interim analyses for the trial or stopping guidelines. There was, 
however, an internal pilot study from which the data contributed to the final analyses. The 
primary reason for the pilot study was to check the assumptions about site set up, patient 
recruitment and feasibility of the trial. The independent oversight committees reviewed the 
progress that was made during the internal pilot and recommended that the trial should 
continue with the planned increase in the number of sites. In the absence of a standard 
deviation for the primary outcome at 52 weeks, this was estimated from the participants 
who were recruited into the internal pilot study. This estimate corroborated the standard 
deviation chosen for the sample size calculation.  
 
Recruitment 
A Research Nurse identified potentially eligible patients, referred from Accident and 
Emergency Departments, or other sources (e.g. walk-in centre, cottage hospital), to fracture 
clinics. The orthopaedic surgeon confirmed eligibility (see Supplementary File 9) and invited 
the patient to consider joining the study. The Research Nurse or clinician provided the patient 
with an information sheet (see Supplementary File 10) and answered any questions. The 
patient was asked to consent at that time or was offered up to 48 hours to discuss the study 
with family or friends before deciding whether to take part or not. When patients gave 
consent (see Supplementary File 11), they were asked to complete a baseline form (see 
Supplementary File 12). The site staff then contacted York Trials Unit (YTU), either by 
telephone or via the internet, to access the secure randomisation service. For patients who did 
not consent, a form was completed to record: reasons for non-consent, patient and surgeon 
treatment preferences, and the agreed treatment plan (see Supplementary File 13). Both 
patients that consented to take part in the trial, using the main trial information sheet (see 
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Supplementary File 10), and those that did not consent into the trial, using a separate 
information sheet (see Supplementary File 14), were invited to take part in an interview. This 
is explained further in Chapter 5.  
 
Strategies for achieving adequate participant enrolment to reach the target sample size 
included seeking advice from a patient focus group, sharing best practice with the Research 
Nurses at participating sites, and bi-annual discussion with our Principal Investigators (PIs) at 
the scientific meetings of the British Society for Surgery of the Hand (BSSH). Hospital staff 
were provided with training about study procedures at the Site Initiation Visits and with a 
Trial Site Manual. During the trial, training and reminders were implemented using e-mail 
bulletins, face-to-face meetings with the PI’s at BSSH conferences and a training day with 
Research Nurses. In addition, the Trial Co-ordinators provided support and guidance to staff 
at participating sites (e.g. when new staff joined or replaced existing site staff) and also 
sought guidance from the Chief Investigator (CI). 
 
Randomisation 
The randomisation sequence was based on a computer-generated randomisation algorithm 
provided by a remote randomisation service (telephone or online access) at YTU. The unit of 
randomisation was the individual patient on a 1:1 basis. As the non-union rate for displaced 
scaphoid fractures is 14% compared with 10% for transverse undisplaced fractures,8, 10, 39 
randomisation was stratified by the presence or not of displacement as assessed by the staff 
at the recruiting site. Random block sizes of six and twelve were used. Displacement was 
defined as a step or gap 1mm to 2mm inclusive as seen on any radiographic view. The 
Research Nurse used the remote randomisation service to register eligible and consenting 
participants before computer generation of the allocation. The Research Nurse then informed 
the treating surgeon of the allocation. This ensured treatment concealment and immediate 
unbiased allocation. 
 
Blinding 
As the trial was pragmatic and compared surgery with initial cast treatment, blinding of 
participants and clinicians to treatment allocation was not possible. When possible, the 
treating surgeon took no part in the postoperative assessment of participants. The statistician 
was blind to group allocation until after data were hard locked and no further changes could 
be made. To minimise bias in the assessment of bone union, all radiographs and CT scans 
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were assessed independently by two consultant musculoskeletal radiologists and a consultant 
orthopaedic surgeon (Chief Investigator). Any disagreement was resolved through discussion.  
 
Statistical methods 
Analyses were conducted using the principles of intention to treat, including all randomised 
participants in the groups to which they were allocated, where data were available.  Analyses 
were conducted in Stata v1577 using two-sided statistical tests assessed at the 5% significance 
level.     
 
Recruitment 
Site and patient recruitment was presented.  The characteristics of the population of patients 
screened, ineligible, and eligible stratified by consent were summarised. The flow of 
participants through the trial was presented in a Consolidated Standards of Reporting Trials 
(CONSORT) diagram. 
 
Baseline characteristics of randomised participants 
Baseline participant characteristics and fracture details were summarised descriptively overall 
and by randomised group both as randomised, and ‘as analysed’ comparing the groups as 
included in the primary outcome analysis model (i.e., have full data for the baseline 
covariates and valid PRWE data for at least one post-randomisation time point). No formal 
statistical comparisons were undertaken on baseline data. 
 
Follow-up 
For each time point, the number of participant questionnaires sent and returned, with median 
(interquartile range [IQR]) days to completion and return was presented by treatment group 
and overall.  The number of questionnaires completed at home, over the telephone or in the 
hospital was reported.  Return rates for hospital forms were tabulated by randomised group 
and time point.   
 
Hospital visits 
Participants were asked to attend for a hospital follow-up visit at six, 12 and 52 weeks post-
randomisation.  Baseline participant characteristics and fracture details were summarised 
descriptively overall and by randomised group according to whether participants attended the 
hospital visit at each time point. 
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Compliance with random allocation and treatment received    
The treatment received by participants in the two groups was summarised, with reasons for 
treatment crossover. 
 
Primary outcome (Patient Rated Wrist Evaluation) analysis 
The PRWE was assessed at baseline (pre and post-injury; prior to randomisation), and at six, 
12, 26 and 52 weeks post-randomisation. The PRWE total score is a value between 0 and 
100, where a higher score indicates worse pain and functioning.  The score is computed by 
scoring the two subscales out of 50 (Pain: sum of items 1-5; Function: sum of items 6-15 
divided by two) and summing them, so that pain and function problems are weighted equally.  
If there was up to one missing item in each subscale, then the missing item was replaced by 
the mean of the completed items within that subscale.78  If two consecutive responses 
(between 0 and 10) to a particular item were selected then the higher of the two (worse 
response) was taken for analysis.  Other ambiguous responses were treated as missing. If 
more than one item was missing in either subscale then a score for that subscale, nor for the 
total, could be calculated. 
 
The number and percentage of participants with valid and partial PRWE data was reported by 
randomised group and time point.  Baseline participant characteristics and fracture details 
were summarised descriptively overall and by randomised group according to whether 
participants had valid PRWE outcome data at each post-randomisation time point.  Total 
PRWE scores were summarised by time point according to whether participants had valid 
data for: i) all post-randomisation time points; ii) at least one, but not all, post-randomisation 
time points; iii) and no post-randomisation time points.  PRWE scores (subscales and total) 
were summarised descriptively by treatment group and overall.   
 
Total PRWE scores were compared between the two groups using a covariance pattern, 
mixed-effect linear regression model incorporating all post-randomisation time points.  
Treatment group, time point, a treatment-by-time interaction, participant age at 
randomisation, baseline fracture displacement and dominance of injured hand were included 
as fixed effects, and participant as a random effect (repeated observations per participant).  
Fracture displacement was used as a stratification factor in the randomisation; however, there 
were several instances where the wrong displacement category was used in the 
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randomisation. Such stratification errors were identified when there was a discrepancy 
between data provided at randomisation and data recorded on the Study Eligibility Form. 
Where the randomisation data were incorrect a file note was raised and the trial statistician 
was notified; where the data on the Study Eligibility Form were incorrect this was amended.  
The displacement used in the randomisation was the variable included in the primary 
analysis, but the errors were discussed.  The primary model was not adjusted for baseline 
total PRWE as in this young population we expected that the pre-injury PRWE would be low 
and have little variability, and post-injury PRWE would be confounded as patients would 
likely be in a plaster cast.       
 
An unstructured covariance pattern for the correlation between the observations for a 
participant over time was specified in the final model based on Akaike’s information criterion 
(AIC)79 (smaller value preferred).   
 
An estimate of the difference between treatment groups in total PRWE score was extracted 
from the repeated measures model for each time point, and overall, with a 95% confidence 
interval (CI) and p-value.  The primary end point is the treatment effect estimate at 52 weeks.  
Estimates for the treatment effect at other time points (six, 12 and 26 weeks) and overall 
serve as secondary outcomes.  This repeated measures approach is more efficient and 
parsimonious than conducting separate linear regressions for each time point, and also allows 
for the ‘overall’ (across the whole 52 weeks) effect to be investigated using the same model.  
The analysis takes advantage of the extra information provided at, and the correlation 
between, all post-randomisation time points.  The standard errors for treatment effects at 
individual time points are calculated using information from all time points and are hence 
more robust and accurate than standard errors calculated from separate analyses at each time 
point.  An additional advantage of the mixed model approach is that the presence of missing 
data across time points does not cause a problem under the assumption that they are missing 
at random.  For the estimates at a single time point, say at 52 weeks, it is primarily the 
observations at that time point that determine the treatment effect and power; however, owing 
to the covariance between the post-randomisation time points, greater power and precision is 
obtained than that from a comparison using only the 52 week data80.    
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Model assumptions were checked as follows:  the normality of the standardised residuals was 
checked using a QQ (Quantile Quantile) plot, and homoscedasticity was assessed by means 
of a scatter plot of the standardised residuals against fitted values.   
 
Sensitivity analyses 
 
Missing data 
Any response bias was partially minimised by using a mixed-effect, repeated measures 
model, which allows the inclusion of intermittent responders in the primary analysis.  
Multiple imputation by chained equations was also used to handle missing PRWE outcome 
data.  Missing outcome and covariate data was predicted by age, fracture displacement, hand 
dominance, and available PRWE data at other follow-up time points.  A ‘burn–in’ of 10 was 
used and 20 imputed datasets were created.  Separate linear regressions were then run on the 
multiply imputed dataset to compare the PRWE between the two groups at six, 12, 26 and 52 
weeks, adjusting for age, displacement and dominance of injured wrist.  Estimates were 
combined using Rubin’s rules via the mi estimate command in Stata81. 
 
Handling multi-site data 
Participants were recruited from multiple sites.  To investigate whether site affects the 
outcome, a sensitivity analysis was conducted including site as a random effect (within which 
participants were nested) in the model as described for the primary analysis.82  
 
Timing of data collection 
The primary analysis model was repeated only including data collected one week either side 
of the six week time point, two weeks either side of the 12 week time point, six weeks either 
side of the 26 week time point, and eight weeks either side of the 52 week time point. 
 
Post-hoc sensitivity analysis including smoking status 
Current smoking status (yes/no) was included as a covariate in the primary analysis model in 
a post-hoc sensitivity check since this factor was found to be imbalanced by chance at 
baseline between the randomised groups and thought to be associated with healing and 
complications.  The decision to conduct this sensitivity analysis was taken after the primary 
analysis results were known and was not pre-specified in the statistical analysis plan.    
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Displacement and lack of fracture as assessed by independent review of baseline imaging 
data 
Discrepancies between the displacement of the fracture (<1 mm, or 1-2 mm inclusive) judged 
by the treating clinician on plain radiographs and stratified on in the randomisation, and the 
judgement agreed by three independent reviewers of the baseline CT scans and radiographs 
were reported.  The primary analysis model was rerun including a variable indicating the 
level of displacement judged by the three raters instead of that randomised on. 
 
The number of cases are reported where consensus was reached between the three raters 
that (i) there was no fracture, or (ii) displacement of the fracture was greater than 2 mm, 
based on their assessment of the baseline radiographs/CT scans, since these were exclusion 
criteria.  Separate sensitivity analyses of the primary outcome model were conducted 
excluding these patients.   
 
Complier average causal effect (CACE) analysis 
To account for non-compliance (surgery to plaster cast) and contamination (plaster cast to 
surgery) a complier average causal effect (CACE) analysis was conducted.  A two-stage least 
squares  instrumental variable (IV) approach83, 84 was used with randomised treatment as the 
IV (implemented using the ivregress command in Stata) to compare PRWE scores at 52 
weeks, adjusting for age, fracture displacement, and hand dominance.  For this analysis, it 
was assumed that participants allocated to the plaster cast group have the same probability of 
non-compliance as those allocated to the surgery group had they been offered the surgery; 
that participants allocated to the surgery group have the same probability of contamination as 
those allocated to the plaster cast group had they been offered non-surgical management; and 
that being simply offered the allocated treatment has no effect on the outcome. These 
assumptions were plausible under randomisation which should balance covariates across the 
two groups. 
 
Subgroup analysis 
In total, three subgroup analyses were undertaken: one exploring patient treatment 
preferences as expressed at baseline; and two exploring fracture displacement.  Due to the 
errors in classification of fracture displacement at randomisation, two approaches for the 
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displacement subgroup analysis were taken: one using displacement as defined at 
randomisation; and one using the classification given on the Study Eligibility Forms.  Total 
PRWE scores are summarised by randomised group and time point, stratified by the levels of 
the baseline factor of interest.  To investigate whether the treatment effect varied across the 
levels of these baseline factors the factor was included in the primary analysis model 
alongside an interaction between randomised treatment allocation and baseline factor, using a 
two-sided p-value of 0.05. Interpretation of these models was made cautiously, since the trial 
was not powered for interactions.85, 86 
 
Descriptive summaries of baseline participant and fracture data, and PRWE scores are 
presented for: 
 participants in the plaster cast arm stratified by whether or not they needed surgery 
due to non-union; and 
 participants in the surgery arm stratified by whether or not the surgical screw used 
was too long and caused cartilage damage as determined on the CT scans by the three 
independent raters. 
 
There were two feasibility requirements for this trial: (i) that a CT scan was performed within 
two weeks of a patient’s injury (or before surgery if this occurred earlier); and (ii) that for 
patients in the surgery arm, surgery was performed within two weeks from presentation to 
A&E or other clinic.  It was considered a protocol deviation if these tasks were performed 
outside of these parameters.  A linear regression for the surgery arm only investigated 
whether time from injury to surgery in days is predictive of total PRWE score at 52 weeks, 
adjusted for age, fracture displacement and hand dominance.  Descriptive summaries of 
baseline participant and fracture data, and PRWE scores are presented for: 
 participants stratified by whether or not their CT scan was performed within two 
weeks of a patient’s injury (or before surgery if this occurred earlier); and 
 participants in the surgery arm stratified by whether or not their surgery was 
performed outside the target two-week period from first presenting at A&E or other 
clinic. 
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Secondary analysis 
 
Secondary outcomes 
The secondary outcomes of pain and function subscales of the PRWE; physical and mental 
health component summaries of the SF-12; and grip strength were summarised descriptively 
for each time point by treatment group and overall, and were analysed using the same method 
as the primary outcome adjusting for the same covariates.  The most appropriate choice of 
covariance structure was identified separately for use with each outcome, which was always 
an unstructured pattern. 
 
Union 
Plain radiographs at six, 12 and 52 weeks and CT images at 52 weeks were reviewed by three 
independent raters at the end of the trial for union of the fracture.  Union, as reviewed on CT 
images at 52 weeks, was measured as a percentage (0-100%), and categorised as: 0% = non-
union, >0-20% = slight union, >20-70% = partial union, >70-100% (but not including 100) = 
mostly united, and 100% = complete union. The same categories of union were used for 
radiograph images at six, 12 and 52 weeks.  Extent of union was presented for each time 
point by trial arm. Participants were dichotomised at each time point as ‘Probably need 
surgery’ (non- and slight union) and ‘Probably don’t need surgery’ (partial to complete 
union) and analysed using a logistic regression model (52 week data only).  It was originally 
planned to additionally conduct a mixed-effect logistic regression model to compare the 
treatment groups at 52 weeks, with participant as a random effect to account for the repeated 
measures of union at six, 12 and 52 weeks, adjusting for age, displacement and dominance of 
injured wrist as fixed effects.  However, this model did not converge.  As an alternative 
sensitivity check, multiple imputation was used to impute the dichotomised union variables at 
six, 12 and 52 weeks (imputation included union variables, age, displacement, dominance of 
injured wrist and allocation).  A ‘burn–in’ of ten was used and 20 imputed datasets were 
created.  A logistic regression was run on the multiply imputed dataset to compare union 
between the two groups at 52 weeks, adjusting for age, displacement and dominance of 
injured wrist.   
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The 52-week PRWE scores for patients overall and who did and did not attend for imaging at 
52 weeks was summarised by treatment group. 
 
Malunion 
Scaphoid height and length was measured by the three independent raters of the CT and plain 
radiographs.  Malunion was defined using a ratio of scaphoid height to length of greater than 
0.6.  During the study, literature was published which suggested that a threshold ratio of 0.7 
might be more appropriate87 than 0.6.64  Rates of malunion at the 0.6 and 0.7 thresholds are 
presented overall and for each treatment group at six, 12 and 52 weeks. 
 
Complications 
Complications were defined as medical, surgical and plaster cast related, and were assessed 
by clinical examination at six, 12 and 52 weeks.  The number of patients who experienced a 
complication of a certain type was summarised by trial arm.  The presence of any medical, 
surgical or cast complication recorded on the Complication Form up to 52 weeks was 
analysed by logistic regression, adjusting for age, hand dominance and fracture displacement.   
 
Cases when two out of the three raters agreed on imaging that there was a complication were 
reported.  
 
Adverse events 
All serious and non-serious adverse events were summarised by treatment group. 
 
Agreement analysis 
A descriptive analysis of agreement between the three raters was performed. Radiographs 
provide categorical grades of fracture, displacement and union and these were summarised by 
cross-tabulating the results from each pair of raters and calculating their percentage 
agreement. The CTs provide continuous measures of displacement and of the percentage 
union. Agreement between these continuous measures was summarised in Bland-Altman 
plots that compare each pair of raters and the limits of agreement were calculated. 95% 
confidence intervals were provided for all numerical summaries. 
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Data management 
All hospital forms, imaging CDs and participant questionnaires were sent from and returned 
to YTU. A central database at YTU was used to prompt the sending out and return of 
participant questionnaires and hospital Case Report Form (CRF). This included automated 
email reminders to participating sites to help ensure the timely return of hospital CRFs.  
 
Essential trial documentation, which individually and collectively permits evaluation of the 
conduct of a clinical trial and the quality of the data produced, was kept with the Trial Master 
File and Investigator Site Files. This documentation will be retained for a minimum of five 
years after the conclusion of the trial in accordance with Good Clinical Practice.  The postal 
questionnaires and hospital CRFs will be stored for a minimum of five years after the 
conclusion of the trial as paper records; and a minimum of 20 years in electronic format.88 
 
Design of patient questionnaires and hospital CRFs 
The patient questionnaires and hospital CRFs were designed using TeleForm software 
(version 10; Cardiff Software, Cambridge, UK). Specification CRFs were populated with 
variable names and appropriate scoring. To maximise data quality, when hospital CRFs were 
returned to YTU, key variables required for the statistical analysis were reviewed for 
completion and accuracy by a Trial Co-ordinator/Research Data Administrator who resolved 
any queries with the Research Nurse at the site. The hospital sites were reimbursed according 
to a payment schedule for the completion of CRFs and provision of research imaging up to a 
total of £430.30. This was agreed between each trust and trial sponsor using a Clinical Trial 
Agreement. No checks regarding data quality of the postal questionnaires were made on 
immediate return to YTU. A Trial Co-ordinator did, however, as a duty of care, check 
whether a participant responded with the extreme answers to the following: questions 4a, 4b, 
6a and 6b of the SF-12; the last EQ-5D question; and checked free text responses for whether 
the participant could be at harm. When this occurred the PI and RN at the reruiting site were 
notified by email. 
 
After this initial check, all postal questionnaires and hospital CRFs were prepared for 
scanning by a Research Data Administrator using the TeleForm software. When a form 
would not scan, the data were manually entered. When a form was scanned, the data were 
then verified depending on what TeleForm identifies as requiring correction. The verified 
data were then temporarily held in the Download Database and available for second 
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checking. This involved each hard copy of all forms being compared against the entry stored 
in the Download Database and correcting the electronic data as necessary. All data were 
scanned, downloaded and second checked in the Validate Database. The automated data 
validation was undertaken by the Data Manager who applied predetermined rules to check for 
agreed variables whether the data were recorded correctly. Data that had been validated were 
then held in the Survey Database and available upon a formal request from the trial 
statistician and health economist. 
 
Strategies to follow-up patients 
Participants at the six, 12, 26 and 52 week follow-ups were notified by post to expect the 
questionnaire (see Supplementary File 15) two weeks before it was due. Reminder letters 
were sent at two and four weeks after the due letter was sent out. When there was no response 
to reminder letters, a Trial Co-ordinator at YTU contacted participants by telephone who 
were invited to answer a minimum of the primary outcome (PRWE) and EQ-5D. At 52 weeks 
only (the primary time-point for the study), in addition to the six week telephone call, a letter 
to non-responding participants requested the completion of the PRWE only. At 26 weeks, 
when participants did not attend a hospital appointment, an unconditional incentive of £5 was 
included with the postal questionnaire. At 52 weeks, a £40 payment was made to participants 
who attended the clinic. For the final 11 months of the follow-up period for the study, 
participants were also offered up to £40 to cover their travel expenses or more if this was 
agreed with the trial team. The participants could complete the follow-up questionnaires 
during the clinic visits. 
 
Various techniques were used to minimise loss to follow-up. This included regular participant 
newsletters which publicised progress about the study at the trial website 
(http://www.swifft.co.uk/). A trial ‘tagline’ was placed on postal envelopes to participants to 
highlight the importance of their involvement in the research i.e. “SWIFFT Study: Patients 
helping to improve healthcare through research”.  As the return of postal questionnaires can 
be improved when participants are included in a prize draw,89 anyone who returned their 
questionnaire at 26 weeks could win an iPad worth £500. Participants who attended their 
hospital clinic appointment at 52 weeks were also entered into a prize draw to win an iPad 
worth £500. If at 52 weeks it was difficult to arrange the hospital appointment, a letter was 
sent from the hospital to the participant along with a leaflet to encourage their attendance. 
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Other strategies to collect follow-up data on participants who did not return their 
questionnaire or attend clinics included: using a participating hospital’s Picture Archiving 
Communication Systems (PACS) for the local area/region to retrieve imaging of patients; 
access Summary Care Records to view participants’ addresses and/or the General Practitioner 
they were registered with to help contact them; and ask a participants General Practitioner 
whether they have had an operation on their scaphoid fracture. 
 
A trial participant could withdraw from the study at any time for any reason but any data 
collected up to that point was used in the analysis. A participant could withdraw from all data 
collection, or from postal questionnaire collection or hospital data collection only, which was 
recorded using a Change in Status Form (see Supplementary File 16).  
 
Data management for the review of imaging 
The forms used to capture assessments of the scaphoid fracture and conduct measurements on 
the imaging collected, were created using the ‘Design’ module in Formic Fusion Software 
(5.5.1 Build 005, Formic Limited, Middlesex, UK) and include SWIFFT Master Radiograph 
Form, SWIFFT Baseline CT Form and SWIFFT 52 Week CT Form. 
 
Once completed by reviewers, variables within each form were checked visually for 
completeness and whether measurements were within an expected range. Completed forms 
were then scanned using the Formic ‘Capture & Process’ module and responses were 
reviewed. The Formic scanning software flagged hand-written text and those checkboxes 
with no mark or more than one mark; these were manually corrected to reflect the entry on 
the form. The scanned image of the form was also held within the data to permit independent 
verification. Once exported to the ‘SWIFFT logging database’ (Microsoft Access) data then 
went through a final electronic check to ensure all measurements were within the limits 
assigned by the Chief Investigator and to check for errors in measurements e.g. cm instead of 
mm. The data was then checked for these rules in Stata v1577 and potential problems were 
flagged and checked by each reviewer.  
 
Data from the three reviewers was assessed and classification conflicts on fracture 
displacement at baseline and state of union at 52 weeks identified and resolved in “conflict 
resolution meetings” using specific forms: SWIFFT Conflict CT Form, SWIFFT Conflict 
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Radiograph Form and SWIFFT 52 Week Inter-Observer Conflict forms which were used 
when conflicts were resolved. Predefined agreement rules were used to generate the final data 
based on all three reviewers’ assessments.   
 
All conflicts identified were reviewed by all reviewers at face to face/teleconference 
meetings. All reviewers looked at images together and a collective decision was made and 
recorded. From the 439 baseline radiographs reviewed, 106 were taken back to a conflict 
meeting. Of the 431 CT’s reviewed at baseline, 155 were taken back to a conflict meeting to 
agree displacement thresholds. These baseline conflicts were reviewed over 26 meetings 
between September 2013 and February 2018. At 52 weeks, 297 radiographs were reviewed 
and 292 CT scans. All radiographs and CT scans at 52 weeks which were classified as a 
“non-union” by any one reviewer were brought back to the conflict resolution meeting for 
confirmation. Of both radiographs and CT scans, only 17 were taken back to three conflict 
meetings to agree the state of union.   
 
Finally, the reviewers also agreed the ones that did not have an identifiable fracture on 
baseline radiographs (one) and CT scans (five). There were also a total of 52 conflicts 
identified on the categorical data at baseline. For baseline radiographs, 15 conflicts were 
identified from the categorical classification of the orientation of the fracture line. These were 
reviewed by all reviewers and were resolved. For baseline CT’s, 37 conflicts were identified 
involving the fracture line (27) and fracture location (10). All of these were reviewed at a 
conflict meeting in January 2018 and were all resolved.  
 
Adverse event management 
Adverse events (AEs) were defined as any untoward medical occurrence in a trial participant 
and which did not necessarily have a causal relationship with the treatment. Serious AEs 
(SAEs) were defined as any untoward medical occurrence that: 
 Result in death 
 Are Life-threatening 
 Require hospitalisation or prolongation of existing inpatient hospitalisation 
 Result in persistent or significant disability or incapacity 
 Is a congenital anomaly or birth defect 
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 Any other important medical condition which, although not included in the above, 
may require medical or surgical intervention to prevent one of the outcomes listed. 
 
(S)AEs related to the scaphoid fracture injury and its treatment during the 12 months after 
randomisation were recorded by site PIs on a CRF (see Supplementary Files 17 and 18). 
SAEs were notified to the trial office within 24 hours of the PI becoming aware of it and AEs 
within five days. The categorisation of causality and expectedness was confirmed by the CI. 
AEs that were expected with this injury to the wrist and related to anaesthesia and/or surgery 
were: infection, CRPS, screw related complications, chondrolysis, delayed wound healing, 
nerve or vessel events, fracture of scaphoid tuberosity and nausea and/or disorientation. AEs 
specific to the plaster cast were: soft cast/broken cast that led to movement of the wrist, 
CRPS, pressure sores, nerve compression or pain due to a tight cast. Movement in a cast was 
considered untoward as it could mean the fracture was not properly immobilised and could 
result in failure to unite.      
 
All (S)AEs were routinely reported to the Trial Management Group, Trial Steering 
Committee, Data Monitoring Committee and Sponsor. SAEs that were related to the research 
and unexpected were reported to REC. The CI reviewed all (S)AEs that were unresolved at 
initial reporting a month later. This was to ensure that adequate action had been taken. 
Additional reviews at one-month intervals were conducted until the CI confirmed that no 
further monitoring was required.  
 
The CI was also informed, by the reviewers of the radiographs/CT scans collected for the 
study, of any abnormalities identified. The CI judged whether the abnormality was clinically 
important and could impact on patient safety (e.g. a protruding screw). The need to notify the 
PI of the site, and whether to record this as an AE, was also considered. No actions or 
treatments were discussed with the PI. 
 
Ethical approval and monitoring 
Standard NHS cover for negligent harm was available. There was no cover for non-negligent 
harm. 
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Ethics committee approval and any changes to the project protocol 
The SWIFFT Trial was approved by Derby Research Ethics Committee – East Midlands on 
21 May 2013 (REC reference 13/EM/0154). NHS permission was given by the Research and 
Development department of each participating site. A summary of the changes made to the 
protocol since the original REC approval have been listed (see  
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Appendix 2). The trial protocol was published in BMC Musculoskeletal Disorders.48  
 
Trial management group (TMG) 
The day-to-day management of the trial was overseen by the TMG who met on a quarterly basis. A representative of the Sponsor attended when 
available. These meetings monitored progress with recruitment (e.g. enrolment, consent, eligibility); allocation to study groups; adherence of the 
trial interventions to the protocol; retention of trial participants; monitoring of (S)AEs and reasons for participant withdrawal. The review of 
progress was undertaken at a participating site level and, as necessary, feedback was given to the PI and Research Nurses at each site.  
 
Trial steering committee (TSC) 
A TSC was appointed by the funding body to provide overall supervision for the trial and to advise on its continuation. Membership is listed in 
the Acknowledgement section. 
 
Data monitoring committee (DMC) 
The DMC was appointed by the funding body with access to the unblinded comparative data as provided by a statistician at YTU who was 
independent of the trial team. The DMC monitored the data and recommended to the TSC whether there were any ethical or safety reasons why 
the trial should not continue. Membership is listed in the Acknowledgement section. 
 
Patient and public involvement 
A patient who had a fracture of their left wrist and was treated at the Sponsor site commented on study documentation and was invited to TMG 
meetings. Alternatively, their opinion was sought outside of these meetings. This patient also contributed to a video that was posted on the trial 
website, which was publicised in a newsletter to participants, to encourage completion of postal questionnaires and attendance at hospital visits. 
In Leicester, a group of eight individuals (six of whom had experience of a scaphoid fracture and two who hadn’t but were typical of the patient 
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population i.e. male under 30) met to advise the TMG on strategies to maximise the retention of trial participants and who were also contacted 
by email for advice.90  This meeting was led by the CI, a senior qualitative researcher and the patient representative on the TMG. This group will 
also advise on the summary of the findings for trial participants and other dissemination activities. In one of our newsletters to participants, a 
photograph and positive feedback about their involvement in the trial, was included from the participant who won the prize draw of the iPad at 
the 26 week follow-up. Two members of the Patient Liaison Group of the British Orthopaedic Association were independent members of the 
TSC and advised on strategies to maximise recruitment and retention. 
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Chapter 3 Clinical effectiveness results 
 
Recruitment  
 
Site recruitment 
In our original protocol we estimated that we would need 17 sites to recruit patients into SWIFFT. The number of sites was increased to meet the 
slightly lower than planned recruitment rate.  Forty sites were approached to take part in SWIFFT between May 2013 and March 2015 and, in 
total, 34 sites were set up and opened to recruitment, the last of which commenced screening/recruitment in June 2015.  Thirty three sites 
screened at least one patient, and thirty one recruited at least one participant (median 10, range 1 to 61).  Two of the three sites that did not 
recruit any participants screened one and two patients respectively, one of which was eligible but non-consenting.  The lead site, Leicester Royal 
Infirmary within the University Hospitals of Leicester NHS Trust, recruited the highest number of patients of all sites (n=61). Table 1 presents 
the number of patients recruited by each site, ordered by when each site was set up to recruit (Leicester first), with sites identified at Trust level.  
One hospital from each Trust took part in the SWIFFT trial.  All sites agreed to recruit an average of one patient per month, but only two sites 
achieved this. 
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Table 1: SWIFFT recruitment by hospital site 
Site 
Date 
Opened 
Months 
Open 
Number 
recruited 
Average 
recruits per 
month 
University Hospitals of Leicester NHS 
Trust 
01/07/2013 37 61 1.6 
South Tees Hospitals NHS Foundation Trust 17/08/2013 36 10 0.3 
University Hospitals Coventry & 
Warwickshire NHS Trust 
09/09/2013 35 24 0.7 
Nottingham University Hospitals NHS Trust 25/09/2013 35 27 0.8 
Chelsea and Westminster Hospital NHS 
Foundation Trust 
19/11/2013 11a 0 0.0 
Southport and Ormskirk Hospitals NHS Trust 21/11/2013 13
a 0 0 
Bolton NHS Foundation Trust 02/12/2013 32 17 0.5 
Northumbria Healthcare NHS Foundation 
Trust 
06/02/2014 30 5 0.2 
Oxford University Hospitals NHS Trust 07/02/2014 30 35 1.2 
University Hospital Southampton NHS 
Foundation Trust 
10/02/2014 30 17 0.6 
Royal Berkshire NHS Foundation Trust 10/02/2014 30 9 0.3 
Salford Royal Hospital NHS Foundation Trust 10/02/2014 30 4 0.1 
Brighton and Sussex University Hospitals 
NHS Trust 
26/02/2014 30 5 0.2 
Worcestershire Acute Hospitals NHS Trust 10/03/2014 8a 0 0.0 
Hampshire Hospitals NHS Foundation Trust 17/03/2014 29 6 0.2 
Royal United Hospital Bath NHS Trust 17/03/2014 29 23 0.8 
Poole Hospital NHS Foundation Trust 22/04/2014 28 5 0.2 
Royal Cornwall Hospitals NHS Trust 09/05/2014 27 24 0.9 
Cardiff and Vale University Health Board 12/05/2014 27 22 0.8 
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Maidstone and Tunbridge Wells NHS Trust 21/05/2014 27 5 0.2 
Taunton and Somerset NHS Foundation Trust 01/06/2014 26 7 0.3 
Plymouth Hospitals NHS Trust 09/06/2014 26 20 0.8 
Peterborough and Stamford Hospitals NHS 
Foundation Trust 
12/06/2014 26 17 0.7 
Cambridge University Hospitals NHS 
Foundation Trust 
16/06/2014 26 5 0.2 
The Royal Liverpool and Broadgreen 
University Hospitals NHS Trust 
17/06/2014 26 5 0.2 
Barts Health NHS Trust 20/06/2014 26 24 0.9 
Gloucestershire  Hospitals NHS Foundation 
Trust 
10/07/2014 25 15 0.6 
North Bristol NHS Trust 01/09/2014 23 13 0.6 
University Hospitals Bristol NHS Foundation 
Trust 
06/10/2014 22 10 0.5 
Newcastle upon Tyne Hospitals NHS 
Foundation Trust 
10/11/2014 21 11 0.5 
Medway NHS Foundation Trust 12/11/2014 21 2 0.1 
Lancashire Teaching Hospitals NHS 
Foundation Trust 
24/11/2014 21 1 0.05 
University Hospitals Birmingham NHS 
Foundation Trust  
16/02/2015 18 6 0.3 
King’s College Hospital NHS Foundation 
Trust 
22/06/2015 14 4 0.3 
a withdrew interest in recruiting to SWIFFT trial 
 
Patient recruitment 
Our required sample size was 438 participants, which we aimed to achieve by the end of March 2016; however, recruitment was slightly slower 
than anticipated in the final few months and we agreed with the trial Sponsor, Funder and REC (February 2016) to extend recruitment beyond 
March 2016 until the 438 patients had been recruited.   
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The first participant was randomised on 23rd July 2013.  As of 31st July 2016, 439 patients had been enrolled in the trial and sites were notified 
that recruitment should cease; thus, patients were recruited over 37 months.  Figure 3 and Figure 4 demonstrate our final recruitment figures.  
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Figure 3: Recruitment into the SWIFFT trial by month 
 
 
Figure 4: Recruitment targets of participants into the SWIFFT trial 
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Characteristics of screened patients 
A total of 1047 patients who met the inclusion criteria (aged 16 or above and skeletally mature, presenting within two weeks of injury with a 
radiologically confirmed clear and bicortical fracture of the scaphoid waist that does not include the proximal pole) were assessed for 
participation in the trial from July 2013 to July 2016, of which 775 (74.0%) were eligible, and 439 (41.9%) were eligible and consenting, and 
were randomised.  The number of participants screened per site ranged from one to 133 (median 23), and the percentage of screened participants 
who were eligible per site ranged from 0 to 100% (median 83.3%).  Table 2 displays the characteristics of the different populations.  Eligible 
patients tended to be younger, and were more likely to be male and have a displaced fracture than ineligible patients. There were no marked 
differences between consenting and non-consenting patients in gender, age and time since injury, however there is an indication that consenting 
patients were more likely to have a displaced fracture than non-consenting patients.  The number (% screened) of patients for whom each of the 
following types of radiograph was used to determine eligibility is: elongated scaphoid (n=910, 86.9%); posterior-anterior view (n=1024, 97.8%); 
45° semi-supine (n=610, 58.3%); lateral view (n=1017, 97.1%); and 45° semi-prone (n=834, 79.7%).  Screened patients had a median of four 
scaphoid radiographic views taken. 
 
Table 2: Patient baseline characteristics of different populations 
Characteristic Screened 
(n=1047) 
Ineligible 
(n=272) 
Eligible (n=775) 
Non-consenting 
(n=336) 
Consenting 
(n=439) 
Gender, n (%)     
  Male 834 (79.7) 203 (74.6) 268 (79.8) 363 (82.7) 
  Female 210 (20.1) 66 (24.3) 68 (20.2) 76 (17.3) 
  Missing 3 (0.3) 3 (1.1) 0 (0.0) 0 (0.0) 
Age (years)     
  n 1040 266 335 439 
  Mean (SD) 33.7 (14.8) 36.6 (17.5) 32.5 (14.6) 32.9 (12.7) 
  Median (min, max) 29.2 (16.0, 94.8) 30.0 (16.2, 94.8) 28.2 (16.0, 79.7) 29.3 (16.1, 80.6) 
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Time since injury (days)a     
  n 1044 269 336 439 
  Mean (SD) 1.0 (1.8) 1.2 (2.5) 1.0 (1.5) 0.8 (1.4) 
  Median (min, max) 0 (0, 14) 0 (0, 14) 1 (0, 9) 1 (0, 10) 
Displacement involvementb, n (%) 
    
  Displacement 342 (32.7) 61 (22.4) 111 (33.0)  170 (38.7) 
  No displacement 651 (62.2) 160 (58.8) 222 (66.1) 269 (61.3) 
  Missing 54 (5.2) 51 (18.8) 3 (0.9) 0 (0.0) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to first contact with NHS (presentation at A&E or other); this is consistent with the inclusion criterion for patients to present at a participating site within two weeks 
of injury 
b as recorded on the Study Eligibility Form 
 
Reasons for exclusion 
A total of 272 (26.0%) of the 1047 patients screened were ineligible for the trial for one or more reasons (see Table 3).  Twenty-nine of these 
should strictly never have been screened for participation in the trial since they did not fulfil the inclusion criteria: injury more than two weeks 
old (n=15); did not have a radiologically confirmed bicortical fracture (n=7); fracture included the proximal pole (n=6); and skeletally immature 
(n=1).  A further 156 patients failed at least one of the exclusion criteria, most commonly having a concurrent other injury in the same limb 
(n=70).  The remaining 87 were ineligible for another reason: the site did not think it was feasible for the patient’s surgery (if allocated) to be 
scheduled within two weeks from presentation (n=30); patient not approached about study (e.g. they presented at the weekend when there was 
no clinician available to confirm eligibility) (n=21); patient deemed unsuitable for surgery (n=16); fracture seen on radiography but not on 
subsequent CT scan (n=8); or other miscellaneous/unknown reason (n=12). 
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Table 3: Reasons for patient ineligibility for the SWIFFT trial 
Reason for ineligibility, n (%) 
Number 
ineligible 
(n=272) 
Exclusion criteria (n=156) – reasons not mutually exclusive  
Fracture displaced by greater than 2 mm  43 (15.8) 
Concurrent wrist fracture in the opposite limb 12 (4.4) 
Trans-scaphoid perilunate dislocation 8 (2.9) 
Multiple injuries in the same limb 70 (25.7) 
Patient not resident in trauma centre catchment area of a participating site 21 (7.7) 
Previous injury or disease in the same wrist 2 (0.7) 
Patient lacks mental capacity and is unable to understand the trial and 
instructions for treatment 
11 (4.0) 
Patient is pregnant 6 (2.2) 
Other reasons (n=116)  
Patient did not meet inclusion criteria to be approached about trial: 
Presenting more than 2 weeks after injury 
No radiologically confirmed bicortical fracture 
Fracture includes proximal pole  
Aged <16 years and/or skeletally immature 
29 (10.7) 
N=15 
N=7 
N=6 
N=1 
No fracture seen on CT prior to randomisation 8 (2.9) 
Surgery not feasible within 2 weeks of injury 30 (11.0) 
Patient not suitable for surgery 16 (5.9) 
Study not discussed with patient (e.g. presented at weekend) 21 (7.7) 
Othera 12 (4.4) 
a no reason provided (n=6); patient currently in prison or young offenders institute (n=2); hospital records show 
6 DNAs to visits so patient deemed unreliable (n=1); clinician deemed fracture ‘would fix irrespective of study’ 
(n=1); scapholunate disruption likely (n=1); patient previously approached about SWIFFT for right scaphoid 
fracture but declined as didn't want surgical intervention – patient not reapproached for left scaphoid fracture 
(n=1)
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Patient consent 
The percentage of eligible patients who consented to take part in the trial varied in the 31 sites that recruited a patient from 13.9 to 100% 
(median 63.2%).  A reason was provided for 325 of the 336 (96.7%) patients who did not consent to the study despite being eligible: preference 
for non-operative treatment (n=206); preference for surgery (n=40); unable to commit to follow-ups (n=24); not wanting to take part in research 
and/or being unhappy with the concept of random treatment allocation (n=13); consent not taken in time to allow surgery (if allocated) to be 
conducted within two weeks of presentation at A&E or other clinic (n=13); patient circumstances would not allow for surgery (if allocated) to be 
conducted within two weeks of presentation at A&E or other clinic (e.g. planned holiday or exams) (n=7); and other miscellaneous reasons e.g. 
patient trying to become pregnant, has multiple comorbidities, etc. (n=22).   
 
Treatment preference data were collected for 320 of the 336 eligible but non-consenting patients: 30 (9.4%) had no treatment preference; 57 
(17.8%) had a preference for surgery; and 233 (72.8%) preferred not to have surgery.  A response to the treatment the surgeon advised the 
patient to have was provided for 325 patients: no surgery n=191 (58.8%); surgery n=32 (9.9%); uncertain n=102 (31.4%).  The agreed treatment 
for 328 of these patients was recorded: surgery (n=45, 13.7%); no surgery (n=283, 86.3%).   
 
In total, the median time spent obtaining consent from participants to participate in the trial was 20 minutes.  In general, approximately ten more 
minutes were spent with participants who went on to be randomised than those who did not (mean (SD) 31.6 (18.9) vs 19.5 (12.7), median 30 vs 
20 minutes). 
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Participant flow 
The flow of patients through the trial is summarised in a CONSORT flow diagram in Figure 5.  Of the 439 randomised participants, 408 (92.9%) 
were eligible for inclusion in the primary analysis model (203/219, 92.7% in the surgery arm, and 205/220, 93.2% in the non-surgery arm). The 
trial was designed to allow for 20% attrition.   
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Figure 5: SWIFFT CONSORT flow diagram 
 
Baseline characteristics of randomised participants 
The 439 participants were randomised using equal allocation to surgery (n=219) or plaster cast management (n=220) of their fractures.  The 
allocation of participants was stratified by fracture displacement at enrolment (<1mm, 1 to 2 mm inclusive). On 24 occasions, the incorrect 
displacement stratum was used in the randomisation: 16 participants with no fracture displacement were randomised within the displacement 
stratum, and eight with displacement were randomised within the no displacement stratum (see Methods, Primary outcome (Patient Rated Wrist 
Evaluation) analysis).  A baseline questionnaire was not received from two participants (both allocated to the surgery group).  The recruited 
participants were predominantly male (82.7%), and the average age was 32 years (range 16 to 80).  Just over half the participants (53.6%) had 
injured their left wrist, and their non-dominant side (56.8%).  Nearly half the participants stated that they did not have a treatment preference at 
enrolment to the trial (47.6%), but of the other 230 most (84.3%) expressed a preference for surgery.  This trend is substantially different to that 
observed in the population of eligible but non-consenting participant who predominantly stated a preference to not receive surgery.  The 
treatment groups as randomised and as analysed appear to be balanced on all measured baseline participant characteristics and fracture details 
(see Table 4 and Table 5) with the exception of ethnicity, education and smoking status. Participants in the plaster cast group were more likely to 
have a degree or higher qualification and less likely to be a smoker and to be white, both as randomised and as analysed.  No formal statistical 
comparisons were conducted and so we cannot see if these differences are statistically significant, but these differences are consistent with a 
chance imbalance.  The trial team considered these imbalances post-hoc and it was decided to include a sensitivity analysis adjusting the primary 
analysis model additionally for smoking status as this is likely to be associated with outcome.  It was not felt that ethnicity and education status 
were likely to be associated with outcome so no sensitivity analyses were conducted with these factors. 
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Table 4: Baseline characteristics of trial participants as randomised and as included in the primary analysis model 
Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Gender, n (%)       
Male 180 (82.2) 183 (83.2) 363 (82.7) 168 (82.8) 169 (82.4) 337 (82.6) 
Female 39 (17.8) 37 (16.8) 76 (17.3) 35 (17.2) 36 (17.6) 71 (17.4) 
Age (years)       
N 219 220 439 203 205 408 
Mean (SD) 32.9 (13.2) 32.9 (12.2) 32.9 (12.7) 33.2 (13.2) 32.9 (12.4) 33.1 (12.8) 
Median (min, max) 28 (16, 80) 29 (16, 76) 29 (16, 80) 29 (16, 80) 29 (16, 76) 29 (16, 80) 
Ethnicity, n (%)       
White 205 (93.6) 195 (88.6) 400 (91.1) 191 (94.1) 180 (87.8) 371 (90.9) 
Black 0 (0.0) 5 (2.3) 5 (1.1) 0 (0.0) 5 (2.4) 5 (1.2) 
Asian 7 (3.2) 10 (4.5) 17 (3.9) 7 (3.4) 10 (4.9) 17 (4.2) 
Other 5 (2.3) 10 (4.5) 15 (3.4) 5 (2.5) 10 (4.9) 15 (3.7) 
Missing 2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Education, n (%)       
No formal 
qualifications 24 (11.0) 27 (12.3) 51 (11.6) 22 (10.8) 25 (12.2) 47 (11.5) 
Some 
qualifications/no 
degree 151 (68.9) 129 (58.6) 280 (63.8) 139 (68.5) 120 (58.5) 259 (63.5) 
Degree or higher 41 (18.7) 64 (29.1) 105 (23.9) 41 (20.2) 60 (29.3) 101 (24.8) 
Missing 3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2) 
Employment 
status, n (%)       
Part-time 20 (9.1) 18 (8.2) 38 (8.7) 20 (9.9) 18 (8.8) 38 (9.3) 
Full-time 127 (58.0) 120 (54.5) 247 (56.3) 119 (58.6) 111 (54.1) 230 (56.4) 
Self-employed 21 (9.6) 36 (16.4) 57 (13.0) 19 (9.4) 31 (15.1) 50 (12.3) 
Student 20 (9.1) 21 (9.5) 41 (9.3) 19 (9.4) 21 (10.2) 40 (9.8) 
Retired 7 (3.2) 5 (2.3) 12 (2.7) 7 (3.4) 5 (2.4) 12 (2.9) 
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Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Looking after 
family/home 1 (0.5) 6 (2.7) 7 (1.6) 0 (0.0) 5 (2.4) 5 (1.2) 
Not employed but 
seeking work 9 (4.1) 5 (2.3) 14 (3.2) 8 (3.9) 5 (2.4) 13 (3.2) 
Other 11 (5.0) 9 (4.1) 20 (4.6) 10 (4.9) 9 (4.4) 19 (4.7) 
Missing 3 (1.4) 0 (0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2) 
Type of 
employment, n 
(%)       
Unskilled manual 25 (11.4) 23 (10.5) 48 (10.9) 24 (11.8) 20 (9.8) 44 (10.8) 
Skilled manual 63 (28.8) 60 (27.3) 123 (28.0) 56 (27.6) 56 (27.3) 112 (27.5) 
Unskilled non-
manual 19 (8.7) 12 (5.5) 31 (7.1) 19 (9.4) 11 (5.4) 30 (7.4) 
Skilled non-manual 33 (15.1) 46 (20.9) 79 (18) 32 (15.8) 44 (21.5) 76 (18.6) 
Professional 20 (9.1) 19 (8.6) 39 (8.9) 20 (9.9) 17 (8.3) 37 (9.1) 
Other 19 (8.7) 30 (13.6) 49 (11.2) 18 (8.9) 28 (13.7) 46 (11.3) 
Missing 40 (18.3) 30 (13.6) 70 (15.9) 34 (16.7) 29 (14.1) 63 (15.4) 
Current smoker, n 
(%)       
Yes 73 (33.3) 56 (25.5) 129 (29.4) 64 (31.5) 50 (24.4) 114 (27.9) 
No 143 (65.3) 163 (74.1) 306 (69.7) 138 (68.0) 154 (75.1) 292 (71.6) 
Missing 3 (1.4) 1 (0.5) 4 (0.9) 1 (0.5) 1 (0.5) 2 (0.5) 
If Yes:       
How many 
cigarettes       
Median (min, max) 10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 40) 10 (1, 30) 10 (1, 40) 
For how many 
years       
Median (min, max) 10 (1, 50) 10 (1, 36) 10 (1, 50) 10 (1, 50) 10 (1, 36) 10 (1, 50) 
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Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Past smoker, n 
(%)       
Yes 116 (53.0) 109 (49.5) 225 (51.3) 110 (54.2) 99 (48.3) 209 (51.2) 
No 85 (38.8) 101 (45.9) 186 (42.4) 81 (39.9) 96 (46.8) 177 (43.4) 
Missing  18 (8.2) 10 (4.5) 28 (6.4) 12 (5.9) 10 (4.9) 22 (5.4) 
Diabetes, n (%)       
Yes 7 (3.2) 4 (1.8) 11 (2.5) 6 (3.0) 4 (2.0) 10 (2.5) 
No 209 (95.4) 216 (98.2) 425 (96.8) 196 (96.6) 201 (98.0) 397 (97.3) 
Missing 3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2) 
Steroid use, n (%)       
Yes 6 (2.7) 4 (1.8) 10 (2.3) 6 (3.0) 4 (2.0) 10 (2.5) 
No 210 (95.9) 216 (98.2) 426 (97.0) 196 (96.6) 201 (98.0) 397 (97.3) 
Missing  3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 5: Baseline fracture details of trial participants as randomised and as included in the primary analysis model 
Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Time since injury 
(days)a       
N 219 220 439 203 205 408 
Mean (SD) 5.1 (3.1) 5.3 (3.3) 5.2 (3.2) 4.9 (3.0) 5.4 (3.3) 5.2 (3.2) 
Median (min, max) 5 (1, 14) 5 (0, 14) 5 (0, 14) 4 (1, 14) 5 (0, 14) 5 (0, 14) 
Affected wrist, n 
(%)       
Left 115 (52.5) 118 (53.6) 233 (53.1) 110 (54.2) 110 (53.7) 220 (53.9) 
Right 104 (47.5) 102 (46.4) 206 (46.9) 93 (45.8) 95 (46.3) 188 (46.1) 
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Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Hand dominance, 
n (%)       
Yes 100 (45.7) 95 (43.2) 195 (44.4) 92 (45.3) 89 (43.4) 181 (44.4) 
No  117 (53.4) 125 (56.8) 242 (55.1) 111 (54.7) 116 (56.6) 227 (55.6) 
Missing 2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Displacement 
(eligibility), n (%)       
No displacement 135 (61.6) 134 (60.9) 269 (61.3) 123 (60.6) 123 (60) 246 (60.3) 
Displacement 84 (38.4) 86 (39.1) 170 (38.7) 80 (39.4) 82 (40) 162 (39.7) 
Displacement 
(randomisation), n 
(%)       
No displacement 131 (59.8) 130 (59.1) 261 (59.5) 119 (58.6) 119 (58) 238 (58.3) 
Displacement 88 (40.2) 90 (40.9) 178 (40.5) 84 (41.4) 86 (42) 170 (41.7) 
Radiographsb, n 
(%)       
Elongated scaphoid 
view 209 (95.4) 210 (95.5) 419 (95.4) 193 (95.1) 195 (95.1) 388 (95.1) 
Posterior-anterior 
view 215 (98.2) 218 (99.1) 433 (98.6) 200 (98.5) 203 (99.0) 403 (98.8) 
Semi 45° supine 159 (72.6) 166 (75.5) 325 (74.0) 144 (70.9) 156 (76.1) 300 (73.5) 
Lateral 
218 (99.5) 217 (98.6) 435 (99.1) 
203 
(100.0) 202 (98.5) 405 (99.3) 
Semi 45° prone 198 (90.4) 196 (89.1) 394 (89.7) 184 (90.6) 183 (89.3) 367 (90.0) 
Previous wrist 
problems on same 
side, n (%)       
Yes 43 (19.6) 45 (20.5) 88 (20.0) 43 (21.2) 42 (20.5) 85 (20.8) 
No 173 (79.0) 173 (78.6) 346 (78.8) 159 (78.3) 161 (78.5) 320 (78.4) 
Missing 3 (1.4) 2 (0.9) 5 (1.1) 1 (0.5) 2 (1.0) 3 (0.7) 
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Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
If Yes, what 
injury, n (%)       
Previous fracture 23 (53.5) 28 (62.2) 51 (58.0) 23 (53.5) 25 (59.5) 48 (56.5) 
Arthritis 2 (4.7) 1 (2.2) 3 (3.4) 2 (4.7) 1 (2.4) 3 (3.5) 
Ligament, tendon or 
nerve injury 10 (23.3) 8 (17.8) 18 (20.5) 10 (23.3) 8 (19.1) 18 (21.2) 
Other 6 (14.0) 8 (17.8) 14 (15.9) 6 (14.0) 8 (19.1) 14 (16.5) 
Missing 2 (4.7) 0 (0.0) 2 (2.3) 2 (4.7) 0 (0.0) 2 (2.4) 
Injury mechanism, 
n (%)       
Fall – standing 28 (12.8) 29 (13.2) 57 (13.0) 26 (12.8) 26 (12.7) 52 (12.7) 
Fall – walking 24 (11.0) 24 (10.9) 48 (10.9) 22 (10.8) 23 (11.2) 45 (11.0) 
Fall – running 40 (18.3) 38 (17.3) 78 (17.8) 37 (18.2) 33 (16.1) 70 (17.2) 
Fall – from height   28 (12.8) 34 (15.5) 62 (14.1) 26 (12.8) 31 (15.1) 57 (14.0) 
Fall – from moving 
object 42 (19.2) 31 (14.1) 73 (16.6) 41 (20.2) 31 (15.1) 72 (17.6) 
Hit on palm of hand 
– object striking 
palm 16 (7.3) 15 (6.8) 31 (7.1) 15 (7.4) 15 (7.3) 30 (7.4) 
Hit on palm of hand 
– handle whipping 
back 9 (4.1) 11 (5.0) 20 (4.6) 8 (3.9) 11 (5.4) 19 (4.7) 
Hit on palm of hand 
– other sudden 
extension 11 (5.0) 8 (3.6) 19 (4.3) 11 (5.4) 8 (3.9) 19 (4.7) 
Punched something 4 (1.8) 12 (5.5) 16 (3.6) 4 (2.0) 10 (4.9) 14 (3.4) 
Road traffic 
accident 9 (4.1) 8 (3.6) 17 (3.9) 9 (4.4) 7 (3.4) 16 (3.9) 
Other 6 (2.7) 10 (4.5) 16 (3.6) 4 (2.0) 10 (4.9) 14 (3.4) 
Missing  2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 
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Characteristic 
As randomised As analysed 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
(n=439) 
Surgery 
(n=203) 
Plaster 
cast 
(n=205) 
Total 
(n=408) 
Place of injuryb, n 
(%)       
Sport 88 (40.2) 78 (35.5) 166 (37.8) 85 (41.9) 72 (35.1) 157 (38.5) 
Home 27 (12.3) 43 (19.5) 70 (15.9) 24 (11.8) 38 (18.5) 62 (15.2) 
Work 22 (10) 18 (8.2) 40 (9.1) 19 (9.4) 17 (8.3) 36 (8.8) 
Road Traffic 
Accident 26 (11.9) 34 (15.5) 60 (13.7) 25 (12.3) 33 (16.1) 58 (14.2) 
Public place 49 (22.4) 48 (21.8) 97 (22.1) 46 (22.7) 46 (22.4) 92 (22.5) 
Other  3 (1.4) 0 (0) 3 (0.7) 3 (1.5) 0 (0.0) 3 (0.7) 
Missing  4 (1.8) 2 (0.9) 6 (1.4) 3 (1.5) 2 (1.0) 5 (1.2) 
Treatment 
preference, n (%)       
Surgery 93 (42.5) 101 (45.9) 194 (44.2) 89 (43.8) 96 (46.8) 185 (45.3) 
No surgery 13 (5.9) 19 (8.6) 32 (7.3) 11 (5.4) 16 (7.8) 27 (6.6) 
No preference 110 (50.2) 99 (45.0) 209 (47.6) 102 (50.2) 92 (44.9) 194 (47.5) 
Missing 3 (1.4) 1 (0.5) 4 (0.9) 1 (0.5) 1 (0.5) 2 (0.5) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
 
Follow-up 
 
Participant questionnaires 
In total, follow-up participant questionnaires were returned for 359 (81.8%), 349 (79.5%), 313 (71.3%) and 364 (82.9%) of the 439 randomised 
participants at six, 12, 26 and 52 weeks, respectively (see Table 6).  Return rates were lower in the plaster cast group at all time-points, except at 
six weeks when they were similar between the two groups. 
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The participant questionnaires were primarily returned by post (50% or over at each time point).  At six, 12 and 52 weeks, when participants 
were invited to attend for a hospital visit, there was the opportunity to complete the questionnaire in clinic.  This occurred in 46.0%, 41.6% and 
34.3% of cases at week six, 12 and 52, respectively.  Questionnaire data was completed by telephone as a last resort for hard to reach 
participants in 84 instances.  
 
The number of days from the date the questionnaire was due (e.g., for the six week questionnaire this was 42 days after randomisation) to the 
completion of the questionnaire as recorded by the patient (‘Days to complete’) and the return of the questionnaire to the YTU (‘Days to return’) 
is presented in Table 6. These were replaced with a 0 if the questionnaire was completed/returned before the due date (i.e., if completed during a 
clinic visit rather than having been posted out by the YTU on the due date).  Median and interquartile range are presented as the data had a right-
skewed distribution since most patients completed and returned their forms promptly. There was no obvious difference between the two groups 
in the time to completion or the time to return. 
 
Table 6: Follow-up participant questionnaires return rates 
Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
 (n=439) 
6 weeks, n (%)    
  Senta 214 (97.7) 217 (98.6) 431 (98.2) 
  Returnedb 178 (83.2) 181 (83.4) 359 (83.3) 
  Days to complete, median (IQR) 5 (1, 11) 2 (0, 9) 4 (0, 11) 
  Days to return, median (IQR) 13 (8, 24) 12 (5, 24) 13 (6, 24) 
  Completed within 1 weekc;d 119 (66.9) 118 (65.2) 237 (66.0) 
  Mode of completiond    
   Post 99 (55.6) 93 (51.4) 192 (53.5) 
   In clinic 78 (43.8) 87 (48.1) 165 (46.0) 
   Telephone 1 (0.6) 1 (0.6) 2 (0.6) 
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Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
 (n=439) 
12 weeks, n (%)    
  Senta 212 (96.8) 217 (98.6) 429 (97.7) 
  Returnedb 182 (85.9) 167 (77.0) 349 (81.4) 
  Days to complete, median (IQR) 7 (2, 21) 5 (0, 19) 6 (0, 20) 
  Days to return, median (IQR) 15 (8, 31) 13 (7, 35) 14 (7, 33) 
  Completed within 2 weeksc;d 122 (67.0) 110 (65.9) 232 (66.5) 
  Mode of completiond    
   Post 97 (53.3) 77 (46.1) 174 (49.9) 
   In clinic 70 (38.5) 75 (44.9) 145 (41.6) 
   Telephone 15 (8.2) 15 (9.0) 30 (8.6) 
26 weeks, n (%)    
  Senta 212 (96.8) 216 (98.2) 428 (97.5) 
  Returnedb 163 (76.9) 149 (69.0) 313 (72.9) 
  Days to complete, median (IQR) 10 (5, 27) 10 (4, 30) 10 (5, 28) 
  Days to return, median (IQR) 20 (10, 38) 19 (10, 37) 20 (10, 37) 
  Completed within 6 weeksc;d 136 (83.4) 131 (87.9) 267 (85.6) 
  Mode of completiond    
   Post 165 (92.7) 165 (91.2) 330 (91.9) 
   Telephone 13 (7.3) 16 (8.8) 29 (8.1) 
52 weeks, n (%)    
  Senta 212 (96.8) 213 (96.8) 425 (96.8) 
  Returnedb 186 (87.7) 178 (83.6) 364 (85.7) 
  Days to complete, median (IQR) 5 (0, 16) 7 (2, 26) 6 (2, 22) 
  Days to return, median (IQR) 12 (7, 33) 17 (8, 36) 14 (7, 35) 
  Completed within 8 weeksc;d 170 (91.4) 157 (88.2) 327 (89.8) 
  Mode of completiond    
   Post 103 (57.9) 110 (60.8) 213 (59.3) 
   In clinic 67 (37.6) 56 (30.9) 123 (34.3) 
   Telephone 8 (4.5) 15 (8.3) 23 (6.4) 
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IQR, interquartile range 
a percentage of randomised participants; b percentage of sent; c of questionnaire due date; d percentage of returned 
 
Hospital data collection forms 
The return of hospital forms is summarised in Table 7. Treatment confirmation forms were collected at six and 12 weeks post-randomisation; at 
least one treatment confirmation form was completed for all but one participant (who was allocated to surgery but withdrew on the day of 
randomisation). A complications form was completed for over 84% of the randomised participants at each of the six, 12 and 52 week time 
points. Wrist range of movement and grip strength forms were received for 389 (88.6%), 336 (76.5%) and 309 (70.4%) participants at six, 12 
and 52 weeks, respectively.  At 52 weeks, there appears to be a difference in the percentage of grip and range forms returned between the two 
groups (Surgery 74.4%; Plaster cast 66.4%), otherwise there are no obvious differences between the two groups in the return rates of hospital 
forms. The return of treatment confirmation and complications forms is higher than for the grip and range forms as completion of these forms 
did not require the participant to attend the hospital visit.   
 
Table 7: Follow-up hospital form return rates 
Hospital form 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
 (n=439) 
Wrist range of movement and grip 
strength form, n (%) 
   
  6 weeks 189 (86.3) 200 (90.9) 389 (88.6) 
  12 weeks 172 (78.5) 164 (74.6) 336 (76.5) 
  52 weeks 163 (74.4) 146 (66.4) 309 (70.4) 
Treatment confirmation form, n (%)    
  6 weeks  200 (91.3) 211 (95.9) 411 (93.6) 
  12 weeks 202 (92.2) 195 (88.6) 397 (90.4) 
  At least one  219 (99.5) 220 (100.0) 438 (99.8) 
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Complications form, n (%)    
  6 weeks 197 (90.0) 206 (93.6) 403 (91.8) 
  12 weeks 181 (82.7) 189 (85.9) 370 (84.3) 
  52 weeks 199 (90.9) 196 (89.1) 395 (90.0) 
 
Patient withdrawals 
Five participants (surgery n=2; plaster cast n=3) withdrew from hospital follow-up but agreed to continue completing participant questionnaires; 
three of these were before the six week visit (no hospital visits attended), and two were following the six week visit (12 and 26 week visits not 
attended).  The reasons provided were: work commitments (surgery n=1; plaster cast n=1); participant moved away from trial catchment area 
(surgery n=1); participant too ill to commit to extra hospital visits (plaster cast n=1); and participant sought further opinion at alternative 
hospital, surgical fixation and follow-ups completed there instead of at recruiting site (plaster cast n=1).   
 
A further 14 participants were withdrawn completely from the trial; eight before the 6 week time point (surgery n=5; plaster cast n=3); two 
between the six and 12 week time points (surgery n=2); one between 12 and 26 weeks (plaster cast n=1); and three between 26 and 52 weeks 
(plaster cast n=3).  Reasons for these withdrawals were: participant no longer wants to take part in study e.g. too busy, sick of questionnaires 
(surgery n= 2; plaster cast n=3); no fracture present on CT scan (surgery n=4; plaster cast n=1); participant unhappy with treatment allocation 
(surgery n=1; plaster cast n=2); and participant emigrating (plaster cast n=1). 
 
Hospital visits 
Baseline participant and fracture data are summarised according to whether patients attended hospital visits at six, 12 and 52 weeks (see 
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Appendix 3, Table 45 to Table 50).  Non-smokers and participants in employment were more likely to attend than smokers, and those not in 
employment, respectively at all time-points.  Participants with fracture displacement at baseline were more likely to attend their six and 52 week 
hospital visits, but were equally likely to attend at 12 weeks.   
 
Compliance with random allocation and treatment received 
For all but four of the randomised participants, their affected wrist was recorded as being immobilised at enrolment, largely by a plaster cast 
(n=328, 74.7%), but alternatively by a splint (n=80, 18.2%), or a backslab (n=27, 6.2%).  From the treatment confirmation and surgery forms, 
we were able to ascertain further treatment received for each participant within the 12 months following randomisation. 
 
Allocated to receive surgery 
Of the 219 patients allocated to surgery, 188 (85.8%) received treatment as allocated (see Table 8). Surgery took place, on average, 10.2 days 
(median 11, range 3 to 20) after injury, 9.5 days (median 10, range 1 to 20) after presenting at A&E or other clinic, and 4.5 days (median 5, 
range 0 to 15) after randomisation.  Of the 188 participants who underwent surgery, 39 (20.7%) received routine treatment i.e., surgery and no 
subsequent plaster cast or splint; 141 (75%) had further routine treatment with plaster cast or splint only following surgery (not recorded as being 
due to a treatment failure); and 8 (4.3%) had at least one other surgery within the 12 months (seven had one other surgery, and one had two).   
 
The reasons for repeat surgeries (for the seven patients with only one extra surgery within 12 months of randomisation) were: removal of screw 
due i) to protrusion (n=3), ii) experiencing pain and poor flexion of wrist (n=1), or iii) scaphoid screw breaching cortex of scaphoid at the 
capitate articulation due to mis-position of the screw (n=1); revision surgery due to pain/prominent metal work (n=1); or for persistent non-union 
(n=1).  For the participant who underwent two further surgeries, the first was to remove the screw and perform iliac bone graft/k-wire 
stabilisation due to non-union of scaphoid fracture; the second was for persistent non-union.   
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The remaining 31 (14.2%) participants allocated to receive surgery were treated non-surgically1 for the following reasons: no fracture observed 
on CT scan subsequent to randomisation (n=10); participant choice not to have surgery (n=9); not a bicortical scaphoid waist fracture (n=8; 
described as: waist plus distal pole fracture (n=2), radial styloid fracture (n=1), unicortical fracture (n=1), lunate fracture (n=1), Y-shaped waist 
fracture involving the tubercle (n=1), associated scaphoid tubercle fracture (n=1), incomplete fracture (n=1)); and other (n=4; surgeon felt 
surgery inappropriate/unnecessary following review of CT scan but no further information available (n=2), no appropriate time for surgery 
available for surgeon or patient (n=1), patient admitted to hospital with pericarditis (n=1)).  Of these, 30 received plaster cast and/or splint 
following randomisation; while one did not receive any treatment due to the fact that the treating clinician deemed that their subsequent CT scan 
indicated no injury (see Table 8). 
 
Following randomisation, 41 participants did not have any plaster cast/splint wear reported, and 65 were only reported to wear a splint (for a 
median of 40 days post-randomisation, range 4 to 97 – though upper range curtailed as final date of splint wear often not recorded/known and 
may be longer than 12 week reporting period of treatment confirmation forms).  Of the remaining 113: 29 had a cast (with thumb incorporated) 
on for a median of 21 days (range 2 to 60) following randomisation, of which 2 then had a cast (with thumb free) applied for a median of 37 
days; and 84 had a cast (with thumb free) on for a median of 18 days following randomisation (range 1 to 63), of which 2 then had a cast with 
thumb incorporated on for a median of 9 days.  Overall, 103/219 (47.0%) participants allocated to the surgery group were still in a plaster cast or 
splint at 6 weeks post-randomisation, and 13 (5.9%) at 12 weeks. 
 
Table 8: Treatment received - surgery group (n=219) 
Treatment 
pathway 
Definition of pathway N (%) Further details 
                                                 
1 The participant with no treatment confirmation form was allocated to the surgery group but withdrew on the day of randomisation and provided no follow-up data.  
However, the reason provided for withdrawal included that the participant wanted conservative treatment; therefore, this patient is assumed not to have received surgery.   
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Crossover Immediate switch to plaster 
cast following consent and 
randomisation, no surgery 
31 (14.2)  Thirty participants received 
plaster cast (n=16), splint 
(n=3), or combination both 
(n=11), for a median of 52 
days (range 9-84) post-
randomisation. 
 One participant did not 
receive any treatment since 
no fracture was observed on 
CT.  
Routine 
treatment 
Participant had one surgery 
within the 12 months from 
randomisation and no 
subsequent plaster cast and/or 
splint  
24 (11.0)  Surgery took place a median 
of 4 days (range 0-9) post-
randomisation, no 
subsequent treatment 
recorded except bandaging. 
Treatment 
failure 
Participant had surgery and 
subsequent plaster cast and/or 
splint due to treatment failure 
e.g. poor stability from surgery 
0 (0.0) - 
Further 
routine 
treatment 
Participant had surgery and 
subsequent plaster cast and/or 
splint following routine 
practice 
156 
(71.2) 
 Surgery took place a median 
of 4 days (range 0-15) post-
randomisation. 
 All received plaster cast 
(n=23), splint (n=40) or a 
combination of both (n=93) 
for a median of 37 days 
(range 2-89) following 
surgery. 
Participant had index surgery 
but subsequent evidence of 
non-union, so offered further 
surgery 
2 (0.9)  One participant received two 
surgeries within 12 months 
from randomisation (259 
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days after initial surgery); 
plaster cast worn for 17 days 
after surgery, followed by a 
splint. 
 One participant underwent 
three surgeries within 12 
months from randomisation; 
the second taking place 176 
days after the index surgery, 
and the third 125 days after 
the second surgery. 
Participant had index surgery 
and received further surgery 
(not for non-union) 
6 (2.7)  Revision surgery (n=1), or 
for removal of screw (n=5)  
 All received a splint (n=2) or 
a combination of plaster cast 
and splint (n=4) for a median 
of 44 days (range 22-105) 
following their index 
surgery. 
 All underwent only one 
further surgery within 12 
months from randomisation; 
this took place a median of 
235 days (range 97-347) 
after the index surgery. 
 
Allocated to receive plaster cast intervention 
Of the 220 patients allocated to not receive immediate surgical fixation, the majority (n=195, 88.6%) were treated conservatively and did not 
receive surgery (see Table 9); though two of these were considered for surgical fixation due to non-union.  Six (2.7%) participants immediately 
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crossed over to surgery following randomisation with no cast applied before this, for the following reasons: participant choice (n=4); CT showed 
displacement (n=1); and radiographs reviewed again at later date and displacement judged to be >2 mm (n=1).  For these six participants, 
surgery took place, on average, 13.5 days (median 12, range 5 to 32) after injury, 12.8 days (median 11.5, range 5 to 31) after presenting at A&E 
or other clinic, and 8.8 days (median 8.5; range 0 to 24) after randomisation.  None of these six participants underwent further surgery within 12 
months from randomisation.   
 
One (0.5%) participant had a plaster cast applied but received surgery 29 days after randomisation due to treatment failure as their fracture was 
displacing with plaster cast.  This participant received a revision surgery, to remove the screw, three months following initial fixation.   
 
One (0.5%) participant received surgery within 6 months of randomisation at a non-participating hospital to fix what the treating surgeon 
deemed to be a historic fracture.  This was noted by the participant on a participant questionnaire.  Limited other information is available for this 
participant as they withdrew from hospital follow-up at their recruiting site. 
 
The remaining 17 (7.7%) participants received surgery as part of their expected treatment pathway when the treating surgeon judged that the 
bone had failed to unite with conservative treatment.  Sixteen of these received only one surgery in the 12 months following randomisation, and 
one received three surgeries (second one for persistent non-union and third to remove the wires from the second operation).  The initial surgery 
took place, on average, 159.0 days (median 161, range 68 to 358) after injury, 157.0 days (median 156, range 67 to 358) after presenting at A&E 
or other clinic, and 151.6 days (median 153; range 61 to 350) after randomisation.  Fourteen participants met the protocol definition of the 
control condition by receiving early surgical fixation of their fractures following detection of persistent non-union after plaster cast management 
(defined here as surgery within 6 months of randomisation), while three had delayed surgical fixation, one of which opted to attend a private 
hospital for their fixation as told there would be a 4-5 month wait for surgery at treating centre.  
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There were two participants who were deemed to have a suspected non-union at 12 weeks and for whom surgical fixation was recommended, 
but who did not receive surgery.  These participants did not fully comply with the anticipated control condition for the trial.  The limited 
information we have about these participants is that for one, the operation was scheduled but then delayed, and the participant self-discharged 
after wait and declined all further treatment including offers of surgery.  For the second, it was the surgeon’s decision not to operate. 
 
Following randomisation, two participants did not have any plaster cast/splint wear reported, and two were only reported to wear a splint (for a 
median of 44 days post-randomisation).  Of the remaining 216: 45 had a cast (with thumb incorporated) on for a median of 42 days (range 7 to 
84) following randomisation, of which 8 then had a cast (with thumb free) applied for a median of 25 days (range 14 to 42); and 171 had a cast 
(with thumb free) on for a median of 42 days (range 7 to 98) following randomisation, of which 5 then had a cast (with thumb incorporated) on 
for a median of 44 days (range 12 to 69).  Overall, 187/220 (85.0%) participants allocated to the plaster cast group were still in a plaster cast or 
splint at 6 weeks post-randomisation, and 47 (21.4%) at 12 weeks. 
 
Table 9: Treatment received – plaster cast group (n=220) 
Treatment 
pathway 
Definition of pathway N (%) Further details 
Crossover Immediate switch to surgery 
following randomisation 
6 (2.7)  Surgery took place a 
median of 9 days (range 0-
24) post-randomisation. 
 Participants received 
plaster cast (n=3), splint 
(n=1) or a combination of 
both (n=2) for a median of 
41 days (range 35-74) 
following surgery. 
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Routine 
treatment 
Participant treated 
conservatively – no surgery 
193 
(87.7) 
 192 participants received a 
plaster cast (n=109) or a 
combination of plaster cast 
and splint (n=83) for a 
median of 43 days (range 
7-101) post-randomisation. 
 One participant was 
followed up at a different 
hospital so treatment 
unknown, but was 
immobilised in plaster cast 
at enrolment to trial. 
Treatment 
failure 
Surgery undertaken to 
stabilise the fracture (before 
five weeks from 
randomisation). This is not a 
cross-over because the patient 
did have a plaster cast 
applied. 
1 (0.5)  Plaster cast worn following 
randomisation but fracture 
seen to be displacing so 
surgical fixation 
undertaken 29 days post-
randomisation; splint worn 
thereafter (unknown length 
of time). 
 Surgery undertaken to 
remove screw 96 days after 
initial fixation. 
Further routine 
treatment – 
surgery (after 
five weeks post-
randomisation) 
Surgery undertaken beyond 
five weeks from 
randomisation – not due to 
failure to unite 
1 (0.5)  One received surgery 
within 6 months of 
randomisation at a non-
participating hospital to fix 
historic fracture. 
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Further routine 
treatment – 
surgery 
recommended 
(after five weeks 
post-
randomisation) 
as per specified 
treatment 
pathway because 
of failure to 
unite. 
Surgery not received 2 (0.9)  Operation scheduled but 
then delayed, participant 
self-discharged after wait 
and declined all further 
treatment/offers of surgery. 
 Non-union suspected at 12 
weeks but surgeon’s 
decision not to operate. 
One surgery performed within 
12 months of randomisation 
16 (7.3)  13 received urgent fixation 
of non-union (within 6 
months of randomisation).   
 Three received late 
fixation, between 6 and 12 
months after 
randomisation.  Reasons 
for two of these unknown; 
one participant opted to 
attend a private hospital for 
their fixation as was told 
there would be a 4-5 month 
wait for surgery at treating 
centre. 
Two or more surgeries 
performed within 12 months 
of randomisation 
1 (0.5)  Patient received initial 
surgical fixation within 3 
months of randomisation, 
further surgery 6 months 
later for persistent non-
union and surgery to 
remove the wires from the 
second operation a month 
later.   
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Surgical fixation details 
A surgery form was received for 210 of the 213 participants in the trial who received surgical fixation of their fracture: surgery group 
n=187/188, (99.5%); and plaster cast group n=23/25 (92.0%).  Surgery was performed by 102 surgeons across 30 sites.  Each surgeon performed 
between 1 and 6 surgeries (median 1).  Details of the operation, for initial surgical fixation procedures only, are provided in Table 10.  Surgery 
lasted a median of 55 minutes (range 15 to 140) with a mean (SD) of 2 (0.9) surgeons in attendance.  Most commonly, the main operating 
surgeon was a consultant (n=139, 66.2%), followed by a specialist trainee (n=49, 23.3%) and a staff grade/associate specialist (n=22, 10.5%).  
Where the main operating surgeon was a specialist trainee, an assisting consultant was recorded as being present in 33 (of 49, 67.4%) of the 
surgeries.  Acutrak screws were the most frequently used type, and a second screw was used for 2 (1.0%) participants.  There were no reported 
intraoperative complications, and most participants (n=113, 53.8%) were treated with a plaster cast post-operatively. 
 
Table 10: Details of initial surgical fixation 
Surgery details Surgery 
(n=210) 
Lead surgeon grade, n (%)  
Consultant 139 (66.2) 
Staff grade/associate specialist 22 (10.5) 
Specialist trainee 49 (23.3) 
Total number of surgeons present in theatre  
N 210 
Mean (SD) 2.0 (0.9) 
Median (min, max) 2 (1, 9) 
Duration of surgery (mins)  
N 197 
Mean (SD) 59.0 (23.6) 
Median (min, max) 55 (15, 140) 
 
 
345 
 
Surgery type, n (%)  
Percutaneous 164 (78.1) 
Open 43 (20.5) 
Both 1 (0.5) 
Missing 2 (1.0) 
Incision, n (%)  
Palmar 171 (81.4) 
Dorsal 33 (15.7) 
Both 2 (1.0) 
Missing 4 (1.9) 
Type of screw used, n (%)  
Acutrak 152 (72.4) 
Medartis 33 (15.7) 
Twinfix 10 (4.8) 
Headless compression screw 10 (4.8) 
Herbert™ 1 (0.5) 
Missing 4 (1.9) 
Second screw, n (%)  
Yes 2 (1.0) 
No 202 (96.2) 
Missing 6 (2.9) 
K-wire used, n (%)  
Yes 39 (18.6) 
No 168 (80.0) 
Missing 3 (1.4) 
Placement of screw:  
   Central position, n (%)  
   Yes 148 (70.5) 
   No 55 (26.2) 
   Missing 7 (3.3) 
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   Position less than perfect but acceptable, n (%)  
   Yes 74 (35.2) 
   No 131 (62.4) 
   Missing 5 (2.4) 
   Uncertain bone hold, n (%)  
   Yes 2 (1.0) 
   No 201 (95.7) 
   Missing 7 (3.3) 
Intraoperative complications, n (%)  
Fracture around screw 0 (0.0) 
Nerve injury 0 (0.0) 
Vascular injury 0 (0.0) 
Tendon injury 0 (0.0) 
Post-operative management, n (%)  
Cast 113 (53.8) 
Bandage 65 (31.0) 
Splint 31 (14.8) 
Missing 1 (0.5) 
Unexpected procedurea, n (%) 2 (1.0) 
a trapezium trimmed 
 
Primary outcome (Patient Rated Wrist Evaluation) analysis 
The PRWE was assessed at baseline (pre and post-injury) and at six, 12, 26 and 52 weeks post-randomisation. The PRWE total score is a value 
between 0 and 100, where a higher score indicates worse pain and functioning.  Pain and function subscale scores are each out of a maximum of 
50 (worst score).  The trial was powered to detect an effect size of 0.3 (assuming a SD of 20); this is equivalent to a difference in total PRWE 
score of six points. 
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Primary end point analysis 
There was no evidence of a difference in PRWE score between the surgery and plaster cast groups at the 52 week time-point, with an adjusted 
mean difference of -2.1 in favour of the surgery group (95% CI -5.8 to 1.6, p=0.27). 
 
This result was extracted from a multilevel model in which participant was treated as a random effect and observations over time (six, 12, 26 and 
52 weeks) were nested within participant. The effect of randomised treatment group was assessed while adjusting for time, group-by-time 
interaction, age, fracture displacement and hand dominance.  The predicted means and associated 95% CIs for each group and time point are 
presented in Table 11 and displayed in Figure 6. 
 
Different covariance structures were applied to the model. An unstructured pattern that models all variances and covariances separately resulted 
in the lowest AIC and so was used in the final model. 
 
Diagnostics of model fit revealed that the standardised residuals demonstrated only a minor deviation from normality, and were uniform against 
fitted values; therefore, analyses were carried out on untransformed values.  Model coefficients for the covariates with 95% CIs are provided as 
software output in Appendix 4 to aid understanding of the fitted model.   
 
Table 11: Difference in adjusted mean PRWE scores over time by randomised group from primary analysis model (n=408; surgery, n= 
203; plaster cast, n=205) 
Time point 
Surgery 
Mean (95% CI) 
Plaster cast 
Mean (95% CI) 
Difference (95% CI) p-value 
6 weeks 35.6 (32.6, 38.6) 39.8 (36.8, 42.8) -4.2 (-8.5, 0.1) 0.06 
12 weeks 21.0 (18.1, 24.0) 26.6 (23.6, 29.6) -5.6 (-9.8, -1.4) 0.01 
26 weeks 16.2 (13.5, 18.9) 16.5 (13.8, 19.2) -0.3 (-4.1, 3.6) 0.89 
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52 weeks 11.9 (9.2, 14.5) 14.0 (11.3, 16.6) -2.1 (-5.8, 1.6) 0.27 
Overall 21.3 (18.9, 23.6) 24.4 (22.0, 26.7) -3.0 (-6.3, 0.3) 0.07 
 
 
Figure 6: Adjusted mean PRWE scores (with 95% CIs) for primary analysis over time by randomised group 
 
Valid data 
The primary analysis included data from 408 patients (surgery n=203; plaster cast n=205) with a valid PRWE score for at least one follow-up 
time point and complete baseline covariates.  A valid response is defined here as sufficient data (maximum of one missing PRWE item in each 
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of the two subscales) to allow the calculation of the total score.  The number of participants with valid PRWE data at each time point is 
presented by randomised group in Table 12, with reasons for missing data.   
  
The percentage of randomised participants with valid PRWE data ranged from 68.8% (26 weeks) to 82.5% (52 weeks) for the post-
randomisation time points.  Overall, 408 (surgery n=203, 92.7%; plaster cast n=205, 93.2%) had valid PRWE data for at least one post-
randomisation time point and so were included in the primary analysis model.   
 
 
 
Table 12: Valid PRWE data by randomised group and time point, with reasons for missing data 
Follow-up Response type 
Surgery 
(n=219) 
Plaster 
cast 
(n=220) 
Total 
 (n=439) 
Baseline (pre-injury) Valid response  205 (93.6) 203 (92.3) 408 (92.9) 
 No or partial responsea: 
Partial response 
All missing responses 
 
0 (0) 
12 (5.5) 
 
2 (0.9) 
15 (6.8) 
 
2 (0.5) 
27 (6.2) 
 Did not return questionnaire 2 (0.9) 0 (0.0) 2 (0.5) 
Baseline (post-injury) Valid response  213 (97.3) 209 (95) 422 (96.1) 
 No or partial responsea: 
Partial response 
All missing responses 
 
4 (1.8) 
0 (0.0) 
 
11 (5) 
0 (0.0) 
 
15 (3.4) 
0 (0.0) 
 Did not return questionnaire 2 (0.9) 0 (0.0) 2 (0.5) 
6 weeks Valid response  176 (80.4) 172 (78.2) 348 (79.3) 
 No or partial responsea: 
Partial response 
All missing responses 
 
2 (0.9) 
0 (0.0) 
 
9 (4.1) 
0 (0.0) 
 
11 (2.5) 
0 (0.0) 
 Did not return questionnaire 36 (16.4) 36 (16.4) 72 (16.4) 
 Withdrawn from questionnaires 5 (2.3) 3 (1.4) 8 (1.8) 
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12 weeks Valid response  178 (81.3) 163 (74.1) 341 (77.7) 
 No or partial responsea: 
Partial response 
All missing responses 
 
4 (1.8) 
0 (0.0) 
 
4 (1.8) 
0 (0.0) 
 
8 (1.8) 
0 (0.0) 
 Did not return questionnaire 30 (13.7) 50 (22.7) 80 (18.2) 
 Withdrawn from questionnaires 7 (3.2) 3 (1.4) 10 (2.3) 
26 weeks Valid response  156 (71.2) 146 (66.4) 302 (68.8) 
 No or partial responsea: 
Partial response 
All missing responses 
 
6 (2.7) 
1 (0.5) 
 
3 (1.4) 
0 (0.0) 
 
9 (2.1) 
1 (0.2) 
 Did not return questionnaire 49 (22.4) 67 (30.5) 116 (26.4) 
 Withdrawn from questionnaires 7 (3.2) 4 (1.8) 11 (2.5) 
52 weeks Valid response  186 (84.9) 176 (80) 362 (82.5) 
 No or partial responsea: 
Partial response 
All missing responses 
 
0 (0.0) 
0 (0.0) 
 
2 (0.9) 
0 (0.0) 
 
2 (0.5) 
0 (0.0) 
 Did not return questionnaire 26 (11.9) 35 (15.9) 61 (13.9) 
 Withdrawn from questionnaires 7 (3.2) 7 (3.2) 14 (3.2) 
a questionnaire returned but missing response data to PRWE items 
 
Demographic and injury characteristics at baseline for participants who provided valid PRWE data at each time point are presented by 
randomised group in 
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Appendix 3, Table 51 to Table 53. 
 
Overall, 249 patients (56.7%) had a valid PRWE response at all post-randomisation follow-up time points (complete responders: surgery n=130, 
59.4%; plaster cast n=119, 54.1%); and a further 159 (intermittent responders: surgery n=73, 33.3%; plaster cast n=86, 39.1%) had a valid 
PRWE response at one or more, but not all, post-randomisation time points.  Table 13 provides the descriptive PRWE total scores for complete 
and intermittent responders, and the baseline PRWE scores for those who had no valid post-randomisation PRWE data. Complete responders 
had, on average, better PRWE outcomes (lower mean score) than intermittent responders pre-injury and at 52 weeks post-randomisation but 
similar outcomes at baseline (post-injury), and at six, 12 and 26 weeks post-randomisation. 
 
Table 13: Unadjusted total PRWE scores for complete, intermittent and non-responders to post-randomisation follow-ups, by time point 
Total PRWE 
Complete 
responders 
(n=249) 
Intermittent 
responders 
(n=159) 
Non-responders 
(n=31) 
Baseline (pre-injury) Mean (SD) 2.7 (9.3) 4.8 (14.7) 1.1 (2.3) 
 Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
 Min, max (0, 85) (0, 90.5) (0, 8) 
Baseline (post-injury) Mean (SD) 74.4 (16.8) 72.4 (21.5) 72.1 (16.5) 
 Median (IQR) 77.5 (65.3, 77.5) 76.8 (62, 76.8) 74.5 (63.8, 74.5) 
 Min, max (0, 100) (0, 100) (35, 96.5) 
6 weeks Mean (SD) 37.3 (19.7) 37.0 (24.6) - 
 Median (IQR) 37 (22.5, 37)         30.5 (17.5, 30.5) - 
 Min, max (0, 85.9) (0, 100) - 
12 weeks Mean (SD) 22.9 (20.0) 23.9 (23.0) - 
 Median (IQR) 17. (8, 17.5) 17 (5, 17) - 
 Min, max (0, 90) (0, 80.5) - 
26 weeks Mean (SD) 15.4 (17.1) 15.3 (21.7) - 
 
 
345 
 
 Median (IQR) 10.5 (3.5, 10.5) 5 (0, 5) - 
 Min, max (0, 84) (0, 91.5) - 
52 weeks Mean (SD) 11.7 (17.5) 15.0 (19.6) - 
 Median (IQR) 4.5 (0, 4.5) 4 (0, 4) - 
 Min, max (0, 96) (0, 88) - 
SD, standard deviation; IQR, interquartile range; min, minimum; max, maximum 
 
Descriptive Patient Rated Wrist Evaluation statistics 
Total mean PRWE scores for pre-injury and at enrolment (post-injury) were similar between the two groups (see Table 14).  Total mean PRWE 
scores improved (decreased) over time following injury in both groups, but were higher (worse) in the plaster cast group than in the surgery 
group at all post-randomisation time points except at 26 weeks.  At 52 weeks, the unadjusted mean difference was -2.8 points (95% CI -6.5 to 
1.0), favouring the surgery group.     
 
Table 14: Unadjusted PRWE total and subscale scores by randomised group and time point 
PRWE Surgery Plaster cast Total 
Baseline (pre-injury)    
Pain subscale Mean (SD) 2.2 (6.6) 2.5 (6.9) 2.4 (6.7) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
 Min, max (0, 50) (0, 41) (0, 50) 
Function subscale Mean (SD) 1.0 (5.1) 1.1 (5.7) 1.0 (5.4) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 
 Min, max (0, 43) (0, 49.5) (0, 49.5) 
Total Mean (SD) 3.1 (10.8) 3.6 (11.8) 3.4 (11.3) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
 Min, max (0, 85) (0, 90.5) (0, 90.5) 
Baseline (post-injury)    
Pain subscale Mean (SD) 34.7 (10.8) 34.3 (9.7) 34.5 (10.2) 
 Median (IQR) 36.0 (30.0, 42.0) 35.0 (28.4, 42.0) 36.0 (29.0, 42.0) 
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PRWE Surgery Plaster cast Total 
 Min, max (0, 50) (0, 50) (0, 50) 
Function subscale Mean (SD) 39.1 (10.4) 38.5 (10.0) 38.8 (10.2) 
 Median (IQR) 41.8 (34.0, 47.0) 40.5 (33.5, 46.0) 41.0 (33.5, 46.5) 
 Min, max (0, 50) (0, 50) (0, 50) 
Total Mean (SD) 73.9 (19.8) 73.2 (17.4) 73.5 (18.6) 
 Median (IQR) 78.5 (65.5, 87.5) 76.0 (63.5, 86.5) 77.5 (64.0, 87.0) 
 Min, max (0, 100) (0, 100) (0, 100) 
6 weeks    
Pain subscale Mean (SD) 18.9 (10.5) 18.4 (10.7) 18.6 (10.6) 
 Median (IQR) 19.0 (10.0, 27.0) 17.0 (10.0, 26.0) 18.0 (10.0, 26.3) 
 Min, max (0, 44) (0, 50) (0, 50) 
Function subscale Mean (SD) 16.8 (12.8) 20.1 (12.4) 18.5 (12.7) 
 Median (IQR) 13.5 (6.5, 25.5) 19.0 (9.8, 27.3) 17.0 (8.0, 26.5) 
 Min, max (0, 47) (0, 50) (0, 50) 
Total Mean (SD) 35.7 (21.4) 38.8 (21.0) 37.2 (21.2) 
 Median (IQR) 33.8 (18.8, 49.0) 38.3 (22.5, 52.3) 35.4 (19.5, 51.5) 
 Min, max (3, 85.5) (0, 100) (0, 100) 
12 weeks    
Pain subscale Mean (SD) 12.8 (11.0) 14.6 (11.2) 13.7 (11.1) 
 Median (IQR) 10.0 (4.5, 18.0) 12.0 (6.0, 21.0) 11.0 (5.0, 19.0) 
 Min, max (0, 45) (0, 47) (0, 47) 
Function subscale Mean (SD) 7.9 (9.3) 11.2 (11.5) 9.5 (10.5) 
 Median (IQR) 5.0 (1.0, 11.0) 7.5 (2.5, 16.0) 6.0 (1.5, 13.0) 
 Min, max (0, 44.5) (0, 46.5) (0, 46.5) 
Total Mean (SD) 20.7 (19.6) 25.9 (21.8) 23.2 (20.8) 
 Median (IQR) 15.0 (6.0, 27.0) 20.0 (8.7, 35.5) 17.5 (7.0, 31.5) 
 Min, max (0, 89.5) (0, 90) (0, 90) 
26 weeks    
Pain subscale Mean (SD) 10.5 (10.6) 9.9 (10.0) 10.2 (10.3) 
 Median (IQR) 7.0 (3.0, 15.0) 8.0 (2.0, 13.0) 8.0 (2.0, 15.0) 
 Min, max (0, 43) (0, 44) (0, 44) 
Function subscale Mean (SD) 5.3 (8.3) 5.4 (8.7) 5.4 (8.5) 
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PRWE Surgery Plaster cast Total 
 Median (IQR) 1.8 (0.0, 5.8) 2.0 (0.0, 6.0) 2.0 (0.0, 6.0) 
 Min, max (0, 41) (0, 47.5) (0, 47.5) 
Total Mean (SD) 15.7 (18.1) 15.1 (17.8) 15.4 (18.0) 
 Median (IQR) 9.0 (3.5, 20.5) 10.5 (2.0, 18.0) 9.5 (3.0, 19.0) 
 Min, max (0, 84) (0, 91.5) (0, 91.5) 
52 weeks    
Pain subscale Mean (SD) 7.7 (10.1) 9.2 (11.3) 8.4 (10.7) 
 Median (IQR) 4.0 (0.0, 10.0) 4.0 (0.0, 14.0) 4.0 (0.0, 12.0) 
 Min, max (0, 42) (0, 48) (0, 48) 
Function subscale Mean (SD) 3.7 (7.2) 4.9 (9.0) 4.3 (8.1) 
 Median (IQR) 0.5 (0.0, 3.5) 0.5 (0.0, 5.0) 0.5 (0.0, 4.5) 
 Min, max (0, 43.5) (0, 48) (0, 48) 
Total Mean (SD) 11.4 (16.6) 14.2 (19.8) 12.8 (18.2) 
 Median (IQR) 4.0 (0.0, 14.0) 4.5 (0.0, 19.3) 4.5 (0.0, 16.5) 
 Min, max (0, 85.5) (0, 96) (0, 96) 
SD, standard deviation; IQR, interquartile range; min, minimum; max, maximum 
 
 
PRWE at the secondary time points 
Adjusted PRWE means and group differences for the primary analysis model are presented in Table 11 and displayed in Figure 6.  The analysis 
showed a statistically significant difference between treatment groups at week 12 (p=0.01) and a borderline result at week six (p=0.06), but not 
at week 26 (p=0.89) or the primary end point of 52 weeks (p=0.27).  There was no overall effect of treatment group (difference of 3.0 points in 
favour of the surgery group; p=0.07).  Although statistically significant, the mean difference observed at 12 weeks was lower than our minimum 
clinically important difference of 6 points, though the confidence interval does include this difference.   
 
 
Sensitivity analyses 
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Missing data 
Adjusted PRWE means and group differences for the separate linear regression analysis models, for each time point, run on the multiply imputed 
dataset are presented in Table 15.  Analyses showed very similar results to the primary analysis i.e., a statistically significant difference between 
treatment groups at weeks 6 (p=0.049) and 12 (p=0.01) but not at week 26 (p=0.93) or the primary end point of 52 weeks (p=0.28).  The 
adjusted mean difference at 52 weeks was -2.0 (95% CI -5.7 to 1.6) in favour of the surgery group.  Since separate linear regressions were 
performed for these analyses as opposed to a repeated measures model, there is no estimate for the overall treatment effect over time.   
 
Handling multi-site data 
Adjusted PRWE means and group differences are presented in Table 15 for the analysis in which the primary outcome model additionally 
included site as a random effect (within which participants were nested).  An unstructured covariance pattern was specified for this model.  The 
analysis showed no statistically significant differences between treatment groups post-randomisation, except at week 12 (p=0.01).  The adjusted 
mean difference at 52 weeks was -1.9 (95% CI -5.6 to 1.8).  There was no overall effect of treatment group (difference of 2.8 points in favour of 
the surgery group; p=0.09). 
 
Timing of data collection 
The primary analysis model was repeated only including data collected one week either side of the six week time point (surgery n=118; plaster 
cast n=112), 2 weeks either side of the 12 week time point (surgery n=121; plaster cast n=108), 6 weeks either side of the 26 week time point 
(surgery n=133; plaster cast n=128), and 8 weeks either side of the 52 week time point (surgery n=170; plaster cast n=155).  A total of 380 
participants were included in this analysis (190 in each group).   
 
Adjusted PRWE means and group differences for the model as specified above are presented in Table 15.  The analysis showed no statistically 
significant differences between treatment groups post-randomisation, except at week 12 (p=0.01).  The adjusted mean difference at 52 weeks is 
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in this population was -3.1 (95% CI -6.7 to 0.6).  There was no overall effect of treatment group (difference of 2.4 points in favour of the surgery 
group; p=0.16). 
 
Post-hoc sensitivity analysis including smoking status 
Smoking status (yes/no) was included as a covariate in the primary analysis model in a sensitivity check since this factor was found to be 
imbalanced by chance at baseline (smoker: surgery group: 33%; plaster cast group: 26%) and thought to be associated with poorer bone healing 
and complications.  The analysis showed similar results to the primary analysis, that is a statistically significant difference between treatment 
groups at week 12 (p=0.01) but at neither week 26 (p=0.67) nor the primary end point of 52 weeks (p=0.14).  Week six was now statistically 
significant at the 5% level (p=0.03).  However, there was evidence of an overall effect of treatment group (difference of 3.6 points in favour of 
the surgery group; p=0.03).  The magnitude of the effect at 52 weeks is increased compared to the primary analysis (from 2.1 to 2.8 points in 
favour of the surgery group), and the 95% confidence interval includes the minimum clinically important difference of six points (see Table 15).  
 
Displacement and lack of fracture as assessed by independent review of baseline imaging data 
The randomisation for the trial was stratified by presence or not of displacement of a scaphoid fracture (<1mm, or 1-2mm inclusive) as seen on 
the plain radiographic views taken at baseline and used by the treating clinician to determine eligibility (though note discrepancies discussed 
in section Baseline characteristics of randomised participants).  This judgement of displacement is included as a covariate in the primary 
analysis model.  Extent of fracture displacement was also subsequently assessed and agreed upon by three independent raters w ho reviewed 
all available participant baseline imaging data (CT scans and radiographs) throughout the trial.   
 
Baseline radiographic images were available and reviewed for all but one participant (in the surgery arm).  Baseline CT images were 
available and reviewed for 431 participants (surgery n=214, 97.3%; plaster cast n=217, 99.1%).  Both baseline and CT images were 
reviewed for 431 (98.2%) participants, radiographs only for 7 (1.6%) participants, and neither for one participant (0.2%).  The 
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maximum fracture displacement, in millimetres, observed on either the CT or radiographic images was identified and used to 
categorise the participant’s fracture displacement as: <1 mm; 1-2 mm inclusive; and >2 mm.  Overall, 213 (81.6%) of the 261 
fractures that were deemed not to be displaced by the treating clinician at baseline were classified as not displaced (<1 mm) on 
review, 39 (14.9%) as displaced 1-2 mm, 8 (3.1%) as >2 mm, and 1 (0.4%) missing (see 
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Appendix 3, Table 54).  Of the 178 fractures that were deemed to be displaced (1-2 mm) by the treating clinician at baseline, 112 (62.9%) 
were classified as not displaced (<1 mm) on review, 47 (26.4%) as displaced 1-2 mm, and 19 (10.7%) as >2 mm.   
 
The primary analysis model was rerun replacing displacement as used in the randomisation as a covariate with the variable ind icating extent 
of displacement agreed by the three raters (see Table 15) providing very similar results to the primary analysis (see Table 11). 
 
Consensus was reached between the three raters that displacement of the fracture was greater than 2 mm, based on their assess ment of the 
baseline radiography/CT scans, for 27 (6.2%) randomised participants.  A fracture could be seen on radiographic imaging for all but one of 
the 438 participants (n=437, 99.8%) for whom these data were available, and on CT imaging for 426 (98.8%) of 431 participants .  For four of 
the five participants for whom a fracture could not be seen on their CT, it could be seen on the radiographic images; thus, consensus was 
reached between the three raters that only one participant did not actually have a fracture (participant allocated to surgery group).  Sensitivity 
analyses of the primary outcome model were conducted that excluded these participants (see Table 15).   
 
The quality of the radiographic imaging on which the one participant was deemed not to have a fracture was deemed to be ‘good’.  For the 
five participants for whom a fracture could not be seen on their CT images, the quality was deemed to be ‘good’ in three cases, and ‘fair’ in 
the other two. 
 
In addition, for patients for whom raters thought there was no fracture on the CT later images were reviewed for evidence of bone healing to 
confirm whether there had been a fracture.  For the participant for whom the baseline radiographic images also indicated there was no 
fracture, this was confirmed in all other images.  In the four others, the radiographic images indicated a fracture: one only had baseline 
imaging so later images could not be reviewed; one had baseline and 52 weeks only, and at 52 weeks the appearances were interpreted as union; 
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one had baseline, 6 week and 52 week imaging and in all subsequent images the fracture was considered to be united; and one had only 6 week 
imaging in which the fracture was considered to have united.  However, union cannot be said to confirm a fracture was initially present. 
 
Table 15: Difference in adjusted mean PRWE scores over time by randomised group for sensitivity analyses 
Time point 
Surgery 
Mean (95% CI) 
Plaster cast 
Mean (95% CI) 
Difference (95% CI) p-value 
Missing dataa (n=439; surgery, n= 219; plaster cast, n=220) 
6 weeks 35.1 (32.1, 38.1) 39.8 (36.7, 42.9) -4.7 (-9.0, -0.5) 0.03 
12 weeks 20.7 (17.9, 23.6) 26.6 (23.7, 29.5) -5.9 (-9.9, -1.9) <0.01 
26 weeks 16.1 (13.4, 18.8) 16.4 (13.7, 19.2) -0.3 (-4.2, 3.5) 0.87 
52 weeks 12.0 (9.3, 14.6) 14.1 (11.4, 16.8) -2.1 (-5.9, 1.6) 0.26 
Handling multi-site data (n=408; surgery, n= 203; plaster cast, n=205) 
6 weeks 36.2 (32.6, 39.8) 40.2 (36.6, 43.8) -4.0 (-8.2, 0.3) 0.07 
12 weeks 21.6 (18.1, 25.1) 27.0 (23.4, 30.6) -5.4 (-9.5, -1.2) 0.01 
26 weeks 16.8 (13.5, 20.1) 16.9 (13.6, 20.3) -0.1 (-3.9, 3.7) 0.96 
52 weeks 12.5 (9.2, 15.7) 14.4 (11.1, 17.7) -1.9 (-5.6, 1.8) 0.31 
Overall 21.9 (18.8, 24.9) 24.8 (21.7, 27.8) -2.8 (-6.1, 0.4) 0.09 
Timing of data collection (n=380; surgery, n=190; plaster cast, n=190) 
6 weeks 37.3 (33.9, 40.7) 37.7 (34.2, 41.2) -0.4 (-5.3, 4.4) 0.86 
12 weeks 20.6 (17.5, 23.8) 26.4 (23.1, 29.7) -5.7 (-10.3, -1.2) 0.01 
26 weeks 15.2 (12.5, 17.9) 15.4 (12.7, 18.1) -0.2 (-4.0, 3.6) 0.93 
52 weeks 10.8 (8.2, 13.3) 13.8 (11.2, 16.5) -3.1 (-6.7, 0.6) 0.10 
Overall 19.9 (17.6, 22.2) 22.2 (19.9, 24.5) -2.4 (-5.6, 0.9) 0.16 
Adjusted for smoking status (n=406; surgery, n=202; plaster cast, n=204) 
6 weeks 35.3 (32.3, 38.3) 40.0 (36.9, 43.0) -4.7 (-9.0, -0.4) 0.03 
12 weeks 20.7 (17.8, 23.7) 26.8 (23.8, 29.8) -6.0 (-10.2, -1.8) 0.01 
26 weeks 15.9 (13.2, 18.6) 16.7 (14.0, 19.5) -0.8 (-4.7, 3.0) 0.67 
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52 weeks 11.3 (8.8, 13.9) 14.2 (11.5, 16.8) -2.8 (-6.5, 0.9) 0.14 
Overall 20.9 (18.6, 23.2) 24.6 (22.2, 26.9) -3.6 (-6.9, -0.3) 0.03 
Including displacement as agreed by three independent raters (n=408; surgery, n= 203; 
plaster cast, n=205) 
6 weeks 35.5 (32.5, 38.5) 39.8 (36.8, 42.8) -4.3 (-8.5, -0.0) 0.05 
12 weeks 21.0 (18.0, 23.9) 26.6 (23.6, 29.6) -5.6 (-9.8, -1.4) 0.01 
26 weeks 16.2 (13.6, 18.9) 16.5 (13.8, 19.2) -0.3 (-4.1, 3.6) 0.89 
52 weeks 11.9 (9.3, 14.5) 13.9 (11.3, 16.6) -2.1 (-5.8, 1.6) 0.27 
Overall 21.2 (18.9, 23.5) 24.4 (22.0, 26.7) -3.1 (-6.3, 0.2) 0.07 
Excluding those with no fracture (n=407; surgery, n= 202; plaster cast, n=205) 
6 weeks 35.7 (32.6, 38.7) 39.8 (36.8, 42.8) -4.1 (-8.4, 0.1) 0.06 
12 weeks 21.1 (18.1, 24.0) 26.6 (23.6, 29.6) -5.5 (-9.7, -1.3) 0.01 
26 weeks 16.3 (13.6, 19.0) 16.5 (13.8, 19.2) -0.2 (-4.1, 3.6) 0.91 
52 weeks 11.9 (9.3, 14.6) 14.0 (11.3, 16.6) -2.0 (-5.8, 1.7) 0.29 
Overall 21.3 (19.0, 23.6) 24.4 (22.0, 26.7) -3.0 (-6.3, 0.3) 0.08 
Excluding those with displacement >2 mm (n=383; surgery, n= 191; plaster cast, n=192) 
6 weeks 35.0 (31.9, 38.0) 39.8 (36.7, 42.9) -4.8 (-9.2, -0.5) 0.03 
12 weeks 20.7 (17.6, 23.7) 26.2 (23.1, 29.3) -5.6 (-9.9, -1.3) 0.01 
26 weeks 15.7 (13.0, 18.3) 16.3 (13.6, 19.0) -0.6 (-4.4, 3.2) 0.76 
52 weeks 11.4 (8.8, 13.9) 13.7 (11.0, 16.3) -2.3 (-6.0, 1.4) 0.22 
Overall 20.7 (18.4, 23.0) 24.1 (21.7, 26.4) -3.3 (-6.6, 0.0) 0.05 
aseparate linear regression analysis models for each time point run on the multiply imputed dataset 
 
Complier average causal effect (CACE) analysis 
The CACE analysis considers the effect of receiving early surgical fixation compared with no surgical fixation of the fracture, and as such does 
not account for the ‘partial’ compliers in the plaster cast group (ie. the two participants for whom surgery was considered for non-union after a 
period of plaster cast management, and the three participants who received delayed surgical fixation (post 6 months after randomisation) of their 
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non-united fracture).  We have considered these a pragmatic aspect of the ‘control’ condition.  Six (2.7%) participants in the plaster cast group 
crossed over to the surgery group and received immediate surgical fixation of their fractures (contamination), while 31 (14.2%) participants in 
the surgery group did not receive surgery but instead were managed conservatively (non-compliance).  The CACE estimate of the treatment 
effect with adjustment for non-compliance and contamination is a difference of -3.1 (95% CI -7.3 to 1.1, p=0.15) in 52 week total PRWE score. 
This difference is in favour of the surgery group and is larger than the ITT treatment effect estimate at 52 weeks, demonstrating a greater, but not 
statistically significant, benefit of surgery amongst participants who complied with their treatment allocation.  The 95% CI is -7.3 to 1.1; 
therefore, we cannot rule out a clinically meaningful difference or no effect.   
 
Subgroup analysis 
 
Patient preference for treatment 
The first subgroup analysis was undertaken to test the hypothesis that participants who expressed a preference for surgery at baseline would 
benefit more from surgery than participants who expressed a preference against surgery or who had no particular treatment preference.   
 
Descriptive summary statistics for the PRWE total score are presented in 
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Appendix 3, Table 55 and displayed in 
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Appendix 3, Figure 14Error! Reference source not found. by treatment group stratified by baseline treatment preference.  No notable 
differences between the two groups are observed at any time point within the subgroup who did not express a treatment preference at baseline.  
Unadjusted mean scores are lower (better) in the surgery group at all time-points except 26 weeks in the subgroup who expressed a preference 
for surgery.  In the subgroup who preferred no surgery, unadjusted mean scores are lower (better) in the surgery group at all time-points except 
baseline (post-injury) in the subgroup who expressed a preference for surgery, and the differences between the groups are larger at six, 12 and 26 
weeks than in the subgroup with a preference for surgery.   
 
No significant interaction was observed between randomised allocation and treatment preference (surgery group and preference for surgery 
p=0.54; surgery group and preference for no surgery p=0.65).  At 52 weeks, the adjusted mean difference in total PRWE score between the 
surgery and plaster cast groups was -0.9 (95% CI -6.0 to 4.2, p=0.72) in the no preference subgroup, -3.0 (95% CI -8.2 to 2.2, p=0.25) in the 
surgery preference subgroup, and -4.2 (95% CI -17.2 to 8.9, p=0.53) in the no surgery preference subgroup. 
 
Fracture displacement (randomisation) 
The second subgroup analysis tested the hypothesis that patients with a displaced fracture at baseline would benefit more from surgery 
than those with a non-displaced fracture.  The relationship between fracture displacement (as stratified on in the randomisation) and 
randomised group in terms of PRWE is illustrated in 
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Appendix 3, Table 56 and 
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Appendix 3, Figure 15.  Overall, participants with a displaced fracture tended to have higher post-randomisation PRWE scores than those with 
no or minimal displacement, and scores in the surgery group were lower than in the plaster cast group at six, 12, 26 and 52 weeks for this 
subgroup.  There was no statistically significant interaction effect (p=0.35); at 52 weeks the adjusted mean difference between the surgery and 
plaster cast group was -0.8 (95% CI -5.4 to 3.8, p=0.73) in the no displacement subgroup, and -4.0 (95% CI -9.3 to 1.4, p=0.15) in the displaced 
subgroup, both favouring the surgery group.   
 
Fracture displacement (study eligibility form)  
A third subgroup analysis tested the hypothesis as above using displacement as recorded on the Study Eligibility Form.  The 
relationship between fracture displacement (as recorded on the Study Eligibility Form) and randomised group in terms of PRWE is 
illustrated in 
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Appendix 3, Table 57 and 
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Appendix 3, Figure 16.  Overall, participants with a displaced fracture tended to have higher post-randomisation PRWE scores than those with 
no or minimal displacement, and scores in the surgery group were lower than in the plaster cast group at six, 12, and 52 weeks for this subgroup.  
There was no statistically significant interaction effect (p=0.70); at 52 weeks the adjusted mean difference between the surgery and plaster cast 
group was -1.6 (95% CI -6.1 to 3.0, p=0.50) in the no displacement subgroup, and -2.9 (95% CI -8.4 to 2.6, p=0.30) in the displaced subgroup, 
both favouring the surgery group.   
 
Surgery patients for whom the screw caused cartilage damage 
A total of 188 (85.8%) participants allocated to the surgery group received treatment as allocated.  For 142 (75.5%) of these, CT images 
at 52 weeks were assessed by three independent raters for surgical screw penetration.  No screw penetration was observed for 49 
(34.5%) participants.  The extent of the penetration was measured for the remaining 93 participants (mean 1.6 mm, SD 0.95, range 0.2 
to 4.7), and was categorised as: minor = <1 mm, unlikely to cause an effect on articular cartilage (n=25/93, 26.9%), moderate = 1-2 mm 
inclusive, probably will have an effect on cartilage causing damage (n=44, 47.3%); severe = >2 mm, definitely will cause lasting damage 
to articular cartilage (n=24, 25.8%).  Descriptive summaries of baseline participant and fracture data and PRWE scores for these 
stratified by whether or not the surgical screw used was too long and caused cartilage damage (none+minor vs moderate+severe) as 
determined on the CT scans are provided in 
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Appendix 3, Table 58Error! Reference source not found., Table 59Error! Reference source not found. and Table 60Error! Reference 
source not found..  Participants with displaced fractures at baseline were less likely to suffer from cartilage damage caused by the screw.  At 52 
weeks, those who did not have significant surgical screw protrusion tended to perform better on the PRWE (total unadjusted mean 8.9 vs 10.8). 
 
Plaster cast patients who required surgery for non-union 
Of the 220 participants allocated to the plaster cast group, six crossed over to receive immediate surgical fixation, while of the remaining 
214, 19 (8.9%) were deemed to require surgical fixation of a non-united fracture following plaster cast management (though two 
participants did not receive the surgery, see Allocated to receive plaster cast intervention).  Descriptive summaries of baseline participant 
and fracture data and PRWE scores for the 214 plaster cast participants stratified by whether or not they needed surgery due to non-
union are presented in 
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Appendix 3, Table 58, Table 59Error! Reference source not found. and Table 60Error! Reference source not found..  Participants with 
displaced fractures at baseline were more likely to require surgery for non-union than those with <1 mm displacement.  Other risk factors include 
being female and a smoker.  Additionally, those that required surgery had had their injuries for slightly longer at enrolment to the trial than those 
who did not require surgery (median 6 vs 4 days).  At 52 weeks, those who did not require surgery for non-union tended to perform better on the 
PRWE (total unadjusted mean 12.8 vs 29.1). 
 
Feasibility requirements 
There were two feasibility requirements for this trial: (i) that a CT scan was performed within two weeks (14 days) of a patient’s injury (and 
before surgery if this occurred earlier); and (ii) for patients in the surgery arm, that surgery was performed within two weeks from presentation to 
A&E or other clinic.   
 
The majority of participants had a CT scan within 2 weeks of their injury (and before surgery if this was earlier): surgery group n=216 (98.6%); 
and plaster cast group n=196 (89.1%) (see 
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Appendix 3, Table 61Error! Reference source not found., Table 62 and Table 63).  Three participants in the surgery group did not meet this 
feasibility requirement: two crossed over treatment and received neither a CT scan nor surgery; and one had their CT scan 15 days after their 
injury, but this was before their surgery which occurred 5 days later.  Twenty four participants in the plaster cast group did not meet this 
feasibility requirement: five received routine treatment and did not receive a CT scan; one immediately crossed over to surgery, which took place 
7 days after injury, but did not receive a CT scan; and 18 had their CT scan between 15 and 47 days after injury (three of which received surgery 
at a later date as part of their further routine treatment for non-union).   
 
Among participants allocated to the surgery group, 182 (83.1%) had surgical fixation of their fracture within 14 days of presenting at the A&E or 
other clinic.  Of the remaining 37, 31 did not receive surgery, and six had their surgery between 15 and 20 days after presentation (see 
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Appendix 3, Table 61, Table 62Error! Reference source not found. and Table 63).  A linear regression for the surgery arm indicated that time 
from injury to surgery in days may be predictive of PRWE score at 52 weeks such that a one day delay in surgery is associated with a 0.78 points 
increase in PRWE score (95% CI -0.01 to 1.57, p=0.054).    
 
Secondary analysis 
 
PRWE subscales: pain and function 
The PRWE subscale scores for pain and function are summarised in Table 14.  Adjusted PRWE pain and function subscale means and 
group differences are presented in Table 16, and displayed 
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Appendix 3, Figure 17.  The pain subscale analysis included data from 409 participants (surgery n=203, 92.7%; plaster cast n=206, 93.6%), and 
the function analysis from 408 participants (surgery n=203, 92.7%; plaster cast n=205, 93.2%).  The analysis of the pain subscale showed no 
statistically significant difference between treatment groups overall or at any individual post-randomisation time point.  The adjusted mean 
difference at 52 weeks was -1.1 (95% CI -3.3 to 1.0) in favour of the surgery group.  However, a statistically significant difference in function 
subscale score, favouring the surgery group, was seen at six and 12 weeks.  This difference did not persist to 26 or 52 weeks, but there is an 
overall statistically significant difference between the two groups over time. 
 
Table 16: Difference in adjusted mean PRWE pain and function subscale scores over time by randomised group 
Time point 
Surgery 
Mean (95% CI) 
Plaster cast 
Mean (95% CI) 
Difference (95% 
CI) 
p-value 
PRWE Pain subscale (n=409; surgery, n= 203; plaster cast, n=206) 
6 weeks 18.8 (17.3, 20.4) 19.0 (17.5, 20.5) -0.1 (-2.3, 2.0) 0.89 
12 weeks 13.1 (11.5, 14.6) 15.0 (13.4, 16.6) -2.0 (-4.2, 0.3) 0.09 
26 weeks 11.0 (9.4, 12.5) 10.6 (9.0, 12.2) 0.4 (-1.8, 2.6) 0.75 
52 weeks 7.9 (6.4, 9.5) 9.1 (7.5, 10.6) -1.1 (-3.3, 1.0) 0.31 
Overall 12.7 (11.5, 14.0) 13.5 (12.2, 14.8) -0.7 (-2.5, 1.1) 0.44 
PRWE Function subscale (n=408; surgery, n= 203; plaster cast, n=205) 
6 weeks 16.7 (14.9, 18.5) 20.5 (18.7, 22.3) -3.8 (-6.3, -1.3) <0.01 
12 weeks 8.1 (6.6, 9.5) 11.5 (10.0, 13.0) -3.4 (-5.6, -1.3) <0.01 
26 weeks 5.4 (4.1, 6.6) 6.0 (4.7, 7.3) -0.6 (-2.4, 1.2) 0.52 
52 weeks 3.9 (2.7, 5.1) 4.9 (3.7, 6.1) -1.0 (-2.6, 0.7) 0.25 
Overall 8.6 (7.5, 9.7) 10.8 (9.7, 12.0) -2.2 (-3.8, -0.6) 0.01 
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SF-12: physical and mental health component scores 
Mean mental and physical SF-12 component scores (MCS, PCS) improved (increased) over time following randomisation in both groups (except 
between 26 and 52 weeks in PCS in the plaster cast arm) (see Table 17).  At 52 weeks, the unadjusted mean difference in MCS was -1.1 points 
(95% CI -3.2 to 1.0) favouring the plaster cast group, but in PCS was 1.8 (95% CI 0.2 to 3.3) favouring the surgery group. 
 
Adjusted SF-12 means and group differences for the models are presented in Table 17, and displayed in 
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Appendix 3, Figure 18.  Both analysis models included data from 408 participants (surgery n=202, 92.2%; plaster cast n=206, 93.6%).  The 
analysis of the MCS subscale showed no statistically significant difference between treatment groups overall or at any individual post-
randomisation time point.  The adjusted mean difference at 52 weeks was -1.2 (95% CI -3.3 to 0.8) in favour of the plaster cast group.  However, 
a statistically significant difference in PCS subscale score, favouring the surgery group, was seen at 12 and 52 weeks, but not at six or 26 weeks, 
nor overall (p=0.08).  The adjusted mean difference at 52 weeks was 1.6 (95% CI 0.2 to 3.1) in favour of the surgery group. 
Table 17: Summaries of, and differences in adjusted mean, SF-12 mental and physical component subscale scores over time by 
randomised group 
SF-12 Surgery Plaster cast Total 
6 weeks    
MCS Mean (SD) 49.5 (11.4) 49.3 (10.8) 49.4 (11.1) 
 Median (IQR) 52.4 (41.2, 58.1) 51.3 (43.9, 57.0) 51.5 (42.5, 57.3) 
 Min, max (12.8, 67.8) (16.0, 68.8) (12.8, 68.8) 
PCS Mean (SD) 43.7 (8.6) 43.9 (8.1) 43.8 (8.3) 
 Median (IQR) 44.0 (38.6, 50.3) 43.9 (38.0, 49.9) 43.9 (38.3, 50.1) 
 Min, max (21.1, 62.1) (23.6, 63.7) (21.1, 63.7) 
12 weeks    
MCS Mean (SD) 50.9 (11.1) 51.5 (10.2) 51.2 (10.7) 
 Median (IQR) 52.8 (44.7, 59.4) 53.2 (45.7, 59.3) 53.0 (45.3, 59.3) 
 Min, max (16.4, 67.9) (15.6, 66.4) (15.6, 67.9) 
PCS Mean (SD) 49.9 (7.5) 47.7 (8.5) 48.9 (8.1) 
 Median (IQR) 51.9 (45.0, 55.9) 49.3 (42.6, 53.5) 50.2 (43.9, 54.8) 
 Min, max (21.5, 62.1) (21.4, 64.6) (21.4, 64.6) 
26 weeks    
MCS Mean (SD) 50.9 (12.1) 52.2 (9.9) 51.5 (11.1) 
 Median (IQR) 54.2 (46.2, 58.4) 54.4 (47.9, 59.1) 54.2 (47.5, 59.1) 
 Min, max (8.2, 67.9) (11.4, 68.2) (8.2, 68.2) 
PCS Mean (SD) 51.8 (7.4) 52.0 (7.6) 51.9 (7.5) 
 Median (IQR) 54.5 (48.9, 56.3) 54.2 (49.5, 56.7) 54.3 (49.1, 56.7) 
 Min, max (25.9, 63.0) (17.8, 62.5) (17.8, 63.0) 
52 weeks    
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MCS Mean (SD) 51.4 (10.1) 52.5 (10.0) 51.9 (10.1) 
 Median (IQR) 54.2 (46.8, 57.6) 55.8 (47.6, 59.3) 54.8 (47.5, 58.2) 
 Min, max (15.3, 64.7) (13.0, 68.5) (13.0, 68.5) 
PCS Mean (SD) 53.2 (6.3) 51.5 (8.1) 52.3 (7.3) 
 Median (IQR) 55.9 (49.3, 57.2) 53.5 (48.4, 56.2) 54.8 (49.0, 56.7) 
 Min, max (33.6, 65.7) (22.2, 69.4) (22.2, 69.4) 
Time point 
Surgery 
Mean (95% CI) 
Plaster cast 
Mean (95% CI) 
Difference (95% 
CI) 
p-value 
SF-12 MCS subscale (n=408; surgery, n= 202; plaster cast, n=206) 
6 weeks 49.7 (48.1, 51.3) 49.1 (47.5, 50.7) 0.5 (-1.7, 2.8) 0.63 
12 weeks 50.6 (49.0, 52.1) 50.7 (49.1, 52.3) -0.2 (-2.4, 2.1) 0.88 
26 weeks 51.0 (49.4, 52.6) 51.6 (49.9, 53.3) -0.6 (-3.0, 1.7) 0.60 
52 weeks 51.0 (49.6, 52.5) 52.3 (50.8, 53.7) -1.2 (-3.3, 0.8) 0.24 
Overall 50.6 (49.3, 51.8) 50.9 (49.7, 52.2) -0.4 (-2.2, 1.4) 0.69 
SF-12 PCS subscale (n=408; surgery, n= 202; plaster cast, n=206) 
6 weeks 43.9 (42.7, 45.1) 43.4 (42.2, 44.6) 0.5 (-1.2, 2.2) 0.59 
12 weeks 49.8 (48.7, 50.9) 47.6 (46.5, 48.8) 2.2 (0.6, 3.8) 0.01 
26 weeks 51.6 (50.5, 52.7) 51.6 (50.5, 52.8) -0.0 (-1.6, 1.5) 0.95 
52 weeks 53.1 (52.1, 54.2) 51.5 (50.5, 52.6) 1.6 (0.2, 3.1) 0.03 
Overall 49.6 (48.8, 50.4) 48.5 (47.7, 49.3) 1.1 (-0.1, 2.2) 0.08 
 
Wrist range of movement and grip strength – affected wrist 
Measures of wrist range of movement and grip strength for the affected wrist are presented in Table 18.  Similar mean values were observed 
across these variables in the two groups at baseline. These were assessed at hospital visits at baseline, and at six, 12 and 52 weeks post-
randomisation.   
 
Table 18: Grip and range measures by randomised group and time point 
Wrist range of movement and grip 
strength – affected wrist 
Surgery Plaster cast Total 
Baseline     
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Beighton Laxity Mean (SD) 1.1 (2.0) 0.9 (1.7) 1.0 (1.8) 
Score Median (IQR) 0.0 (0.0, 2.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
 Min, max (0.0, 10.0) (0.0, 8.0) (0.0, 10.0) 
Extension (°) Mean (SD) 32.0 (18.6) 28.9 (17.2) 30.4 (17.9) 
 Median (IQR) 30.0 (20.0, 42.0) 30.0 (18.0, 40.0) 30.0 (20.0, 40.0) 
 Min, max (0.0, 135.0) (-15.0, 90.0) (-15.0, 135.0) 
Flexion (°) Mean (SD) 35.0 (25.5) 34.9 (21.7) 35.0 (23.6) 
 Median (IQR) 30.0 (20.0, 45.0) 35.0 (22.0, 44.0) 32.0 (20.0, 45.0) 
 Min, max (0.0, 160.0) (0.0, 162.0) (0.0, 162.0) 
Radial Deviation 
(°) 
Mean (SD) 14.3 (9.5) 14.3 (9.6) 14.3 (9.6) 
 Median (IQR) 13.0 (10.0, 20.0) 14.0 (9.0, 20.0) 13.0 (9.0, 20.0) 
 Min, max (0.0, 60.0) (0.0, 70.0) (0.0, 70.0) 
Ulnar Deviation (°) Mean (SD) 18.0 (10.9) 18.6 (11.0) 18.3 (10.9) 
 Median (IQR) 17.0 (10.0, 22.5) 18.0 (10.0, 25.0) 18.0 (10.0, 25.0) 
 Min, max (0.0, 70.0) (0.0, 60.0) (0.0, 70.0) 
Forearm Rotation  Mean (SD) 66.9 (26.7) 63.6 (27.8) 65.3 (27.3) 
Supination (°) Median (IQR) 75.0 (56.5, 85.0) 70.0 (50.0, 85.0) 73.0 (50.0, 85.0) 
 Min, max (0.0, 124.0) (-10.0, 118.0) (-10.0, 124.0) 
Forearm Rotation  Mean (SD) 72.2 (23.1) 71.2 (25.0) 71.7 (24.0) 
Pronation (°) Median (IQR) 80.0 (67.5, 90.0) 80.0 (68.5, 90.0) 80.0 (68.0, 90.0) 
 Min, max (0.0, 100.0) (0.0, 105.0) (0.0, 105.0) 
Grip Strength (kg) Mean (SD) 9.6 (10.0) 9.8 (10.6) 9.7 (10.3) 
 Median (IQR) 6.0 (2.0, 15.3) 7.0 (2.0, 12.7) 6.7 (2.0, 14.4) 
 Min, max (0.0, 61.7) (0.0, 58.0) (0.0, 61.7) 
6 weeks    
Extension (°) Mean (SD) 51.0 (20.2) 40.0 (18.3) 45.4 (20.0) 
 Median (IQR) 50.0 (38.0, 60.0) 40.0 (28.0, 50.0) 45.0 (30.0, 56.0) 
 Min, max (5.0, 135.0) (0.0, 90.0) (0.0, 135.0) 
Flexion (°) Mean (SD) 51.6 (28.3) 40.1 (23.4) 45.7 (26.5) 
 Median (IQR) 49.0 (30.0, 65.0) 35.0 (25.0, 50.0) 40.0 (30.0, 60.0) 
 Min, max (5.0, 162.0) (-5.0, 158.0) (-5.0, 162.0) 
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Radial Deviation 
(°) 
Mean (SD) 21.7 (10.7) 21.3 (12.8) 21.5 (11.8) 
 Median (IQR) 20.0 (15.0, 28.0) 20.0 (11.0, 28.0) 20.0 (13.0, 28.0) 
 Min, max (0.0, 60.0) (0.0, 70.0) (0.0, 70.0) 
Ulnar Deviation (°) Mean (SD) 29.3 (12.1) 23.5 (13.0) 26.3 (12.9) 
 Median (IQR) 30.0 (20.0, 38.0) 20.0 (15.0, 30.0) 25.0 (18.0, 35.0) 
 Min, max (1.0, 60.0) (0.0, 70.0) (0.0, 70.0) 
Forearm Rotation  Mean (SD) 82.4 (15.7) 74.9 (20.3) 78.5 (18.6) 
Supination (°) Median (IQR) 90.0 (80.0, 90.0) 80.0 (65.0, 90.0) 85.0 (72.0, 90.0) 
 Min, max (0.0, 131.0) (0.0, 108.0) (0.0, 131.0) 
Forearm Rotation  Mean (SD) 82.8 (14.4) 80.1 (15.5) 81.4 (15.0) 
Pronation (°) Median (IQR) 90.0 (80.0, 90.0) 85.0 (75.0, 90.0) 90.0 (80.0, 90.0) 
 Min, max (0.0, 110.0) (10.0, 104.0) (0.0, 110.0) 
Grip Strength (kg) Mean (SD) 24.1 (12.7) 20.1 (14.0) 22.0 (13.5) 
 Median (IQR) 23.3 (15.3, 32.7) 18.2 (9.3, 28.7) 20.0 (11.3, 30.7) 
 Min, max (0.0, 77.3) (0.0, 81.7) (0.0, 81.7) 
12 weeks    
Extension (°) Mean (SD) 61.1 (17.7) 56.9 (19.5) 59.1 (18.7) 
 Median (IQR) 60.0 (50.0, 70.0) 55.0 (43.5, 70.0) 60.0 (45.0, 70.0) 
 Min, max (13.0, 125.0) (2.0, 125.0) (2.0, 125.0) 
Flexion (°) Mean (SD) 62.0 (23.7) 55.3 (22.3) 58.7 (23.2) 
 Median (IQR) 60.0 (45.0, 75.0) 55.0 (41.0, 70.0) 58.0 (45.0, 72.0) 
 Min, max (15.0, 144.0) (5.0, 144.0) (5.0, 144.0) 
Radial Deviation 
(°) 
Mean (SD) 26.1 (12.7) 26.2 (14.5) 26.1 (13.6) 
 Median (IQR) 25.0 (18.0, 30.0) 23.0 (15.0, 32.0) 24.0 (18.0, 30.0) 
 Min, max (5.0, 80.0) (0.0, 80.0) (0.0, 80.0) 
Ulnar Deviation (°) Mean (SD) 35.4 (12.7) 31.6 (13.7) 33.5 (13.3) 
 Median (IQR) 35.0 (28.0, 40.0) 30.0 (22.0, 40.0) 31.0 (25.0, 40.0) 
 Min, max (10.0, 80.0) (0.0, 80.0) (0.0, 80.0) 
Forearm Rotation  Mean (SD) 87.1 (13.8) 82.3 (18.2) 84.7 (16.3) 
Supination (°) Median (IQR) 90.0 (85.0, 90.0) 90.0 (80.0, 90.0) 90.0 (80.0, 90.0) 
 Min, max (10.0, 140.0) (0.0, 126.0) (0.0, 140.0) 
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Forearm Rotation  Mean (SD) 86.5 (8.5) 83.4 (13.8) 85.0 (11.5) 
Pronation (°) Median (IQR) 90.0 (85.0, 90.0) 90.0 (80.0, 90.0) 90.0 (80.0, 90.0) 
 Min, max (26.0, 104.0) (0.0, 120.0) (0.0, 120.0) 
Grip Strength (kg) Mean (SD) 30.8 (12.5) 28.2 (14.4) 29.5 (13.5) 
 Median (IQR) 29.3 (22.3, 39.3) 28.5 (18.7, 37.8) 28.7 (20.0, 38.7) 
 Min, max (0.0, 82.0) (0.0, 89.0) (0.0, 89.0) 
52 weeks    
Extension (°) Mean (SD) 68.4 (21.0) 68.8 (15.5) 68.6 (18.6) 
 Median (IQR) 70.0 (56.0, 80.0) 70.0 (56.0, 80.0) 70.0 (56.0, 80.0) 
 Min, max (15.0, 140.0) (40.0, 115.0) (15.0, 140.0) 
Flexion (°) Mean (SD) 69.8 (20.3) 68.4 (16.4) 69.1 (18.5) 
 Median (IQR) 70.0 (55.0, 85.0) 70.0 (60.0, 80.0) 70.0 (58.0, 80.0) 
 Min, max (20.0, 152.0) (22.0, 105.0) (20.0, 152.0) 
Radial Deviation 
(°) 
Mean (SD) 32.2 (17.4) 32.5 (14.5) 32.4 (16.1) 
 Median (IQR) 28.0 (20.0, 40.0) 30.0 (22.0, 40.0) 30.0 (20.0, 40.0) 
 Min, max (6.0, 90.0) (8.0, 80.0) (6.0, 90.0) 
Ulnar Deviation (°) Mean (SD) 40.6 (14.8) 39.9 (13.7) 40.3 (14.3) 
 Median (IQR) 40.0 (30.0, 50.0) 40.0 (30.0, 49.0) 40.0 (30.0, 50.0) 
 Min, max (8.0, 90.0) (12.0, 80.0) (8.0, 90.0) 
Forearm Rotation  Mean (SD) 88.3 (13.3) 85.2 (13.9) 86.8 (13.6) 
Supination (°) Median (IQR) 90.0 (86.0, 90.0) 90.0 (80.0, 90.0) 90.0 (85.0, 90.0) 
 Min, max (30.0, 136.0) (30.0, 122.0) (30.0, 136.0) 
Forearm Rotation  Mean (SD) 86.8 (10.5) 86.2 (9.5) 86.5 (10.0) 
Pronation (°) Median (IQR) 90.0 (85.0, 90.0) 90.0 (85.0, 90.0) 90.0 (85.0, 90.0) 
 Min, max (5.0, 114.0) (40.0, 109.0) (5.0, 114.0) 
Grip Strength (kg) Mean (SD) 36.9 (12.7) 37.4 (14.2) 37.2 (13.4) 
 Median (IQR) 36.2 (28.7, 44.8) 38.5 (28.7, 46.2) 37.3 (28.7, 45.2) 
 Min, max (10.3, 109.7) (4.7, 88.3) (4.7, 109.7) 
 
 
 
345 
 
Grip strength 
On average, grip strength, in kilograms, increased over time in both groups and was higher in the surgery group than the plaster cast group at all 
post-randomisation time points except 52 weeks.   
 
Adjusted grip strength means and group differences are presented in Table 19, and displayed in 
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Appendix 3, Figure 19.  The analysis models included data from 407 participants (surgery n=201, 91.8%; plaster cast n=206, 93.6%) and showed 
a statistically significant difference between treatment groups at 6 weeks post-randomisation (p<0.001) favouring the surgery group, a borderline 
statistically significant result at 12 weeks (p=0.06), and no difference at 52 weeks.  The adjusted mean difference at 52 weeks was -1.0 (95% CI -
3.7, 1.8)) favouring the plaster cast group.   
 
Table 19: Difference in adjusted mean grip strength over time by randomised group (n=407; surgery, n= 201; plaster cast, n=206) 
Time point 
Surgery 
Mean (95% CI) 
Plaster cast 
Mean (95% CI) 
Difference (95% CI) p-value 
6 weeks 23.8 (22.0, 25.6) 19.4 (17.6, 21.2) 4.4 (1.8, 6.9) 0.001 
12 weeks 30.9 (29.0, 32.8) 28.3 (26.4, 30.2) 2.6 (-0.1, 5.3) 0.06 
52 weeks 37.0 (35.1, 39.0) 38.0 (36.1, 40.0) -1.0 (-3.7, 1.7) 0.48 
Overall 30.1 (28.5, 31.7) 27.9 (26.3, 29.5) 2.0 (-0.3, 4.2) 0.08 
 
Union 
Assessment of union via radiographs was possible for 188 (85.8%) participants in the surgery group, and 201 (91.4%) in the plaster cast group at 
6 weeks, of which 13 (6.9%) and 32 (15.9%), respectively, displayed non- or only slight-union (see Table 20).  At week 12, radiographic images 
were available for assessment of union for fewer participants than at six weeks: 169 (77.2%) in the surgery group, and 163 (74.1%) in the plaster 
cast arm.  A lower proportion of those reviewed were graded as having non- or slight-union at this time point in both groups (n=7, 4.1% and 
n=23, 14.1%).  
 
The proportion of participants assessed for union decreased at each time point in both groups.  At 52 weeks, the grading of union was based on 
CT images, or radiographic images where CT was not available, and was assessed for 314 participants (surgery n=164, 74.9%; plaster cast 
n=150, 68.2%) of which 13 (4.1%) were deemed to have non- or only slight union of their fracture (surgery n=4, 2.4%; plaster cast n=9, 6.0%).  
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In Table 20, the proportion of participants with full union in the surgery group appears to decrease between 12 and 52 weeks from 46.6% to 
42.5%; however, when we consider the proportions from non-missing data only, these increase from 49.7% and 52.3%, respectively, as 
expected.   
 
The 52-week PRWE scores, where available, are summarised for the two groups according to whether or not the participants had imaging 
available for union assessment at 52 weeks (see Table 20).  Overall, there is little difference in the mean PRWE scores for those who attended 
and did not attend for imaging (12.7 vs 13.2); however, there are differences between the two randomised groups.  In the surgery group, 
participants who did not attend for imaging tended to have higher (worse) scores than those who did attend for imaging (mean 16.4 vs 10.6), and 
so are perhaps less likely to have full union of their fractures.  However, the trend reverses in the plaster cast group, with those not attending for 
imaging having lower (better) scores, and so more likely to have better union.  
 
Participants in the surgery group were less likely to have non- or only slight union of their fracture at 52 weeks but this difference was not found 
to be statistically significant in a logistic regression model adjusting for age, fracture displacement and hand dominance (OR 0.40, 95% CI 0.12 
to 1.33, p=0.13). Similarly, results following multiple imputation of the union variables at six, 12 and 52 weeks indicated that the likelihood of 
participants having non- or only slight union of their fracture at 52 weeks was lower for participants allocated to the surgery group (OR 0.51, 
95% CI 0.17 to 1.57) but not statistically significantly so (p=0.24).  In the surgery group, 4/219 participants were deemed to have non- or slight-
union at 52 weeks (1.8%) and 9/220 in the plaster cast group (4.1%).  Based on these figures, the number of participants needed to be offered 
surgery over plaster cast management (followed by fixation of fractures that fail to unite with cast immobilisation) in order to prevent one extra 
non- or slight union at 52 weeks is 44 (number needed to treat; NNT).  However, over a quarter of participants have missing data, and this 
calculation, by default, assumes that all those with missing data have at least partial union.  At the other extreme, assuming all missing have 
slight or non-union, the NNT is 11.  For non-union alone, the NNT is 73 and 12 in the two scenarios respectively.   
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Table 20: Summary of union assessment by time point and randomised group 
Time pointa Union 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
6 weeks Union 47 (21.5) 26 (11.8) 73 (16.6) 
 Almost full union 81 (37) 73 (33.2) 154 (35.1) 
 Partial union 47 (21.5) 70 (31.8) 117 (26.7) 
 Slight union 11 (5.0) 23 (10.5) 34 (7.7) 
 Non-union 2 (0.9) 9 (4.1) 11 (2.5) 
 Missing 31 (14.2) 19 (8.6) 50 (11.4) 
12 weeks Union 102 (46.6) 63 (28.6) 165 (37.6) 
 Almost full union 45 (20.5) 44 (20.0) 89 (20.3) 
 Partial union 15 (6.8) 33 (15.0) 48 (10.9) 
 Slight union 7 (3.2) 13 (5.9) 20 (4.6) 
 Non-union 0 (0.0) 10 (4.5) 10 (2.3) 
 Missing 50 (22.8) 57 (25.9) 107 (24.4) 
52 weeks Union 93 (42.5) 72 (32.7) 165 (37.6) 
 Almost full union 64 (29.2) 59 (26.8) 123 (28) 
 Partial union 3 (1.4) 10 (4.5) 13 (3) 
 Slight union 3 (1.4) 5 (2.3) 8 (1.8) 
 Non-union 1 (0.5) 4 (1.8) 5 (1.1) 
 Missing 55 (25.1) 70 (31.8) 125 (28.5) 
PRWE totalb Attend imaging 161, 10.6 (15.5) 145, 15.0 (20.1) 306, 12.7 (18.0) 
 Did not attend  25, 16.4 (22.1) 31, 10.6 (17.7) 56, 13.2 (19.8) 
a 6 and 12 weeks from radiographic images, 52 weeks from CT unless missing in which case radiographic 
imaging was considered 
b Total 52 week PRWE score, where available, according to whether patients attended or not for imaging at 
52 weeks; n, mean (SD) 
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The one participant in the plaster cast group with non-union assessed at 52 weeks by the three raters had surgical fixation of their fracture the 
day after randomisation, followed by wearing a splint for two weeks, and no concerns about non-union were raised and recorded in the treatment 
confirmation form at six or 12 weeks.  Of the four participants in the plaster cast group with non-union assessed, one had surgery to fix non-
union three months after randomisation, a further surgery for persistent non-union six months after that, and a month later surgery to remove the 
wires from the second operation.  The remaining three received routine treatment with a plaster cast and were not offered surgery, two since non-
union was not suspected by the treating clinician on review of radiography, while the third did not attend for radiography at six or 12 weeks. 
 
Malunion 
Malunion was determined by calculating the ratio of the scaphoid height to length, and determined using thresholds of both 0.6 and 0.7 (see 
Table 21).  By default, more participants are classified as having malunion using the 0.6 threshold than 0.7.  Considering those with non-missing 
data only, at six weeks, 175 (93.6%) participants in the surgery group and 180 (90.0%) in the plaster cast group had malunion based on the 0.6 
threshold.  At 0.7, the figures are 52 (27.8%) and 51 (25.5%), respectively.  Malunion at both thresholds remained reasonably steady in both 
groups at six, 12 and 52 weeks as determined via radiographic images.  However, at 52 weeks, on CT, the rate of malunion dramatically 
decreases to 60 (38.29%) participants in the surgery group and 45 (33.3%) in the plaster cast group at the 0.6 threshold, and 7 (4.5%) and 7 
(5.2%), respectively, at 0.7.       
 
Table 21: Malunion assessed at thresholds of scaphoid ratio height to length of 0.6 and 0.7 by randomised group and time point 
Time point Union 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
0.6 threshold     
Baseline No malunion 30 (13.7) 28 (12.7) 58 (13.2) 
(Radiographs) Malunion 182 (83.1) 190 (86.4) 372 (84.7) 
 Missing 7 (3.2) 2 (0.9) 9 (2.1) 
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Baseline No malunion 154 (70.3) 160 (72.7) 314 (71.5) 
(CT) Malunion 63 (28.8) 54 (24.5) 117 (26.7) 
 Missing 2 (0.9) 6 (2.7) 8 (1.8) 
6 weeks No malunion 12 (5.5) 20 (9.1) 32 (7.3) 
 Malunion 175 (79.9) 180 (81.8) 355 (80.9) 
 Missing 32 (14.6) 20 (9.1) 52 (11.8) 
12 weeks No malunion 10 (4.6) 12 (5.5) 22 (5.0) 
 Malunion 159 (72.6) 151 (68.6) 310 (70.6) 
 Missing 50 (22.8) 57 (25.9) 107 (24.4) 
52 weeks No malunion 9 (4.1) 13 (5.9) 22 (5.0) 
(Radiographs) Malunion 148 (67.6) 128 (58.2) 276 (62.9) 
 Missing 62 (28.3) 79 (35.9) 141 (32.1) 
52 weeks No malunion 97 (44.3) 90 (40.9) 187 (42.6) 
(CT) Malunion 60 (27.4) 45 (20.5) 105 (23.9) 
 Missing 62 (28.3) 85 (38.6) 147 (33.5) 
0.7 threshold     
Baseline No malunion 167 (76.3) 173 (78.6) 340 (77.4) 
(Radiographs) Malunion 45 (20.5) 45 (20.5) 90 (20.5) 
 Missing 7 (3.2) 2 (0.9) 9 (2.1) 
Baseline No malunion 214 (97.7) 212 (96.4) 426 (97) 
(CT) Malunion 3 (1.4) 2 (0.9) 5 (1.1) 
 Missing 2 (0.9) 6 (2.7) 8 (1.8) 
6 weeks No malunion 135 (61.6) 149 (67.7) 284 (64.7) 
 Malunion 52 (23.7) 51 (23.2) 103 (23.5) 
 Missing 32 (14.6) 20 (9.1) 52 (11.8) 
12 weeks No malunion 117 (53.4) 118 (53.6) 235 (53.5) 
 Malunion 52 (23.7) 45 (20.5) 97 (22.1) 
 Missing 50 (22.8) 57 (25.9) 107 (24.4) 
52 weeks No malunion 96 (43.8) 101 (45.9) 197 (44.9) 
(Radiographs) Malunion 61 (27.9) 40 (18.2) 101 (23.0) 
 Missing 62 (28.3) 79 (35.9) 141 (32.1) 
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52 weeks No malunion 150 (68.5) 128 (58.2) 278 (63.3) 
(CT) Malunion 7 (3.2) 7 (3.2) 14 (3.2) 
 Missing 62 (28.3) 85 (38.6) 147 (33.5) 
 
Complications 
At least one surgical complication, up to and including 52 weeks post-randomisation, was experienced by 31 (14.2%) participants randomised to 
the surgery group, and 3 (1.4%) participants in the plaster cast group.  The most common surgical complication was screw protrusion (see Table 
22), reported for 10 participants in the surgery group and one in the plaster cast group at six, 12 or 52 weeks.  A nerve event (of any kind) was 
reported for one participant in the plaster cast group (hypoaesthesia at 52 weeks) and for 10 unique participants in the surgery group.  Table 22 
only presents complications that were reported for at least one participant throughout the course of the study; however, we also explicitly asked 
about the following surgical complications, of which none were reported: superficial division of radial nerve, vessel events, and avascular 
necrosis.          
   
Table 22: Surgery related complications as assessed by clinical examination by randomised group and time point.  Figures are n (%), 
number of unique participants and percentage of those randomised 
Surgery related complications Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
Surgical site infection 6 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 1 (0.5) 2 (0.9) 3 (0.7) 
Delayed wound healing 6 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 1 (0.5) 1 (0.5) 2 (0.5) 
Regional pain syndrome 6 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 12 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
 52 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
Nerve event     
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Hypoaesthesia 6 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 1 (0.5) 1 (0.5) 2 (0.5) 
Numbness 6 weeks 3 (1.4) 0 (0.0) 3 (0.7) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
Superficial division 6 weeks 3 (1.4) 0 (0.0) 3 (0.7) 
of median nerve 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
Other nerve event 6 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 12 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 52 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
Screw Related Complications     
Protrusion 6 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 12 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
 52 weeks 7 (3.2) 1 (0.5) 8 (1.8) 
Bending 6 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
Radiolucent halo 6 weeks 1 (0.5) 0 (0.0) 1 (0.2) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
Implant problem – movement 6 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 3 (1.4) 0 (0.0) 3 (0.7) 
Othera 6 weeks 3 (1.4) 0 (0.0) 3 (0.7) 
 12 weeks 2 (0.9) 0 (0.0) 2 (0.5) 
 52 weeks 1 (0.5) 1 (0.5) 2 (0.5) 
≥1 surgical complication 6 weeks 14 (6.4) 0 (0.0) 14 (3.2) 
 12 weeks 6 (2.7) 0 (0.0) 6 (1.4) 
 52 weeks 15 (6.9) 3 (1.4) 18 (4.1) 
 Any time point 31 (14.2) 3 (1.4) 34 (7.7) 
a Other includes: 6 weeks (all surgery group) – painful, swollen, and stich sinus (n=1); stich still in situ (n=1); 
tingling sensation in fingers (n=1).  12 weeks (all surgery group) – pins and needles, and problems lifting 
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(n=1); pain, stiffness and swelling (n=1).  52 weeks – scar tenderness (surgery group, n=1); allergic reaction 
to dressing (plaster cast group, n=1) 
 
At least one issue relating to the plaster cast, up to and including 52 weeks, was reported for five (2.3%) participants randomised to the surgery 
group, and 40 (18.2%) participants in the plaster cast group (see Table 23).  The most commonly reported issue was that the cast caused soreness 
(this was generally minor rubbing of the skin), reported for three surgery participants and 23 plaster cast participants at six or 12 weeks. 
 
Table 23: Plaster cast related complications as assessed by clinical examination by randomised group and time point.  Figures are n (%), 
number of unique participants and percentage of those randomised 
Plaster cast issues Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
Cast broken 6 weeks 0 (0.0) 7 (3.2) 7 (1.6) 
 12 weeks 1 (0.5)   1 (0.5) 1 (0.5) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
Cast too soft 6 weeks 1 (0.5) 9 (4.1) 10 (2.3) 
 12 weeks 0 (0.0) 1 (0.5) 1 (0.2) 
 52 weeks 0 (0.0) 1 (0.5) 1 (0.2) 
Cast too tight 6 weeks 2 (0.9) 8 (3.6) 10 (2.3) 
 12 weeks 0 (0.0) 1 (0.5) 1 (0.2) 
 52 weeks 0 (0.0) 2 (0.9) 2 (0.5) 
Cast caused soreness 6 weeks 3 (1.4) 20 (9.1) 23 (5.2) 
 12 weeks 0 (0.0) 3 (1.4) 3 (0.7) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
Othera 6 weeks 0 (0.0) 5 (2.3) 5 (1.1) 
 12 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
≥1 cast complication 6 weeks 5 (2.3) 40 (18.2) 45 (10.3) 
 12 weeks 1 (0.5) 4 (1.8) 5 (1.1) 
 52 weeks 0 (0.0) 3 (1.4) 3 (0.7) 
 Any time point 6 (2.7) 45 (20.5) 51 (11.6) 
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a Other includes: 6 weeks (all Plaster cast group) - cast itchy (n=2); mild numbness of thumb (n=2); 
nerve event: hypoaesthesia left first branch at median nerve (n=1)  
 
At least one medical complication, up to 52 weeks, was reported for 4 (1.8%) participants randomised to the surgery group, and 5 (2.3%) 
participants in the plaster cast group.  These were either a chest infection or other issue (gastric upset; depression; or tenderness of affected wrist, 
see Table 24).  We also explicitly asked about the following medical complications, of which none were reported: myocardial infarction, stroke, 
DVT requiring treatment, and pulmonary embolism requiring treatment.          
 
 
Table 24: Other medical complications as assessed by clinical examination by randomised group and time point.  Figures are n (%), 
number of unique participants and percentage of those randomised 
Medical complications Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
Chest infection 6 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
 12 weeks 1 (0.5) 2 (0.9) 3 (0.7) 
 52 weeks 4 (1.8) 0 (0.0) 4 (0.9) 
Other 6 weeks 0 (0.0) 2 (0.9) 2 (0.5) 
 12 weeks 0 (0.0) 1 (0.5) 1 (0.2) 
 52 weeks 0 (0.0) 0 (0.0) 0 (0.0) 
≥1 medical complication 6 weeks 0 (0.0) 2 (0.9) 2 (0.5) 
 12 weeks 1 (0.5) 3 (1.4) 4 (0.9) 
 52 weeks 4 (1.8) 0 (0.0) 4 (0.9) 
 Any time point 4 (1.8) 5 (2.3) 9 (2.1) 
a Other includes: 6 weeks (all Plaster cast group) – gastric upset, possibly caused by ibuprofen (n=1); depression 
(n=1).  12 weeks (Plaster cast group) – tenderness of affected wrist (n=1) 
 
There was no evidence of a difference in the likelihood of participants experiencing at least one surgical, medical or cast complication (as 
recorded on the Complications form and detailed in Table 22, Table 23 and Table 24) up to 52 weeks between the two groups (surgery group 
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n=39 (17.8%) vs plaster cast group n=51 (23.2%); OR 0.72, 95% CI 0.45 to 1.15, p=0.17).  We must be careful in over interpreting this finding 
that the likelihood of experiencing a surgical, cast or medical complication is similar in both groups. Cast complications were observed more 
frequently among the plaster cast group, and surgical complications more frequently among the surgery group.  Plaster cast related complications 
tended to be relatively minor and would not result in ongoing problems (see Table 23). However, surgery related complications are more severe 
and are more likely to have potentially long-lasting consequences for the individual (see Table 22). As an example, Table 23 shows in the plaster 
cast group that half (30 of 58 events) of the complications were from the cast being broken, soft or tight which are given the same importance as 
complex regional pain syndrome or an infection in the statistical analysis of the complications. There was recording of non-union symptoms 
(n=8) as an adverse event or complication when this was an expected part of the control pathway and how a non-union was identified. There are 
also some discrepancies between the reporting of events on the complications form compared with the reporting of adverse events in the 
following section. For example the adverse events log three participants as having complex regional pain syndrome but the complication form 
only records two. The three raters’ review of the imaging identified further complications that were not accounted for in the adverse event forms 
or the complication forms, particularly after surgery. This could have been influenced by whether the problem had been recognised or the 
surgeon’s decision on whether this needed to be reported or whether the complication was identified on imaging done solely for research 
purposes and hence not available to clinicians. The logistic regression included complications from the hospital forms only and did not include 
those from other data sources (i.e. adverse event reporting or imaging). 
 
Cases when two out of the three raters agreed on imaging that there was a complication on review of imaging data are reported by randomised 
group and time point in Table 25.   
 
Osteoarthritis (OA) was detected at baseline on either radiographic or CT images for 25 (11.4%) participants in the surgery group, and 31 
(14.1%) in the plaster cast group.  OA was more likely to be detected on CT images than plain radiographic views.  Of these 25 in the surgery 
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group, 23 had radiographic or CT imaging at 52 weeks, and 17 were seen to have OA on either of these. OA was detected for a further 28 
participants at 52 weeks in the surgery group.  Of the 31 participants in the plaster cast group with OA at baseline, 22 had radiographic or CT 
imaging at 52 weeks, and 20 were seen to have OA on either of these. OA was detected for a further 22 participants at 52 weeks in the plaster 
cast group. 
 
Penetration of the screw (used during surgical fixation) of the radio-scaphoid joint (RSJ), scapho-trapezium joint (STJ) or other joint was 
reported for a total of 104 unique participants at six, 12 or 52 weeks (surgery n=94, 42.9%; plaster cast n=10, 4.6%).  At 52 weeks, the CT scans 
of 80 participants in the surgery group were reported to show screw penetration in one or more joints: RSJ n=44/80 (55.0%); STJ n=48/80 
(60.0%), and other joint n=19/80 (23.8%).  For the cast group, for which a smaller proportion underwent surgery, the CT scans of 9 participants 
were reported to show screw penetration in one or more joints: RSJ n=4/9, 44.4%; STJ n=6/9, 66.7%, and other joint n=0/9 (0.0%).  On CT 
scans at 52 weeks, the maximum screw protrusion was measured and seen to be, on average, 1.7 mm (SD 0.9, range 0.4 to 4.7) and was similar 
between the two groups.  Overall, maximum screw protrusion was categorised as <1 mm (20.7%), 1-2 mm (52.4%), and >2 mm (26.8%).      
 
Lucency was assessed based on categories on follow up radiographic images (worst of each view available) and 52-week CT scan (worst of each 
of three multiplanar reconstructions (MPRs) available) agreed by three observers using agreement rules.  This was only considered where an 
implant was present.  Serious lucency (1-2 mm) was only observed, on radiography, for one participant in the surgery group at six weeks, two 
(including the one at six weeks) at 12 weeks and 4 (including the one at 12 weeks who did not display lucency at six weeks) at 52 weeks.   
 
Prevalence of avascular necrosis (aka osteonecrosis) is summarised for the two groups in Table 25, and appears to be similar across the two 
group at baseline, but at later time points the plaster cast group has a higher proportion of more significant AVN cases.    
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Table 25: Complications reported on review of imaging data at six, 12 and 52 weeks by three independent raters by randomised group 
and time point. Figures are n (%), number of unique participants and percentage of those randomised 
Complication observed 
on independent review 
of imaging data 
Time point 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
Osteoarthritisa Baseline 
(radiography) N=218 N=220 N=438 
  21 (9.6) 22 (10.0) 43 (9.8) 
 Baseline (CT) N=217 N=214 N=431 
  22 (10.1) 26 (12.2) 48 (11.1) 
 6 weeks N=188 N=201 N=389 
  15 (8.0) 21 (10.5) 36 (9.3) 
 12 weeks N=169 N=163 N=332 
  21 (12.4) 28 (17.2) 49 (14.8) 
 52 weeks 
(radiography) N=157 N=142 N=299 
  25 (15.9) 24 (16.9) 49 (16.4) 
 52 weeks (CT) N=157 N=135 N=292 
  42 (26.8) 36 (26.7) 78 (26.7) 
Avascular necrosisa, b Baseline 
(radiography) N=218 N=220 N=438 
 None 204 (93.6) 204 (92.7) 408 (93.2) 
 Just 14 (6.4) 15 (6.8) 29 (6.6) 
 Missing 0 (0.0) 1 (0.5) 1 (0.2) 
 Baseline (CT) N=217 N=214 N=431 
 None 197 (90.8) 187 (87.4) 384 (89.1) 
 Just 20 (9.2) 27 (12.6) 47 (10.9) 
 6 weeks N=188 N=201 N=389 
 None 141 (75.0) 131 (65.2) 272 (69.9) 
 Just 46 (24.5) 61 (30.4) 107 (27.5) 
 Marked 1 1 (0.5) 8 (4.0) 9 (2.3) 
 Marked >1 0 (0.0) 1 (0.5) 1 (0.3) 
 12 weeks N=169 N=163 N=332 
 None 130 (76.9) 109 (66.9) 239 (72.0) 
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 Just 39 (23.1) 51 (31.3) 90 (27.1) 
 Marked 1 0 (0.0) 1 (0.6) 1 (0.3) 
 Marked >1 0 (0.0) 2 (1.2) 2 (0.6) 
 52 weeks 
(radiography) N=157 N=142 N=299 
 None 135 (86.0) 110 (77.5) 245 (81.9) 
 Just 22 (14.0) 27 (19.0) 49 (16.4) 
 Marked 1 0 (0.0) 4 (2.8) 4 (1.3) 
 Missing 0 (0.0) 1 (0.7) 1 (0.3) 
 52 weeks (CT) N=157 N=135 N=292 
 None 80 (51.0) 57 (42.2) 137 (46.9) 
 Just 72 (45.9) 69 (51.1) 141 (48.3) 
 Marked 1 5 (3.2) 5 (3.7) 10 (3.4) 
 Marked >1 0 (0.0) 3 (2.2) 3 (1.0) 
 Fragmented 0 (0.0) 1 (0.7) 1 (0.3) 
Screw penetrationc 6 weeks N=172 N=6 N=178 
  57 (33.1) 1 (16.7) 58 (32.6) 
 12 weeks N=156 N=6 N=162 
  55 (35.3) 2 (33.3) 57 (35.2) 
 52 weeks 
(radiography) N=135 N=15 N=150 
  52 (38.5) 5 (13.3) 57 (38.0) 
 52 weeks (CT) N=136 N=11 N=147 
  75 (55.1) 8 (72.7) 83 (56.5) 
Screw lucencyc 6 weeks N=172 N=6 N=178 
 None 139 (80.8) 4 (66.7) 143 (80.3) 
 <1 mm 32 (18.6) 2 (33.3) 34 (19.1) 
 1-2 mm 1 (0.6) 0 (0.0) 1 (0.6) 
 12 weeks N=156 N=6 N=162 
 None 113 (72.4) 6 (100.0) 119 (73.5) 
 <1 mm 41 (26.3) 0 (0.0) 41 (25.3) 
 1-2 mm 2 (1.3) 0 (0.0) 2 (1.2) 
 52 weeks 
(radiography) N=135 N=15 N=150 
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 None 99 (73.3) 7 (46.7) 106 (70.7) 
 <1 mm 32 (23.7) 8 (53.3) 40 (26.7) 
 1-2 mm 4 (3.0) 0 (0.0) 4 (2.7) 
 52 weeks (CT) N=136 N=11 N=147 
 None 108 (79.4) 7 (63.6) 115 (78.2) 
 <1mm 22 (16.2) 3 (27.3) 25 (17.0) 
 >1mm 4 (2.9) 1 (9.1) 5 (3.4) 
 Uneven 2 (1.5) 0 (0.0) 2 (1.4) 
a N represents those with imaging; b >1 indicates density observed on more than one view or MPR;  c N 
represents number for which screw was observed on imaging  
 
Adverse events 
At least one non-serious adverse event was reported for 24 (11.0%) participants in the surgery group, and 29 (13.2%) in the plaster cast group 
(difference in percentages -2.2%, 95% CI -8.3 to 3.9%) (see Table 26).  Of those that experienced at least one event, most reported only one 
event (surgery group n=19, 79.2%; plaster cast group n=23, 79.3%) but participants reported up to three events each.  In total, 30 [36] events 
were reported for participants in the surgery [plaster cast] group, of which 24 (80.0%) [4 (11.1%)] were related to receiving anaesthesia and/or 
surgery, 3 (3.0%) [23 (63.9%)] were related to cast treatment, and 3 (3.0%) [9 (25.0%)] were other events. Sixteen events (surgery group n=5, 
16.7%; plaster cast group n=11, 30.6%) were deemed to be unexpected by the reporting clinician. 
 
Table 26: Non-serious adverse events by randomised group 
Non-serious adverse events 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
No. participants reporting ≥1 adverse events, n (%) 24 (11.0) 29 (13.2) 53 (12.1) 
Total number of non-serious adverse events 30 36 66 
Number of non-serious events per participant, n (%)    
0 195 (89.0) 191 (86.8) 386 (87.9) 
1 19 (8.7) 23 (10.5) 42 (9.6) 
2 4 (1.8) 5 (2.3) 9 (2.1) 
3 1 (0.5) 1 (0.5) 2 (0.5) 
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Adverse events of anaesthesia and/or surgerya, n (%)    
Screw related complication 9 (30.0) 1 (2.8) 10 (15.2) 
Nerve or vessel event 4 (13.3) 1 (2.8) 5 (7.6) 
Infection 2 (6.7) 2 (5.6) 4 (6.1) 
Complex Regional Pain Syndrome 3 (10.0) 0 (0.0) 3 (4.6) 
Symptoms consistent with non-union 1 (3.3) 0 (0.0) 1 (1.5) 
Other 5 (16.7) 0 (0.0) 5 (7.6) 
Any of the above 24 (80.0) 4 (11.1) 28 (42.4) 
Adverse events of cast treatmenta, n (%)    
Pain related to the cast 2 (6.7) 6 (16.7) 8 (12.1) 
Symptoms consistent with non-union 0 (0.0) 8 (22.2) 8 (12.1) 
Pressure sores 0 (0.0) 5 (13.9) 5 (7.6) 
Pain due to tight cast 1 (3.3) 2 (5.6) 3 (4.6) 
Soft cast/broken cast that leads to movement of wrist 0 (0.0) 2 (5.6) 2 (3.0) 
Any of the above 3 (3.0) 23 (63.9) 26 (39.4) 
Othera, n (%)    
Reinjury 2 (6.7) 7 (19.4) 9 (13.6) 
Allergy to dressing 0 (0.0) 2 (5.6) 2 (3.0) 
Substance abuse 1 (3.3) 0 (0.0) 3 (1.5) 
Any of the above 3 (3.0) 9 (25.0) 12 (18.2) 
Gradingb, n (%)    
Mild 22 (73.3) 28 (77.8) 50 (75.8) 
Moderate 7 (23.3) 7 (19.4) 14 (21.2) 
Severe 1 (3.3) 0 (0.0) 1 (1.5) 
Missing 0 (0.0) 1 (2.8) 1 (1.5) 
Causalityb, n (%)    
Not related 2 (6.7) 8 (22.2) 10 (15.2) 
Unlikely to be related 2 (6.7) 2 (5.6) 4 (6.1) 
Possibly related 10 (33.3) 2 (5.6) 12 (18.2) 
Probably related 4 (13.3) 1 (2.8) 5 (7.6) 
Definitely related 12 (40.0) 23 (63.9) 35 (53.0) 
Expectednessb, n (%)    
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Expected 25 (83.3) 25 (69.4) 50 (75.8) 
Unexpected 5 (16.7) 11 (30.6) 16 (24.2) 
a retrospectively and independently classified by two clinicians, disagreements discussed and resolved; b 
classifications as provided on Adverse Event Initial Report Form by reporting clinician    
 
There were three reported serious adverse events, all for three (1.4%) participants in the surgery group (see Table 27).  All three were related to 
anaesthesia and/or surgery, and two were deemed to be unexpected at the time of reporting. 
 
Table 27: Serious adverse events by randomised group 
Serious adverse events 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
Total 
(n=439) 
No. participants reporting ≥1 adverse events, n (%) 3 (1.4) 0 (0.0) 0 (0.0) 
Total number of serious adverse events 3 0 0 
Number of serious events per participant, n (%)    
0 216 (98.6) 220 (100.0) 436 (99.3) 
1 3 (1.4) 0 (0.0) 3 (0.7) 
Type of eventb, n (%)    
Hospitalisation 2 (66.7) 0 (0.0) 2 (66.7) 
Persistent or significant disability/incapacity 1 (33.3) 0 (0.0) 3 (33.3) 
Adverse events of anaesthesia and/or surgerya, n (%)    
Anaesthetic complication 2 (66.7) 0 (0.0) 2 (66.7) 
Symptoms consistent with non-union 1 (33.3) 0 (0.0) 1 (33.3) 
Causalityb, n (%)    
Definitely related 3 (100.0) 0 (0.0) 3 (100.0) 
Expectednessb, n (%)    
Expected 1 (33.3) 0 (0.0) 1 (33.3) 
Unexpected 2 (66.7) 0 (0.0) 2 (66.7) 
Durationb, n (%)    
≤24 hours 2 (66.7) 0 (0.0) 2 (66.7) 
>24 hours 1 (33.3) 0 (0.0) 1 (33.3) 
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a retrospectively and independently classified by two clinicians, disagreements discussed and resolved; b 
classifications as provided on Adverse Event Initial Report Form by reporting clinician    
 
 
Agreement analysis 
Descriptive analyses of the agreement between the three independent raters on review of radiographic and CT imaging is presented in Appendix 
5. 
 
Participant use of home exercises to care for wrist 
When entered into the study, participants should have been provided with written advice about home exercises to perform to care for 
their wrist.  Participants were asked on the 12 week participant questionnaire how they found doing these exercises.  Responses to these 
questions are provided in 
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Appendix 3, Table 64.  Of those that provided a response to the question, 151/176 (85.8%) in the surgery group, and 123/155 (79.4%) in the 
plaster cast group reported that they found the exercises very or quite useful. Among those that performed the exercises, they were reported to 
have been performed on a median of 41 days (range 1 to 168) in the surgery group, and 35 (range 2 to 137) in the plaster cast group.  On the 52-
week complication form, data were collected on whether the participant was referred for physiotherapy for the treatment of their wrist injury 
during the previous year.  Approximately twice as many participants allocated to the surgery group had been referred for physiotherapy than 
those in the plaster cast group (n=58, 26.5% vs n=30, 13.6%).   
 
Participant perceptions of their wrist and treatment preference at 52 weeks  
On the 52 week questionnaire, participants were asked about the state of their wrist now compared to a year ago (see 
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Appendix 3, Table 65Error! Reference source not found.).  Of those that provided a 
response to the question, a very similar proportion in the two groups reported that their wrist 
felt much or slightly better (surgery group 166/181, 91.7%; plaster cast group 156/174, 
89.7%).  Participants were also asked, based upon their experiences of the treatment received 
as part of the trial, if they injured their wrist to the same extent as they did 52 weeks ago, 
which treatment they would prefer.  Of those that provided a response to the question, three 
quarters in the surgery group reported that they would have surgery again (137/181, 75.7%), 
36 (19.9%) did not have a preference, and 8 (4.4%) reported that they would not have 
surgery.  In the plaster cast group, there was a reasonably equal split among the three 
categories: surgery n=59/175, 33.7%; no preference n=68, 38.9%, and not surgery n=48, 
27.4%. 
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Chapter 4 Economic evaluation 
The role of economic evaluation is to consider the relative merits of competing treatment 
alternatives weighed against their costs, using a consistent analytical perspective.  This 
Chapter investigates the possible impact of available treatments for adults with bi-cortical, 
minimally displaced fractures of the scaphoid waist on the health of the patient and costs to 
the NHS and personal social services (PSS), both in the short and long-term.   
 
This is achieved in two ways, firstly, the short-term health and costs to the NHS of the 
treatment are considered through a within-trial analysis, using direct results of the clinical 
trial up to 52 weeks of follow up.  This analysis focusses on the short-term health 
implications of treatment and the immediate period of rehabilitation and the associated costs 
of this care. Secondly, as  persistent non-union of the fracture and the development of 
osteoarthritis have potentially lifelong implications, it is necessary to consider the long-term 
implications of the treatments.  This is achieved through an extrapolated analysis, where 
mathematical modelling of the expected future health of the patients is used to estimate the 
health and resource use implications beyond the timeframe of this SWIFFT report.  
 
Within trial analysis - methods 
The SWIFFT trial collected a rich array of information from both patients and clinicians on 
the health and resource use during and after treatment.  This within trial analysis will consider 
the quality of life, as reported by the EQ-5D, and the level of NHS costs, estimated through 
the treatment received and the patient reported estimates of interaction with the NHS, at a per 
patient level for the 52 weeks after randomisation into the trial (the ‘within analysis period’).  
This analysis was conducted using the Stata software package.91  
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The base-case is an intention to treat (ITT) analysis.  An additional scenario of per protocol is 
presented, whereby any patients who were deemed to crossover from one treatment allocation 
to another are excluded from the analysis.   
 
Missing data is imputed for both cost and quality of life components, as detailed later in this 
section.  Relevant summary statistics and estimates of the quality of life and costs associated 
with patients are reported at both a complete case level (i.e. dropping all cases of missing 
data) and after imputation.  Regression analyses are also conducted on total quality of life and 
costs in the within trial period to consider the impact of key patient characteristics on quality 
of life and costs, beyond the treatment allocation.  The approach taken to missing data and the 
regression analyses conducted on quality of life and costs in this chapter are consistent with 
those outlined for the PRWE in statistical methods section of Chapter 2.  
 
The primary clinical justification for surgical intervention is the reduced future risk of 
osteoarthritis and other long-term adverse events which may not become evident until after 
the within trial period, and as such consideration of the cost-effectiveness of the treatment 
options with only a within trial timeframe would be misleading.  As a result, conclusions 
about the cost-effectiveness of the treatment options will be limited to the presentation of a 
within trial point estimate incremental cost-effectiveness ratio (ICER), the difference in 
average costs between two treatment pathways divided by the difference in average quality of 
life for the within trial period. 
 
Quality of life – EQ-5D 
The EQ-5D is a validated questionnaire to assess the generic health status or quality of life of 
a patient, consisting of questions covering five dimensions of health mobility, self-care, usual 
activity, pain/discomfort, and anxiety/depression.92 It is the most widely used means of 
consistently estimating the general health of a patient, and is used by NICE as its preferred 
measure.93  While other disease specific estimation questionnaires are available, such as the 
PRWE, they do not allow for comparison across disease areas, and cannot be used to 
determine the optimal allocation of limited NHS resources.  A score of 0 is equivalent to 
death, and 1 represents perfect health, negative scores are considered worse than death.  
Under the UK preference weighting achievable scores range from -0.594 (worst response 
across all five dimensions) to 1 (best responses). 
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EQ-5D questionnaires were collected at baseline, and then at six, 12, 26, and 52 weeks after 
randomisation.  In this section the combined EQ-5D score using the preference weighting are 
presented, such that each patient who completed a questionnaire at each time point has a 
single EQ-5D quality of life ‘score’ given to them based on their responses to the 
questionnaire.  These scores are carried forward to the missing data analysis discussed later in 
this section and the within trial analyses.   
 
After having imputed for any missing questionnaires (see later section) the quality of life 
scores are combined to estimate a score for the patient across the full within trial period, 
using the equation reported below, where ti is the time in days at which questionnaire ‘i’ was 
conducted, and QoLi is the quality of life score reported at time ‘i’.   𝑄𝑜𝐿𝑤𝑖𝑡ℎ𝑖𝑛 𝑡𝑟𝑖𝑎𝑙 =  (𝑄𝑜𝐿𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × 𝑡6𝑤𝑘−𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒2 +  𝑄𝑜𝐿6𝑤𝑘 × (𝑡6𝑤𝑘−𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒2 + 𝑡12𝑤𝑘−𝑡6𝑤𝑘2 ) +𝑄𝑜𝐿12𝑤𝑘 × (𝑡12𝑤𝑘−𝑡26𝑤𝑘2 + 𝑡26𝑤𝑘−𝑡12𝑤𝑘2 ) +  𝑄𝑜𝐿26𝑤𝑘 × (365−𝑡26𝑤𝑘2 +𝑡26𝑤𝑘−𝑡52𝑤𝑘2 ) +  𝑄𝑜𝐿52𝑤𝑘 × 365−𝑡26𝑤𝑘2 ) / 365  
 
This combined quality of life score is used to inform the regression analysis conducted to 
estimate the impact of patient characteristics, including treatment allocation, on quality of 
life.   
 
Resource Use and Unit Costs 
Costs to the NHS are considered in two ways: those reported by clinical staff, and those 
reported by patients at six, 12, 26 and 52 weeks during the trial (see trial CRFs in 
Supplementary File 15).  As the trial did not directly seek to report the costs of care, but the 
frequency of various interactions and care provision, all elements reported have to be linked 
with an appropriate unit cost to estimate total costs.  We assumed that all interactions with the 
NHS were captured by the trial CRFs.   
 
Relevant resource use is reported from the time of randomisation into the trial, and do not 
include the cost of initial presentation with the injury, nor care that might occur prior to 
randomly allocated treatment, typically immobilisation with a cast or splint.  Randomisation 
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should ensure that these initial treatment options and costs are balanced between the two 
groups.  
 
For the purpose of the costing of the within trial analysis only those interactions reported as 
being related to the patient’s wrist are included.  Unrelated interactions reported by the 
patients should not impact the incremental cost but risks introducing bias if patients had high 
cost but completely unrelated healthcare.  An investigation into the level of NHS and PSS 
interactions for reasons other than the wrist injury confirmed that there was no statistically 
significant difference between the trial arms (mean number of interactions 5.65 for plaster 
immobilisation, 5.91 for surgical fixation, p-value of 0.828).  
 
The unit costs associated with each component of the within trial analysis are presented in 
Table 28.  
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Table 28: Unit costs associated with within trial analysis 
Stage Cost item Value Source/assumption 
T
re
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d
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Cost of casts, 
both initial at 
diagnosis and 
additional casts  
£10 Consistent with NICE NG38.90  
Assumes costs of hospital attendance etc. 
are covered in patient reported activity.  
Cost of primary 
surgery (patients 
randomised to 
surgical arm) 
£1,632 
 
Weighted average of adult HT44 
(intermediate hand procedures for trauma, 
mapped from all open OPCS code), 
Reference Cost 2015/1694 
 
Cost of 
secondary 
surgery (repeat 
surgery for 
surgical arm and 
surgery for cast 
arm of trial) 
£2,509 Weighted average of adult HT43 (Major 
hand procedures for trauma, mapped from 
all closed OPCS code), Reference Cost 
2015/1694 
Cost of 
radiograph 
£30  Reference Costs 15/16, DAPF, Direct 
Access Plain Film 
Cost of CT 
scans 
£94 Reference Costs 15/16, RD20A, 
Computerised Tomography Scan of one 
area, without contrast, 19 years and over94 
Cost of MRI £145 Reference Costs 15/16, RD01A, Magnetic 
Resonance Imaging Scan of one area, 
without contrast, 19 years and over94 
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GP – at practice £37 Based on estimates from PSSRU (11.7 
minute consultation)95 
GP – at home £74 Based on estimates from PSSRU (11.4 
minute consultation plus 12 minute of 
travel)95 
GP – by phone £22 Based on estimates from PSSRU (7.1 
minute consultation)95 
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Physiotherapist 
– at GP practice 
£49  Reference cost 2015/16 A08A1 
(physiotherapist, adult, one to one, 
community)94 
Nurse – at GP 
practice 
£12 Based on estimates of duration of contact 
and cost per hour of face to face time from 
PSSRU 95 
District/commu
nity nurse 
£38 Reference Costs 15/16 (N02AF, district 
nurse, adult, face to face, community) 94 
Occupational 
therapist 
£79  Reference Costs 15/16 (A06A1, 
occupational therapist, adult, one to one, 
community) 94 
Hospital – 
physiotherapist 
£46  Reference Costs 15/16, WF01A, Non-
Admitted Face to Face Attendance, 
Physiotherapy94 
Hospital – 
occupational 
therapist 
£58  Reference Costs 15/16, WF01A, Non-
Admitted Face to Face Attendance, 
Occupational therapist94 
Hospital – A&E £157  Reference Costs 15/16, WF01B, Non-
Admitted Face to Face Attendance, First, 
Accident & Emergency 94 
Hospital – 
fracture clinic 
£110  Reference Costs 15/16, WF01A, Non-
Admitted Face to Face Attendance, Trauma 
and orthopaedics94 
Hospital – pain 
management 
clinic 
£131  
 
Reference Costs 15/16, WF01A, Non-
Admitted Face to Face Attendance, Pain 
Management94 
 
Hospital – in 
patient stay 
£269 per day Weighted average of Reference Costs 15/16 
HE41 hand fracture without intervention 
excess bed days94 
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Patient reported costs are estimated at six, 12, 26, and 52 weeks for the purpose of the 
missing data analysis, and treatment and imaging costs estimated for the full within trial 
period.   
 
After imputation for patient reported costs at the four time points and imaging costs, costs are 
combined into an estimate of the total patient level cost for the within trial period.   
Patient reported medications, aids, and out of pocket costs such as private healthcare related 
to the initial injury are excluded from this analysis.  In the case of medications, all reported 
cases were identified as being low cost pain killers which either cost less than the patient 
prescription cost or could have been purchased by patients over the counter.  Aids are not 
routinely provided to patients on the NHS, as reflected by the trial data and as such reflect a 
private cost which, alongside out of pocket costs, fall outside of NHS and PSS perspective 
taken in this Chapter.  
 
Missing data 
Missing data was imputed across the patient reported questionnaires related to quality of life 
and resource use in addition to imaging.  Using the framework described in Faria 96 the 
missing data was assumed to be missing at random (MAR).  Imputation was conducted 
across all nine cost and quality of life variables identified as having missing data, i.e. costs at 
six, 12, 26, and 52 weeks, and quality of life at baseline, six, 12, 26, and 52 weeks.  
Consistent with the missing data approach outlined in the PRWE analysis in the previous 
Chapter these missing variables were assumed to be correlated to each other as well as 
treatment allocation, age at randomisation, whether the patient’s dominant hand was 
fractured, and displacement of the fracture.  Number of imputations was set equal to the 
proportion of missing values in the variable with the largest level of missingness, presented in 
the results section.  Imputation was conducted using the ‘ICE’ multiple imputation package in 
Stata, and reporting using the ‘MIM’ package.97, 98  
 
Impact of lost employment and unpaid activities 
In addition to consideration of costs to the NHS and PSS and quality of life to the patients, 
this within trial analysis reports the impact of treatment allocation on days of lost 
employment and unpaid activities.  The method of this analysis are reported in Appendix 6, 
Section 1. 
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Extrapolated model - methods 
As the implications, both in terms of NHS costs and patient health, of the different treatment 
options and associated adverse events can persist beyond the 52 week follow-up of the trial 
an extrapolation model is required to estimate cost-effectiveness over a lifetime.  These 
beyond trial implications were discussed in Chapter 1 and can be broadly categorised by the 
future burden of osteoarthritis, SNAC and long-term pain or limited mobility, that occur as a 
direct result of the initial injury and its treatment.   
 
Systematic review of existing cost-effectiveness evidence 
A literature review was conducted to determine whether previous economic evaluations had 
sufficiently determined the cost-effectiveness of surgical fixation versus plaster cast 
immobilisation for bi-cortical, minimally displaced fractures of the scaphoid waist in adults.  
A secondary aim of the search was to determine if previous mathematical models could be 
adapted to estimate the long-term cost-effectiveness, and thus remove the need to construct a 
de novo mathematical model.  Full details and results of the search strategy and results are in 
Appendix 6, Section 2.  
 
The review found no suitably robust cost-effectiveness analysis.  Therefore, we determined 
that a de novo mathematical model was required to investigate the long-term cost 
effectiveness of surgical fixation compared to cast immobilisation.   
 
Cost-effectiveness analysis: analytical methods and model inputs 
This section details the scope of the de novo extrapolated model and provides details on its 
structure, base-case inputs, and scenarios considered.  
 
Analytical approach 
The analysis presented here uses a methodology consistent with the NICE Guide to the 
Methods of Technological Appraisal,93 and Decision Modelling for Health Economic 
Evaluation.99 In brief, real world observations from trial data, published literature and expert 
opinion were used to estimate the expected lifetime health and resource use per patient for 
each treatment comparator.   
 
Conventional outcomes of these models used to determine the cost-effectiveness of the 
different treatment pathways are lifetime cost, expected life years, and expected Quality 
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Adjusted Life Years (QALYs).  These estimates are compared across treatment pathways by 
estimating the ICER.  A cost-effectiveness threshold of  £20,000/QALY is used as the base-
case value to estimate the net health benefit (NHB) of each of the treatment options,100 
calculated by: 
NHB = expected mean QALYs of intervention – (mean cost of treatment option / cost-
effectiveness threshold)  
 
To incorporate the uncertainty present in the estimation of such models, two approaches are 
used: 1) probabilistic sensitivity analysis (PSA) and 2) scenario analysis.  PSA explicitly 
incorporates the uncertainty present in parameter estimates by using the range of values over 
which these estimates exist (characterised by an informative distribution), rather than single 
point estimates, as inputs into the mathematical models.99   
 
Scenario analyses are used to test the structural uncertainty of the models, where the 
underlying structure and sources of evidence are changed to explore the impact of such 
uncertainty on the results of the models.   
 
Value of information analysis explored the population expected value of perfect information 
(EVPI), an assessment of the benefit of resolving all uncertainty in the parameter estimates of 
the base case model.  
 
Analytical perspective 
Consistent with the within trial analysis, the full, extrapolated, analysis takes as its primary 
perspective the health outcomes to the patient, expressed in QALYs, and the costs to the 
NHS, expressed in UK pound sterling at 2017 prices. A lifetime time horizon is used in the 
base-case analysis to reflect the full duration of impact of potential adverse events including 
osteoarthritis and SNAC. Both costs and outcomes are discounted using a 3.5% annual 
discount rate consistent with current guidelines.93 The model was developed using Microsoft 
Excel 2013.   
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Decision problem 
Consistent with the SWIFFT trial protocol this analysis seeks to estimate the most cost-
effective treatment pathway for adults presenting with an undisplaced (<1mm step or gap) 
and minimally displaced (1mm to 2mm inclusive) bicortical fracture of the scaphoid waist.  
An important element of any analysis that seeks to determine the cost-effective treatment is 
the full incorporation of all possible treatment alternatives, including those beyond the two 
considered in the SWIFFT.  A brief review of the literature, using the framework outlined in 
Appendix 6, Section 2, and discussions with the SWIFFT Trial Management Group, 
highlighted that no active treatments beyond combinations of cast and surgical fixation were 
considered relevant to an NHS setting, with the only other treatment identified, pulsed 
electromagnetic fields, rarely used in the UK.  To ensure the extrapolated model includes all 
possible treatment options the following four are considered; the first two are extensions of 
the SWIFFT trial: 
 
1) No treatment – All patients who experience a scaphoid waist fracture are left untreated. 
While unlikely to happen in practice, and considered unethical to include 
in the SWIFFT trial, this is an important anchor point to ensure that all 
active treatments are well demonstrated to be effective and cost-effective 
compared to providing no intervention, and a means of model validation.  
Furthermore, the Trial Management Group confirmed some patients 
choose to not have treatment, often not attending for diagnosis or 
refusing recommended treatment. This arm therefore is important to 
explore the validity of patients decision.  
2) Cast immobilisation only – All patients are treated with cast immobilisation alone, such 
that patients who are identified as having non-union are not able to 
progress to surgery.  While not incorporated into the SWIFFT trial 
this allows the analysis to test whether the addition of surgical 
fixation for non-union patients is cost-effective compared to casting 
alone.  Furthermore, it represents the historic treatment option in 
many cases, before fixation surgery was routinely offered. In this and 
all other similar cases ‘cast’ refers to all forms of non-surgical 
immobilisation, including casts with thumb incorporated and 
excluded, and splints. 
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3) Cast immobilisation followed by immediate surgery – In line with the SWIFFT trial 
population patients are initially treated with casting 
with immediate surgical fixation soon after cast 
removal offered to all patients who have non-union 
detected. 
4) Surgical fixation – In line with the SWIFFT trial patients are initially treated with 
surgical fixation, if primary fixation is unsuccessful (either due to 
implant problems or failure of union) patients are offered additional 
surgery.  
The assumptions related to each are considered later in this chapter. 
 
Population  
The population considered in the extrapolated model is consistent with the SWIFFT trial, as 
described in Chapter 2.  
 
Inevitably, when an economic evaluation model has to use evidence from the existing 
literature to inform an extrapolation there are some differences between the analysed 
population and that considered in the relevant literature.  These are identified and discussed 
later in this chapter, with biases explored where possible.  
 
Model structure 
The model itself has two components: 1) a short-term decision model, which characterises the 
first 52 weeks after initial presentation, consistent with the SWIFFT trial period,, and 2) a 
long-term element, over which the implications of the treatment and union status on long-
term outcomes and costs are considered.  These two components are presented separately 
below for clarity but are intricately linked.  
 
The model takes as a starting point the time at which a treatment decision is made, such that 
patients have already experienced the injury and attended hospital for initial assessment.  As 
a result, the nature of the fracture is known and the patient has been identified as within this 
population.   
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Short-term decision model  
Covering the first year since treatment the short-term element closely matches the within-trial 
analysis by drawing directly from the findings of the SWIFFT trial with the additional 
treatment pathways of no treatment and primary cast immobilisation only.  Figure 7 provides 
an overview of the short-term element of the model through this 52 week period, from the 
treatment decision to the 52 week time point, at which point patients enter the long-term 
‘Markov’ model, symbolised by the M in the figure. The key features of each treatment arm 
in the short-term element are as follows: 
 
No treatment – After having been identified as within the population considered in this 
analysis all patients receive no active treatment, i.e. neither cast nor surgery.  As a result no 
short-term treatment costs are incurred but patients are assumed in the base-case analysis to 
never achieve union of the fracture.  While it is expected that some untreated fractures would 
unite, as the literature provides examples of such,101, 102 it is not possible to estimate this as a 
proportion of all cases and as such the base-case assumes no cases of union.  This assumption 
is explored in a later scenario.  
 
Cast immobilisation only – Primary cast immobilisation is assumed to be the only treatment 
available to patients, such that all are initially immobilised in a cast but should the fracture 
fail to unite no subsequent surgery is available. Treatment characteristics and rates of union 
are drawn directly from the SWIFFT trial primary cast immobilisation arm but all those 
offered post-cast surgery for non-union are assumed to remain as non-unions. 
 
Cast immobilisation with immediate surgery for non-union – This treatment arm is 
consistent with the cast only arm except that patients who fail to achieve union are offered 
surgical fixation as in the SWIFFT trials, a proportion of who will opt for it.  The patients 
who failed to achieve union with the cast and chose to not have surgery are assumed to end 
the short-term component still having non-union, while patients who opted for surgical 
fixation can achieve union or non-union at a rate determined by the SWIFFT trial results.  
 
Primary surgery – As per the arm of the SWIFFT trial patients are treated with surgical 
fixation as their primary treatment, many patients initially receive a cast which is removed 
and surgery performed.  After surgery patients can achieve union or non-union.  A small 
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proportion determined by the SWIFFT trial have multiple rounds of surgery if the primary 
surgery is unsuccessful or there are complications.  Furthermore, most patients are provided 
with a cast after surgery as part of routine therapy. 
 
All cost and quality of life impacts that occur within this first year are included in the 
estimates presented later in this section. Mortality within the first year is not explicitly 
modelled as scaphoid related death is not expected to occur and the primary population is 
young, with no related or unrelated deaths observed in the SWIFFT trial.   
 
 
Figure 7: schematic of the short-term element of the economic evaluation model 
 
 
Long-term Markov model 
The long-term cost and health outcomes extrapolated beyond the 52 weeks short-term model 
are estimated using two Markov models, presented in Figure 8 and Figure 9.  In a Markov 
model, patients reside in one out of a set of mutually exclusive health states at particular 
points in time.103  During discrete time intervals, these patients can either remain in a 
particular health state or move to a separate health state, typically because they have 
experienced a particular clinical event.  
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As shown in Figure 8 and Figure 9 the Markov model patients enter is dependent on their 
union status at the end of the short-term decision model, with patients achieving union 
entering the model outlined in Figure 8 and non-union patients the one in Figure 9.  This is 
consistent with the very different long-term clinical expectations associated with the two 
groups, as discussed in Chapter 1, with union patients likely to regain usual health and 
function, but those with non-union likely to have long-term health concerns. 
 
The treatment pathway a patient experienced to get to their union status is informative to their 
rate of transition through the respective model. In other words, while a patient’s prior 
treatment is assumed to not impact the set of long-term health states they can achieve, it does 
impact the likelihood with which they achieve them.  
 
Patients achieving successful union at the end of the short-term element are placed in one of 
two starting states in the union Markov: ‘no osteoarthritis (OA) or other adverse events 
(AEs)’, and ‘no OA but long-term AEs’.  This distinction is made due to the prevailing 
evidence that a number of patients experience lifelong symptomatic adverse events associated 
with the original injury and treatment that are not related to the development of OA.  
Specifically, Lindström & Nyström104 reported the presence of pain and weakness not 
associated with OA in their long-term follow-up study of patients treated with cast 
immobilisation.  Limitations in the available evidence on the long-term transitions 
necessitated the assumption that these patients represent a separate group than those who will 
go on to develop OA.   
 
Patients who experience permanent long-term symptomatic adverse events without OA 
remain in this state until they die of other causes, as the treatment or related events are 
unlikely to cause death.  We also assumed that these non-OA AEs are fixed for the patient’s 
remaining lifetime, with all time limited adverse-events being resolved within the short-term 
element of the model (i.e. within a year of injury).  
 
Patients who enter the long-term model in the adverse event free state (i.e. no OA nor other 
AEs) can similarly stay in this state until they die of other causes, or they may develop OA, 
which is modelled as being either symptomatic or non-symptomatic, again informed by the 
literature.  As is discussed later, limitations in the data mean we are unable to model the 
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potential development of OA from non-symptomatic to symptomatic, or the potential for 
different levels of symptomatic presentation.  From each of the OA states patients stay in the 
state until they die of other causes. 
 
The dearth of evidence relating to the development and transition between adverse events in 
this population necessitated the assumption that patients do not transit between the three 
adverse event states.  As a result, the analysis assumes that patients only experience at most 
one lifelong adverse event.  As there is no difference in the cost or utility difference in the 
two symptomatic states, discussed later in this section, and the asymptomatic OA state is 
based on long-term observational data, this model assumption does not impact the result of 
the analysis. 
 
 
Figure 8: Long-term Markov model for successful union 
 
In contrast, patients who end the short-term element in a non-union state are modelled based 
on their risk of developing SNAC, as shown in Figure 9.  As discussed in Chapter 1, SNAC 
represents a serious adverse event which results from non-union, whereby the proximal 
M  
Union 
OA without 
any 
symptoms  OA with 
symptoms  
No OA but 
long-term 
symptoms  
Death   
No OA nor 
other AEs  
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carpal row can no longer stabilise the distal carpal row, and hence the wrist. The resulting 
abnormal loading leads to carpal collapse, cartilage degeneration and arthritis. Due to a 
dearth of evidence relating to the natural history of events associated with non-union we were 
not able to model separate states reflecting the development of OA and other symptoms 
within the non-union Markov. Patients in this Markov model enter in the no SNAC state and 
throughout their lifetime face a risk of progressing to SNAC or dying from unrelated causes.  
As with OA in the union Markov, SNAC is modelled as being a binary disease state, but 
unlike OA is assumed to always be symptomatic due to the severity of the condition.  Due to 
the challenging nature of treating SNAC, and lifetime implications even if treatment is 
successful, patients are modelled as remaining in the SNAC state for the rest of their life if it 
develops.  Unlike the union model, patients are not modelled as separately having non-OA 
related long-term symptoms and non-symptomatic OA.  This assumption is due to the 
observation by Dias105 that almost all patients (9 of 10) had pain or stiffness after a mean of 
2.1 years.  Therefore, our base-case model assumes that all non-union patients had some 
quality of life decrement, incorporating a range of adverse events including low grade OA 
and non-OA adverse events.  
 
 
 
Figure 9: Long-term Markov model for non-union 
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Model inputs 
Much of the evidence defining the patient cohort and the short-term element are sourced 
directly from the SWIFFT trial.    As the SWIFFT trial currently only has 52 weeks of patient 
follow up, all long-term model inputs are informed by the wider literature.  .  
 
Consistent with the SWIFFT trial, the base-case patient cohort is modelled as being 33 years 
old, with 84% being male.  A patient’s age is assumed to only impact the rate of mortality, as 
while there is likely to be a correlation between age and OA and other adverse events, there 
was insufficient evidence to incorporate such a correlation.  Similarly, the gender mix only 
impacts the mortality rate.  
 
 
Short- and long-term element transition estimates 
The short- and long-term model transitions estimates are reported in Table 29. The base case 
mean estimates are reported alongside the 95% confidence interval and the informative 
distribution used to inform the PSA. The distributions are reported in terms of the distribution 
selected, conforming to conventional approaches,99 and the parameters required to describe 
the respective distribution. 
 
Table 29: Probabilities applied in the model 
Parameter Base case value 
(95% CI) 
Distribution 
(informative 
parameters) 
Source 
1. Short-term element of the model 
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Cast 
immobilisation 
0.090 (0.005 to 
0.130) 
Beta (alpha 20, beta 
200) 
SWIFFT trial, the 20 
cases include those 17 
who had surgery plus 3 
who had not had 
surgery at 52 weeks but 
had an identification of 
non-union 
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Surgery as 
initial 
treatment 
0.037 (0.016 to 
0.065) 
Beta (alpha 8, beta 
221) 
SWIFFT trial, the 8 
cases include the 8 who 
had secondary surgery 
Probability of having surgery 
post cast non-union 
0.948 (0.901 to 
0.981) 
Beta (alpha 110, 
beta 6) 
Review of the existing 
literature  
Probability of having repeat 
surgery post initial surgery non-
union or issue 
0.948 (0.901 to 
0.981) 
Beta (alpha 110, 
beta 6) 
Probability of non-union after 
second line surgery 
0.059 (0.002 to 
0.206) 
Beta (alpha 1, beta 
16) 
SWIFFT trial, of 17 
patients who underwent 
secondary surgery 1 had 
confirmed non-union 
Probability of having non-union 
after no treatment 
1 Fixed Assumption 
2.a. Long-term element of the model – Union Markov 
Probability of having long-term adverse symptoms that are not OA related 
Cast immobilisation 0.048 (0.024 to 
0.079) 
Beta (alpha 11, beta 
218) 
Lindström and 
Nyström104 
Surgery as last treatment 
provided 
0.048 (0.024 to 
0.079) 
Beta (alpha 11, beta 
218) 
Assumed same as cast  
Probability of developing OA  
Cast immobilisation Limiting value – 
0.056 
Time constant – 
1.5 
CI – 0.035 to 0.087 
Exponential decay 
towards a limiting 
value, with limiting 
value characterised 
as a beta 
distribution, see 
Appendix 6, 
Section 3 
Lindström and 
Nyström, 104 5.6% of 
218 patients had OA 
after primary healing 
with a minimum follow 
up of 7 years 
Surgery as initial treatment Limiting value – 
0.056 
Time constant – 
1.5 
CI – 0.035 to 0.087 
Exponential decay 
towards a limiting 
value, with limiting 
value characterised 
as a beta 
distribution 
Assumed same as cast  
Probability that developed OA is symptomatic 
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Cast 0.992 (0.918 to 
1.00) 
Beta (alpha 11.9, 
beta 0.1) 
Lindström and 
Nyström104 
Surgery 0.992 (0.918 to 
1.00) 
Beta (alpha 11.9, 
beta 0.1) 
Assumed same as cast  
Mortality from all causes As per published 
tables 
Fixed ONS National Life 
Tables, England and 
Wales, 2014-16106 
2.a. Long-term element of the model – Non-Union Markov 
Survival function of no SNAC 
to SNAC 
Lambda  0.0069 
Gamma   1.77 
Weibull Weibull function fitted 
to time to event data 
from Moritomo107 
Mortality from all causes As per published 
tables 
Fixed ONS National Life 
Tables, England and 
Wales, 2014-16106 
 
 
The parameters required for the short-term element of the model are derived from the 
SWIFFT trial, with the exception of the assumption that all untreated patients have a non-
union.  This assumption biases against a no treatment scenario, and while some of the 
literature suggests rates of union in an untreated population,101, 102 there is insufficient 
evidence to determine a rate of non-union in the population considered here. 
 
The long-term Markov models are reliant on published literature until the five year follow-up 
of the SWIFFT trial is completed.  In the base-case model, the choice and frequency of the 
different treatment options only impacts a patient’s long-term health through its ability to 
effect union of the fracture, this core assumption is relaxed in a series of scenarios.  The 
model parameters for which this assumption applies are presented in Table 29. 
 
Base-case estimates of the probability of having long-term adverse symptoms that are not OA 
related are drawn from the study by Lindström & Nyström104 who reported the presence of 
pain and weakness not associated with OA in their long-term follow-up study of patients 
treated with cast immobilisation, finding that 4.8% of patients had long-term non-OA adverse 
events.   
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The probability of developing OA as a result of the initial injury and treatment is modelled as 
an exponential decay. It is estimated by fitting an exponential function to three time points 
extracted from Lindström & Nyström:104 time zero where no patients had developed related 
OA, year 1 where 2.6% had radiological OA, and year 7 when 5.6% had radiological OA, 
presented in more detail in Appendix 6, Section 3.  We assume that no OA, which can 
directly be linked to the original fracture and treatment, occurs beyond 10 years.  Authors 
such as Duppe108 report prevalence of OA in union patients with greater follow-up, 36 years 
after the initial event, finding 15% had OA.  However, they found no significant difference 
between the rate of OA in the injured and uninjured wrists assessed, suggesting much of the 
identified OA was unrelated to the original fracture.  While literature does suggest that repeat 
intervention and surgery may exacerbate rates of OA,109 we found insufficient evidence 
directly exploring these factors.  Therefore, the probability of developing OA is assumed to 
be treatment independent, as discussed earlier.  This assumption is justified by limited data on 
the rate of OA collected during the SWIFFT trial which showed no statistically significant 
difference in the rate of early OA between the two trial arms. 
 
Once developed, the probability of OA being symptomatic is modelled as a time invariant 
probability applied at the point of development.  In the base-case analysis the probability is 
estimated from Lindström and Nyström104 who found that all those who developed OA (n=12 
of 229 patients) were symptomatic.  Scenarios exploring the treatment independence of this 
parameter and alternative estimates are explored. 
 
For the non-union patients the probability of developing SNAC is modelled as a Weibull 
function fitted to time to event patient level data reported by Moritomo et al.,107 using only 
those patients reported as having a fracture to the middle third.  The Weibull function 
represented the best fitting function to the extracted Kaplan-Meier of those tried based on 
AIC, details of the regressions explored are detailed in Appendix 6, Section 4.  The Cholesky 
decomposition method was used to reflect uncertainty in the analysis.99  One major limitation 
of the Moritomo et al. study is that it considers a symptomatic population alone, albeit one 
where some non-union patients have symptoms but not radiologically detectable SNAC.  The 
findings of Moritomo et al. are similar to elsewhere in the literature, for example Mack et al. 
110 who, again looking at only patients presenting symptomatically, found that arthritis is 
likely to develop if sufficient time passes since the time of non-union development.  Similarly 
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Dias et al.105 identified that after only a 2.1 year mean review period 5 of 10 patients with 
non-union had signs of OA and dorsal intercalated segment instability, suggesting significant 
degeneration. Vender et al.  111 also conducted a retrospective radiological review of 64 
symptomatic non-unions in an untreated population, finding a similar time to arthritis onset.  
 
In both the union and non-union Markov models patients are subject to a mortality risk 
throughout, conditional on the cohort age and gender mix alone, such that non-union, OA, 
SNAC and all other modelled factors were assumed to have no impact on the rate of 
mortality.  The required estimates were drawn from ONS National Life Tables, England and 
Wales, 2014-16.106 
 
We assume that patients are only at risk of developing OA caused by the initial injury or 
subsequent treatment for 10 years, this assumption is to reduce the potential impact of 
conflation of OA caused by the injury with that occurring due to other causes. Additionally, 
we assume that all OA detected in the informative studies for 10 years since injury is a direct 
result of the initial injury and treatment.  
 
In the base-case we assumed that the patient populations, treatments used, and clinical 
definitions (e.g. union and OA) evaluated in each of the informative studies match with those 
analysed in this study, or where they do vary do not introduce any bias so large as to make 
them uninformative or misleading.  A review of the key characteristics and definitions 
including all studies pertinent to the base-case and scenario analyses is given in Appendix 6, 
Section 2.  Table 67 shows that many of the characteristics appear consistent, with some 
limitations around insufficient detail, for example displacement of the original fracture.  The 
potentially inconsistent definitions are relating to symptom, with some of the key studies only 
considering pain but others pain and weakness.  
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Resource use and cost estimates 
The costs used in the mathematical model are presented in Table 30.  Consistent with the 
model structure the costs incurred by the NHS during the first year, as described by the short-
term model, are directly taken from the SWIFFT trial, with the additional two treatment arms 
(no treatment and cast immobilisation only).  The short-term model costs are composed of the 
initial cost of each treatment alongside treatment specific costs incurred for the first year post 
injury, and any additional treatments within that period (i.e. secondary surgery).    The no 
treatment option is assumed to have no costs in this first year, as no interactions with the 
NHS are expected until patients’ progress into the extrapolated model.  The casting without 
surgery arm is assumed to have the same cost as the SWIFFT casting with surgery for non-
union arm with the exclusion of any surgical interventions. 
 
The costs associated with the long-term model, also reported in Table 30, reflect the structure 
of the Markov model, shown in Figure 8, to reflect the occurrence of OA, symptomatic 
adverse events that are not related to OA, and non-union related events.  In the base-case 
union model patients in the ‘healthy group’ of no adverse events including OA as well as the 
non-symptomatic OA group are assumed to not be associated with any costs to the NHS as 
both are categorised by the lack of symptoms with which they would present to an NHS 
setting for investigation and treatment.  Similarly, the non-union base case assumes that 
patients in the non-SNAC state will be associated with no additional regular cost to the NHS, 
under the assumption that all suitable interventions would have been attempted, and thus 
costed, prior to the diagnosis of non-union.  Once a patient progresses to SNAC a one-off 
treatment cost is applied to reflect any active interventions attempted to resolve or reduce the 
impact of the collapse.  Little evidence was identified relating to the range and frequency of 
treatments for SNAC.  Shah and Stern 112 describe highly personalised treatment of SNAC, 
including initial non-surgical treatment, wrist immobilisation with splints, anti-inflammatory 
medication, corticosteroid injections, coupled with surgical options for refractory cases.  We 
assumed costs of half of the patients being treated with immobilisation, with the other half 
progressing to major surgery, in addition to the associated 52 week follow-up costs estimated 
from the trial data.  A standard error equal to half of the mean SNAC cost is assumed to 
reflect the lack of certainty around the variable.  
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Table 30: Cost considered in short- and long-term sections of the mathematical model 
Parameter Base case value 
(95% CI) 
Distribution Source 
Short-term costs modelled (first year) 
Follow up cost for 
cast as first 
treatment (not 
including any 
surgery costs) 
£587 (£390 to 
£559) 
Gamma Estimated from the trial data,, 
includes the cost of all re-
casting, NHS interactions, and 
imaging, but not surgery, using 
the ITT population, after 
imputation for missing values as 
detailed later 
Cost of initial 
surgical treatment 
(not including 
follow-up) 
£1,632 Fixed As per within trial, see Table 28 
Cost of secondary 
surgery (not 
including follow-up) 
£2,509 
Follow up cost after 
surgery (not 
including any 
surgery costs) 
£618 (£656 to 
£789) 
Gamma Estimated from the trial data, 
includes the cost of all re-
casting, NHS interactions, and 
imaging, but not surgery, using 
the ITT population, after 
imputation for missing values as 
detailed later 
Long-term costs modelled (52 week to end of analysis) 
Cost of diagnosis of 
symptomatic OA 
£74 Fixed Assumption of two GP visits 
with no radiological 
investigation, cost drawn from 
PSSRU 2015 (11.7 minute 
consultation)95 
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Annual cost of 
treating symptomatic 
OA 
£38 (£10 to £83) Gamma Assumed mean one GP visit per 
year with no investigation or 
treatment cost (as treated with 
over the counter medication), 
SE assumed to be half of the 
mean.  
Annual cost of 
treating non-OA 
symptomatic adverse 
events 
£38 (£10 to £83) Gamma 
 Cost of SNAC £2,551 (£695 to 
£5,592) 
Gamma Modelled as one off cost 
assuming half of patients 
receive very major surgery 
(£3,440, Reference Cost 
HN42A)94 and half receive 
casting, both with associated 
cost per year of care from trial, 
SE assumed to be half of the 
mean. 
 
Health related quality of life (QoL) inputs 
As with the estimation of cost for the mathematical model, the health related quality of life 
(QoL) inputs into the short-term model are determined by the SWIFFT trial, such that 
patients have a QoL score for the first year of the analysis which is estimated from the trial 
data described earlier in this chapter.  The base-case analysis assumes that the quality of life 
inputs section to reflect that in the base-case analysis patients in both the no treatment and 
cast immobilisation only arms are assumed to have the same quality of life as the cast plus 
surgery for non-union arm of the SWIFFT trial as a conservative estimate of their quality of 
life.  
 
In the long-term model the QoL impact of being in a state associated with adverse health (e.g. 
symptomatic OA, SNAC, and non-union) are applied as decrements to the expected quality 
of life a ‘normal’ patient who is otherwise free of associated problems would expect to 
experience. These QoL norms are drawn from extensive surveys of the general public using 
the EQ-5D by Ara and Brazier113 and are stratified by age and gender.  Patients in the ‘no OA 
 
 
 172 
or other permanent adverse events’ of the union Markov are assumed to achieve this QoL 
norm.   
 
Evidence on the QoL of OA and SNAC relevant to this analysis is limited and diverse.  Our 
review of the literature identified four relevant studies: Kovacs et al. ,114 Neuprez et al.,115 
Slatkowsky-Christensen et al.,116 and the economic evaluation by Davis et al..117The base-
case analysis uses the Slatkowsky-Christensen et al.  116 estimated QoL decrement of OA to 
represent the QoL of patients in the symptomatic OA, non-OA related adverse events, and 
non-union ‘no SNAC’ states under the assumption that all represent, on average, a similar 
level of quality of life decrement.  While we were unable to identify any evidence which 
explored the quality of life impact of non-union prior to the development of SNAC we 
believe this assumption is the most appropriate in the base-case as patients would not be 
expected to regain full quality of life with non-union.  This is one of the many uncertainties 
that will be explored during the five-year follow up.  
 
In contrast, the severe state of SNAC is estimated by applying the Kovacs et al.  114 QoL 
score as a decrement using the Slatkowsky-Christensen et al.  116 ‘healthy’ population 
baseline to ensure a consistent baseline.  The Kovacs estimate is used here as it represents a 
more severe patient population which we believe to be the best fit to a SNAC outcome.  
While the use of QoL scores estimated using different tools (i.e. SF-6D and EQ-5D) is 
discouraged in current best guidance93 due to risks of inconsistency, we believe that, given 
available evidence, this is the optimal approach.  As with other parameters in the model these 
are subject to PSA and exploration through sensitivity analysis. 
 
All QoL decrements are applied for the duration of a patient’s time in each state, as while 
treatment may alleviate some symptoms, the progressive nature of many of these adverse 
events will have the opposite effect.  As a result it was not possible, given existing evidence, 
to model changes in the QoL within each state over time, as reflected in the structural model 
assumptions discussed earlier in this chapter.  
 
In order to reflect the QoL implications of additional surgery, patients who required surgery 
as a secondary line of treatment received an additional QoL decrement equal to that observed 
in the first year after surgery from the SWIFFT trial.  This assumption is relaxed in a 
scenario. 
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The full set of informative QoL estimates are reported in Table 31. All uncertain QoL 
parameters are characterised as gamma distributions for the PSA to reflect the bounding of 
possible QoL scores.99 
 
Table 31: Health-related quality of life model inputs 
Parameter Base case value 
(95% CI) 
Distribution Source 
Short-term HRQoL modelled (first year) 
QoL for first year 
post cast 
0.812 (0.780 to 
0.844) 
Gamma Directly drawn from 
the trial data, using 
the ITT population, 
after imputation for 
missing values as 
detailed later 
QoL for first year 
post surgery 
0.834 (0.788 to 
0.843) 
Gamma Directly drawn from 
the trial data, using 
the ITT population, 
after imputation for 
missing values as 
detailed later 
QoL for first year 
for those who are 
untreated 
0.812 (0.780 to 
0.844) 
Gamma Assumed same as 
cast as the least 
invasive intervention 
Long-term HRQoL modelled (52 week to end of analysis), all applied as decrements to 
population norms113 
Union and no OA or 
other adverse events 
decrement 
0 Fixed Assumption  
symptomatic OA 
decrement 
-0.130 (-0.120 to -
0.140) 
Gamma decrement estimated 
from Slatkowsky-
Christensen116 
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non-OA 
symptomatic adverse 
events decrement 
-0.130 (-0.120 to -
0.140) 
Gamma Assumed to be the 
same as decrement 
for OA 
non-symptomatic 
OA decrement 
0 Fixed Assumption that 
lack of symptoms 
implies no HRQoL 
decrement  
non-union (no 
SNAC state) 
decrement 
-0.130 (-0.120 to -
0.140) 
Gamma Assumed to be the 
same as decrement 
for OA 
SNAC decrement -0.275 (-0.0689 to -
0.4811) 
Gamma Modelled as being 
from time of 
development to end 
of life. Estimated by 
comparing the 
response in Kovacs 
(0.495) to the 114 
“healthy” control 
used in Slatkowsky-
Christensen116 (0.77) 
 
 
Scenario analyses  
In order to develop the mathematical model into the form presented above a number of 
simplifying assumptions and interpretations of the available evidence were necessary, as is 
true of all mathematical models.99  While the assumptions made in the base-case analysis are 
considered to be the most reasonable given the evidence available it is important to test the 
impact of different approaches on the results of the analysis.  A number of scenarios, detailed 
in Appendix 6, Section 5, have been constructed to conduct these tests, as far as possible 
other sources of evidence are used to inform the scenarios. 
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Results 
 
Within trial analysis - results 
In this section we present the results of the within trial analysis.  The section is structured 
around four different scenarios relating to an ITT or per-protocol analysis and whether a 
complete case or after multiple imputation approach is taken.  The ITT analysis is presented 
as the base-case, and the summary statistics relating to quality of life and costs are only 
reported for this analysis.  The majority of within trial analyses results are presented in 
Appendix 6, Section 6, with the focus here on the regression analyses conducted across the 
QoL and cost outcomes. 
 
Regression analyses 
The dependent variable for both regressions are total cost, and average quality of life over the 
within trial period.  Additional regressions are reported adjusting for quality of life at baseline 
(Table 32 and Table 33).  
 
Table 32: Cost regression results for the four within trial scenarios, adjusted and 
unadjusted for baseline QoL 
 Scenario Regression 
constant 
Surgical 
allocation 
QoL at 
baseline 
Fracture 
displacement 
Dominant 
wrist 
injured 
age 
U
n
a
d
ju
sted
 
Complete 
case ITT 
589.96 
(0.120) 
1,580.27 
(0.000) 
N/A 180.06  
(0.490) 
-16.66 
(0.934) 
1.48 
(0.833) 
With MI 
ITT 
882.80 
(0.002) 
1,228.13 
(0.000) 
N/A 225.47 
(0.168) 
74.39 
(0.622) 
1.58 
(0.767) 
Complete 
case PP 
678.06 
(0.072) 
1,770.87 
(0.000) 
N/A 128.68 
(0.595) 
141.08 
(0.467) 
4.273  
(0.535) 
With MI 
PP 
799.81 
(0.004) 
1,549.14 
(0.000) 
N/A 190.84 
(0.252) 
86.87 
(0.578) 
2.716 
(0.624) 
A
d
ju
sted
 
Complete 
case ITT 
939.86 
(0.001) 
1,308.11 
(0.000) 
-530.67 
(0.022) 
183.41 
(0.223) 
32.24 
(0.804) 
-0.08 
(0.984) 
With MI 
ITT 
1,160.66 
(0.000) 
1,294.53 
(0.000) 
-593.71 
(0.015) 
212.60 
(0.164) 
1.856 
(0.989) 
0.19 
(0.964) 
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Complete 
case PP 
911.11 
(0.002) 
1.615.50 
(0.000) 
-519.08 
(0.055) 
143.33 
(0.340) 
-17.04 
(0.904) 
1.73 
(0.692) 
With MI 
PP 
1,091.85 
(0.000) 
1,594.40 
(0.000) 
-562.63 
(0.036) 
173.21 
(0.255) 
-28.19 
(0.841) 
1.39 
(0.764) 
ITT – intention to treat, MI – multiple imputation, PP – per protocol, QoL – quality of life 
Values in brackets are the p values for each coefficient 
 
 
 
Table 33: Quality of life regression output for the four within trial scenarios, 
unadjusted for baseline QoL 
 Scenario Regression 
constant 
Surgical 
allocation 
QoL at 
baseline 
Fracture 
displacement 
Dominant 
wrist 
injured 
age 
U
n
a
d
ju
sted
 
Complete 
case ITT 
0.8162  
(0.000) 
0.0208 
(0.319) 
N/A -0.0283 
(0.176) 
-0.0285 
(0.163) 
-0.0011 
(0.091) 
With MI 
ITT 
0.8042 
(0.000) 
0.0182 
(0.304) 
N/A -0.0350 
(0.047) 
-0.0399 
(0.027) 
-0.0016 
(0.010) 
Complete 
case PP 
0.8112 
(0.000) 
0.0257 
(0.233) 
N/A -0.0342 
(0.118) 
-0.0348 
(0.101) 
-0.0012 
(0.076) 
With MI 
PP 
0.7984 
(0.000) 
0.0173 
(0.331) 
N/A -0.0423 
(0.021) 
-0.0433 
(0.018) 
-0.0015 
(0.026) 
A
d
ju
sted
 
Complete 
case ITT 
0.6947 
(0.000) 
0.0250 
(0.289) 
0.2895 
(0.000) 
-0.0202 
(0.371) 
0.0046 
(0.826) 
-0.0020 
(0.020) 
With MI 
ITT 
0.6733 
(0.000) 
0.0158 
(0.379) 
0.2732 
(0.000) 
-0.0261 
(0.164) 
0.0229 
(0.203) 
-0.0020 
(0.005) 
Complete 
case PP 
0.6761 
(0.000) 
0.0238 
(0.315) 
0.3272 
(0.000) 
-0.0168 
(0.494) 
0.0033 
(0.884) 
-0.0021 
(0.018) 
With MI 
PP 
0.6690 
(0.000) 
0.0118 
(0.505) 
0.2823 
(0.000) 
-0.0265 
(0.175) 
0.0218 
(0.227) 
-0.0019 
(0.009) 
ITT – intention to treat, MI – multiple imputation, PP – per protocol, QoL – quality of life 
Values in brackets are the p values for each coefficient 
 
The regression analyses highlight a number of interesting findings.  Firstly, as expected, 
across all scenarios allocation to the surgical arm of the trial is associated with greater 
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incremental costs and greater quality of life.  However, while the correlation with costs are 
found to be statistically significant the correlation with quality of life are not significant 
across any of the scenarios considered.  The per protocol analyses find a larger impact on cost 
and quality of life as it removes the cross-over patients whose inclusion reduces the reported 
benefit of surgical allocation.   
 
Also consistent to a-priori expectations increased fracture displacement (i.e. minimally (1mm 
to 2mm inclusive) compared to undisplaced (<1mm step or gap)) was associated with a lower 
quality of life (statistically significantly also in the two MI scenarios), and a higher cost.  Age 
was also found to be associated with a decrease in quality of life and an increase in costs 
while those who had injured their non-dominant hand had increased quality of life but had no 
consistent impact on costs.  
 
Adjusting for baseline quality of life using a regression approach only had a relatively small 
impact on the treatment allocation regression estimate, with no consistent direction across the 
different scenarios.  The scale of this change, while surprising given the relative size of the 
incremental mean different in baseline reported in Table 34, is due to many of the differences 
being already explained by the existing explanatory variables in the unadjusted regressions, 
and the random component of the variable.  The impact of quality of life at baseline on the 
cost regression is expected to be the result of adjusting for some level of co-morbidities or 
patients willingness to interact with the NHS. 
 
Table 34: Incremental costs and quality of life estimates and ICER 
Adjusted 
for baseline 
QoL 
Scenario Incremental cost  
(95% CI) 
Incremental 
QALYs  
(95% CI) 
ICER surgery 
versus cast 
unadjusted Complete case ITT  £1,580 
(£1,282 to £1,879) 
0.0208 
(-0.0200 to 0.0616) 
£75,962/QALY 
With MI ITT £1,228 
(£1,011 to £1,445) 
0.0182 
(-0.0165 to 0.0530) 
£67,473/QALY 
Complete case PP £1,771  
(£1,490 to £2,052) 
0.0257  
(-0.0165 to 0.0678) 
£68,910/QALY 
With MI PP £1,549 0.0173 £89,538/QALY 
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(£1,344 to £1,754) (-0.0176 to 0.0522) 
adjusted Complete case ITT  £1,308 
(£1,063 to £1,609) 
0.0250 
(-0.0240 to 0.0694) 
£52,320/QALY 
With MI ITT 
(base case) 
£1,295 
(£1,084 to £1,504) 
0.0158 
(-0.0221 to 0.0570) 
£81,962/QALY 
Complete case PP £1,616 
(£1,314 to £1,988) 
0.0238 
(-0.0247 to 0.0649) 
£67,899/QALY 
With MI PP £1,594 
(£1,296 to £1,961) 
0.0118 
(-0.0123 to 0.0529) 
£135,085/QALY 
 
 
Clearly, using the limited time scale of the within trial analysis, the use of surgical fixation is 
not cost-effective, especially if the difference in baseline quality of life is adjusted for.  
However, as discussed, such a limited timescale overlooks many of the outcomes correlated 
with the choice of treatment for scaphoid waist fractures, primarily the impact of non-union 
after this period of treatment on incidence of arthritis, SNAC and other related adverse 
events.   
 
Impact of lost employment  
The summary statistics of the patient reported days of lost employment are reported in Table 
35.  Primarily the table shows that the majority of patients experienced some days of lost 
employment in the first six weeks of the analysis period (with only 21.6% and 31.3% 
reporting no lost days over that period for surgery and cast respectively), but from 12 weeks 
onwards most were back to fulltime work (with medians of zero for all other periods).  There 
did, however, remain a number of patients who were forced to continue missing work as a 
result of their wrist, characterised by the persistent mean number of days lost despite close to 
90% reporting no lost days.  A very few cases of patients having to miss work for most of if 
not all the period covered by the questionnaire were reported. 
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Table 35: Summary statistics for days of lost employment reported since last 
questionnaire 
Questionnaire 
period   
Treatment 
allocation 
Number of 
responses 
Mean Median (95% 
percentile) 
Percentage 
reporting 0 
days 
6 weeks Surgery 148 12.07 6 (40) 21.6% 
Cast 150 12.13 4 (42) 31.3% 
12 weeks Surgery 159 2.38 0 (21) 76.7% 
Cast 145 3.90 0 (30) 69.0% 
26 weeks Surgery 140 1.34 0 (5) 91.4% 
Cast 135 3.72 0 (32) 88.9% 
52 weeks Surgery 164 1.51 0 (4) 91.5% 
Cast 160 1.94 0 (6) 91.8% 
Total, 
compete case 
Surgery 102 16.62 9.5 (51) 13.7% 
Cast 91 17.57 5 (67) 28.6% 
 
Detailed description for this table and estimation methods are provided in Appendix 6 
Section 1 which also includes details on impact on unpaid work.  
 
Extrapolated model - results 
In this section the results of the extrapolated mathematical model are reported.  Firstly, we 
reported the headline cost-effectiveness results, i.e. the expected costs, QALYs and resultant 
ICER and NHB, alongside a consideration of how the NHB accumulate over time.  We then 
go on to consider the decision uncertainty present in the decision model, this is reported in 
two ways: the probability of each of the four strategies being cost-effective at a given cost-
effectiveness threshold represented by the CEAC, a series of scenario analysis exploring the 
impact of structural uncertainty on the result.  
 
Base-case analysis 
Table 36 reports the cost-effectiveness results for the base-case analysis in terms of each 
treatment options expected costs and QALYs alongside a range of ICERs and the NHB at 
threshold of £20,000 and £30,000/QALY.   
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Table 36: Discounted expected cost-effectiveness of all treatments per patient treated 
Treatment Cost (£) QALYs ICER (£/QALY), versus… NHB at threshold of …  
 
Lowest cost 
(cast only) 
Next least 
effective non-
dominated 
£20,000/QALY £30,000/QALY 
Cast only 836  18.72  - - 18.68 18.70 
Cast + 
surgery 
 921  19.07   243 243 19.02 19.04 
No 
treatment 
 1,749   14.75  Dominated Dominated 14.67 14.70 
Surgery 2,404  19.12   3,952 29,660 19.00 19.04 
 
The results show that taking a lifetime perspective results in surgery being the most 
expensive option, followed by no treatment, cast plus surgery for non-union, and finally cast 
only.  The high cost of the surgery arm is driven by the high upfront cost of the initial 
treatment, in contrast to the no treatment cost which is the result of high future costs.  These 
different cost accumulations are shown in Figure 10 which shows the cumulative discount 
costs, clearly showing the large costs in the non-treatment arm after the initial treatment 
period, which result from high costs that result from the long-term implications of non-union. 
The total QALYs for the no treatment arm are much less than for any of the active treatment 
arms due to the lifetime impact of non-union related adverse events.  The surgical arm was 
found to result in the highest total QALYs followed by cast plus surgery, and cast only. 
The ICERs and NHBs show that, at their expected values (i.e. not taking into account any 
uncertainty) cast plus surgery is the most cost-effective option, with the highest NHB at a 
conventional threshold of £20,000/QALY, followed by primary surgery, cast only, and 
finally no treatment.   
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Figure 10: cumulative costs 
 
The accumulation of NHB over time can be seen in Figure 11 which shows the cumulative 
incremental NHB over the analysis period at a threshold of £20,000/QALY, compared to no 
treatment.  It shows that with the exception of the first year all three active treatment options 
have a positive cumulative incremental NHB throughout.  The closeness of the primary 
surgery and cast plus surgery lines show that there is a very low absolute difference in the 
two over time, with the impact of the higher upfront cost in the surgery treatment never being 
overcome by future health or cost gains, such that at any time-point in the analysis cast plus 
surgery is the most cost effective when considering mean values at a threshold of 
£20,000/QALY. 
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Figure 11: cumulative incremental NHB in relation to no treatment (QALY) 
 
There are a number of ways of reporting the parametric uncertainty associated with the base-
case analysis (i.e. how much the modelled uncertainty in each of the parameters impacts our 
decision), Figure 12 provides the conventional cost-effectiveness acceptability curve 
(CEAC), which reports the probability of each of the four arms being the most cost-effective 
option for a range of cost-effectiveness thresholds.  The CEAC shows that at very low 
threshold values, below £300/QALY, the cast only treatment is the most cost-effective, this 
swaps to the cast plus surgery for thresholds between £300 and £29,660/QALY, after which 
surgery becomes the most cost-effective for all higher thresholds.  As the threshold increases 
to extreme values primary surgery becomes the more cost-effective option due to its slightly 
higher estimated lifetime QALYs but there remains a large level of uncertainty in the 
decision. 
 
The CEAC further shows that if a threshold of £13,000/QALY was used, as indicated by 
recent research,118 cast plus surgery would remain the most cost-effective, with 79% of the 
simulations favouring it, with the expected incremental NHB when compared to primary 
surgery increasing to 0.07.  
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Figure 12: Cost-effectiveness acceptability curve (CEAC) 
 
Another important factor to consider is the relative rank of each treatment option as it is 
important to understand the situation when a treatment option is not the most cost-effective. 
Table 37 provides the probability of each treatment option being ranked at each place at a 
cost-effectiveness threshold of £20,000/QALY.  It shows that surgery and cast plus surgery 
are always the top two treatment options.  Additionally, cast only is almost always third 
ranked and no treatment last.  This distribution becomes more marked at higher threshold 
values.  This combined with the base-case result and CEAC allow us to conclude that the cast 
plus surgical option results in the highest NHB and is the most likely to be cost-effective at a 
range of conventional threshold values, additionally, even in cases where it is not most cost-
effective it is almost always the second most cost-effective option.  The table also shows the 
large level of uncertainty in the decision at conventional thresholds, with the parametric 
uncertainty in our analysis resulting in two-thirds of simulations favouring cast plus surgery 
over initial surgical fixation. 
 
Table 37: Probability of cost-effectiveness by rank, threshold of £20,000/QALY 
Rank No treatment Cast + surgery 
for non-union 
Surgery  Cast only 
1 0.00 0.61 0.39 0.00 
2 0.00 0.39 0.60 0.01 
3 0.00 0.00 0.01 0.99 
4 1.00 0.00 0.00 0.00 
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Furthermore, Appendix 6, Section 7, reports the cost-effectiveness scatter plots generated 
from the PSA analyses, alongside predictions made by the model for the rate of OA and 
SNAC at 1, 5, and 10 years to facilitate future validation of this analysis.  
 
Value of information analysis 
In addition to considering which treatment option is the most cost-effective and the 
probabilities of cost-effectiveness as we have done so far, it is also important to consider the 
implications of that decision uncertainty.  For example, if a treatment is estimated as being 
the most cost-effective 80% of the time but when it is incorrect the resultant NHB are 
catastrophic, it may not be deemed the best option by decision makers until further research 
can be used to reduce this level of uncertainty.   
 
To calculate the population EVPI an estimate of the population size and time frame is 
required. We assumed a ten year time frame and a per annum population of 4,650.  The per 
annum population was estimated by using the 7,265 total scaphoid fractures reported by 
Garala4, with 64% (ibid.) estimated as being located in the waist.  
The population EVPI is presented in Figure 13, showing how the value of generating 
additional information varies as the threshold varies.  In this case the figure shows that at 
lower threshold values there is a relatively low level of EVPI, associated with a high value of 
additional information, as there is a low level of uncertainty about the most cost-effective 
treatment option, as shown earlier in this section. However, the value of perfect information 
increases at an increasing rate as the threshold increases, as both the probability and the 
implications of an incorrect decision increase.  The “kink” in the curve is the point at which 
primary surgery becomes the treatment most likely to be cost-effective, but as the level of 
uncertainty remains high the value of resolving it continues to increase.  One approach to 
interpreting population EVPI is as a framework to measure conditions under which future 
research is potentially cost-effective.99   
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Figure 13: population EVPI across different threshold values 
 
Scenario analyses 
A number of scenarios were conducted to explore some of the elements of uncertainty not 
well captured by the PSA.  The full methods and results of these scenarios are presented in 
Appendix 6, Section 5.  In brief, the scenarios show that the headline result of the analysis is 
not sensitive to the majority of parameter changes but are to changes in how union is defined 
(scenario 1) and the assumption made regarding what happens to the patients who failed to 
achieve initial union with cast immobilisation only (scenario 2).  These sensitivities are 
because the model result is almost completely driven by the rate of non-union between the 
treatment options, which were very similar in the SWIFFT trial at 52 weeks follow-up.    
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Chapter 5 Qualitative study 
 
Introduction  
 
Context of the qualitative study 
A number of factors suggest the value of integrating qualitative research within the SWIFFT 
trial. That the fracture of the scaphoid waist is common in a younger, active (and 
economically active) population suggests that the impact of the injury may be wide-reaching 
and significant. A failure rate of 10-12% for plaster cast management, the potential for 
complications associated with surgery, and that cast and surgical treatments are of a different 
order (one invasive, one conservative) might suggest that patients will have opinions about 
the appropriateness of (and preference for) the treatment options available. Furthermore, a 
comparison of medical and surgical treatments creates its own challenge of trial delivery, in 
ensuring equipoise, managing expectations of treatment, and ensuring long-term engagement 
with trial procedures.  
 
This nested study will seek to generate personalised, contextualised and specific insight about 
participants’ experience of a scaphoid fracture and about their involvement in the SWIFFT 
trial. It will generate additional insight that will complement the findings of the main trial and 
will offer insight which will support the design and delivery of future surgical trials.  
 
Aims and objectives 
The aim of this study is to provide complementary, detailed and person-centred insight that 
will inform the interpretation of trial findings and which might support future clinical 
decision making.   
 
Study objectives: 
I. To explore participant experience of a fracture of the scaphoid waist. 
II. To explore participant experience of treatment of a scaphoid waist fracture. 
III. To consider preference for treatment options, and those factors which might be 
pertinent in this. 
IV. To consider involvement in a surgical, randomised clinical trial. 
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Fracture and recovery – a patient’s perspective 
With the exception of hip fracture, qualitative investigation of patient experience of fracture 
is limited with only a small number of papers which address injury of the hand/wrist/arm.119-
126 Despite some variation (“wrist fracture”, “wrist disorder”, “hand injury”, “hand 
disability”, “finger fracture”, “flexor tendon surgery”) this body of work points to a number 
of common themes which are likely to be pertinent to a fracture of the scaphoid waist: 
functional ability; relationships with others; perceptions of treatment/recovery; and, recovery 
goals. 
 
Functional ability 
Functional ability was addressed in all studies.119-126 “Wrist disorders” are described as 
impacting on all aspects of life (including domestic, recreational and economic) and spanning 
activities that require fine motor skills as well as those that require strength.124 Employment 
was presented as an area where limitations might have significant impact, in changed roles, 
reliance upon others, and challenges to self-confidence.119, 122, 126 The financial consequences 
of absence from work were a further potential consequence of a wrist injury.124, 125 These and 
other limitations might lead individuals to feel anxious, frustrated, emotionally distressed or 
even depressed,121, 123, 124, 126 some authors propose a holistic approach to managing injuries 
(which incorporates psychological as well as clinical therapy).119, 121, 123, 125 
  
Watson et al. are alone in their assessment that the nature and extent of limitations might vary 
amongst a heterogeneous patient population, with factors such as single-parent status and 
self-employment associated with an increased impact.125 They also propose that time spent in 
a cast might be associated with how limitations are perceived – a longer period in a cast 
increasing the experience of limitations associated with the injury.125  
 
Relationships with others  
Functional limitations associated with immobilised hand/wrists may lead individuals to 
become more reliant upon others for practical help and support,124-126 husbands/wives, friends 
or family might all play an important role in helping an individual to maintain normal 
activities.124 Such support, whilst generally perceived positively, might have some negative 
consequences for those that find a lack of independence or a reliance upon others emotionally 
challenging.123 Schier and Chan describe that social roles (as a spouse, a caregiver, a worker) 
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might be fundamentally changed after a hand injury, and that a ‘sense of loss’ for ‘previous 
social roles’ is conceivable.119  
 
A more positive perspective is offered by Chan and Spencer who identify that supportive 
relationships can be a motivator for patients making positive adaptive behaviours, e.g. 
adhering to rehabilitation programmes so as to resume parenting activities.121 Supportive 
relationships might also provide moral (rather than practical) support at clinic appointments 
and in gathering information about injury and treatment.125 
 
Perceptions of treatment/recovery  
A potential disconnect between how an injury is perceived and the complexity/duration of 
treatment can have consequences for adherence to rehabilitation programmes120 and for 
remaining optimistic about recovery.126 That a treatment might feel excessive when compared 
to how the injury is understood (simple, uncomplicated, minor?) offers conceptual challenges 
in accepting treatment and imagining recovery.  
 
Removal of a cast was associated with “a sense of relief, improved function and the start of 
recovery” [emphasis added];125 this demonstrates the pertinence of lay conceptions of 
treatment and highlights that a patient’s own sense of recovery might be at odds with their 
clinical recovery. That is, that perceptions of recovery might be more about regaining 
normality than about the clinical/physical repair of the fracture or injury. In the same study 
participants describe uncertainty and anxiety about the removal of a cast, concerned by the 
loss of protection and uncertainty about the status of the wrist repair.125 A lack of feedback 
and information about recovery is a source of anxiety for some patients126 and elsewhere 
patients describe the importance of feeling confident that they are receiving the right care 
and feeling certain about their recovery trajectory.125  
 
It might seem that patient understanding of injury and recovery are influential in shaping 
their experience of treatment and satisfaction with it.  
 
Recovery goals  
Uncertainty about achievable levels of functionality,123 acceptance about possible longer-
term limitations,121 and “readjusting expectations and accepting limitations” 126 all point to 
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some sense of uncertainty about what long-term recovery might look like. That such concerns 
are less manifest in this body of work, and less present in initial clinical consultations,125 
reinforces the assessment that “wrist fracture is perceived too trivial to warrant 
[detailed/longer term concern]”.125 
 
Amman et al. offer that patients “had an inner drive to strive for normality”,122 which mirrors 
a concern for “regaining normality”  demonstrated in orthopaedic trauma patients (which 
includes wrist, elbow and shoulder injuries).127 Pre-injury wrist status might be important in 
establishing some sense of what this might mean,124 although to borrow from the hip fracture 
literature notions of normality will be shaped by broader conceptions of prior health and by 
what is considered acceptable with regard to natural deterioration (such as that associated 
with aging).128 
 
Summary and assessment of literature  
It is evident that hand/wrist injury can have wide-ranging impact upon functional abilities in 
domestic, leisure and employment environments; and that such difficulties can lead to a 
greater reliance upon other people. A lack of clarity about longer term goals, and the potential 
for dissonance between how injury (minor) and treatment (complex/long-term) are 
conceived, may lead to uncertainty about recovery. A patient’s (subjective) ‘sense of 
recovery’ may thus be important in their level of satisfaction with treatment. That subjective 
experience is influenced by clinical, personal, social or even economic factors suggests a 
wide variation in how recovery might be managed.  
 
It should be noted that this assessment is based upon a limited literature and that the existing 
evidence base varies in scope and method: from detailed reviews of two or three interviews 
119, 121, 123 to more structured assessment of larger data sets.124 Differences in focus (hand, 
wrist, finger) and reach (from one-off interviews to longitudinal studies) also make synthesis 
and confident extrapolation difficult. Little has been written about wrist fracture,125, 126 and 
fracture of the scaphoid waist is not explicitly identified in these papers. Surgical treatment is 
not explicitly explored and an investigation of patient preference for treatment is lacking.    
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Randomised trials in surgery 
Difficulties recruiting to randomised clinical trials are well documented 129-134 with issues of 
participant retention gaining increased consideration.135-139 For clinical trials where surgery is 
compared to a non-surgical treatment these difficulties are recognised to be more pronounced 
140 and McCulloch et al. identify a range of factors which they consider as inhibiting surgical 
trial delivery.141 Amongst these are surgeons’ equipoise, patients’ equipoise, surgical learning 
curves, issues with blinding, life threatening and urgent conditions, definitions (of 
procedures) and quality control monitoring.141 
 
More general assessment points to the relevance of contextual and specific characteristics in 
trial delivery; the setting of a study, the population of interest, and specific procedures may 
all pose challenges to the appeal or completion of a study.135, 142 For SWIFFT a younger, 
active male population suggests some challenge to its delivery. Previous research has 
demonstrated that females are more likely to participate in research,143 and that older people 
are more likely to fulfil their commitment to a study.144 Insight generated in this qualitative 
research might provide further insight into the challenges of delivering a trial with this 
population; and might point to factors that enhance or inhibit success.  
 
Methods 
 
Study design 
A nested interview study was conducted to explore participants’ experience of the fracture of 
the scaphoid waist, its treatment and their experience (or opinion about) involvement in 
clinical research. This study involved both individuals recruited to the SWIFFT pragmatic 
RCT, as well as a small number of individuals who declined to participate in the trial. 
Interviews were conversational (semi-structured rather than structured) and analysed using an 
inductive, thematic approach. 
 
Participants 
A purposive sample 145 of those SWIFFT trial participants who indicated a willingness to be 
interviewed were recruited to this study. Interviewees were purposively selected to ensure 
that both men and women, experiencing different treatments, of different ages, and 
occupations were interviewed. A pre-defined sampling frame (Table 38) was constructed to 
guide participant selection and to ensure that the sample broadly reflects general patterns in 
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the incidence of scaphoid fractures, i.e. to prioritise younger people (under 30) and to 
prioritise male participants. The sampling frame also distinguishes manual and non-manual 
occupations to enable this comparison in analysis.  
 
Table 38: Target sample – within trial 
              
  Gender   Age   Occupation 
  Male Female 
Under 
30 
Over 
30 
manual 
non-
manual 
 
Surgery 
 
12 
 
6 
 
12 
 
6 
 
9 
 
9 
Cast 12 6 12 6 9 9 
   
24 
 
12 
 
24 
 
12 
 
18 
 
18 Total 
 
Those who declined to participate in the SWIFFT trial were also invited to take part in this 
interview study. This second group was recruited to support a broader consideration of 
patient preference for treatment, i.e. to reflect that those who declined may have different 
attitudes about treatment. Again, a sampling frame was constructed to prioritise interviews 
with male participants and with those under 30 years of age (Table 39).  
 
Table 39: Target sample – declined participation in SWIFFT trial 
               
  Gender    Age   Occupation 
  Male 
 
Female 
Under 
30 
Over 
30 
manual 
non-
manual 
 
Total 
 
6 
  
3 
 
6 
 
3 
 
- 
 
- 
        
 
Recruitment to this element of the SWIFFT research was also informed by concerns for data 
saturation; that is, the point at which no new insight is generated in the undertaking of 
additional data collection.146  Prior assessment has suggested that core topics and themes 
might be established with as few as 6 interviews and that more complete data saturation is 
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commonly achieved with 10-13.147-149 Here, 18 in-trial interviews per treatment arm were 
proposed as sufficient to reach data saturation, and sufficient to be confident of interpretation 
of combinations such as male/cast (n=12) or surgery/under 30 (n=12).  
 
In total 36 in-trial interviewees and 9 interviews with those who declined to participate in 
SWIFFT were proposed. 
 
All interviewees were separately consented for this element of the SWIFFT research. 
 
Data collection 
All participants were interviewed within 6 weeks of randomisation and those in the trial were 
interviewed again at 52 weeks. Both earlier and later interviews covered similar topics and 
were organised in three parts: i) wrist fracture and its impact, ii) treatment of fracture, and 
iii) participation in clinical research. Interviews at 6 weeks were intended to capture an 
immediate response to the scaphoid injury; interviews at 52 weeks were intended to reflect on 
treatment options and individual recovery. At both time-points, questions about clinical 
research were included to generate general (understanding and perceptions of) and specific 
(to support delivery of SWIFFT trial) insight.  
 
The same interview schedule was used for all interviews at 6 weeks - with some adjustment 
in the prompts used and how questions were phrased for those who declined participation in 
the trial. Interview schedules are included here as Supplementary File 19. 
 
Where possible interviews were undertaken face-to-face at a time and location convenient to 
the participant. In other cases, where the participant preferred or where geography made face-
to-face meeting impractical, interviews were undertaken via telephone. Interview questions 
and prompts were used as a guide for discussion only (rather than as a strict script)150-153 and 
interviewees were encouraged to develop issues that they felt important and to introduce new 
topics which had not otherwise been considered. In this way these interviews were intended 
to be discursive, generating personalised and contextualised accounts of injury and treatment. 
In this way the body of data generated was intended to capture the range of different 
individual experiences. 
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All interviews were digitally recorded and transcribed in full, transcripts were anonymised 
with all personally identifying data removed. Data was stored on a password protected, 
networked drive and handled using the N’Vivo (version 11) software package. 
 
Data analysis 
The discursive nature of the data generated (i.e. guided by but not restricted by an interview 
schedule) suggests a thematic approach to data analysis.146, 154 Furthermore, the exploratory 
nature of the study would suggest an inductive, thematic approach as described by Braun and 
Clarke.155 This approach describes a systematic and structured method undertaken in a series 
of iterative steps. It is a form of qualitative analysis which explores data on its own terms and 
which prioritises the organic insight generated therein. 
 
Interview transcripts were read and re-read in an initial stage of Data Familiarisation. Next, 
open (inductive) coding was used to identify points of interest in a process of Generating 
Initial Codes. This process was managed independently by a study researcher, with the 
qualitative study lead ensuring consistency and validity of the coding. 
 
In stage 3 these initial codes were merged and grouped according to topic or sentiment in the 
Identification of Themes. Here, themes and sub-themes were organised within three broad 
topic areas which reflect the aims and objectives of the study, i.e. focused upon injury, 
treatment and research. These early stages (1-3) were undertaken alongside data collection 
with emergent findings presented to the SWIFFT trial management group at its regular 
meetings.  
 
Stage 4 saw Themes Reviewed and refined to ensure their internal and external coherence. At 
this stage themes were also interrogated to establish their utility in serving the aims and 
objectives of the research. Following this, themes were finalised in Definition and Name and 
connected to form broad narratives which provide insight into: 1. The injury and its impact; 
2. Cast treatment; 3. Surgical treatment; and, 4. Research. Themes and thematic models were 
validated by the study CI and other members of the SWIFFT trial management group. 
 
Braun and Clarke 155 offer Producing the Report as the final stage of thematic analysis, 
stressing that interpretation continues as data is organised in an authored form. The final 
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narratives (presented below) were validated by the SWIFFT trial management and author 
groups. 
 
Results 
 
Data overview and code book 
A total of 64 interviews were undertaken with 49 individuals. 
 
36 in-trial interviews were carried out at 6 weeks and 19 interviews at 52 weeks; 9 interviews 
with individuals who declined the main trial were carried out at 6 weeks (Table 40, Table 41, 
Table 42 describe the demographics of the sample). Of the 49 individuals interviewed, 36 in-
trial participants were recruited at baseline, 9 who declined participation in SWIFFT were 
recruited at baseline, and 4 in-trial participants were recruited at 52 weeks (to compensate for 
drop out). Of these, 35 were male (14 female) and 26 under the age of 30.  Approximately 
half of all interviews were with our key demographic - males under the age of 30 (17/36 at 
six weeks, 9/19 at 52 weeks, 5/9 declined trial).  
 
Topics, themes and sub-themes were consistent across the sample; data collection ceased 
following the addition of 4 younger, male interviewees who were interviewed at 52 weeks 
only (to ensure data saturation for this key population).  
 
Participants were recruited from 13 centres: Bath, Bolton, Cardiff, Coventry, Leicester, 
Newcastle, Nottingham, Oxford, Peterborough, Plymouth, Royal London, Southampton, and 
Teesside.  
 
Interviews varied in length from 14–73 minutes at 6 weeks, and 13-41 minutes at 52 weeks. 
Interviews were typically 40-45 minutes at 6 weeks, and 20-25 minutes at 52 weeks. 
 
Table 40: Interviews at 6wks with trial participants 
              
  Gender   Age   Occupation 
  Male Female 
Under 
30 
Over 
30 
manual 
non-
manual 
Surgery 13 4 9 8 7 10 
Cast 12 7 10 9 7 12 
  25 11 19 17 14 22 
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Total 
 
Table 41: Interviews at 52wks with trial participants 
              
  Gender   Age   Occupation 
  Male Female 
Under 
30 
Over 
30 
manual 
non-
manual 
Surgery 8 1 6 3 5 4 
Cast 5 5 4 6 6 4 
  
13 6 10 9 11 8 
Total 
 
Table 42: Interviews with those declined participation in SWIFFT trial 
Gender   Age   
Male Female Under 30 Over 30 
6 3 5 4 
 
Initial analysis was structured around three broad topics (injury, treatment, and research) 
with codes subsequently organised within 11 core themes and 37 sub-themes (see Table 43a). 
This represents stages 1–4 of the inductive thematic analysis.155 Stages 5–6 are presented 
from the thematic analysis section onwards.  
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Table 43a: SWIFFT code book for qualitative data 
Topic: Theme: Sub-theme: 
 
Injury 
 
A minor injury? 
 
Delayed seeking medical help 
  Not worthy of serious treatment 
 
 Practical difficulties Driving 
  Leisure pursuits 
  Washing 
  Domestic chores 
  Difficulties at work. 
 
 Psycho-social difficulties Loss of independence 
  Mood 
  Relationships with others 
 
 Other difficulties Employment 
  Money and finances 
 
 
Treatment 
 
Plaster cast 
 
Inconvenient and immobilising 
  Passive 
  Safe and natural 
  Preference for plaster cast 
 
 Surgery Preference for surgery 
  Active 
  Quicker recovery 
 
 
 197 
  Risks 
 
 Factors in preference The need for speed – employment and money 
  The need for speed – familial responsibilities 
  The need for speed – lifestyle and other 
events 
  Access to practical support 
  Prior clinical experience 
 
 Recovery Return to normal 
  Progress made 
  Long-term concerns 
 
 
Research  
 
Reasons for participating 
 
Access to treatment options 
  Clinical benefits 
  Money as incentive 
 
 Positive assessment of 
research 
Research processes acceptable 
  Research nurses 
  Facilitators of research 
 
 Negative assessment of 
research 
Barriers to research processes 
  Research processes unacceptable 
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Thematic analysis 
 
Model 1 – the injury and its impact  
Thematic model – Fracture of the scaphoid waist is often initially considered a relatively 
minor injury. It can, however, have wide-reaching impact in limiting function. Limited 
function may be associated with greater reliance upon other people and may have other 
psycho-social consequences.  
 
An Inconsequential injury?  
For many the fracture was the result of what they considered to be an inconsequential 
incident - a trip, a clash on the football pitch, a bang at work, falling off a bike. Few 
considered the injury serious and many continued what they were doing: “Strapped it up, 
checked I could still catch and pass the ball, and then went back on” [Plaster cast 1121, male, 
under 30, 6wk2]; “I carried on working… I had to make the job safe before I walked away, so 
I worked for probably an hour after” [Surgery 1008, male, under 30, 6wk]; “oh yeah I 
carried on dancing, it didn’t hurt at the time” [P1245, female, under 30, 6wk]. Even an 
assessment that some damage might have been done did not necessarily mean that immediate 
action was taken:  
 
“I knew as soon as I’d landed, it was obvious … I could tell it was more than a sprain 
…  I thought I’d damaged it … [but] I did what I needed to do, I just finished the 
delivery, and drove the van to where it was needed  … by the time I got back here it 
was 9 o’clock [at night] …  So I went down the hospital first thing on Saturday 
morning” 
[P1451, male, over 30, 6wk] 
 
In the few cases where more immediate medical attention was sought it was often because of 
multiple injuries, with the wrist commonly considered the least of these: “I went because of 
the blood gushing from my chin … I did my tooth, my chin, everything else as well” [P1023, 
male, under 30, 6wk*]; “the ladders slipped underneath me … it was my back … I didn’t 
know I’d hurt my wrist” [P1282, male, under 30, 6wk]. 
 
                                                 
2 The convention for identifying participants is as follows – “P(laster cast) Participant ID number, gender, age, 
6/52wk interview” or “S(urgery) Participant ID number, gender, age, 6/52wk interview”; an * indicates an 
interview with someone who declined to participate in the main trial. 
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For most, swelling, pain or bruising prompted them to seek medical attention within 24 
hours, although for some it was a number of days before they sought any treatment: P1823 
[female, under 30, 6wk] went to A&E three days after her fall; P1161 [male, over 30, 6wk] 
went to hospital six days after a trip. Even when seeking medical attention some still 
suspected that they had only sprained their wrist, and a number were surprised at the fracture 
diagnosis. The severity of the consequences of the injury (and the potential for surgery) were 
surprising to some: 
 
“I think when you initially do it, you always think well your wrists are nothing and it’s 
not until somebody sits down and explains to you just exactly how complicated a wrist 
or a foot or hand is that you suddenly realise hang on a minute”  
[S1175, male, over 30, 52wk] 
 
“I was like well it didn't really hurt so how can it be that bad … [the hospital] said ‘it 
could be six to ten weeks in a cast and then an operation’ … I was like ‘oh no, I don't 
want any of this! I only just went ice-skating and accidentally got pushed over’… I 
didn't realise the severity of it kind of thing, well I just didn't, I still can't quite believe 
it now to be fair” 
[S1244, female, over 30, 6wk] 
 
Practical difficulties associated with the injury 
Despite any initial assessment that the fracture might be a minor injury, all interviewees 
described some degree of practical limitation, from work to washing and dining to driving.  
 
The impact upon leisure pursuits was telling for some: “the only real impact it’s had is my 
leisure activities, so I haven't really felt that I'm comfortable going to play football just in 
case I fall again” [P1201, male, under 30, 6wk]; “my leisure time is somewhat disrupted, I’m 
a church bell-ringer, which involves my hands, and I can’t really do that so much now” 
[P1856, male, under 30, 6wk]; “I do quite a bit of cycling. I haven’t been on the bike since 
just because of grabbing the handlebar might be quite difficult, so I haven’t been able to do 
that” [P1360, male, under 30, 6wk].  
 
The impact upon work more so for others, especially when pay is affected by an absence 
from work: “the worse thing was knowing that I had to have time off work … [I’m] classed as 
self-employed so … it was just the thought of not being able to work really … knowing that 
there’s kind of a month’s pay that’s going to be missing” [P1327, male, under 30, 6wk];  
“Well I’d just gone self-employed, so I’m not going to be earning now. I’m out of pocket in 
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that respect” [P1451, male, over 30, 6wk]. Driving was a common area of discussion with 
interviewees often concerned by advice not to drive, and about what this might mean for their 
independence:  
 
“3 months of not driving for me would be 3 months of hell really … it would have 
affected my work so much, not being able to drive for 3 months.” 
[S2097, male, under 30, 52wk] 
 
“I live right in the middle of nowhere really, so in terms of getting the bus to work 
that’d not be impossible … I was relying on my girlfriend for lifts and friends picking 
me up … But in terms of getting to places, yeah I was just really reliant on people 
giving me lifts which was awful” 
[S1691, male, under 30, 6wk] 
 
Psychological and social impact of the injury 
This final quote points to the fact that practical difficulties often translated into reliance upon 
others and potential changes to relationships. Some (younger, often students) described 
becoming more reliant upon (or even moving back in with) parents or other family members. 
Others described being unable to contribute at home and to a reliance upon wives, husbands 
or partners for practical support: 
 
“[Interviewer - How did your wife cope?] With great difficulty because I was 
someone who was very active and I turned into someone who … wasn’t able just to 
take the mower out of the shed and mow the lawn or take my daughter to the park on 
the swings ...  So I couldn't drive so it meant me not being able to take my son to 
sports. ... Everything was kind of left to her.” 
[P1020, male, over 30, 52wk] 
 
Few suggested that this was problematic, although some indicated feeling low about the 
injury: “I need to find other things to do with my time … I feel really bad, I feel depressed …” 
[S2284, male, under 30, 52wk]; “I started to get very depressed and it affected me badly. I 
wasn’t coming out of my room” [P1023, male, under 30, 6wk*]; “Saturday was the day I felt 
a bit low … I was just a bit like I hate relying on everyone … I felt ‘oh my God this is crap’” 
[S1244, female, over 30, 6wk]. Less remarkable complaints about frustration and boredom 
were common: 
 
“So I just had to sit there and watch TV and in the end it was getting boring to the 
point where I was just going out for a walk randomly, just to try and get out. “ 
[S1008, male, under 30, 6wk] 
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“I’ve definitely been frustrated with it yeah. Because it’s just so well so silly falling 
off my bike. And then having like everything, everything changes you know just 
because of that really.” 
[S1691, male, under 30, 6wk] 
 
Model 2 – plaster cast treatment  
Thematic model – In comparison to surgery, initial treatment in a plaster cast is recognised 
as less risky and possibly more ‘natural’. It is, however, perceived to be more limiting, and 
more limiting for a longer period of time. That repair beneath the cast is unseen is a concern 
for some.  
 
A more natural option 
For some interviewees plaster cast treatment was conceived as more natural and less risky. 
This assessment was of course informed by concerns about surgery – about anaesthesia, 
scarring, surgical error, etc. – but also seemed to reflect an attitude that there is benefit in 
allowing the body to heal naturally [P1986, female, over 30*; P1023, male, under 30*; 
P1360, male, under 30; amongst others].  
 
Plaster cast was considered a convenient and straightforward option by some: 
 
“[when allocated to cast treatment] I thought ‘oh flipping heck’.  But now, in 
hindsight, I’m so pleased I had the plaster because you’ve no scar or anything. You 
risk infection don’t you if you have an operation? I’ve no scar or anything, it’s 
perfectly healed, so no, I’m quite happy, I would have the plaster again I think.” 
[P1617, female, over 30, 52wk] 
 
It is pertinent to note that these assessments reflect participants whose recovery was positive 
and straight-forward. Not all those who were interviewed experienced such outcomes and 
their assessment acknowledged that plaster cast treatment might be more or less attractive 
given the nature and severity of the injury, and different lifestyles and commitments: 
 
“I prefer non-intervention if possible … my upfront view was never do surgical 
intervention if you don’t need to… [cast is better] assuming that the bits are all in the 
right position … but I’m starting to wonder if I’ve done more damage [than I 
thought]” 
[P1542, female, over 30, 6wk] 
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“And who’s to say if I was entering a different situation in a different time, I’d be like 
oh I really do hope that I do get the surgery because I cannot be in a cast for more 
than two weeks, you know” 
[P1030, male, over 30, 6wk] 
 
An inconvenience 
More common in the data were comments about the inconvenience of wearing a plaster cast: 
 
“The worst thing … restricted movement. That’s it you know. That’s all it is. That’s 
even worse than [the original injury and pain] … just being restricted from doing 
what you’d normally do. … I think just that, just being restricted you know… That to 
me, that’s the main one, just the restriction of the cast.” 
[P1161, male, over 30, 6wk] 
 
“when I had the cast on, being a bit limited for stuff you know. Which was a bit 
awkward, doing buttons up on shirts and stuff you know because it did used to hurt at 
the start.  But because I used to do running and couldn’t really run with the cast on, 
that was a bit of a pain.” 
[P1161, male, over 30, 52wk]   
 
An inability to work, difficulties at work, and difficulties driving were all associated with the 
restrictive nature of the cast; and whilst these complaints varied person to person the 
consequences for some were significant and long-term (for a few still evident at 52 weeks). 
Feelings of being disabled and about losing independence were associated this:  
 
“I’ve become more reliant on other people …In a sense I’ve learnt how to sort of let 
people do more things … I try and do what I usually do and I get annoyed ‘cause I 
can’t do it, I sort of just sit back and faff about and then try and sort of relinquish that 
duty to someone else … err, so I’ve become more submissive I suppose in that sense, 
and sort of wait for someone to help out.” 
[P1485, male, under 30, 6wk] 
 
Other complaints focused upon more mundane, personal, everyday activities. Difficulties 
going to the toilet, “I couldn't flush the toilet normal, I couldn't wipe my backside” [P1020, 
male, over 30, 6wk]. Difficulties using cutlery, “[eating] would be a struggle, I can’t use a 
knife and fork” [P1245, female, under 30, 6wk]. Difficulties sleeping, “I’m quite fidgety when 
I sleep, then I sleep on my side quite a bit so the arm gets in the way quite a lot” [P1575, 
male, under 30, 6wk]. Issues with clothing were also mentioned, “it’s ruined so many clothes 
the plaster rubbing up against your dress or blouse.” [P1316, female, over 30, 52wk]. 
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Difficulties washing might be added to this list, both with regard to keeping the cast dry as 
well as the dexterity required to wash with one hand and/or a non-dominant hand; “I’ve got 
one nice smelling armpit, one less so” [P1451, male, over 30, 6wk]. The itching associated 
with a plaster cast was distracting to some, and individuals described using knives, knitting-
needles, pens, forks, amongst other things to scratch beneath the cast. The state of the cast 
and the potential for it to become “manky” [P1121, male, under 30, 6wk] was described by 
some who were concerned about hygiene, “it’s not the nicest smelling thing in the world – as 
much as you try wash your hands it really does smell like cheese” [P1485, male, under 30, 
6wk], “I don’t like the fact that there’s one thing on my arm for 6 weeks you know. I’m a bit 
of a clean freak and it’s quite annoying”. [P1823, female, under 30, 6wk]; and about how it 
might appear to others, “I don’t wear short sleeve when I’ve got the cast … like it’s not 
exactly the most pleasant looking” [P1575, male, under 30, 6wk]. 
 
Uncertain recovery  
Around half of those treated in a plaster cast interviewed at 52 weeks expressed some on-
going concerns about their recovery. P1020 [male, over 30, 52wk] described his recovery as 
being at 70%. Others described feeling some weakness in their wrist [P1560, female, over 30, 
52wk; P1245, female, under 30, 52wk]; described wearing a wrist support [P1542, female, 
over 30, 52wk]; and described hoping for some further improvement, “I’m hoping that it isn’t 
going to be like this forever, I’m hoping that it’s going to be one of those things that’ll sort 
itself out one day” [P1121, male, under 30, 52wk]. Of those describing a more positive 
recovery there was some disappointment at how they had been incapacitated:  
 
“because it hadn’t fully healed after the six weeks I had to have it on for another six 
weeks, and 12 weeks is kind of pushing it really, for how long I was to wear this thing 
for.”  
[P1807, male, under 30, 52wk] 
 
“I was probably a bit surprised with how long it took to heal ... [when the cast came 
off] it wasn’t completely healed.  …  I do remember them saying it hadn’t completely 
healed. I don’t know, I think it was probably around 70% or something.”  
[P1161, male, over 30, 52wk] 
 
A  common observation was that cast treatment requires a long period for healing to take 
place: “a bit of disappointment that I was going to have to be stuck in the cast for so much 
longer … it’s going to be on for a longer time than it would have been for surgery” [P1856, 
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male, under 30, 6wk].  A less common, but perhaps equally pertinent, observation was that 
the period in a cast is an uncertain period, a time where improvement and outcome are 
unclear. These two elements combined (duration and uncertainty) might make cast treatment 
less attractive to some: 
 
“being in a cast for maybe four to six weeks and then maybe another decision being 
made …. I think, you know, kind of six to 12 weeks of uncertainty”  
[P1360, male, under 30, 6wk]  
 
“[it would be good] if you could see the healing process before the six weeks [when 
the cast is removed], because I think six weeks is a hell of a long time for somebody to 
kind of stop doing 50% of the things that they'd normally do to then still not be any 
better off. It’s kind of a kick in the teeth.  I mean if you was in the cast for three weeks 
and your healing [could be checked] or just to know something halfway through 
probably would have been a little bit better.” 
[P1020, male, over 30, 52wk] 
 
 
Model 3 - surgical treatment 
Thematic model – In comparison to cast treatment, initial surgery is perceived as a more 
active form of treatment. The benefits of a more quickly removed cast is important to those 
whose personal, economic or familial circumstances exaggerate the impact of limited 
functionality. 
 
A preference for surgery 
For a number of participants the opportunity for surgical treatment was an important factor in 
their willingness to participate in the trial.  These individuals felt that surgery was the right 
option for them; for some this was an intuitive preference born of previous fractures, for 
others it was an assessment reached through discussion with their consultant and the nurses 
recruiting to the trial. Speed of recovery, strength of repair, and certainty of treatment were 
all factors in this; employment circumstances, family commitments, leisure pursuits and even 
holidays were also identified as being pertinent to surgery being more attractive:  
 
“my mind was already sort of going towards the surgery side anyway ... me and a 
friend of mine we run an events catering business and June and July are the busiest 
months of the year … if I’d have been stuck in a cast you know I was able to come to 
work but my skill level dropped off when it comes to using knives” 
[S1345, male, over 30, 6wk]  
 
 
 205 
 
“I said to be honest, I’d just like to have the option of the operation if it will be 
quicker. … Because we were buying this house and we needed the money to be 
coming in. ... I’ve got no such thing as light duties. It’s either all in or all out and I’ve 
had to put a few jobs off”  
[S1008, male, under 30, 6wk] 
 
A need for speed – a quicker recovery 
At the most basic level the inconvenience of a cast was a push factor for favouring surgery: 
 
“But for someone like me who is very independent and I have to work and drive and, 
you know, do all of these things, the thought of being in a cast for eight to ten weeks, 
maybe longer… that was quite scary.” 
[S1749, female, over 30, 6wk]  
 
For others a slow, delayed recovery might lead them to do more than they should, potentially 
aggravating or re-injuring their fracture: 
 
“[in a cast] I would have wanted to become independent again and I would have done 
other stuff, you know, I wouldn’t have been able to just sit around with a cast on, I 
would have been doing other stuff. So I would have probably have put myself at risk 
by wanting to become independent again.” 
[S1658, female, over 30, 6wk] 
 
“they said it could be six weeks but after those six weeks you could still need 
surgery…  To be out of work for so long I’d then run the risk of, you know, trying to 
get back quicker and then ending up [hurting myself again] and being twice as long. 
So you know, it seemed like a smarter option … I did feel as though it [surgery] was 
probably the best treatment for the injury.” 
[S1759, male, under 30, 52wk] 
 
The risk of the fracture not healing whilst in a cast was also present in other individual’s 
assessments:   
 
“Yeah that’s what they said, if we just put the cast on it it could end up like having 
surgery later on, so I thought I might as well have the surgery done now … I thought 
oh well it’s best to have the surgery done now and then avoid [more problems later]” 
[S2097, male, under 30, 52wk] 
 
“ after six to ten weeks [in a cast] you still might need an operation anyway because it 
might not have healed … I was thinking oh no I don't want that, well I don't want to 
go through doing that and then having the operation anyway, so that’s the other 
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reason, I thought well you're just better off going for the operation anyway.” 
[S1244, female, over 30, 6wk] 
 
That surgery following the failure of cast treatment was perceived to be a more complex 
procedure reinforced the appeal of immediate surgical treatment; better to have 
straightforward surgery immediately than to risk a more challenging procedure later. 
 
A need for speed – a more active form of treatment 
Important in the assessment that surgery offers a quicker and more certain recovery was the 
perception that the more invasive and interventional nature of surgery offers benefits to the 
healing process. By this way of thinking surgery was doing something beneficial, rather than 
simply waiting for healing to take place. Surgery was seen as offering a more certain 
treatment pathway, was considered to involve a more active repair of the wrist, and was 
considered beneficial in kick-starting the healing process:  
 
“I suppose you feel [it’s a] more involved healing process ... The fact that you're 
going to hospital and getting it treated rather than just waiting for it to heal in a 
cast.” 
[S1339, male, under 30, 6wk] 
 
“Yeah. I think there’s just a lot more certainty in the [surgery] treatment. … there’s 
just some sense that the surgery would just feel like something’s happening. It’s 
happening now, I’m going to be getting better.” 
[P1360, male, under 30, 6wk] 
 
The insertion of a pin was intuitively appealing to some, adding strength to the fractured 
bone. This assessment was particularly important to those who were concerned about manual 
or physically demanding activities:  
 
“I was to knock it again it wasn't just going to break because the screw would hold it 
in place … The operation would be better in my circumstances [self-employed joiner] 
because it will be a stronger fix.” 
[S1008, male, under 30, 6wk] 
 
“because it’s got a screw in it, for me, mechanically minded [motocross cyclist], it’s 
going to be stronger, so – I don’t know – I think that’s why I liked it a lot more.” 
[S1265, male, under 30, 6wk] 
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Assessment of surgical procedures 
Those exposed to surgery expressed few concerns about the appropriateness of the procedure. 
That surgeons expressed confidence in the procedure was important, more so that the surgery 
was commonly offered within the NHS. All were generally content with their initial recovery 
and those interviewed at 52 weeks (n=9) indicated that their recovery had exceeded 
expectations (in both speed and completeness).  Those interviewed at 52 weeks also indicated 
that they would recommend surgery to others.  
 
“the fact that it is pretty much back to exactly the way it was, obviously there’s just a 
pin in there, or a screw, whatever it is, you know, I mean there’s no loss of movement, 
there’s no stiffness in the movement, so I am quite surprised in the fact that I've had 
an injury like that and there’s no, … you know, to be honest you kind of almost 
wouldn't really know it had happened in a way.” 
[S1345, male, over 30, 52wk] 
 
There were some minor concerns about scarring and some comments about pain following 
surgery, but none of these were considered a barrier to the appeal of surgery. The only barrier 
identified by some was a reluctance to undergo surgery under a local (rather than general) 
anaesthetic. 
 
“[local anaesthetic] I suppose it’s more a bit modern and a bit … it just didn't appeal 
to me really … I know that you can't feel it or whatever and you probably couldn't see 
what’s going on, I was just like ‘oh no’ and she said instantly in my face she could see 
how I weren't up for that!” 
[S1244, female, over 30, 52wk] 
 
“they said to me at first they was going to like knock me out, but then when they got 
there they said they wasn’t, they was going to do it on the local anaesthetic. And 
that’s when I started to get a bit worried. I didn’t really want to hear it. I asked them 
straight away, well what about, would I be able to see it? And they said no, they’d put 
a screen up. And then eventually I asked for some sedative and I had it and went 
straight to sleep.” 
[S1452, male, under 30, 52wk]  
 
 
Model 4 - research 
Thematic model – Surgical treatment made participation more appealing to some, although 
for others surgery (and randomisation) were reasons for not taking part in the wider study. 
Study burden was considered acceptable and some felt that taking part in a clinical trial 
might improve clinical care.  
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The appeal of research 
In both arms of the trial individuals expressed similar opinion about agreeing to participate 
because of the possibility of being randomised to the surgical treatment arm:  
 
“I was approached to join the study and yeah I was fully willing to join and I thought 
it would probably be the best … I wanted surgery from the start, I know it was 
randomised, but I told them I wanted surgery”  
[S1452, male, under 30, 52wk] 
 
“I think she explained to me that with the operation it could heal quicker I think … I 
said to her “Look, OK, fair enough. Whatever’s quicker” you know but I mean 
obviously it came that I’ve got to have the cast on” [P1161, male, under 30, 6wk] 
 
In contrast some of those who declined the main trial expressed uncertainty about the surgical 
procedure. At least one trial decliner indicated feeling “scared of surgery” [P1774, male, 
under 30, 6wk*]; another suggested that surgery felt quite serious for a relatively minor 
injury:  
 
“I just felt [surgery is] a more drastic approach for something which is fairly 
common.  …   I was a little bit shocked, to be honest, when they offered me surgery 
…  I think of surgery as something more, for more serious injuries I think I could 
probably heal without and, like I say, all the side effects put me off.” 
[P1023, male, under 30, 6wk*] 
 
In addition a number of interviewees speculated that participating in a major clinical study 
might bring with it other benefits, either with regard to improved clinical care or simply less 
waiting at appointments:  
 
“you get seen quite quickly when you're doing it … Actually I think you get treated a 
bit better when you're doing it!” [P1245, female, under 30, 52wk] 
 
“and the other thing is because it’s research, when it comes to the treatment, 
everything has to be within a certain period for that information to be relevant … So I 
thought everything will be pushed through quicker than just being on a waiting list as 
well” [S1008, male, under 30, 6wk] 
 
More commonly participants indicated altruistic reasons (benefiting other patients, 
contributing to the NHS) for taking part in the trial. 
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Research processes 
A few of those who declined to participate pointed to study burden as a factor in their 
decision, although for those involved in the study this was rarely commented upon. More 
likely interviewees would confirm their commitment to fulfilling their involvement as a point 
of principle, “you know it’s just a mind-set really and I said I would do it, so I was quite 
happy to go ahead with it … I wouldn’t have stopped” [P1617, female, over 30, 52wk]. Some 
gripes about the questionnaires (long, repetitive) and about follow-up appointments (parking, 
timing, etc.) were mentioned, but these were rarely described as serious problems. 
 
Continuity of contact and support from the research nurses was commended by some and 
described as a key factor in their fulfilment of the study requirements:  
 
“I think that my experience of all the follow ups and stuff was absolutely spot on.  I 
had the same nurse that I saw the first day … she kept in contact with me, she told me 
everything I need to know, always there if I needed to speak to someone … I think that 
I was very well looked after and always kept informed and very helpful at all times.” 
[S1452, male, over 30, 52wk] 
 
“we’ve actually been treated really nicely and it was – obviously the research nurse 
that I went to in the hospital, or who I’d spoken to, she was lovely.  She rings me 
about my appointments and stuff and…things like that.  And I know what’s going on.” 
[P1245, female, under 30, 6wk] 
 
Most interviewees indicated that they had a reasonable comprehension of randomisation, 
although in some cases this included notions that individual circumstances would be 
considered [S1008, male, under 30, 6wk] and that the process might be modified according to 
the doctor’s opinion [S1175, male, over 30, 6wk]. That both treatments were established and 
safe was important in accepting randomisation, and whilst many had an initial preference for 
one treatment or the other all demonstrated a willingness to adhere to the randomised 
treatment. Amongst those who declined the main trial an uncertainty about randomisation 
was the most clearly expressed reason for not wanting to take part. These individuals were 
unhappy with their clinical care being compromised by research procedures:   
 
“I just didn’t like the fact it was not the doctor giving me the best advice that he 
would normally give you … You know - they’d say this is what I recommend. I didn’t 
at all like the fact [that] … something else would then decide which way to do it, and 
I didn’t like that at all and it wasn’t what I was expecting … I didn’t think it’s really 
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appropriate. … I’d rather have the doctor telling me what he thought I should do.” 
[P1464, female, under 30, 6wk*] 
 
“I personally don't like the big question mark as to whether you're [getting surgery 
or plaster cast] … Not with health issues, you know, I don't like the lottery effect… I 
like to know what is happening rather than a random number out of a hat.” 
[P1986, female, over 30, 6wk*] 
 
Some of those who declined to participate in the main trial indicated that being provided with 
more information about the benefits of surgery might have changed their opinion about 
taking part: “if someone then had taken time at that point and sit me down and say talk me 
through the benefits of what having a screw would give ... I would have been extremely open 
to go on the trial” [P1263, male, over 30, 6wk*]. 
 
Discussion 
  
Summary of key results 
A number of points might be made about a scaphoid waist fracture: 
 Initial assessment is often that this is a minor injury.  
 Functional limitations associated with the fracture may impact across domestic, 
employment, familial and social activities. 
 Individuals may become more reliant upon others due to these limitations.  
 Individual circumstances may exaggerate or mitigate the impact of a fracture - 
personal, familial or other contextual circumstance (including severity of the fracture, 
dominant/non-dominant hand) may influence how limitations are experienced.  
 
A number of points might be made about how treatment options are viewed: 
 Cast treatment is recognised as conservative and less risky. It is, however, associated 
with an extended period of immobilisation. 
 Uncertainty about healing may exaggerate concerns about the duration of 
immobilisation. 
 Surgery is associated with a more active repair, and is perceived to offer a speedier 
recovery.  
 Again, individual circumstances may inform treatment preference – where personal, 
familial or other contextual circumstances demand a quicker recovery surgery may be 
perceived advantageous. 
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A number of points might be made about the delivery of this trial: 
 The potential for surgery was appealing to many of those interviewed. Conversely, 
amongst those who declined to take part in SWIFFT concerns were expressed about 
surgery. 
 Trial procedures were not considered burdensome and there was recognition that trial 
processes may enhance navigation and experience of clinical processes.  
 
Reflections upon the results 
This work contributes to the limited literature upon patient experience of hand/wrist/arm 
injury. It reinforces and extends a number of themes in this literature – specifically, the wide-
ranging functional impact of an injury,119-126 the relevance of an individual’s subjective 
“sense of recovery”,124-126 and the potential for personal or contextual factors to shape 
these.125 It also adds insight about how treatments are perceived, and about personal and 
contextual characteristics which may shape this.  
 
Fracture of the scaphoid waist 
Data generated here reinforces that a wrist fracture can have far-reaching consequences 124-126 
and that these might exceed any initial assessment that this is a trivial injury.125 Impact upon 
functional limitations 119-126 were commonly reported, and interviewees described (to a 
greater or lesser degree) limitations in all aspects of their life. Impact in employment was 
common and concerns for the financial distress125 were evident where interviewees described 
being self-employed. Changes to domestic and employment responsibilities suggest social 
role changes previously described.119  
 
Moving in with parents, relying on others for lifts, help tying shoe laces, and help cutting 
food all illustrate a need for practical support that has been reported previously.124-126 They 
also suggest a challenge to independence that Fitzpatrick and Finlay identify.123 Complaints 
about boredom, frustration and depression mirror those concerns for the psychological 
consequences of a hand/wrist injury.121, 123, 124, 126  
 
That individual reports of functional limitation varied significantly – from those continuing 
as normal, to those feeling significantly disabled – reminds us that this is a heterogeneous 
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population. This reinforces the importance of establishing what patients deem to be normal, 
122, 128 reflection upon pre-injury wrist function126 and consideration of those contextual 
factors which exaggerate or mediate disability.125 In this, the data generated here takes us 
beyond a simple comparison of men and women, manual and non-manual and supports the 
relevance of specific circumstances, 125 such as  occupation, familial responsibilities, access 
to familial (or other social) support and leisure/lifestyle pursuits (amongst many others).  
 
Assessment of treatment options 
That surgery is often uncritically assessed as a quicker, stronger and a more active repair 
overlooks important clinical facts – that cast is 90% successful, that surgery can be marked 
by complications (and risks non-union), that bone repair takes the same amount of time 
irrespective of treatment, etc..  Yet despite this the appeal of surgery is clear, a number of 
things might help us to understand this. 
 
Firstly, it reiterates and reinforces Watson’s recognition that an individual’s “sense of 
recovery” might be distinct from the repair of the bone and actual (objective) recovery. That 
non-union following conservative treatment (plaster cast) is possible (irrespective of how 
likely) informs a subjective judgement that the relative risks/complications of surgery are 
consequently less important.  
 
That, in Watson’s work, the removal of the plaster cast represents the “start of recovery” also 
suggests a confusion between the removal of a cast with a more abstract sense of personal 
recovery.125 This interpretation suggests that participants perceive an initial remedial phase 
(either in surgery or in a cast) as preceding a phase of more active recovery where normal 
function is regained. That this remedial phase takes longer in a plaster cast means that 
returning to normal 122, 127 is consequently perceived to take longer to achieve. That this 
overlooks the clinical reality would seem less important if we accept that understanding 
treatment is, in part at least, a subjective assessment.  
 
As with functional limitations it is pertinent to reflect that individual assessment of treatment 
may also be influenced by contextual factors which demand a speedier return to normality. 
This might help us to understand why the student able to return to the parental home (P1023) 
found surgery less appealing than the self-employed caterer (S1345). Again, we should 
 
 
 213 
reflect that our data has moved us beyond those simple dichotomies (male/female, 
younger/older) to recognise that the experience of, and preference for, a particular treatment 
will be shaped by a complex set of personal circumstances. 
 
Concerns about clarity in treatment 125 were important to interviewees.  A dislike about not 
knowing and about uncertainty 125, 126 may also help us to understand why some interviewees 
found plaster cast treatment challenging. Surgery may offer no more certain outcome, but that 
this outcome might be known more quickly better satisfies our impatience and [for some at 
least] lessens the likelihood that impetuous behaviour may lead to further injury.  
 
One final set of circumstances should be highlighted. Due to participant drop-out our data is 
skewed towards interviews undertaken at 6 weeks. At this point the worst aspects of cast 
treatment and the best attributes of surgery might be manifest – on one side participants 
might be bored by on-going immobility or frustrated by a dirty plaster cast; on the other they 
might be surprised by their mobility and pleased at how quickly normality has been regained. 
Whilst we might expect these trends to even out over the longer term it is unfortunate that 
amongst those interviewed at 52 weeks 5 (of 10) treated in a plaster cast demonstrated some 
form of on-going concern.  
 
Irrespective of this, it is evident that assessment of treatment (and consequent preference) is 
shaped by an individual’s own sense of recovery and that this is in turn informed by their 
personal circumstances. That cast removal, and a return to more normal functioning, is 
conceived of as a significant threshold in this perhaps helps us to understand the appeal of 
surgery to those interviewed here.  
 
Recruitment and retention in surgical, clinical trials  
The challenge of recruiting to a surgical trial 140 is manifest here in an almost contradictory 
fashion – surgery both attracting and discouraging participation. Amongst those interviewed 
the appeal of surgery was often commented upon as a motivating factor; however, for those 
who declined the trial surgery was considered a reason not to take part. This of course points 
to the challenge of patient equipoise 141 and might suggest that the SWIFFT trial population 
favours those eager for surgery? Other elements of the SWIFFT data will address this issue 
more directly. 
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This of course also places pressure on clinical equipoise 141 and reinforces the importance of 
how a trial is introduced to a potential participant. That some of those who declined to take 
part in SWIFFT subsequently (when given more information about) suggested that they 
might have changed their mind, demonstrates the complexity of getting this right.  
 
The challenge of retaining young male participants 143, 144 is manifest here with attrition in 
this population exceeding that for other demographics. For younger females, older males and 
older females approximately 50% declined or were unavailable for interview at 52 weeks, for 
younger males this proportion increased to 70%. We have commented about the challenge of 
this elsewhere 139 but it is worth reiterating that comments about a positive experience, 
continuity of contact and accessibility of research nurses suggest those softer, ‘valuing a 
study’ type strategies that we have previously described.139 
 
Closing comments and recommendations  
Insight generated here points to the importance of a patient’s subjective experience of 
scaphoid fracture and treatment, and points to the pertinence of their own sense of recovery in 
this. This has a number of implications for clinical practice. 
 
 It suggests that clinical consultations might include a more detailed consideration of a 
patient’s circumstances. We have argued here that a patient’s experience is shaped (not 
simply by age, gender and occupation, but) by a range of specific personal, familial and 
economic circumstances which influence how immobilisation is experienced. 
 
 It suggests that tailored information about a patient’s fracture and recovery might be 
beneficial. Here we have argued that a participant’s sense of recovery and treatment 
preference was often based on incomplete (possibly inaccurate) understanding of their 
injury.   
 
 Finally, it suggests that earlier removal of a cast, supported by the use of alternative forms 
of immobilisation, might facilitate a stronger sense of recovery for patients. We have 
argued that functional limitation was a common complaint and that cast removal was 
perceived to be an important threshold in this.  
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This study has also offered insight into the delivery of the clinical trial, specifically 
highlighting issues of patient and clinician equipoise. For future trials, where medical and 
surgical treatments are being compared, recommendations might be suggested.  
 
 That those who recruit participants should have knowledge of all treatments being 
investigated. This may mean that Research Nurses are drawn from pertinent specialities 
and/or that participants have access to clinicians who have experience of treatments. This 
will lessen the potential for stereotypical comparisons (conservative/progressive, 
simple/complex, quicker/slower) and support a more informed commentary on treatment 
options.  
 
 That all information provided should demonstrate equipoise, both in fact and in 
impression. It is evident here that some participants understood surgery to be a quicker 
solution and that this impression shaped how they experienced their recovery.  
 
 Where issues of retention might be difficult (such as with a young, male population) there 
is value in building in retention strategies from the outset. In this study the introduction of 
an I-pad lottery 139 might have had a greater effect had been established sooner. 
 
Insight generated here points to a number of uncertainties which might benefit from further 
investigation. 
 
 Further qualitative research with younger, male patients would respond to the high drop-
out rate in this group here. Exploring whether this group has their own distinctive sense of 
recovery, or displays certain commonalities in treatment experience and expectation, 
would provide insight to shape clinical consultations. It may also help to reduce re-injury 
associated with impulsive or impatient behaviour that some predicted.  
 
 Exploring the reasons for late clinical presentation of a scaphoid fracture would support 
awareness raising of this injury, and would complement prior work which has 
demonstrated gendered patterns in healthcare seeking behaviour.156 Such research might 
challenge those initial assessments that this is an inconsequential injury and might also 
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offer insight into whether late presentation is significant in expectations for recovery and 
treatment experience. 
 
 Research which considers the provision of information about the treatment a scaphoid 
fracture might similarly inform clinical consultations and inform a patient’s sense of 
recovery. Research in this area might be two-fold: firstly in developing the information 
content and mechanisms for delivery; and secondly, in testing whether it improves 
experience of, and satisfaction with, treatment. 
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Chapter 6 Discussion and conclusion 
 
Outcomes 
This report is based on assessment of primary and secondary outcomes at 52 weeks (the 
primary time-point) after 439 participants with a clear bicortical scaphoid waist fracture were 
randomised to have the control treatment of immobilisation in a plaster cast and early 
identification of non-union followed by urgent surgical fixation (n=220) or to have early 
surgical fixation using CE marked headless screws (n=219).  
 
Primary outcome  
PRWE at 52 weeks 
The main finding of this pragmatic trial is that there is no statistically significant difference in 
pain and function assessed by the PRWE at 52 weeks between participants randomised to 
receive initial cast treatment and those randomised to immediate fixation of clear and 
bicortical fractures of the scaphoid with 2mm or less displacement. The adjusted mean 
difference in the total PRWE score was -2.1 in favour of those in the surgical fixation group 
(95% CI -5.8 to 1.6, p=0.27). This difference is unlikely to be considered important by 
patients as the CIs of the adjusted mean difference excludes the clinically relevant difference 
of 6 points in PRWE scores. 
 
In the early period at six and 12 weeks the difference, which favours surgery, is statistically 
significant and, although the mean difference is below the clinically relevant difference of 6 
points, the lower CI is below -6 points is some analyses (indicating the possibility that the 
true treatment effect might be an increase of 6 points on the PRWE in the surgery group). 
Therefore, these differences are statistically significant but of borderline clinical importance. 
Importantly, 47% and 6% of participants in the surgery group respectively, were still in 
plaster cast or a splint at six and 12 weeks post-randomisation. This compares with 85% and 
21% of patients still in plaster cast in the non-surgical group at these time-points. So 
participants in the plaster cast group were more likely to still be in a cast and have 
consequential functional limitations. This is corroborated when looking at the pain and 
function components of the PRWE: there is no difference between groups in pain but there is 
a difference in function at these early time points. After 12 weeks there is no statistically 
significant difference between groups. 
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Sensitivity analyses of the PRWE 
The sensitivity analyses using multiple imputation, checking for an influence of the recruiting 
site, investigating those scores that were obtained within the time-point windows, adjusting 
for smoking status and displacement of the fracture, and a CACE analysis all broadly support 
the primary analysis. Subgroup analyses of baseline treatment preference, and displacement, 
also support the results of the primary analysis.  
 
Secondary outcomes of bone union, grip strength and SF-12, support the primary analysis 
findings. 
 
Immobilisation of the broken scaphoid in different types of casts has been compared to 
immediate fixation using a headless screw in at least eight reported trials18, 23-28, 75 and one 
cohort study.157  These studies (Table 43) have used different methods of assessing function 
and disability (three used DASH, one used PEM and another used PRWE, the other four 
studies used a variety of assessments including their own questionnaire, a satisfaction 
questionnaire and the modified Green & O’Brien score) and at different time-points (4 to 144 
months). The studies reported are small, with different time-points and some reviews29 and 
meta-analyses have also included case series.24, 44, 158, 159  The data from these studies has 
been extracted systematically and meta-analysed on numerous occasions.29-34, 36, 37 
 
One study reported PRWE at 10 years in 75 of 83 patients randomised to scaphoid cast 
treatment or surgical fixation with a Herbert headless screw and the mean score was 6 in each 
group.28 No data was available for the 52 week time-point. Two studies reported a PROM 
score at 52 weeks. One3 used the PEM score which ranges from 0-100, with 100 being worse 
and reported an unadjusted mean difference of -1.3 favouring surgery although the difference 
was not statistically significant. The second18 reported on 60 patients randomised to either a 
below elbow cast leaving the thumb free or an Acutrac headless screw; authors used the 
Mayo modification of the Green and O’Brien score160 to assess function (pain and function) 
and impairment (range of wrist movement and grip strength) and noted that this score was 
13% better (higher) in those having surgery but this difference was not statistically 
significant. This finding is not reflected in our study. 
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As the non-union rate for displaced fractures is 14% compared with 10% for transverse 
undisplaced fractures,8, 10, 39 randomisation was stratified by the presence or not of 
displacement (<1mm, or 1-2mm inclusive) of a scaphoid fracture as seen on radiographs 10, 
39 and used by the treating clinician to determine eligibility.  The three raters identified 
displacement of the fracture greater than 2 mm in 27 (6.2%) participants.  When these 
patients were excluded, the PRWE difference between treatment groups at 52 weeks was -
2.1 favouring surgery. The difference was not significant (p=0.07) and was below the 
clinically meaningful threshold. 
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Table 43: Randomised trials of treatments for fracture of the scaphoid bone 
Author Year Participants Follow up PROM used Non-union Conclusion 
  
n Surgery Plaster cast (months) 
 
Surgery  Plaster cast  Summarised from text 
Saedén 2001 62 32 30 144 Own Questionnaire, no 
difference 
1 0 Surgery allows early return of function and is an alternative to 
conservative treatment 
Bond 2001 25 11 14 25 Satisfaction no 
difference 
0 0 Surgery for undisplaced fractures resulted in faster union and 
return to military duty compared with plaster cast  
Adolfsson 2001 53 25 28 4 none 1 0 Surgery had better movement at 16 weeks but similar grip 
strength. Early surgery allows early mobilisation without 
adverse effects on fracture healing 
Dias 2005 88 44 44 12 PEM no difference, at 
8 weeks surgery better 
0 2 Plaster cast treatment, carefully assessing fracture-healing with 
plain radiographs, and computed tomography scans, after six 
to eight weeks and recommending surgery at that time if non-
union is confirmed achieved fracture union in over 95% 
Dias 2008 88 44 44 93 PEM no difference at 8 
weeks surgery better 
0 2 No medium-term difference in function or radiological 
outcome between surgery and plaster cast. 
Arora 2007 47 23 24 6 DASH, surgery better 1 0 Surgery for nondisplaced scaphoid fractures had faster union 
and quicker return to work . Although surgery is more 
expensive, the total cost was not  higher. 
Vinnars 2008 83 43 42 120 PRWE no difference 0 0 No long-term benefit of surgery, compared with plaster cast, 
for acute nondisplaced or minimally displaced fractures. The 
long-term risks of surgery should be considered. 
McQueen 2008 60 30 30 12 Green/O’Brien score, 
no difference. Surgery 
better before 1 year 
 
1 4 Surgery had a faster return of function, sport and work 
compared to plaster cast. Surgery had a low complication rate. 
All active patients should be offered surgery. 
Clementson 2015 45 21 24 72 DASH no difference, at 
6 and 10 weeks surgery 
better 
0 0 Non- and minimally displaced scaphoid waist fractures are 
best treated in a plaster cast. Surgery may provide improved 
function in the short term but at an increased risk of arthritis in 
the long-term. 
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Complications 
Surgical complications noted by the treating clinician at the recruiting site confirmed that 31 
(14.2%) participants randomised to the surgery group had a complication while the rate was 
much lower in the plaster cast group (n=3, 1.4%). The review of radiographs identified 
penetration of joints by the screw in 94 participants in the surgery group (42.9%) compared to 
10 (4.6%) in the plaster cast group. Half the penetrations had the screw protruding by 1-2mm 
in the joint and a quarter had significant protrusion of over 2 mms. The concern about such 
screw protrusion is that articular cartilage will be damaged irreversibly and lead to early 
degenerative arthritis within the involved joint. 
 
Cast complications, in contrast, were minor, had no lasting consequence and were reported in 
six (2.7%) participants allocated to the surgery fixation group, probably reflecting the 
frequent changes of cast to inspect the wound and the cast initial application by the surgeon. 
Cast problems (soft, tight or broken cast, skin soreness) were reported for 45 (20.5%) 
participants in the plaster cast group which would usually be applied by experienced fracture 
clinic staff and not changed as frequently.  
 
Malunion of the scaphoid was assessed using the height to length ratio on radiographs and the 
baseline and 52-week CT scan. ten Berg et al. noted that a ratio of 0.69 as the upper 95% CI 
of a normal population so we used this to define a malunion rather than the 0.6 we had 
proposed in our protocol. At 52 weeks, using the 0.7 threshold (i.e. ratio of the scaphoid 
height to length), malunion increased between baseline and 52 weeks on CT scans and was 
similar (3.2%) in both treatment groups.  Radiographs had a higher rate but again 
demonstrated an increasing rate in time and a greater rate in those in the surgery group. 
 
Re-operations 
Eight participants in the surgery group had 11 re-operations, subsequent to their initial 
fixation; for six of these participants the re-operations were for implant related problems and 
for two they were for non-union, with one requiring scaphoid excision and a four-corner 
fusion. One participant required re-operation for a persistent non-union following fixation of 
a non-union after initial cast fixation. The overall rate of re-operation for all causes (assuming 
that none who were not followed up required re-operation) was eight of 219 (3.7%) after 
early surgery and one of 220 (0.5%) after initial cast treatment and surgery to fix a non-union. 
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Secondary outcomes 
Union 
The aim of immobilising a broken scaphoid is to get it to unite. Failure of union, if left 
untreated, mostly results in wrist arthritis12, 161, 162 as there is abnormal loading between the 
distal scaphoid and the radius.163 So, an important outcome after treatment is to establish the 
state of fracture union on imaging. In clinical practice, union is commonly assessed on 
radiographs of the scaphoid in different projections. Bony continuity on all radiographic 
views is interpreted as trabeculae crossing the fracture line, and sometimes there may be 
sclerosis at the fracture line. Both these features suggest union especially if there are no 
adverse features of (a) a gap at the fracture line on any view, (b) progressive displacement of 
the fracture or (c) if implants are used then lucency around it may suggest failure of union59. 
The usual advice is that radiological union is only considered to have occurred when 
“bridging trabeculae” are seen across the whole cross-section of the scaphoid on radiographs 
or a CT scan164 with the latter being more reliable. 
 
The bone may unite partially with a gap seen across part of the fracture site and bony 
continuity identified across the remainder of the fracture.  This can be identified on the 
scaphoid radiographic views but can be quantified on a CT scan.61 Partial union has been 
reported in around 42% of scaphoid fractures and usually consolidates in time but the wrist 
may need protection for a while.61 
 
Non-union is the absence of radiographic signs of healing with a clear gap on radiographs on 
any view and confirmed on a CT scan.164-166 A high-quality CT scan (fine cut, bone window) 
helps establish that the fracture has not united. An ununited scaphoid fracture will eventually 
lead to collapse of the carpus and degenerative osteo-arthritis termed as SNAC.161 
 
Clinically there would be a concern if union was <20% at 52 weeks and suggest treatment to 
bone-graft and stabilise the fracture although this partial union threshold has not been 
formally investigated.  On radiographs, this extent of union is likely to be interpreted as a 
“non-union” by the treating clinician. 
 
The rate of non-union recorded in this study is very low for both groups. In the 188 who had 
screw fixation in the surgery group there was one non-union. In the 198 in the plaster cast 
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group who fully complied with the control pathway (treated in a cast and surgery to fix a non-
union) there was also just one non-union. This study has not identified evidence that the rate 
of non and slight union is statistically significantly different between surgical fixation and 
cast immobilisation in an ITT logistic regression model which adjusted for age, fracture 
displacement and hand dominance (OR 0.40, 95% CI 0.12 to 1.33, p=0.13). We observed this 
state in four (three slight union and one non-union) participants in the surgery group and nine 
(five slight union and four non-union) of those who were treated in a plaster cast.  Three 
meta-analyses30, 36, 37 reported on union rates, two36, 37 found no difference while one30 
reported a significant difference in favour of surgery. These meta-analyses reviewed four to 
seven small trials comparing surgical fixation to plaster cast treatment for scaphoid fractures. 
 
The control treatment pathway in the SWIFFT trial was initial cast treatment with early 
identification of failure of union and early fixation of un-united fractures. Of 18 participants 
who had surgery for early identified non-union, 15 had it early within 6 months from 
randomisation and a further three were treated after six months. The reasons for this have 
been described in the Results chapter.  
 
Union rate after early fixation of less than 20% after initial cast immobilisation is high. There 
are four papers3, 157, 158, 167 reporting prospectively collected data and present results of early 
identification of non-union after cast treatment and early fixation of these. One is a RCT3 and 
the other three are prospective comparative case series. These reported on 166 scaphoid 
fractures treated in a below elbow cast. Twenty non-unions were identified when the cast was 
discontinued. Seventeen of these had early surgery, 2 declined the offer of surgery and had a 
persisting non-union at 52 weeks. Of the 17 that were fixed all united (100%). Two 
retrospective studies168, 169 also reported on 210 acute scaphoid fractures treated in a cast with 
12 non-unions 11 of which were fixed early and all united (100%). One 80-year-old man was 
not offered surgery. There is only one retrospective case series170 which reported on  308 
acute fractures of which  27 did not unite. Of these 24 had fixation and 21 united, 3 did not 
join (87.5% union) two of these were re-operated and one healed. Overall the reported rate of 
union after early identification of failure to unite and fixation is very high. Our study 
confirms that it is unlikely that the risk of non-union following surgery for non-union after 
initial cast immobilisation is greater than if surgery is carried out in the first 14 days after the 
injury. 
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In SWIFFT, 18 patients in the plaster cast group were also offered and had surgery as 
clinicians treating them were concerned about the state of union after cast treatment. Only 
one had a persistent non-union at 52 weeks. In these patients the total PRWE was worse 
(mean 29.1 (SD 32.4)) compared to those who did not need surgery (mean 12.8 (SD 17.4)). 
This may reflect the delay in fixation of the non-union.   
 
The numbers of scaphoid fractures we would need to fix in order to avoid one additional non-
union or slight union is 44.  All these patients would be exposed to the risks of surgery. 
 
Range of wrist movement 
One year after the fracture there is no difference between groups for range of wrist 
movement. This confirms that treatment method does not have a measurable effect on the 
range of wrist movement at 52 weeks. At six weeks, when participants treated in a plaster 
cast are likely still immobilised, the range is worse than those left out of a cast after surgery 
and screw fixation. Wrist movement returns to normal and most studies that compared cast 
with surgery were unable to establish a difference between groups at later time-points to 52 
weeks. 
 
One study 36 found that there was no difference between groups after six months and others34, 
171 found no difference between groups at any time point.  Another meta-analyses30 
highlighted the observation that several trials24, 27, 28 had noted a better range of wrist 
movement after treatment in a plaster cast. 
 
Grip strength 
The strength of the hand, assessed using a Jamar dynamometer, was similar between groups. 
Grip strength measured in kilograms was slightly worse in those treated in a cast at 6 weeks 
(by around 4 kg) and 12 weeks after injury (by around 2.6 kg) but better at 52 weeks (Cast 
37.4 kg (SD 14.2) vs Surgery 36.2 kg (SD 12.7)).  The cast is usually removed between 6 and 
12 weeks so this is an expected difference at these time-points. 
 
Five meta-analyses30, 31, 34, 36, 171 have commented about the recovery of grip strength 
reporting on various combination of several small trials.3, 18, 23-25, 27, 28 One36 commented that 
patients having surgery had better grip strength up to a year after surgery. They also reported 
 
 
225 
 
that the difference between groups was greatest at 8 weeks combining results of two studies.3, 
18  Another30 felt that they were unable to conduct a meta-analysis because of  the different 
ways of recording this. This study collated the results from seven studies3, 18, 23-25, 27, 28 in a 
table. They noted a consistent trend that those having early surgery had better strength but 
recommended caution in interpretation. Another meta-analysis found no difference between 
groups.171 
 
Return to work and unpaid activities 
This study, in contrast to most previous trials, found little difference in days of lost 
employment. On average the time that those treated in a cast were off work was for 21.7 days 
while those who had the broken scaphoid fixed were off work for 17.3 days. Of note was the 
time off work was the same in the first six weeks and was only 12 days. 
 
Five meta-analyses29, 31, 34, 36, 37 reviewed randomised controlled trials and reported on the 
time to return to work.  One study29 included a prospective comparative study158 which was 
not randomised. All five, extracting data from different combinations of studies, noted that 
patients who had their scaphoid fracture fixed returned to work quicker (range 1.6 to 7 weeks 
earlier) than those treated in a cast.  
 
This study finds little difference in time off work, especially in the early period and this may 
reflect the common practice of immobilising the operated fracture in a plaster cast or splint. 
One reason may be that around 77.7% were treated initially in a cast which did not include 
the thumb and therefore permitted early resumption of hand function. Another may be that 
patients may have felt more secure working in a cast. Finally, patients may have had direct 
reassurance regarding return to work in a cast and encouraged to do so. 
 
The overall days of lost unpaid activity was also similar in the two groups. There was a larger 
impact on lost unpaid activity in the surgery group for the 6 weeks after randomisation. For 
all time points after this, patients allocated to the surgical arm report a smaller impact on 
unpaid activities which is consistent with the findings for days of lost employment.  
 
 
 
226 
 
SF-12 
The SF-12 was completed to measure the potential broader consequences of a scaphoid 
fracture on both the participants’ physical and mental health along with EQ5D. The analyses 
of the mental composite scores (MCS), reassuringly showed participants mental health 
improved in both treatment groups at each time-point and overall. The between-group 
differences in the MCS were not statistically different at any time-point with an adjusted 
mean difference at 52 weeks of -1.2 (95% CI -3.3 to 0.8) in favour of the plaster cast group. 
A statistically significant difference in the physical health composite score (PCS), favouring 
the surgery group was seen at 12 and 52 weeks, but not at 6 or 26 weeks, nor overall 
(p=0.08).  The adjusted mean difference at 52 weeks was 1.6 (95% CI 0.2 to 3.1) in favour of 
the surgery group. These findings corroborate the overall PRWE results and its’ function sub-
scale but appear inconsistent across time-points and the differences are below that considered 
clinically meaningful (range 3.3 up to 12.6 points) in other musculoskeletal (spine and knee) 
disorders.172-175    
 
Trial validity and minimising bias 
Various measures were taken to ensure trial validity and minimise bias, or to explore the 
potential for bias, of which some are discussed here.  
 
The secure randomisation method helped to ensure that there was comparability in the 
characteristics of the two treatment groups with the exception of ethnicity, education and 
smoking status, by chance. The imbalance in the number of smokers, with participants in the 
plaster cast group less likely to be a smoker, was examined in a post-hoc sensitivity analysis. 
Adjusting for smoking status (yes/no) found similar results to the primary analysis, except at 
12 weeks when a clinically relevant six-point improvement in the PRWE in favour of the 
surgery group could not be ruled out. Also, at baseline, it was important that the series of five 
radiographic views were performed to ensure the correct diagnosis of the fracture for 
inclusion of a patient in the trial. Except for one view (semi 45° supine), nearly all 
randomised patients were enrolled based on these radiographs. The three raters agreed that 
6% of randomised participants had displacement of the fracture at baseline that was greater 
than 2mm, which was a reason to exclude a patient. Only one participant was agreed to not 
have a fracture (in the surgery group). Sensitivity analyses of the primary outcome model that 
excluded these participants, supported findings of the primary analysis. A further sensitivity 
analysis also provided reassurance that the perceived threat to validity of low recruitment at 
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sites did not affect the results on the PRWE. Also, the subgroup analyses found participant 
treatment preferences at baseline, which if there was a preference it favoured surgery, did not 
affect the results of the PRWE at 52 weeks. However, this represented participants with a 
preference for surgery or in treatment equipoise as those preferring cast treatment were 
under-represented. This helps, in part, to mitigate against concerns that a lack of blinding can 
introduce bias in participant self-reported completion of the primary outcome.  
 
Although it was not possible to blind assessing clinicians to the treatment allocations this 
multicentre study with its pragmatic design had multiple clinicians assessing objective 
outcomes. The statisticians and health economists were only presented with data after 
collection and cleaning was completed and the statistician undertaking the analyses was 
different to the one monitoring the study data collection processes. The DMEC and the TSC 
also provided independent advice and support throughout the conduct of this study. 
 
To help ensure good standard of care, surgeons were advised to use techniques with which 
they were familiar, which also helped to avoid learning curve problems. The majority of 
operations were conducted by consultant surgeons, who were also present for the majority of 
operations when the main operating surgeon was a specialist trainee. Predominantly a 
percutaneous approach with a palmar incision was performed, which is consistent with 
current practice. No intra-operative complications were reported. All participants were 
provided with standardised, written physiotherapy advice detailing the exercises they needed 
to perform. At 12 weeks, the majority of participants in both treatment groups, self-reported 
that the written advice was quite or very useful and that they had performed home exercises. 
 
The high rate of return of participant questionnaires at the primary end-point of the trial, 
reflects the success of the extensive measures taken to achieve the required retention rates. 
Critically, this included continuous engagement and advice from three involved groups 
(patients, research nurses and clinicians) as explained elsewhere.139  The participant 
questionnaire return rates were lower in the plaster cast group, except at six weeks when they 
were similar. The baseline characteristics of participants who completed a valid primary 
outcome at 52 weeks were comparable between the two groups, except for the continued 
difference in ethnicity, education and smoking status. Any response bias that could be 
introduced from these imbalances in return rates and characteristics of a responder, was 
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minimised by using a mixed-effect, repeated measures model which included intermittent 
responders. Consequently only 7% of participants were not included in the primary analysis 
model with an almost identical numbers of participants included for each treatment group. 
The use of this statistical model had the benefit of increasing the statistical power of the 
analyses, compared with the use of a two sample -test for the sample size calculation.  
Multiple imputation analyses to explore the effect of this minimal missing data, helped to 
reassure that this did not have an effect on the results of the PRWE. There was, however, 
missing data on imaging for nearly 30% of participants at 52 weeks. There were quite marked 
differences in the PRWE in those participants who did or did not attend for imaging between 
groups. Participants in the surgery group who attended, tended to have better scores than 
those in the plaster group. This may have contributed to lower reporting of non-union in the 
surgery group. Furthermore, the lower than expected non-union reported for both groups, 
could be attributed to the participation of largely specialist hand units in this study and a more 
rigorous assessment of non-union than in previous studies.3, 18, 23-28 The other finding on 
imaging that 43% of participants in the surgery group had penetration of the screw into the 
adjacent joint and this was 1mm or greater on 52 week CT scan in 68 participants and 
therefore considered to be likely to have an adverse effect on the joint cartilage and probably 
explains the worse PRWE in this participant group. This emphasises the need for imaging 
during surgery. In our study, imaging was reviewed by three independent raters, two senior 
radiologists and a surgeon not involved in the clinical care processes, with robust methods of 
identification and resolution of conflicts. The senior clinicians reviewing imaging could 
identify participants that had their fracture stabilised with a screw but did not know the 
allocation after randomisation. Also having three reviewers independently reviewing the 
imaging and performing measurements helped mitigate against any bias in measurements.  
Finally, a potential threat to study validity is non-compliance. This is when the treatment was 
not delivered as planned which can potentially dilute the treatment effect observed in the 
intention-to-treat (ITT) primary analysis. In the surgery group, 31 patients (14%) did not have 
surgery compared with six patients (3%) in the plaster cast group who immediately switched 
to surgery following randomisation. There were a combination of factors as to why 
participants did not get their allocated surgery. This included a fracture not being seen on the 
baseline CT scan, on further review of imaging/further imaging at baseline the surgeon 
deciding that the participant had a different type of fracture or the participant changed their 
mind. ITT analysis was used throughout, which includes all participants in the group to which 
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they were randomly assigned. This preserves the original random allocation and reflects the 
pragmatic nature of administering treatment in clinical practice.  Complier Average Causal 
Effect (CACE) analysis was also conducted to explore the potential dilution of the treatment 
effect of the six participants (3%) who crossed over to surgery in the plaster cast group and 
the 31 participants (14%) in the surgery group who were managed conservatively. The CACE 
analysis reproduced a difference in favour of surgery amongst participants who complied 
with their treatment which was larger than the ITT treatment effect on the total PRWE at 52 
weeks. Although it remained a non-statistically significant result nor a clinically important 
treatment effect, the upper confidence limit now included the clinically important effect.  In 
terms of further non-compliance in the control pathway, of 17 participants in the plaster cast 
group who had surgery for early identified non-union in the plaster cast group, 14 had it 
within six months from randomisation and three were treated after six months. Three of the 
four participants in the plaster cast group who had a non- or slight union at 52 weeks were 
also not offered surgery. Therefore 6 of 21 participants did not have the expected immediate 
surgical fixation when there was non-union in the plaster cast group.   
 
Applicability of results 
Characteristics of the trial population 
Review of the baseline characteristics of the trial participants and the fact that the three raters 
agreed on the baseline imaging that only one participant did not actually have a fracture at 
enrolment, helps to confirm the inclusion of appropriate participants in the SWIFFT trial.  
 
The application of the eligibility criteria meant that a quarter of the population of patients 
considered for the trial were excluded for genuine clinical reasons, predominantly because 
the inclusion of these patients meant the surgeon would not be in equipoise about how to treat 
a patient. A further third of the population screened did not consent to take part. Therefore, 
just over 40% of the patients screened for participation were randomised. A comparison of 
the four key baseline characteristics revealed that eligible patients tended to be a few years 
younger than those excluded, and marginally more likely to be male and have a displaced 
fracture. Consenting and non-consenting patient characteristics were comparable, except that 
consenting patients were more likely to have a displaced fracture. As previously discussed, 
the statistical method used to analyse the primary outcome meant that only 7% of consenting 
participants were not included in the primary analysis. Multiple imputation analysis to 
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explore the effect of this minimal missing data, confirmed this did not bias the treatment 
effect in the PRWE. 
 
Applicability of the trial findings 
The pragmatic design of the SWIFFT trial helps to ensure that there is immediate application 
to the NHS. The criteria used to enrol participants in the trial were minimised as much as 
possible. Nor were there stringent criteria as to which surgeons could operate on participants. 
Those surgeons who did operate, or were present during the operation, were mostly 
consultants, as would be expected. The provision of standardised, written physiotherapy 
advice detailing the exercises participants needed to perform may not be entirely reflective of 
NHS practice. It did, however, help to ensure that a good standard of practice was applied 
consistently across both groups as was confirmed when participants self-reported this at 12 
weeks. The follow-up clinics that were organised at six and 12 weeks were also to be 
consistent with routine clinical practice. The follow-up clinic at 52 weeks, which was the 
primary end-point, was to ensure as much as feasible that participants in both treatment 
groups had the time to complete the treatment pathway being delivered. The findings are also 
applicable to both participants with undisplaced or minimally displaced fractures, with the 
sub-group analysis showing that participants with a displaced fracture did not statistically 
significantly benefit more from surgery than those with an undisplaced fracture.  
 
Most of the previous small trials addressing this research question involved a single centre. In 
contrast, the SWIFFT trial recruited participants from 30 NHS hospitals in England, and one 
in Wales, which reflected a variety of geographical locations to improve the generalisability 
of results. There were also 95 surgeons who operated on participants. Whilst the large 
number of hospitals and surgeons involved improves generalisability, there could be concerns 
about how the limited number of participants operated on by a single surgeon can influence 
patient outcome. Including the adjustment of hospital site in the primary model, produced 
similar findings.  Importantly, unlike previous RCTs, a thorough and detailed economic 
evaluation was undertaken to assess the relative cost-effectiveness of the two treatment 
options within the trial follow-up period and the lifetime implications of treatment decisions 
made. The primary analysis is that of the NHS and will therefore have direct applicability to 
informing future policy and commissioning decisions. 
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Cost effectiveness of early surgery compared to initial cast treatment 
 
Incremental cost effectiveness ratio 
The within study analysis, an assessment of the costs and quality of life associated with the 
patients for the first year post randomisation, found that up to 52 weeks early fixation was not 
cost-effective with an ICER of £67,473/QALY to £135,085/QALY.  This range of values was 
based on the approach taken to trial population, missing data, and adjustment for baseline 
quality of life.  The most reasonable scenario is considered to be 81,962 /QALY, a scenario 
of an intention to treat population with multiple imputation for missing values and baseline 
quality of life adjusted for.  
 
Long-term model 
“Initial use of cast with immediate fixation of confirmed non-union” was associated with a 
61% probability of being cost-effective.  The extrapolated model is driven by the relatively 
and absolutely small numbers of non-unions, alongside the uncertain long-term estimates.   
 
Long-term model uncertainty 
 “Initial use of cast with immediate fixation of confirmed non-union” was associated with a 
67% probability of being cost-effective.  The extrapolated model is driven by the relatively 
and absolutely small numbers of non-unions, alongside the uncertain long-term estimates.   
 
This result was influenced by the relatively low cost of initial cast immobilisation compared 
to surgery and the finding that if cast immobilisation was unsuccessful surgical fixation was 
offered, accepted by almost all, and then highly likely unite.   
 
The long-term Markov model was based on data from small retrospective case series and was 
driven mainly by the very small difference in union rate at 52 weeks between the two groups- 
highlighting the considerable uncertainty surrounding the model. The uncertainty in this 
model will be addressed after the medium term five year review as this will help improve our 
assumptions and hence the confidence in such a model. 
 
 
 
232 
 
Health economic summary 
The key finding is that if initial cast immobilisation is unsuccessful but surgical intervention 
is offered soon after confirming non-union, it is highly likely to be the most cost-effective, as 
it avoids the high upfront cost of fixing all broken scaphoids, but still avoids a long-term non-
union and the risks of both high surgical rate and poor quality of life for patients who develop 
SNAC. 
 
Health economics strengths and limitations 
The economic evaluation of the treatment of these types of scaphoid fractures, described in 
Chapter 4, was associated with a number of strengths and weaknesses. 
 
It was the first evaluation of this area to not only provide an analysis of the cost and quality 
of life implications of the treatments available using evidence from a RCT, but to combine 
these with a long-term model, using evidence from the literature to consider the lifetime 
implications of treatment decisions made.  The ‘within-trial’ model provided a 
methodologically rigorous exploration of the cost and quality of life of patients in both arms 
of the SWIFFT trial, including extensive missing data estimation alongside a series of 
regression analyses seeking to explore the role of confounding factors.  The mathematical 
model presented extends the findings of the SWIFFT trial by not only considering the 
lifetime implications of the two treatments, but also by incorporating treatment scenarios of 
cast immobilisation only and no treatment, not considered in the trial.  This allows for a 
complete evaluation of all possible treatment options available and the long-term implications 
of each.  This structure, alongside the PSA and extensive scenario analyses, allowed a 
detailed exploration and presentation of the significant role of uncertainty in this decision 
problem due to both the small incremental differences between the outcomes of the two arms 
of the trial alongside the limited long-term evidence available in the literature.  
 
However, as with any such evaluation, there are additionally weaknesses of the analysis. 
Including those as a consequence of the available evidence and are detailed in Chapter 4.  
The primary weaknesses relate to the potential over-simplification of the mathematical 
model, and the limited connection between the trial data and the long-term model.  The 
insensitivity of the decision-tree to the explicit role of the time lag between the observation of 
potential non-union after cast immobilisation and the occurrence of surgical fixation is one, 
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and while it would not be expected to change the base-case result, it limits our ability to 
explore the impact of changes to such a parameter.  For example, it would be expected that 
there exists some time threshold at which unless surgery occurs before it, the cast plus 
surgery arm becomes less cost-effective than initial surgery for all patients.  Similarly, the 
simplistic approach to OA, non-OA related AEs, and SNAC in the long-term model, while 
necessitated by the available evidence, risks incorrectly specifying the risks and benefits of 
each treatment arm.  Finally, the use of the rate of non-union as the link between the short 
and long-term model, and the use of literature based estimates of adverse-event profiles, 
rather than from the trial, makes the result of the analysis highly sensitive to the rate of non-
union estimates from the trial.  This results in the model being highly sensitive to factors such 
as the assumption made about the three patients who had non-union at 52 weeks but were yet 
to have surgery, and the definition of slight union as indicative of non-union or not.  
However, given the available evidence and level of clinical understanding the models should 
represent the most robust base-case scenario.   
 
The Markov Model was limited by the assumptions made and the data available. The latter 
were very small case series which were historic. We have addressed the uncertainty using 
many scenarios but feel that the five year study of SWIFFT participants will help resolve 
much of the uncertainty in the Markov model. 
 
Nested qualitative study: what treatment patients prefer and their experience of 
treatment  
The nested qualitative study explored the impact of a scaphoid fracture, as well as experience 
of treatment and treatment preference. The study offers detailed, contextualised insight with 
each interviewee offering a distinct and personalised narrative. This data complements the 
clinical and other data generated elsewhere in SWIFFT and provides an additional 
perspective to support the implementation of trial findings. The qualitative data generated 
here provides a valuable, subjective viewpoint that will aid clinicians in understanding their 
patients’ experiences and in shaping their discussions about clinical options.  
 
Sense of recovery 
Insight generated here highlights that a patient’s understanding of fracture and their sense of 
recovery is important in assessing treatment success. It also shows that an individual’s sense 
 
 
234 
 
of recovery is shaped by specific personal, familial and economic circumstances; 
employment, social responsibilities or even hobbies and leisure pursuits will shape how they 
feel recovery is progressing. A broader consideration of a patient’s personal circumstances 
might shape more productive clinical consultations and might enhance the management of 
recovery. 
 
Certainty 
The act of plaster cast removal is an important threshold in a patient’s return to normal. 
Patients did not appreciate the uncertainty of the duration of immobilisation or the possible 
need for further treatment even though the rate of this was very low. 
 
Preference 
A broadly positive assessment of surgery amongst those interviewed reflects a more general 
trend amongst those recruited to the study: of 780 eligible patients only 12% of those 
preferring cast treatments consented to take part, compared to 77% of those preferring 
surgery and 87% of those with no preference. Consequently, it is difficult to assess treatment 
preference based on the comments and insights offered here.  
 
Disability 
One interesting observation was the feeling of some weakness, described by several of the 
women interviewed. This was experienced to an extent that some chose to use an external 
wrist support to help accommodate this. Some also experienced concern that this impairment 
may be permanent. 
 
Return to normality while healing 
Two elements of cast treatment concerned participants, the duration of immobilisation and 
the possibility that some (however small) could need further treatment. 
 
Many suggestions were made: One participant suggested that clinicians check the state of 
healing halfway through immobilisation to identify failure earlier, although assessment of 
union is unreliable at earlier time-points especially on radiographs.62 There was also a sense 
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that patients regarded surgery as “doing something” rather than “just waiting” and regarded it 
as more active and readily assumed that the risks and failures would not happen to them. A 
small number understood and verbalised that if the fracture is displaced, fixing it would 
reduce the displacement and make it heal in a better and reduced position. 
 
The main reflection of this chapter is that considering this trial confirms the mode of initial 
treatment does not have significant impact on fracture union, clinicians should focus more on 
the impact of treatment choices on the patient’s day to day life and their work. There is a 
clear need to focus on becoming “normal” again. If external immobilisation is considered, 
then restoring independence and minimising the impacts on ADL by using removable splints 
at an earlier time-point in the pathway may help patients “recover”. This may need a careful 
and planned discussion at the outset when the injury is diagnosed. Another is the discussion 
about uncertainty in the recovery after both pathways as the control cast & fix non-union 
pathway required 1 re-operation up to 52 weeks while those having early surgery required 11 
re-operations in 8 participants and the surgery pathway had one significant non-salvageable 
consequence and a high rate of screw penetration.  
 
Qualitative interviews strengths and limitations 
The qualitative substudy study offers detailed, contextualised insight into the experiences of a 
fracture of the scaphoid waist with each interviewee offering a distinct and personalised 
narrative about their injury and experience of treatment. This data complements the clinical 
and other data generated elsewhere in SWIFFT and provides an additional perspective to 
support the implementation of trial findings. The qualitative data generated here provides a 
valuable, subjective viewpoint which will aid clinicians in understanding their patients’ 
experiences and in shaping their discussions about clinical options.  
 
That our sample broadly achieved its purposive aim – approximately half of all interviews 
were with males under the age of 30 - adds pertinence and credibility to the findings. That the 
sample is larger than other comparable qualitative investigations of patient experience of 
hand/wrist/arm injury also adds credibility to the findings reached. The findings add to the 
current literature with a more explicit focus upon how surgical and plaster cast treatments are 
perceived and experienced; and in extending those personal, contextual factors (domestic, 
social, economic) which might shape an individual’s experience of fracture and treatment. 
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It is, of course, important to reflect that this sub-study explores participant’s subjective 
experience of fracture and their subjective understanding of treatment and recovery. It 
reflects how they think things are or should be; this does not always, or automatically, 
translate into how things actually are.  
 
It should also be noted that interviewees are to some extent self-selected – restricted in the 
main to those who agreed to take part in the trial, and that amongst this group participants 
could opt out of the interview sub-study. Generalising is difficult across the different 
demographics included here (which includes both students and the retired) and differences in 
experience (both positive and negative) also make interpretation and generalisation difficult. 
It is perhaps, however, the taciturn and mono-syllabic responses of some young men that 
make interpretation most difficult.  
 
A key limitation that must be acknowledged is that attrition between the 6 week and 52 week 
interviews exceeds that which had been predicted (50% rather than 30%) and that this limits 
the potential for direct comparison and building narrative accounts of fracture and recovery. 
Most often participants were not contactable – not responding to approach (on at least 3 
occasions) via telephone call, SMS messaging or email – although some respondents 
explicitly indicated that they did not wish to take part in a second interview. That attrition 
was most pronounced in the younger male sample is pertinent and this led to new male 
interviewees (n=4) being added at the 52 week interview point. It should also be noted that 
older females are over-represented in the final interview sample - fewer younger females 
consented to the interview sub-study and consequently additional older females were 
recruited to achieve the target for female interviewees (n=11). That these female participants 
were least likely to drop-out means that older females are the second largest group 
interviewed at 52 weeks (n=5/19).  
 
Recommendations for future research 
Evidence from eight published meta-analyses29-32, 34-37 to evaluate surgical fixation compared 
with conservative treatments for acute undisplaced or minimally displaced scaphoid fractures 
is based on 416 patients. The SWIFFT trial is therefore the largest study in the world and has 
doubled the existing evidence-base and should be used to update the meta-analyses in order 
to further address the uncertainty and to confirm whether no further trials are necessary.   
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The five year follow-up of SWIFFT participants will be important to investigate the outcome 
of the partial union of the scaphoid fracture and whether these unite over time and to explore 
the consequences of the progress of degenerative arthritis, malunion and screw problems 
(mal-position and penetration within joints) on participants’ quality of life. This long-term 
follow-up will further inform the areas of uncertainty in the extrapolated model.  
Findings from the qualitative study suggest in future trials that compare medical and surgical 
treatments, patients should have access to a clinician who can adequately explain the 
treatments to ensure both balance in the presentation of information and lessen the potential 
for stereotypical comparisons of the treatments that could affect recruitment. Extensive 
retention strategies should also be included from the outset for a difficult patient population 
such as predominantly young, males.  Finally, research which considers the nature, form and 
delivery of information about a scaphoid fracture and its treatment might similarly inform 
future clinical consultations and inform a patient’s sense of recovery.  This could include 
providing the patient with a leaflet to encourage surgical fixation when non-union occurs, 
explaining that surgery will help reduce the rate of future arthritis. Further detailed 
qualitative, longitudinal research with younger, male scaphoid fracture patients would also be 
useful to explore their sense of recovery that may help to reduce re-injury associated with 
impulsive or impatient behaviour. 
 
Conclusion 
This prospective, pragmatic randomised controlled trial could not identify at the primary end-
point of 52 weeks a statistically significant or clinically meaningful difference between the 
offer of cast treatment with early urgent fixation of non-unions compared with having all 
scaphoid fractures fixed surgically at the outset. The most cost-effective pathway is definitive 
cast treatment, with early fixation of only those fractures that do not unite with a cast. Patient 
treatment preferences following their injury, reflect their desire to have a “sense of 
recovering” and surgeons should address this at the outset. 
 
The SWIFFT study results supports the treatment of all undisplaced and minimally displaced 
scaphoid waist fractures in a cast. Then to investigate for non-union at six to 12 weeks and fix 
all confirmed non-unions immediately. 
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Appendices 
Appendix 1: Participating trusts 
Barts Health NHS Trust  
Bolton NHS Foundation Trust  
Brighton and Sussex University Hospitals NHS Trust  
Cambridge University Hospitals NHS Foundation Trust  
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Chelsea and Westminster Hospital NHS Foundation Trust  
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Hampshire Hospitals NHS Foundation Trust  
King’s College Hospital NHS Foundation Trust  
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Maidstone and Tunbridge Wells NHS Trust  
Medway NHS Foundation Trust  
Newcastle upon Tyne Hospitals NHS Foundation Trust  
North Bristol NHS Trust  
Northumbria Healthcare NHS Foundation Trust  
Nottingham University Hospitals NHS Trust  
Oxford University Hospitals NHS Trust  
Peterborough and Stamford Hospitals NHS Foundation Trust  
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Royal United Hospital Bath NHS Trust  
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Taunton and Somerset NHS Foundation Trust  
The Royal Liverpool and Broadgreen University Hospitals NHS Trust  
University Hospital Southampton NHS Foundation Trust  
University Hospitals Birmingham NHS Foundation Trust  
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Appendix 2: Table of amendments 
 
Table 44. Table of amendments 
 
Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
Non-substantial 
Amendment 1 
13/06/13 Update to Trial Protocol (Version 1.1 date 
05/06/13) 
Update to Main Trial Patient Information 
Leaflet (Version 1.1 date 05/06/13) 
Update to Main Trial Consent Form (Version 
1.1 date 05/06/13) 
Update to Linked Interview Consent Form 
(Version 1.1 date 05/06/13) 
Update to Main Interview Consent Form 
(Version 1.1 date 05/06/13) 
1. Clarification in the protocol regarding timing of baseline CT 
and surgery: 
 Baseline research Computed Tomography scan could be 
performed post-randomisation if not feasible on the day of 
consent. 
 Surgery should be performed within two weeks of 
presentation to A&E and not within two weeks of their 
injury as originally stated.      
2. Minor changes to patient information leaflets in response to 
the Trial Steering Committee patient representative 
recommendations.  Consequently Consent Form updated to 
reflect change in patient information leaflet version. 
3. Change to Consent Status Form to capture time to consent as 
stated in the protocol.  
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
Update to Linked Interview Patient 
Information Leaflet (Version 1.1 date 
05/06/13) 
Non-substantial 
Amendment 2 
10/07/13 Hospital Poster Version 1.1 (02/07/13)  
 
1. Update of eligibility criteria listed on the hospital poster to 
match those stated in the protocol.   
Non-substantial 
Amendment 3 
29/08/13 Update to Main Trial Patient Information 
Leaflet (Version 1.2 dated 16/08/13) 
Update to Main Trial Consent Form (Version 
1.2 dated 16/08/13) 
Update to Interview Consent Form (Version 
1.2 dated 16/08/13) 
1. Correction of Birmingham site details. 
2. Addition of new participating sites.  
3. Addition of potential radiation risk from 
radiographs/Computed Tomography scan in the main trial 
patient information leaflet that was not previously explained. 
Non-substantial 
Amendment 4 
09/09/13 N/A 1. Change in Principal Investigator at Liverpool. 
Non-substantial 
Amendment 5 
08/10/13 N/A 1. Addition of new participating sites. 
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
Substantial 
Amendment 1 
03/12/13 Update to Trial Protocol (Version 2.0 date 
20/10/13) 
Update to Main Trial Patient Information 
Leaflet (Version 2.0 date 20/10/13) 
Update to Main Trial Consent Form (Version 
2.0 date 20/10/13) 
Update to Interview Consent Form (Version 
2.0 date 20/10/13) 
Update to Hospital Poster (Version 2.0 date 
20/10/13) 
Update to Consent Status Form (Version 2.0 
date 06/11/13) 
Update to Baseline  Form (Version 2.0 date 
20/10/13) 
1. Update to eligibility criteria in the protocol 
 ‘Previous injury or disease in same wrist’ removed as an 
exclusion criterion.   
 "of a participating site" added to the criterion about 
excluding patients who are not resident to the trauma 
catchment area.  
 Changed the phrase “cognitive impairment” to “lacks 
mental capacity”.  
 Added pregnancy as an exclusion criterion because of 
radiation exposure from imaging.  
2. Obtaining consent 
 Addition that consent can be performed not only by 
Research Nurses but also clinicians. 
3. Timing of radiographs at baseline 
 Change to allow collection of missing baseline 
radiographs after consent, if necessary.  
4. Collection of PRWE at baseline for both: 
 In the week since injury 
 In the week before injury 
5. Adjustment for baseline covariates in the analyses plan 
 Removal of adjustment on baseline PRWE as a covariate, 
with grip strength and range as the latter allows for more 
variability as measured without the patient’s wrist in 
plaster cast. 
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
Non-substantial 
Amendment 6 
14/01/14 Update to Trial Protocol (Version 2.1 date 
06/01/14) 
Update to Hospital Poster (Version 2.1 date 
06/01/14) 
 
1. Change of Principal Investigator at Maidstone and Cardiff 
2. Addition of new participating sites 
3. Update the protocol about referral pathway to fracture clinic 
to include points of contact other than Accident and 
Emergency. 
4. Changes to exclusion criteria in protocol: 
 Removal of fractures of the proximal pole as not 
applicable 
 Addition of concurrent wrist fracture 
5. Addition of expected plaster cast adverse events to protocol 
(Soft/broken cast, pressure sores, Complex Regional Pain 
Syndrome, nerve compression, pain due to tight cast) 
Non-substantial 
Amendment 7 
19/06/14 N/A 1. Change of Principal Investigator at Royal London and 
Redditch. 
Non-substantial 
Amendment 8 
19/08/14 Update to Trial Protocol (Version 2.2 date 
14/08/14) 
 
1. Minor modifications to trial protocol 
 Clarification that adverse events are followed up at one 
month only if unresolved at initial reporting.  
 Primary analysis to be adjusted on grip strength in 
opposite wrist to the one fractured. 
 Primary analysis adjustment based on wrist range 
removed. 
 Correction of grip strength measurement instructions to 
reflect recommendations in Trampisch et al (2012). 
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
 Addition of Beighton Joint Laxity Score at baseline.  
2. Submission of correct version of Consent Status Form  
3. Change in Principal Investigator at Birmingham 
Substantial 
Amendment 2 
23/02/15 Update to Trial Protocol (Version 3.0 date 
19/01/15) 
 
1. Reinstatement of patients previously withdrawn due to 
equivocal Computed Tomography scan about the presence of 
a fracture 
 Letter to send to previously withdrawn ‘Randomised in 
error’ patients to agree to be reinstated and followed-up.  
2. Verbal consent for qualitative sub-study 
 Permission to obtain verbal consent at time of telephone 
interview with written consent gained retrospectively 
3. Outline of patient engagement activities (newsletter, video, 
website, postal envelope tagline) and example documents for 
approval. 
4. Update to statistical analysis plan 
 Inclusion of greater detail about planned analyses and 
removal of one of the subgroup analyses that involved a 
three-way interaction.  
5. Clarification regarding collection of patient questionnaires in 
clinic.  
 Removed ambiguity so that it is clear that a questionnaire 
is completed by a participant not the Research Nurse. 
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
Substantial 
Amendment 3 
26/11/15 Update to Trial Protocol (Version 4.0 date 
20/10/15) 
Update to Main Trial Consent Form (Version 
3.0 date 20/10/15) 
Update to Main Trial Patient Information 
Leaflet (Version 3.0 date 20/10/15) 
1. Inclusion of letter and primary outcome only questionnaire at 
6 weeks after initial 52 week follow-up questionnaire being 
sent. 
2. Inclusion of prize draws at 26 weeks for participant 
completion of a returning questionnaire, and 52 weeks and 
five years for attending the hospital clinic visit.   
3. Removal of adjustment on covariant ‘baseline grip strength 
of opposite wrist’ from analysis plan.  
4. Clarification that there will be a five year follow-up. 
Non-substantial 
Amendment 9 
11/03/16 N/A 1. Extension to recruitment period. 
Non-substantial 
Amendment 10 
24/08/16 N/A 1. Change in Principal Investigator at Reading. 
Substantial 
Amendment 4 
17/10/16 Update to Trial Protocol (Version 5.0 date) 
 
1. Permission to use email to contact patients for 52 week 
follow-up. 
2. Inclusion of a patient letter from the hospital site to 
encourage attendance at 52 week clinic appointment. 
3. Payment of travel expenses to patients attending 52 week 
clinic appointment. 
4. Permission to retrieve imaging for participants attending 
other hospitals via Picture Archiving and Communications 
Systems.  
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Type 
(Non-
substantial or 
Substantial)  
Approved 
date  
Documents amended Brief Description of Amendment 
5. The use of the Summary Care Records to check contact 
details for patients who the trial team lose contact with.  
6. Permission to contact the patient’s GP to check whether they 
have had any further surgery for their scaphoid fracture.  
7. Change to the categorisation of non-union, slight union etc. to 
remove cases of overlap.  
Non-substantial 
Amendment 11 
11/05/17 N/A 1. Change in Principal Investigator at Coventry. 
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Appendix 3: Tables and figures 
 
 
Table 45: Baseline characteristics of trial participants according to whether or not they 
attended for the week 6 hospital clinic visit 
 
Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
Gender, n (%)       
Male 154 (81.5) 167 (83.9) 321 (82.7) 26 (86.7) 16 (76.2) 42 (82.4) 
Female 35 (18.5) 32 (16.1) 67 (17.3) 4 (13.3) 5 (23.8) 9 (17.6) 
Age (years)       
N 189 199 388 30 21 51 
Mean (SD) 33.2 (13.3) 32.7 (12.4) 32.9 (12.8) 31.2 (12.6) 34.8 (10.9) 32.7 (11.9) 
Median (min, max) 29 (16, 80) 29 (16, 76) 29 (16, 80) 25 (18, 57) 34 (21, 55) 28 (18, 57) 
Ethnicity, n (%)       
White 179 (94.7) 174 (87.4) 353 (91.0) 26 (86.7) 21 (100.0) 47 (92.2) 
Black 0 (0.0) 5 (2.5) 5 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Asian 7 (3.7) 10 (5.0) 17 (4.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Other 3 (1.6) 10 (5.0) 13 (3.4) 2 (6.7) 0 (0.0) 2 (3.9) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9) 
Education, n (%)       
No formal 
qualifications 18 (9.5) 24 (12.1) 42 (10.8) 6 (20.0) 3 (14.3) 9 (17.6) 
Some 
qualifications/no 
degree 132 (69.8) 114 (57.3) 246 (63.4) 19 (63.3) 15 (71.4) 34 (66.7) 
Degree or higher 38 (20.1) 61 (30.7) 99 (25.5) 3 (10.0) 3 (14.3) 6 (11.8) 
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9) 
Employment 
status, n (%)       
Part-time 20 (10.6) 16 (8.0) 36 (9.3) 0 (0.0) 2 (9.5) 2 (3.9) 
Full-time 113 (59.8) 114 (57.3) 227 (58.5) 14 (46.7) 6 (28.6) 20 (39.2) 
Self-employed 18 (9.5) 26 (13.1) 44 (11.3) 3 (10.0) 10 (47.6) 13 (25.5) 
Student 17 (9.0) 21 (10.6) 38 (9.8) 3 (10.0) 0 (0.0) 3 (5.9) 
Retired 7 (3.7) 5 (2.5) 12 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Looking after 
family/home 0 (0.0) 4 (2.0) 4 (1.0) 1 (3.3) 2 (9.5) 3 (5.9) 
Not employed but 
seeking work 5 (2.6) 5 (2.5) 10 (2.6) 4 (13.3) 0 (0.0) 4 (7.8) 
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Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
Other 8 (4.2) 8 (4.0) 16 (4.1) 3 (10.0) 1 (4.8) 4 (7.8) 
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9) 
Type of 
employment, n 
(%)       
Unskilled manual 23 (12.2) 17 (8.5) 40 (10.3) 2 (6.7) 6 (28.6) 8 (15.7) 
Skilled manual 55 (29.1) 54 (27.1) 109 (28.1) 8 (26.7) 6 (28.6) 14 (27.5) 
Unskilled non-
manual 17 (9.0) 10 (5.0) 27 (7.0) 2 (6.7) 2 (9.5) 4 (7.8) 
Skilled non-manual 30 (15.9) 44 (22.1) 74 (19.1) 3 (10.0) 2 (9.5) 5 (9.8) 
Professional 19 (10.1) 15 (7.5) 34 (8.8) 1 (3.3) 4 (19.0) 5 (9.8) 
Other 17 (9.0) 30 (15.1) 47 (12.1) 2 (6.7) 0 (0.0) 2 (3.9) 
Missing 28 (14.8) 29 (14.6) 57 (14.7) 12 (40.0) 1 (4.8) 13 (25.5) 
Current smoker, n 
(%)       
Yes 56 (29.6) 45 (22.6) 101 (26.0) 17 (56.7) 11 (52.4) 28 (54.9) 
No 132 (69.8) 153 (76.9) 285 (73.5) 11 (36.7) 10 (47.6) 21 (41.2) 
Missing 1 (0.5) 1 (0.5) 2 (0.5) 2 (6.7) 0 (0.0) 2 (3.9) 
If Yes:       
How many 
cigarettes       
Median (min, max) 10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (2, 20) 10 (5, 15) 10 (2, 20) 
For how many 
years       
Median (min, max) 10 (1, 50) 10 (1, 36) 10 (1, 50) 9 (1, 44) 10 (4, 20) 10 (1, 44) 
Past smoker, n 
(%)       
Yes 99 (52.4) 94 (47.2) 193 (49.7) 17 (56.7) 15 (71.4) 32 (62.7) 
No 79 (41.8) 96 (48.2) 175 (45.1) 6 (20.0) 5 (23.8) 11 (21.6) 
Missing  11 (5.8) 9 (4.5) 20 (5.2) 7 (23.3) 1 (4.8) 8 (15.7) 
Diabetes, n (%)       
Yes 6 (3.2) 4 (2.0) 10 (2.6) 1 (3.3) 0 (0.0) 1 (2.0) 
No 182 (96.3) 195 (98.0) 377 (97.2) 27 (90.0) 21 (100.0) 48 (94.1) 
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9) 
Steroid use, n (%)       
Yes 5 (2.6) 4 (2.0) 9 (2.3) 1 (3.3) 0 (0.0) 1 (2.0) 
No 183 (96.8) 195 (98.0) 378 (97.4) 27 (90.0) 21 (100.0) 48 (94.1) 
Missing  1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9) 
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Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 46: Baseline fracture details of trial participants according to whether or not they 
attended for the week 6 hospital clinic visit 
 
Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
Time since injury 
(days)a       
N 189 199 388 30 21 51 
Mean (SD) 4.9 (3.1) 5.3 (3.4) 5.1 (3.3) 5.9 (2.7) 5.3 (3.2) 5.7 (2.9) 
Median (min, max) 4 (1, 14) 5 (0, 14) 4 (0, 14) 6 (1, 12) 5 (1, 12) 5 (1, 12) 
Affected wrist, n 
(%)       
Left 105 (55.6) 110 (55.3) 215 (55.4) 10 (33.3) 8 (38.1) 18 (35.3) 
Right 84 (44.4) 89 (44.7) 173 (44.6) 20 (66.7) 13 (61.9) 33 (64.7) 
Hand dominance, 
n (%)       
Yes 85 (45.0) 83 (41.7) 168 (43.3) 15 (50.0) 12 (57.1) 27 (52.9) 
No  104 (55.0) 116 (58.3) 220 (56.7) 13 (43.3) 9 (42.9) 22 (43.1) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9) 
Displacement 
(eligibility), n (%)       
No displacement 113 (59.8) 117 (58.8) 230 (59.3) 22 (73.3) 17 (81.0) 39 (76.5) 
Displacement 76 (40.2) 82 (41.2) 158 (40.7) 8 (26.7) 4 (19.0) 12 (23.5) 
Displacement 
(randomisation), n 
(%)       
No displacement 109 (57.7) 113 (56.8) 222 (57.2) 22 (73.3) 17 (81.0) 39 (76.5) 
Displacement 80 (42.3) 86 (43.2) 166 (42.8) 8 (26.7) 4 (19.0) 12 (23.5) 
Radiographsb, n 
(%)       
Elongated scaphoid 
view 180 (95.2) 189 (95.0) 369 (95.1) 29 (96.7) 21 (100.0) 50 (98.0) 
Posterior-anterior 
view 187 (98.9) 197 (99.0) 384 (99.0) 28 (93.3) 21 (100.0) 49 (96.1) 
Semi 45° supine 134 (70.9) 151 (75.9) 285 (73.5) 25 (83.3) 15 (71.4) 40 (78.4) 
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Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
Lateral 189 
(100.0) 196 (98.5) 385 (99.2) 29 (96.7) 21 (100.0) 50 (98.0) 
Semi 45° prone 170 (89.9) 179 (89.9) 349 (89.9) 28 (93.3) 17 (81.0) 45 (88.2) 
Previous wrist 
problems on same 
side, n (%)       
Yes 40 (21.2) 41 (20.6) 81 (20.9) 3 (10.0) 4 (19.0) 7 (13.7) 
No 148 (78.3) 158 (79.4) 306 (78.9) 25 (83.3) 15 (71.4) 40 (78.4) 
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 2 (9.5) 4 (7.8) 
If Yes, what 
injury, n (%)       
Previous fracture 21 (52.5) 26 (63.4) 47 (58.0) 2 (66.7) 2 (50.0) 4 (57.1) 
Arthritis 1 (2.5) 1 (2.4) 2 (2.5) 1 (33.3) 0 (0.0) 1 (14.3) 
Ligament, tendon or 
nerve injury 10 (25.0) 7 (17.1) 17 (21.0) 0 (0.0) 1 (25.0) 1 (14.3) 
Other 6 (15.0) 7 (17.1) 13 (16.0) 0 (0.0) 1 (25.0) 1 (14.3) 
Missing 2 (5.0) 0 (0.0) 2 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Injury mechanism, 
n (%)       
Fall – standing 24 (12.7) 27 (13.6) 51 (13.1) 4 (13.3) 2 (9.5) 6 (11.8) 
Fall – walking 20 (10.6) 22 (11.1) 42 (10.8) 4 (13.3) 2 (9.5) 6 (11.8) 
Fall – running 37 (19.6) 35 (17.6) 72 (18.6) 3 (10.0) 3 (14.3) 6 (11.8) 
Fall – from height   24 (12.7) 31 (15.6) 55 (14.2) 4 (13.3) 3 (14.3) 7 (13.7) 
Fall – from moving 
object 35 (18.5) 31 (15.6) 66 (17.0) 7 (23.3) 0 (0.0) 7 (13.7) 
Hit on palm of hand 
– object striking 
palm 15 (7.9) 14 (7.0) 29 (7.5) 1 (3.3) 1 (4.8) 2 (3.9) 
Hit on palm of hand 
– handle whipping 
back 7 (3.7) 10 (5.0) 17 (4.4) 2 (6.7) 1 (4.8) 3 (5.9) 
Hit on palm of hand 
– other sudden 
extension 10 (5.3) 7 (3.5) 17 (4.4) 1 (3.3) 1 (4.8) 2 (3.9) 
Punched something 4 (2.1) 9 (4.5) 13 (3.4) 0 (0.0) 3 (14.3) 3 (5.9) 
Road traffic 
accident 9 (4.8) 6 (3.0) 15 (3.9) 0 (0.0) 2 (9.5) 2 (3.9) 
Other 4 (2.1) 7 (3.5) 11 (2.8) 2 (6.7) 3 (14.3) 5 (9.8) 
Missing  0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9) 
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Characteristic 
Attended visit (n=388) Did not attend visit (n=51) 
Surgery 
(n=189) 
Plaster 
cast 
(n=199) 
Total 
(n=388) 
Surgery 
(n=30) 
Plaster 
cast 
(n=21) 
Total 
(n=51) 
Place of injuryb, n 
(%)       
Sport 79 (41.8) 72 (36.2) 151 (38.9) 9 (30.0) 6 (28.6) 15 (29.4) 
Home 20 (10.6) 38 (19.1) 58 (14.9) 7 (23.3) 5 (23.8) 12 (23.5) 
Work 18 (9.5) 17 (8.5) 35 (9.0) 4 (13.3) 1 (4.8) 5 (9.8) 
Road Traffic 
Accident 24 (12.7) 32 (16.1) 56 (14.4) 2 (6.7) 2 (9.5) 4 (7.8) 
Public place 44 (23.3) 42 (21.1) 86 (22.2) 5 (16.7) 6 (28.6) 11 (21.6) 
Other  3 (1.6) 0 (0.0) 3 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 
Missing  3 (1.6) 1 (0.5) 4 (1.0) 1 (3.3) 1 (4.8) 2 (3.9) 
Treatment 
preference, n (%)       
Surgery 80 (42.3) 92 (46.2) 172 (44.3) 13 (43.3) 9 (42.9) 22 (43.1) 
No surgery 10 (5.3) 16 (8.0) 26 (6.7) 3 (10.0) 3 (14.3) 6 (11.8) 
No preference 98 (51.9) 90 (45.2) 188 (48.5) 12 (40.0) 9 (42.9) 21 (41.2) 
Missing 1 (0.5) 1 (0.5) 2 (0.5) 2 (6.7) 0 (0.0) 2 (3.9) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
 
Table 47: Baseline characteristics of trial participants according to whether or not they 
attended for the week 12 hospital clinic visit 
 
Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
Gender, n (%)       
Male 143 (82.7) 134 (81.2) 277 (82.0) 37 (80.4) 49 (89.1) 86 (85.1) 
Female 30 (17.3) 31 (18.8) 61 (18.0) 9 (19.6) 6 (10.9) 15 (14.9) 
Age (years)       
N 173 165 338 46 55 101 
Mean (SD) 33.7 (13.5) 34.1 (12.8) 33.9 (13.1) 30.0 (11.9) 29.1 (9.6) 29.5 (10.6) 
Median (min, max) 29 (16, 80) 31 (16, 76) 30 (16, 80) 26 (18, 57) 25 (17, 55) 25 (17, 57) 
Ethnicity, n (%)       
White 163 (94.2) 144 (87.3) 307 (90.8) 42 (91.3) 51 (92.7) 93 (92.1) 
Black 0 (0.0) 3 (1.8) 3 (0.9) 0 (0.0) 2 (3.6) 2 (2.0) 
Asian 6 (3.5) 8 (4.8) 14 (4.1) 1 (2.2) 2 (3.6) 3 (3.0) 
Other 4 (2.3) 10 (6.1) 14 (4.1) 1 (2.2) 0 (0.0) 1 (1.0) 
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Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (2.0) 
Education, n (%)       
No formal 
qualifications 16 (9.2) 21 (12.7) 37 (10.9) 8 (17.4) 6 (10.9) 14 (13.9) 
Some 
qualifications/no 
degree 120 (69.4) 91 (55.2) 211 (62.4) 31 (67.4) 38 (69.1) 69 (68.3) 
Degree or higher 36 (20.8) 53 (32.1) 89 (26.3) 5 (10.9) 11 (20.0) 16 (15.8) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0) 
Employment 
status, n (%)       
Part-time 19 (11.0) 15 (9.1) 34 (10.1) 1 (2.2) 3 (5.5) 4 (4.0) 
Full-time 106 (61.3) 93 (56.4) 199 (58.9) 21 (45.7) 27 (49.1) 48 (47.5) 
Self-employed 15 (8.7) 23 (13.9) 38 (11.2) 6 (13.0) 13 (23.6) 19 (18.8) 
Student 14 (8.1) 16 (9.7) 30 (8.9) 6 (13.0) 5 (9.1) 11 (10.9) 
Retired 7 (4.0) 5 (3.0) 12 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 
Looking after 
family/home 0 (0.0) 4 (2.4) 4 (1.2) 1 (2.2) 2 (3.6) 3 (3.0) 
Not employed but 
seeking work 3 (1.7) 4 (2.4) 7 (2.1) 6 (13.0) 1 (1.8) 7 (6.9) 
Other 8 (4.6) 5 (3.0) 13 (3.8) 3 (6.5) 4 (7.3) 7 (6.9) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0) 
Type of 
employment, n 
(%)       
Unskilled manual 19 (11.0) 11 (6.7) 30 (8.9) 6 (13.0) 12 (21.8) 18 (17.8) 
Skilled manual 51 (29.5) 44 (26.7) 95 (28.1) 12 (26.1) 16 (29.1) 28 (27.7) 
Unskilled non-
manual 18 (10.4) 9 (5.5) 27 (8.0) 1 (2.2) 3 (5.5) 4 (4.0) 
Skilled non-manual 28 (16.2) 38 (23) 66 (19.5) 5 (10.9) 8 (14.5) 13 (12.9) 
Professional 17 (9.8) 15 (9.1) 32 (9.5) 3 (6.5) 4 (7.3) 7 (6.9) 
Other 16 (9.2) 23 (13.9) 39 (11.5) 3 (6.5) 7 (12.7) 10 (9.9) 
Missing 24 (13.9) 25 (15.2) 49 (14.5) 16 (34.8) 5 (9.1) 21 (20.8) 
Current smoker, n 
(%)       
Yes 49 (28.3) 31 (18.8) 80 (23.7) 24 (52.2) 25 (45.5) 49 (48.5) 
No 123 (71.1) 133 (80.6) 256 (75.7) 20 (43.5) 30 (54.5) 50 (49.5) 
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 0 (0.0) 2 (2.0) 
If Yes:       
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Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
How many 
cigarettes       
Median (min, max) 10 (1, 40) 11 (1, 36) 10 (1, 40) 10 (1, 20) 10 (4, 20) 10 (1, 20) 
For how many 
years       
Median (min, max) 10 (1, 50) 10 (1, 40) 10 (1, 50) 10 (1, 44) 10 (2, 20) 10 (1, 44) 
Past smoker, n 
(%)       
Yes 91 (52.6) 70 (42.4) 161 (47.6) 25 (54.3) 39 (70.9) 64 (63.4) 
No 72 (41.6) 88 (53.3) 160 (47.3) 13 (28.3) 13 (23.6) 26 (25.7) 
Missing  10 (5.8) 7 (4.2) 17 (5.0) 8 (17.4) 3 (5.5) 11 (10.9) 
Diabetes, n (%)       
Yes 6 (3.5) 4 (2.4) 10 (3.0) 1 (2.2) 0 (0.0) 1 (1.0) 
No 166 (96.0) 161 (97.6) 327 (96.7) 43 (93.5) 55 (100.0) 98 (97.0) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0) 
Steroid use, n (%)       
Yes 4 (2.3) 4 (2.4) 8 (2.4) 2 (4.3) 0 (0.0) 2 (2.0) 
No 168 (97.1) 161 (97.6) 329 (97.3) 42 (91.3) 55 (100.0) 97 (96.0) 
Missing  1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 48: Baseline fracture details of trial participants according to whether or not they 
attended for the week 12 hospital clinic visit 
 
Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
Time since injury 
(days)a       
N 173 165 338 46 55 101 
Mean (SD) 4.8 (3.1) 5.4 (3.5) 5.1 (3.3) 6.0 (3.0) 5.2 (2.9) 5.6 (3.0) 
Median (min, max) 4 (1, 14) 4 (0, 14) 4 (0, 14) 6 (1, 14) 5 (0, 12) 6 (0, 14) 
Affected wrist, n 
(%)       
Left 93 (53.8) 94 (57.0) 187 (55.3) 22 (47.8) 24 (43.6) 46 (45.5) 
Right 80 (46.2) 71 (43.0) 151 (44.7) 24 (52.2) 31 (56.4) 55 (54.5) 
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Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
Hand dominance, 
n (%)       
Yes 76 (43.9) 68 (41.2) 144 (42.6) 24 (52.2) 27 (49.1) 51 (50.5) 
No  97 (56.1) 97 (58.8) 194 (57.4) 20 (43.5) 28 (50.9) 48 (47.5) 
Missing    2 (4.3) 0 (0.0) 2 (2.0) 
Displacement 
(eligibility), n (%)       
No displacement 107 (61.8) 101 (61.2) 208 (61.5) 28 (60.9) 33 (60.0) 61 (60.4) 
Displacement 66 (38.2) 64 (38.8) 130 (38.5) 18 (39.1) 22 (40.0) 40 (39.6) 
Displacement 
(randomisation), n 
(%)       
No displacement 104 (60.1) 97 (58.8) 201 (59.5) 27 (58.7) 33 (60.0) 60 (59.4) 
Displacement 69 (39.9) 68 (41.2) 137 (40.5) 19 (41.3) 22 (40.0) 41 (40.6) 
Radiographsb, n 
(%)       
Elongated scaphoid 
view 164 (94.8) 158 (95.8) 322 (95.3) 45 (97.8) 52 (94.5) 97 (96.0) 
Posterior-anterior 
view 171 (98.8) 
165 
(100.0) 336 (99.4) 44 (95.7) 53 (96.4) 97 (96.0) 
Semi 45° supine 121 (69.9) 121 (73.3) 242 (71.6) 38 (82.6) 45 (81.8) 83 (82.2) 
Lateral 173 
(100.0) 164 (99.4) 337 (99.7) 45 (97.8) 53 (96.4) 98 (97.0) 
Semi 45° prone 156 (90.2) 147 (89.1) 303 (89.6) 42 (91.3) 49 (89.1) 91 (90.1) 
Previous wrist 
problems on same 
side, n (%)       
Yes 35 (20.2) 33 (20.0) 68 (20.1) 8 (17.4) 12 (21.8) 20 (19.8) 
No 137 (79.2) 131 (79.4) 268 (79.3) 36 (78.3) 42 (76.4) 78 (77.2) 
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 1 (1.8) 3 (3.0) 
If Yes, what 
injury, n (%)       
Previous fracture 18 (51.4) 20 (60.6) 38 (55.9) 5 (62.5) 8 (66.7) 13 (65.0) 
Arthritis 2 (5.7) 1 (3.0) 3 (4.4)    
Ligament, tendon or 
nerve injury 8 (22.9) 7 (21.2) 15 (22.1) 2 (25) 1 (8.3) 3 (15.0) 
Other 6 (17.1) 5 (15.2) 11 (16.2) 0 (0.0) 3 (25.0) 3 (15.0) 
Missing 1 (2.9) 0 (0.0) 1 (1.5) 1 (12.5) 0 (0.0) 1 (5.0) 
Injury mechanism, 
n (%)       
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Characteristic 
Attended visit (n=338) Did not attend visit (n=101) 
Surgery 
(n=173) 
Plaster 
cast 
(n=165) 
Total 
(n=338) 
Surgery 
(n=46) 
Plaster 
cast 
(n=55) 
Total 
(n=101) 
Fall – standing 22 (12.7) 21 (12.7) 43 (12.7) 6 (13.0) 8 (14.5) 14 (13.9) 
Fall – walking 20 (11.6) 21 (12.7) 41 (12.1) 4 (8.7) 3 (5.5) 7 (6.9) 
Fall – running 33 (19.1) 28 (17.0) 61 (18.0) 7 (15.2) 10 (18.2) 17 (16.8) 
Fall – from height   25 (14.5) 25 (15.2) 50 (14.8) 3 (6.5) 9 (16.4) 12 (11.9) 
Fall – from moving 
object 34 (19.7) 27 (16.4) 61 (18.0) 8 (17.4) 4 (7.3) 12 (11.9) 
Hit on palm of hand 
– object striking 
palm 12 (6.9) 12 (7.3) 24 (7.1) 4 (8.7) 3 (5.5) 7 (6.9) 
Hit on palm of hand 
– handle whipping 
back 5 (2.9) 8 (4.8) 13 (3.8) 4 (8.7) 3 (5.5) 7 (6.9) 
Hit on palm of hand 
– other sudden 
extension 9 (5.2) 4 (2.4) 13 (3.8) 2 (4.3) 4 (7.3) 6 (5.9) 
Punched something 4 (2.3) 7 (4.2) 11 (3.3) 0 (0.0) 5 (9.1) 5 (5.0) 
Road traffic 
accident 7 (4.0) 5 (3.0) 12 (3.6) 2 (4.3) 3 (5.5) 5 (5.0) 
Other 2 (1.2) 7 (4.2) 9 (2.7) 4 (8.7) 3 (5.5) 7 (6.9) 
Missing     2 (4.3) 0 (0.0) 2 (2.0) 
Place of injuryb, n 
(%)       
Sport 73 (42.2) 60 (36.4) 133 (39.3) 15 (32.6) 18 (32.7) 33 (32.7) 
Home 17 (9.8) 29 (17.6) 46 (13.6) 10 (21.7) 14 (25.5) 24 (23.8) 
Work 17 (9.8) 13 (7.9) 30 (8.9) 5 (10.9) 5 (9.1) 10 (9.9) 
Road Traffic 
Accident 24 (13.9) 27 (16.4) 51 (15.1) 2 (4.3) 7 (12.7) 9 (8.9) 
Public place 39 (22.5) 38 (23.0) 77 (22.8) 10 (21.7) 10 (18.2) 20 (19.8) 
Other  2 (1.2) 0 (0.0) 2 (0.6) 1 (2.2) 0 (0.0) 1 (1.0) 
Missing  3 (1.7) 1 (0.6) 4 (1.2) 1 (2.2) 1 (1.8) 2 (2.0) 
Treatment 
preference, n (%)       
Surgery 72 (41.6) 76 (46.1) 148 (43.8) 21 (45.7) 25 (45.5) 46 (45.5) 
No surgery 10 (5.8) 13 (7.9) 23 (6.8) 3 (6.5) 6 (10.9) 9 (8.9) 
No preference 90 (52.0) 75 (45.5) 165 (48.8) 20 (43.5) 24 (43.6) 44 (43.6) 
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 0 (0.0) 2 (2.0) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
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Table 49: Baseline characteristics of trial participants according to whether or not they 
attended for the week 52 hospital clinic visit 
Characteristic 
Attended visit (n=310) Did not attend visit (n=129) 
Surgery 
(n=164) 
Plaster 
cast 
(n=146) 
Total 
(n=310) 
Surgery 
(n=55) 
Plaster 
cast 
(n=74) 
Total 
(n=129) 
Gender, n (%)       
Male 137 (83.5) 122 (83.6) 259 (83.5) 43 (78.2) 61 (82.4) 104 (80.6) 
Female 27 (16.5) 24 (16.4) 51 (16.5) 12 (21.8) 13 (17.6) 25 (19.4) 
Age (years)       
N 164 146 310 55 74 129 
Mean (SD) 34.6 (13.7) 34.6 (13.2) 34.6 (13.4) 27.8 (10.0) 29.5 (9.4) 28.7 (9.6) 
Median (min, max) 31 (16, 80) 31 (16, 76) 31 (16, 80) 24 (18, 57) 26 (17, 55) 25 (17, 57) 
Ethnicity, n (%)       
White 153 (93.3) 130 (89.0) 283 (91.3) 52 (94.5) 65 (87.8) 117 (90.7) 
Black 0 (0.0) 2 (1.4) 2 (0.6) 0 (0.0) 3 (4.1) 3 (2.3) 
Asian 7 (4.3) 8 (5.5) 15 (4.8) 0 (0.0) 2 (2.7) 2 (1.6) 
Other 4 (2.4) 6 (4.1) 10 (3.2) 1 (1.8) 4 (5.4) 5 (3.9) 
Missing    2 (3.6) 0 (0.0) 2 (1.6) 
Education, n (%)       
No formal 
qualifications 14 (8.5) 21 (14.4) 35 (11.3) 10 (18.2) 6 (8.1) 16 (12.4) 
Some 
qualifications/no 
degree 114 (69.5) 80 (54.8) 194 (62.6) 37 (67.3) 49 (66.2) 86 (66.7) 
Degree or higher 35 (21.3) 45 (30.8) 80 (25.8) 6 (10.9) 19 (25.7) 25 (19.4) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6) 
Employment 
status, n (%)       
Part-time 15 (9.1) 14 (9.6) 29 (9.4) 5 (9.1) 4 (5.4) 9 (7.0) 
Full-time 105 (64.0) 86 (58.9) 191 (61.6) 22 (40.0) 34 (45.9) 56 (43.4) 
Self-employed 14 (8.5) 19 (13.0) 33 (10.6) 7 (12.7) 17 (23.0) 24 (18.6) 
Student 12 (7.3) 11 (7.5) 23 (7.4) 8 (14.5) 10 (13.5) 18 (14.0) 
Retired 7 (4.3) 5 (3.4) 12 (3.9)    
Looking after 
family/home 0 (0.0) 4 (2.7) 4 (1.3) 1 (1.8) 2 (2.7) 3 (2.3) 
Not employed but 
seeking work 3 (1.8) 3 (2.1) 6 (1.9) 6 (10.9) 2 (2.7) 8 (6.2) 
Other 7 (4.3) 4 (2.7) 11 (3.5) 4 (7.3) 5 (6.8) 9 (7.0) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6) 
Type of 
employment, n 
(%)       
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Characteristic 
Attended visit (n=310) Did not attend visit (n=129) 
Surgery 
(n=164) 
Plaster 
cast 
(n=146) 
Total 
(n=310) 
Surgery 
(n=55) 
Plaster 
cast 
(n=74) 
Total 
(n=129) 
Unskilled manual 17 (10.4) 10 (6.8) 27 (8.7) 8 (14.5) 13 (17.6) 21 (16.3) 
Skilled manual 48 (29.3) 39 (26.7) 87 (28.1) 15 (27.3) 21 (28.4) 36 (27.9) 
Unskilled non-
manual 18 (11.0) 7 (4.8) 25 (8.1) 1 (1.8) 5 (6.8) 6 (4.7) 
Skilled non-manual 27 (16.5) 37 (25.3) 64 (20.6) 6 (10.9) 9 (12.2) 15 (11.6) 
Professional 17 (10.4) 13 (8.9) 30 (9.7) 3 (5.5) 6 (8.1) 9 (7.0) 
Other 16 (9.8) 19 (13.0) 35 (11.3) 3 (5.5) 11 (14.9) 14 (10.9) 
Missing 21 (12.8) 21 (14.4) 42 (13.5) 19 (34.5) 9 (12.2) 28 (21.7) 
Current smoker, n 
(%)       
Yes 49 (29.9) 27 (18.5) 76 (24.5) 24 (43.6) 29 (39.2) 53 (41.1) 
No 114 (69.5) 118 (80.8) 232 (74.8) 29 (52.7) 45 (60.8) 74 (57.4) 
Missing 1 (0.6) 1 (0.7) 2 (0.6) 2 (3.6) 0 (0.0) 2 (1.6) 
If Yes:       
How many 
cigarettes       
Median (min, max) 10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 20) 10 (4, 25) 10 (1, 25) 
For how many 
years       
Median (min, max) 10 (1, 50) 11 (1, 36) 10 (1, 50) 9 (1, 40) 8 (2, 30) 8 (1, 40) 
Past smoker, n 
(%)       
Yes 86 (52.4) 62 (42.5) 148 (47.7) 30 (54.5) 47 (63.5) 77 (59.7) 
No 68 (41.5) 78 (53.4) 146 (47.1) 17 (30.9) 23 (31.1) 40 (31.0) 
Missing  10 (6.1) 6 (4.1) 16 (5.2) 8 (14.5) 4 (5.4) 12 (9.3) 
Diabetes, n (%)       
Yes 6 (3.7) 4 (2.7) 10 (3.2) 1 (1.8) 0 (0.0) 1 (0.8) 
No 157 (95.7) 142 (97.3) 299 (96.5) 52 (94.5) 74 (100.0) 126 (97.7) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6) 
Steroid use, n (%)       
Yes 5 (3.0) 2 (1.4) 7 (2.3) 1 (1.8) 2 (2.7) 3 (2.3) 
No 158 (96.3) 144 (98.6) 302 (97.4) 52 (94.5) 72 (97.3) 124 (96.1) 
Missing  1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 50: Baseline fracture details of trial participants according to whether or not they 
attended for the week 52 hospital clinic visit 
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Characteristic 
Attended visit (n=310) Did not attend visit (n=129) 
Surgery 
(n=164) 
Plaster 
cast 
(n=146) 
Total 
(n=310) 
Surgery 
(n=55) 
Plaster 
cast 
(n=74) 
Total 
(n=129) 
Time since injury 
(days)a       
N 164 146 310 55 74 129 
Mean (SD) 4.9 (3.1) 5.3 (3.4) 5.1 (3.3) 5.7 (3.1) 5.4 (3.2) 5.5 (3.1) 
Median (min, max) 4 (1, 14) 4 (1, 14) 4 (1, 14) 5 (1, 14) 5 (0, 14) 5 (0, 14) 
Affected wrist, n 
(%)       
Left 86 (52.4) 77 (52.7) 163 (52.6) 29 (52.7) 41 (55.4) 70 (54.3) 
Right 78 (47.6) 69 (47.3) 147 (47.4) 26 (47.3) 33 (44.6) 59 (45.7) 
Hand dominance, 
n (%)       
Yes 73 (44.5) 69 (47.3) 142 (45.8) 27 (49.1) 26 (35.1) 53 (41.1) 
No  91 (55.5) 77 (52.7) 168 (54.2) 26 (47.3) 48 (64.9) 74 (57.4) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 2 (1.6) 
Displacement 
(eligibility), n (%)       
No displacement 96 (58.5) 86 (58.9) 182 (58.7) 39 (70.9) 48 (64.9) 87 (67.4) 
Displacement 68 (41.5) 60 (41.1) 128 (41.3) 16 (29.1) 26 (35.1) 42 (32.6) 
Displacement 
(randomisation), n 
(%)       
No displacement 94 (57.3) 83 (56.8) 177 (57.1) 37 (67.3) 47 (63.5) 84 (65.1) 
Displacement 70 (42.7) 63 (43.2) 133 (42.9) 18 (32.7) 27 (36.5) 45 (34.9) 
Radiographsb, n 
(%)       
Elongated scaphoid 
view 157 (95.7) 138 (94.5) 295 (95.2) 52 (94.5) 72 (97.3) 124 (96.1) 
Posterior-anterior 
view 161 (98.2) 145 (99.3) 306 (98.7) 54 (98.2) 73 (98.6) 127 (98.4) 
Semi 45° supine 118 (72.0) 111 (76.0) 229 (73.9) 41 (74.5) 55 (74.3) 96 (74.4) 
Lateral 164 
(100.0) 144 (98.6) 308 (99.4) 54 (98.2) 73 (98.6) 127 (98.4) 
Semi 45° prone 148 (90.2) 132 (90.4) 280 (90.3) 50 (90.9) 64 (86.5) 114 (88.4) 
Previous wrist 
problems on same 
side, n (%)       
Yes 34 (20.7) 30 (20.5) 64 (20.6) 9 (16.4) 15 (20.3) 24 (18.6) 
No 129 (78.7) 115 (78.8) 244 (78.7) 44 (80.0) 58 (78.4) 102 (79.1) 
Missing 1 (0.6) 1 (0.7) 2 (0.6) 2 (3.6) 1 (1.4) 3 (2.3) 
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Characteristic 
Attended visit (n=310) Did not attend visit (n=129) 
Surgery 
(n=164) 
Plaster 
cast 
(n=146) 
Total 
(n=310) 
Surgery 
(n=55) 
Plaster 
cast 
(n=74) 
Total 
(n=129) 
If Yes, what 
injury, n (%)       
Previous fracture 16 (47.1) 18 (60.0) 34 (53.1) 7 (77.8) 10 (66.7) 17 (70.8) 
Arthritis 2 (5.9) 1 (3.3) 3 (4.7)    
Ligament, tendon or 
nerve injury 8 (23.5) 7 (23.3) 15 (23.4) 2 (22.2) 1 (6.7) 3 (12.5) 
Other 6 (17.6) 4 (13.3) 10 (15.6) 0 (0.0) 4 (26.7) 4 (16.7) 
Missing 2 (5.9) 0 (0.0) 2 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Injury mechanism, 
n (%)       
Fall – standing 21 (12.8) 19 (13.0) 40 (12.9) 7 (12.7) 10 (13.5) 17 (13.2) 
Fall – walking 19 (11.6) 20 (13.7) 39 (12.6) 5 (9.1) 4 (5.4) 9 (7.0) 
Fall – running 32 (19.5) 28 (19.2) 60 (19.4) 8 (14.5) 10 (13.5) 18 (14.0) 
Fall – from height   24 (14.6) 20 (13.7) 44 (14.2) 4 (7.3) 14 (18.9) 18 (14.0) 
Fall – from moving 
object 32 (19.5) 21 (14.4) 53 (17.1) 10 (18.2) 10 (13.5) 20 (15.5) 
Hit on palm of hand 
– object striking 
palm 10 (6.1) 12 (8.2) 22 (7.1) 6 (10.9) 3 (4.1) 9 (7.0) 
Hit on palm of hand 
– handle whipping 
back 6 (3.7) 9 (6.2) 15 (4.8) 3 (5.5) 2 (2.7) 5 (3.9) 
Hit on palm of hand 
– other sudden 
extension 8 (4.9) 4 (2.7) 12 (3.9) 3 (5.5) 4 (5.4) 7 (5.4) 
Punched something 2 (1.2) 6 (4.1) 8 (2.6) 2 (3.6) 6 (8.1) 8 (6.2) 
Road traffic 
accident 7 (4.3) 3 (2.1) 10 (3.2) 2 (3.6) 5 (6.8) 7 (5.4) 
Other 3 (1.8) 4 (2.7) 7 (2.3) 3 (5.5) 6 (8.1) 9 (7.0) 
Missing  0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 2 (1.6) 
Place of injuryb, n 
(%)       
Sport 66 (40.2) 53 (36.3) 119 (38.4) 22 (40.0) 25 (33.8) 47 (36.4) 
Home 20 (12.2) 28 (19.2) 48 (15.5) 7 (12.7) 15 (20.3) 22 (17.1) 
Work 16 (9.8) 13 (8.9) 29 (9.4) 6 (10.9) 5 (6.8) 11 (8.5) 
Road Traffic 
Accident 20 (12.2) 22 (15.1) 42 (13.5) 6 (10.9) 12 (16.2) 18 (14.0) 
Public place 40 (24.4) 31 (21.2) 71 (22.9) 9 (16.4) 17 (23.0) 26 (20.2) 
Other  1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6) 
Missing  3 (1.8) 2 (1.4) 5 (1.6) 1 (1.8) 0 (0.0) 1 (0.8) 
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Characteristic 
Attended visit (n=310) Did not attend visit (n=129) 
Surgery 
(n=164) 
Plaster 
cast 
(n=146) 
Total 
(n=310) 
Surgery 
(n=55) 
Plaster 
cast 
(n=74) 
Total 
(n=129) 
Treatment 
preference, n (%)       
Surgery 71 (43.3) 67 (45.9) 138 (44.5) 22 (40.0) 34 (45.9) 56 (43.4) 
No surgery 10 (6.1) 9 (6.2) 19 (6.1) 3 (5.5) 10 (13.5) 13 (10.1) 
No preference 83 (50.6) 69 (47.3) 152 (49.0) 27 (49.1) 30 (40.5) 57 (44.2) 
Missing 0 (0.0) 1 (0.7) 1 (0.3) 3 (5.5) 0 (0.0) 3 (2.3) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
 
Table 51: Baseline characteristics of trial participants with valid PRWE data by time 
point (6 and 12 weeks) 
Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Gender, n (%)       
Male 143 (81.3) 141 (82.0) 284 (81.6) 150 (84.3) 134 (82.2) 284 (83.3) 
Female 33 (18.8) 31 (18.0) 64 (18.4) 28 (15.7) 29 (17.8) 57 (16.7) 
Age (years)       
N 176 172 348 178 163 341 
Mean (SD) 33.5 (13.3) 33.3 (12.9) 33.4 (13.1) 33.4 (13.1) 33.4 (12.8) 33.4 (13.0) 
Median (min, max) 30 (16, 80) 30 (16, 76) 30 (16, 80) 30 (16, 80) 30 (16, 76) 30 (16, 80) 
Ethnicity, n (%)       
White 166 (94.3) 150 (87.2) 316 (90.8) 167 (93.8) 143 (87.7) 310 (90.9) 
Black 0 (0.0) 5 (2.9) 5 (1.4) 0 (0.0) 3 (1.8) 3 (0.9) 
Asian 6 (3.4) 7 (4.1) 13 (3.7) 7 (3.9) 7 (4.3) 14 (4.1) 
Other 4 (2.3) 10 (5.8) 14 (4.0) 4 (2.2) 10 (6.1) 14 (4.1) 
Education, n (%)       
No formal 
qualifications 19 (10.8) 21 (12.2) 40 (11.5) 17 (9.6) 21 (12.9) 38 (11.1) 
Some 
qualifications/no 
degree 121 (68.8) 95 (55.2) 216 (62.1) 119 (66.9) 91 (55.8) 210 (61.6) 
Degree or higher 35 (19.9) 56 (32.6) 91 (26.1) 41 (23.0) 51 (31.3) 92 (27.0) 
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.6) 0 (0.0) 1 (0.3) 
Employment 
status, n (%)       
Part-time 17 (9.7) 15 (8.7) 32 (9.2) 18 (10.1) 14 (8.6) 32 (9.4) 
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Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Full-time 106 (60.2) 92 (53.5) 198 (56.9) 109 (61.2) 94 (57.7) 203 (59.5) 
Self-employed 15 (8.5) 25 (14.5) 40 (11.5) 17 (9.6) 21 (12.9) 38 (11.1) 
Student 16 (9.1) 19 (11.0) 35 (10.1) 14 (7.9) 18 (11.0) 32 (9.4) 
Retired 6 (3.4) 5 (2.9) 11 (3.2) 7 (3.9) 5 (3.1) 12 (3.5) 
Looking after 
family/home 0 (0.0) 5 (2.9) 5 (1.4) 0 (0.0) 4 (2.5) 4 (1.2) 
Not employed but 
seeking work 5 (2.8) 5 (2.9) 10 (2.9) 6 (3.4) 3 (1.8) 9 (2.6) 
Other 10 (5.7) 6 (3.5) 16 (4.6) 6 (3.4) 4 (2.5) 10 (2.9) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 1 (0.6) 0 (0.0) 1 (0.3) 
Type of 
employment, n 
(%)       
Unskilled manual 20 (11.4) 13 (7.6) 33 (9.5) 19 (10.7) 12 (7.4) 31 (9.1) 
Skilled manual 52 (29.5) 49 (28.5) 101 (29.0) 53 (29.8) 41 (25.2) 94 (27.6) 
Unskilled non-
manual 15 (8.5) 8 (4.7) 23 (6.6) 14 (7.9) 10 (6.1) 24 (7.0) 
Skilled non-manual 28 (15.9) 34 (19.8) 62 (17.8) 30 (16.9) 37 (22.7) 67 (19.6) 
Professional 18 (10.2) 15 (8.7) 33 (9.5) 19 (10.7) 14 (8.6) 33 (9.7) 
Other 17 (9.7) 25 (14.5) 42 (12.1) 15 (8.4) 24 (14.7) 39 (11.4) 
Missing 26 (14.8) 28 (16.3) 54 (15.5) 28 (15.7) 25 (15.3) 53 (15.5) 
Current smoker, n 
(%)       
Yes 50 (28.4) 37 (21.5) 87 (25.0) 53 (29.8) 31 (19.0) 84 (24.6) 
No 126 (71.6) 134 (77.9) 260 (74.7) 124 (69.7) 131 (80.4) 255 (74.8) 
Missing 0 (0.0) 1 (0.6) 1 (0.3) 1 (0.6) 1 (0.6) 2 (0.6) 
If Yes:       
How many 
cigarettes       
Median (min, max) 10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 20) 10 (1, 30) 10 (1, 30) 
For how many 
years       
Median (min, max) 10 (1, 50) 10 (1, 30) 10 (1, 50) 10 (1, 50) 10 (1, 36) 10 (1, 50) 
Past smoker, n 
(%)       
Yes 95 (54) 80 (46.5) 175 (50.3) 95 (53.4) 69 (42.3) 164 (48.1) 
No 73 (41.5) 83 (48.3) 156 (44.8) 71 (39.9) 87 (53.4) 158 (46.3) 
Missing  8 (4.5) 9 (5.2) 17 (4.9) 12 (6.7) 7 (4.3) 19 (5.6) 
Diabetes, n (%)       
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Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Yes 6 (3.4) 3 (1.7) 9 (2.6) 6 (3.4) 4 (2.5) 10 (2.9) 
No 170 (96.6) 169 (98.3) 339 (97.4) 171 (96.1) 159 (97.5) 330 (96.8) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.3) 
Steroid use, n (%)       
Yes 5 (2.8) 3 (1.7) 8 (2.3) 4 (2.2) 4 (2.5) 8 (2.3) 
No 171 (97.2) 169 (98.3) 340 (97.7) 173 (97.2) 159 (97.5) 332 (97.4) 
Missing  0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.3) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 51: Baseline fracture details of trial participants with valid PRWE data by time 
point (6 and 12 weeks) 
Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Time since injury 
(days)a       
N 176 172 348 178 163 341 
Mean (SD) 4.8 (3.0) 5.4 (3.5) 5.1 (3.3) 4.9 (3.0) 5.5 (3.4) 5.2 (3.2) 
Median (min, max) 4 (1, 4) 5 (0, 14) 4 (0, 14) 4 (1, 14) 5 (1, 14) 5 (1, 14) 
Affected wrist, n 
(%)       
Left 95 (54.0) 96 (55.8) 191 (54.9) 97 (54.5) 89 (54.6) 186 (54.5) 
Right 81 (46.0) 76 (44.2) 157 (45.1) 81 (45.5) 74 (45.4) 155 (45.5) 
Hand dominance, 
n (%)       
Yes 80 (45.5) 73 (42.4) 153 (44) 80 (44.9) 69 (42.3) 149 (43.7) 
No  96 (54.5) 99 (57.6) 195 (56) 98 (55.1) 94 (57.7) 192 (56.3) 
Displacement 
(eligibility), n (%)       
No displacement 109 (61.9) 107 (62.2) 216 (62.1) 106 (59.6) 102 (62.6) 208 (61.0) 
Displacement 67 (38.1) 65 (37.8) 132 (37.9) 72 (40.4) 61 (37.4) 133 (39.0) 
Displacement 
(randomisation), n 
(%)       
No displacement 105 (59.7) 103 (59.9) 208 (59.8) 104 (58.4) 100 (61.3) 204 (59.8) 
Displacement 71 (40.3) 69 (40.1) 140 (40.2) 74 (41.6) 63 (38.7) 137 (40.2) 
Radiographsb, n 
(%)       
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Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Elongated scaphoid 
view 168 (95.5) 163 (94.8) 331 (95.1) 168 (94.4) 155 (95.1) 323 (94.7) 
Posterior-anterior 
view 174 (98.9) 170 (98.8) 344 (98.9) 175 (98.3) 161 (98.8) 336 (98.5) 
Semi 45° supine 124 (70.5) 129 (75.0) 253 (72.7) 123 (69.1) 121 (74.2) 244 (71.6) 
Lateral 176 
(100.0) 169 (98.3) 345 (99.1) 
178 
(100.0) 160 (98.2) 338 (99.1) 
Semi 45° prone 158 (89.8) 154 (89.5) 312 (89.7) 161 (90.4) 145 (89.0) 306 (89.7) 
Previous wrist 
problems on same 
side, n (%)       
Yes 36 (20.5) 35 (20.3) 71 (20.4) 37 (20.8) 35 (21.5) 72 (21.1) 
No 139 (79.0) 135 (78.5) 274 (78.7) 140 (78.7) 128 (78.5) 268 (78.6) 
Missing 1 (0.6) 2 (1.2) 3 (0.9) 1 (0.6) 0 (0.0) 1 (0.3) 
If Yes, what 
injury, n (%)       
Previous fracture 21 (58.3) 20 (57.1) 41 (57.7) 20 (54.1) 21 (60.0) 41 (56.9) 
Arthritis 1 (2.8) 1 (2.9) 2 (2.8) 1 (2.7) 1 (2.9) 2 (2.8) 
Ligament, tendon or 
nerve injury 8 (22.2) 7 (20) 15 (21.1) 9 (24.3) 8 (22.9) 17 (23.6) 
Other 6 (16.7) 7 (20) 13 (18.3) 6 (16.2) 5 (14.3) 11 (15.3) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7) 0 (0.0) 1 (1.4) 
Injury mechanism, 
n (%)       
Fall – standing 19 (10.8) 23 (13.4) 42 (12.1) 23 (12.9) 19 (11.7) 42 (12.3) 
Fall – walking 21 (11.9) 20 (11.6) 41 (11.8) 22 (12.4) 17 (10.4) 39 (11.4) 
Fall – running 32 (18.2) 28 (16.3) 60 (17.2) 35 (19.7) 28 (17.2) 63 (18.5) 
Fall – from height   22 (12.5) 28 (16.3) 50 (14.4) 22 (12.4) 27 (16.6) 49 (14.4) 
Fall – from moving 
object 37 (21.0) 27 (15.7) 64 (18.4) 35 (19.7) 29 (17.8) 64 (18.8) 
Hit on palm of hand 
– object striking 
palm 14 (8.0) 11 (6.4) 25 (7.2) 12 (6.7) 13 (8.0) 25 (7.3) 
Hit on palm of hand 
– handle whipping 
back 6 (3.4) 9 (5.2) 15 (4.3) 5 (2.8) 8 (4.9) 13 (3.8) 
Hit on palm of hand 
– other sudden 
extension 10 (5.7) 5 (2.9) 15 (4.3) 9 (5.1) 3 (1.8) 12 (3.5) 
Punched something 3 (1.7) 7 (4.1) 10 (2.9) 4 (2.2) 6 (3.7) 10 (2.9) 
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Characteristic 
6 weeks 12 weeks 
Surgery 
(n=176) 
Plaster 
cast 
(n=172) 
Total 
 (n=348) 
Surgery 
(n=178) 
Plaster 
cast 
(n=163) 
Total 
 (n=341) 
Road traffic 
accident 9 (5.1) 6 (3.5) 15 (4.3) 9 (5.1) 6 (3.7) 15 (4.4) 
Other 3 (1.7) 8 (4.7) 11 (3.2) 2 (1.1) 7 (4.3) 9 (2.6) 
Place of injuryb, n 
(%)       
Sport 74 (42.0) 61 (35.5) 135 (38.8) 77 (43.3) 61 (37.4) 138 (40.5) 
Home 20 (11.4) 31 (18.0) 51 (14.7) 19 (10.7) 26 (16.0) 45 (13.2) 
Work 17 (9.7) 16 (9.3) 33 (9.5) 18 (10.1) 14 (8.6) 32 (9.4) 
Road Traffic 
Accident 23 (13.1) 27 (15.7) 50 (14.4) 21 (11.8) 29 (17.8) 50 (14.7) 
Public place 39 (22.2) 38 (22.1) 77 (22.1) 39 (21.9) 36 (22.1) 75 (22.0) 
Other  2 (1.1) 0 (0.0) 2 (0.6) 2 (1.1) 0 (0.0) 2 (0.6) 
Missing  3 (1.7) 2 (1.2) 5 (1.4) 3 (1.7) 0 (0.0) 3 (0.9) 
Treatment 
preference, n (%)       
Surgery 75 (42.6) 76 (44.2) 151 (43.4) 77 (43.3) 75 (46.0) 152 (44.6) 
No surgery 10 (5.7) 14 (8.1) 24 (6.9) 10 (5.6) 15 (9.2) 25 (7.3) 
No preference 90 (51.1) 81 (47.1) 171 (49.1) 91 (51.1) 72 (44.2) 163 (47.8) 
Missing 1 (0.6) 1 (0.6) 2 (0.6) 0 (0.0) 1 (0.6) 1 (0.3) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
 
Table 52: Baseline characteristics of trial participants with valid PRWE data by time 
point (26 and 52 weeks) 
Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
Gender, n (%)       
Male 129 (82.7) 119 (81.5) 248 (82.1) 153 (82.3) 140 (79.5) 293 (80.9) 
Female 27 (17.3) 27 (18.5) 54 (17.9) 33 (17.7) 36 (20.5) 69 (19.1) 
Age (years)       
N 156 146 302 186 176 362 
Mean (SD) 33.2 (13.2) 34.0 (13.3) 33.6 (13.2) 33.9 (13.4) 33.9 (12.9) 33.9 (13.2) 
Median (min, max) 30 (16, 80) 30 (16, 76) 30 (16, 80) 30 (16, 80) 30 (16, 76) 30 (16, 80) 
Ethnicity, n (%)       
White 148 (94.9) 129 (88.4) 277 (91.7) 175 (94.1) 156 (88.6) 331 (91.4) 
Black 0 (0) 3 (2.1) 3 (1) 0 (0.0) 3 (1.7) 3 (0.8) 
Asian 6 (3.8) 7 (4.8) 13 (4.3) 7 (3.8) 9 (5.1) 16 (4.4) 
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Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
Other 2 (1.3) 7 (4.8) 9 (3) 4 (2.2) 8 (4.5) 12 (3.3) 
Education, n (%)       
No formal 
qualifications 15 (9.6) 18 (12.3) 33 (10.9) 17 (9.1) 23 (13.1) 40 (11.0) 
Some 
qualifications/no 
degree 105 (67.3) 83 (56.8) 188 (62.3) 128 (68.8) 100 (56.8) 228 (63.0) 
Degree or higher 35 (22.4) 45 (30.8) 80 (26.5) 40 (21.5) 53 (30.1) 93 (25.7) 
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3) 
Employment 
status, n (%)       
Part-time 16 (10.3) 15 (10.3) 31 (10.3) 19 (10.2) 16 (9.1) 35 (9.7) 
Full-time 91 (58.3) 81 (55.5) 172 (57) 114 (61.3) 98 (55.7) 212 (58.6) 
Self-employed 13 (8.3) 20 (13.7) 33 (10.9) 16 (8.6) 27 (15.3) 43 (11.9) 
Student 15 (9.6) 15 (10.3) 30 (9.9) 16 (8.6) 17 (9.7) 33 (9.1) 
Retired 6 (3.8) 5 (3.4) 11 (3.6) 7 (3.8) 5 (2.8) 12 (3.3) 
Looking after 
family/home 0 (0) 4 (2.7) 4 (1.3) 0 (0.0) 5 (2.8) 5 (1.4) 
Not employed but 
seeking work 7 (4.5) 2 (1.4) 9 (3) 5 (2.7) 4 (2.3) 9 (2.5) 
Other 7 (4.5) 4 (2.7) 11 (3.6) 8 (4.3) 4 (2.3) 12 (3.3) 
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3) 
Type of 
employment, n 
(%)       
Unskilled manual 17 (10.9) 12 (8.2) 29 (9.6) 23 (12.4) 15 (8.5) 38 (10.5) 
Skilled manual 45 (28.8) 39 (26.7) 84 (27.8) 51 (27.4) 43 (24.4) 94 (26.0) 
Unskilled non-
manual 13 (8.3) 9 (6.2) 22 (7.3) 19 (10.2) 10 (5.7) 29 (8.0) 
Skilled non-manual 26 (16.7) 30 (20.5) 56 (18.5) 30 (16.1) 42 (23.9) 72 (19.9) 
Professional 15 (9.6) 14 (9.6) 29 (9.6) 19 (10.2) 17 (9.7) 36 (9.9) 
Other 13 (8.3) 19 (13) 32 (10.6) 18 (9.7) 23 (13.1) 41 (11.3) 
Missing 27 (17.3) 23 (15.8) 50 (16.6) 26 (14.0) 26 (14.8) 52 (14.4) 
Current smoker, n 
(%)       
Yes 43 (27.6) 25 (17.1) 68 (22.5) 56 (30.1) 35 (19.9) 91 (25.1) 
No 112 (71.8) 120 (82.2) 232 (76.8) 129 (69.4) 140 (79.5) 269 (74.3) 
Missing 1 (0.6) 1 (0.7) 2 (0.7) 1 (0.5) 1 (0.6) 2 (0.6) 
If Yes:       
 
 
282 
 
Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
How many 
cigarettes       
Median (min, max) 10 (1, 40) 10 (1, 25) 10 (1, 40) 10 (1, 40) 10 (1, 30) 10 (1, 40) 
For how many 
years       
Median (min, max) 10 (1, 40) 8 (1, 36) 10 (1, 40) 10 (1, 50) 10 (1, 36) 10 (1, 50) 
Past smoker, n 
(%)       
Yes 78 (50) 60 (41.1) 138 (45.7) 98 (52.7) 77 (43.8) 175 (48.3) 
No 66 (42.3) 80 (54.8) 146 (48.3) 76 (40.9) 92 (52.3) 168 (46.4) 
Missing  12 (7.7) 6 (4.1) 18 (6) 12 (6.5) 7 (4.0) 19 (5.2) 
Diabetes, n (%)       
Yes 5 (3.2) 4 (2.7) 9 (3) 6 (3.2) 4 (2.3) 10 (2.8) 
No 150 (96.2) 142 (97.3) 292 (96.7) 179 (96.2) 172 (97.7) 351 (97.0) 
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3) 
Steroid use, n (%)       
Yes 4 (2.6) 3 (2.1) 7 (2.3) 6 (3.2) 4 (2.3) 10 (2.8) 
No 151 (96.8) 143 (97.9) 294 (97.4) 179 (96.2) 172 (97.7) 351 (97.0) 
Missing  1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3) 
SD, standard deviation; min, minimum; max, maximum 
 
Table 53: Baseline fracture details of trial participants with valid PRWE data by time 
point (26 and 52 weeks) 
Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
Time since injury 
(days)a       
N 156 146 302 186 176 362 
Mean (SD) 4.7 (3.0) 5.3 (3.4) 5.0 (3.2) 4.8 (3.0) 5.3 (3.4) 5.1 (3.2) 
Median (min, max) 4 (1, 13) 4 (1, 14) 4 (1, 14) 4 (1, 14) 4 (0, 14) 4 (0, 14) 
Affected wrist, n 
(%)       
Left 82 (52.6) 82 (56.2) 164 (54.3) 101 (54.3) 94 (53.4) 195 (53.9) 
Right 74 (47.4) 64 (43.8) 138 (45.7) 85 (45.7) 82 (46.6) 167 (46.1) 
Hand dominance, 
n (%)       
Yes 72 (46.2) 62 (42.5) 134 (44.4) 83 (44.6) 78 (44.3) 161 (44.5) 
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Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
No  84 (53.8) 84 (57.5) 168 (55.6) 103 (55.4) 98 (55.7) 201 (55.5) 
Displacement 
(eligibility), n (%)       
No displacement 96 (61.5) 89 (61.0) 185 (61.3) 114 (61.3) 106 (60.2) 220 (60.8) 
Displacement 60 (38.5) 57 (39.0) 117 (38.7) 72 (38.7) 70 (39.8) 142 (39.2) 
Displacement 
(randomisation), n 
(%)       
No displacement 92 (59.0) 88 (60.3) 180 (59.6) 110 (59.1) 103 (58.5) 213 (58.8) 
Displacement 64 (41.0) 58 (39.7) 122 (40.4) 76 (40.9) 73 (41.5) 149 (41.2) 
Radiographsb, n 
(%)       
Elongated scaphoid 
view 147 (94.2) 138 (94.5) 285 (94.4) 177 (95.2) 167 (94.9) 344 (95.0) 
Posterior-anterior 
view 154 (98.7) 145 (99.3) 299 (99.0) 183 (98.4) 174 (98.9) 357 (98.6) 
Semi 45° supine 109 (69.9) 109 (74.7) 218 (72.2) 131 (70.4) 131 (74.4) 262 (72.4) 
Lateral 156 
(100.0) 144 (98.6) 300 (99.3) 
186 
(100.0) 173 (98.3) 359 (99.2) 
Semi 45° prone 139 (89.1) 133 (91.1) 272 (90.1) 169 (90.9) 158 (89.8) 327 (90.3) 
Previous wrist 
problems on same 
side, n (%)       
Yes 34 (21.8) 35 (24.0) 69 (22.8) 37 (19.9) 37 (21) 74 (20.4) 
No 121 (77.6) 111 (76.0) 232 (76.8) 148 (79.6) 138 (78.4) 286 (79.0) 
Missing 1 (0.6) 0 (0.0) 1 (0.3) 1 (0.5) 1 (0.6) 2 (0.6) 
If Yes, what 
injury, n (%)       
Previous fracture 20 (58.8) 22 (62.9) 42 (60.9) 21 (56.8) 23 (62.2) 44 (59.5) 
Arthritis 2 (5.9) 1 (2.9) 3 (4.3) 1 (2.7) 1 (2.7) 2 (2.7) 
Ligament, tendon or 
nerve injury 6 (17.6) 8 (22.9) 14 (20.3) 7 (18.9) 8 (21.6) 15 (20.3) 
Other 5 (14.7) 4 (11.4) 9 (13.0) 6 (16.2) 5 (13.5) 11 (14.9) 
Missing 1 (2.9) 0 (0.0) 1 (1.4) 2 (5.4) 0 (0) 2 (2.7) 
Injury mechanism, 
n (%)       
Fall – standing 18 (11.5) 22 (15.1) 40 (13.2) 26 (14.0) 23 (13.1) 49 (13.5) 
Fall – walking 16 (10.3) 18 (12.3) 34 (11.3) 20 (10.8) 20 (11.4) 40 (11.0) 
Fall – running 32 (20.5) 26 (17.8) 58 (19.2) 36 (19.4) 28 (15.9) 64 (17.7) 
Fall – from height   17 (10.9) 20 (13.7) 37 (12.3) 23 (12.4) 25 (14.2) 48 (13.3) 
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Characteristic 
26 weeks 52 weeks 
Surgery 
(n=156) 
Plaster 
cast 
(n=146) 
Total 
 (n=302) 
Surgery 
(n=186) 
Plaster 
cast 
(n=176) 
Total 
 (n=362) 
Fall – from moving 
object 35 (22.4) 26 (17.8) 61 (20.2) 36 (19.4) 29 (16.5) 65 (18.0) 
Hit on palm of hand 
– object striking 
palm 13 (8.3) 8 (5.5) 21 (7.0) 12 (6.5) 13 (7.4) 25 (6.9) 
Hit on palm of hand 
– handle whipping 
back 7 (4.5) 8 (5.5) 15 (5.0) 7 (3.8) 10 (5.7) 17 (4.7) 
Hit on palm of hand 
– other sudden 
extension 7 (4.5) 2 (1.4) 9 (3.0) 10 (5.4) 6 (3.4) 16 (4.4) 
Punched something 1 (0.6) 6 (4.1) 7 (2.3) 3 (1.6) 8 (4.5) 11 (3) 
Road traffic 
accident 8 (5.1) 4 (2.7) 12 (4.0) 9 (4.8) 6 (3.4) 15 (4.1) 
Other 2 (1.3) 6 (4.1) 8 (2.6) 4 (2.2) 8 (4.5) 12 (3.3) 
Place of injuryb, n 
(%)       
Sport 70 (44.9) 55 (37.7) 125 (41.4) 76 (40.9) 63 (35.8) 139 (38.4) 
Home 16 (10.3) 25 (17.1) 41 (13.6) 22 (11.8) 34 (19.3) 56 (15.5) 
Work 15 (9.6) 12 (8.2) 27 (8.9) 19 (10.2) 15 (8.5) 34 (9.4) 
Road Traffic 
Accident 21 (13.5) 23 (15.8) 44 (14.6) 22 (11.8) 30 (17.0) 52 (14.4) 
Public place 31 (19.9) 34 (23.3) 65 (21.5) 44 (23.7) 35 (19.9) 79 (21.8) 
Other  2 (1.3) 0 (0.0) 2 (0.7) 2 (1.1) 0 (0.0) 2 (0.6) 
Missing  3 (1.9) 0 (0.0) 3 (1.0) 3 (1.6) 2 (1.1) 5 (1.4) 
Treatment 
preference, n (%)       
Surgery 69 (44.2) 64 (43.8) 133 (44.0) 82 (44.1) 81 (46.0) 163 (45.0) 
No surgery 8 (5.1) 12 (8.2) 20 (6.6) 10 (5.4) 14 (8.0) 24 (6.6) 
No preference 79 (50.6) 70 (47.9) 149 (49.3) 94 (50.5) 80 (45.5) 174 (48.1) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.3) 
SD, standard deviation; min, minimum; max, maximum 
a time from injury to screening; b response categories not mutually exclusive 
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Table 54: Displacement of fractures as stratified on in the randomisation (based on 
radiographic images at time of enrolment), and as agreed by three independent reviews 
(based on baseline radiographs and CT imaging) 
Displacement agreed 
by three raters from 
baseline CT and 
radiographic images 
Surgery 
(n=219) 
Plaster cast 
(n=220) 
No displacement 
(n=131) 
Displacement 
(n=88) 
No displacement 
(n=130) 
Displacement 
(n=90) 
<1 mm 106 (80.9) 54 (61.4) 107 (82.3) 58 (64.4) 
1-2 mm, inclusive 19 (14.5) 26 (29.6) 20 (15.4) 21 (23.3) 
>2 mm 5 (3.8) 8 (9.1) 3 (2.3) 11 (12.2) 
Missing 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 
 
Table 55: Descriptive PRWE statistics over time by randomised group and treatment 
preference at baseline 
Time point Surgery Plaster cast Total 
No preference 
Pre-injury Mean (SD) 4.5 (14.1) 3.1 (12.1) 3.8 (13.2) 
 Median (IQR) 0.0 (0.0, 3.0) 0.0 (0.0, 1.0) 0.0 (0.0, 2.0) 
 Min, max (0, 85) (0, 80.11111) (0, 85) 
Baseline (post-injury) Mean (SD) 72.9 (20.9) 70.0 (19.7) 71.5 (20.3) 
 Median (IQR) 78.5 (64.0, 88.0) 73.0 (59.5, 84.5) 75.0 (62.0, 86.5) 
 Min, max (0, 100) (0, 100) (0, 100) 
6 weeks Mean (SD) 33.8 (21.1) 35.9 (19.0) 34.8 (20.1) 
 Median (IQR) 31.3 (18.0, 46.5) 35.5 (19.5, 49.0) 34.0 (19.0, 48.0) 
 Min, max (3, 82) (0, 80) (0, 82) 
12 weeks Mean (SD) 20.3 (20.5) 24.8 (21.5) 22.3 (21.0) 
 Median (IQR) 11.5 (5.5, 28.5) 20.3 (8.0, 31.5) 16.5 (6.0, 30.5) 
 Min, max (0, 89.5) (0, 90) (0, 90) 
26 weeks Mean (SD) 16.1 (18.9) 15.3 (16.7) 15.7 (17.8) 
 Median (IQR) 9.0 (4.0, 20.0) 10.5 (4.0, 18.0) 9.5 (4.0, 18.5) 
 Min, max (0, 84) (0, 77) (0, 84) 
52 weeks Mean (SD) 12.0 (18.1) 13.3 (18.7) 12.6 (18.3) 
 Median (IQR) 4.0 (0.0, 13.0) 4.8 (0.3, 16.3) 4.3 (0.0, 15.0) 
 Min, max (0, 85.5) (0, 80.5) (0, 85.5) 
Preference for surgery 
Pre-injury Mean (SD) 1.7 (5.5) 4.4 (12.6) 3.1 (9.9) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 
 Min, max (0, 42) (0, 90.5) (0, 90.5) 
Baseline (post-injury) Mean (SD) 74.5 (19.1) 76.9 (14.5) 75.7 (16.9) 
 Median (IQR) 77.8 (65.4, 88.0) 78.5 (70.0, 89.5) 78.5 (68.0, 89.0) 
 Min, max (0, 98) (27, 96.5) (0, 98) 
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6 weeks Mean (SD) 37.0 (21.3) 40.7 (23.1) 38.8 (22.2) 
 Median (IQR) 34.5 (19.0, 52.0) 38.8 (24.3, 55.3) 37.5 (22.0, 53.5) 
 Min, max (4, 85.5) (0, 100) (0, 100) 
12 weeks Mean (SD) 21.7 (19.1) 26.9 (22.8) 24.2 (21.1) 
 Median (IQR) 17.0 (7.0, 30.0) 18.5 (10.0, 35.5) 18.0 (9.8, 33.0) 
 Min, max (0, 80.5) (0, 84.5) (0, 84.5) 
26 weeks Mean (SD) 16.0 (18.1) 13.7 (19.2) 14.9 (18.6) 
 Median (IQR) 10.0 (3.0, 22.0) 8.0 (0.0, 16.7) 9.5 (1.0, 19.0) 
 Min, max (0, 74) (0, 91.5) (0, 91.5) 
52 weeks Mean (SD) 10.2 (14.4) 15.0 (21.1) 12.6 (18.1) 
 Median (IQR) 4.5 (0.5, 14.0) 4.0 (0.0, 24.5) 4.5 (0.0, 17.5) 
 Min, max (0, 64) (0, 96) (0, 96) 
Preference for no surgery 
Pre-injury Mean (SD) 2.2 (5.3) 2.3 (4.9) 2.3 (5.0) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 3.0) 0.0 (0.0, 2.0) 
 Min, max (0, 17) (0, 19.5) (0, 19.5) 
Baseline (post-injury) Mean (SD) 77.1 (15.2) 67.5 (15.2) 71.6 (15.7) 
 Median (IQR) 78.8 (69.8, 86.0) 68.5 (62.3, 78.0) 72.8 (64.3, 81.5) 
 Min, max (43, 100) (36, 94) (36, 100) 
6 weeks Mean (SD) 42.1 (24.8) 46.2 (17.3) 44.5 (20.4) 
 Median (IQR) 45.0 (23.5, 54.5) 48.5 (30.0, 58.5) 46.3 (28.5, 57.8) 
 Min, max (4, 78.5) (16.5, 72.5) (4, 78.5) 
12 weeks Mean (SD) 17.5 (16.3) 27.2 (19.0) 23.3 (18.3) 
 Median (IQR) 14.8 (4.5, 25.0) 24.0 (8.0, 45.0) 23.0 (8.0, 43.5) 
 Min, max (0, 54.5) (0, 57) (0, 57) 
26 weeks Mean (SD) 9.1 (8.8) 21.6 (16.4) 16.6 (15.0) 
 Median (IQR) 6.0 (2.5, 15.0) 16.8 (11.5, 30.5) 13.5 (5.0, 24.3) 
 Min, max (0, 25.5) (0, 51) (0, 51) 
52 weeks Mean (SD) 15.8 (19.5) 15.5 (18.7) 15.6 (18.6) 
 Median (IQR) 8.0 (2.0, 24.5) 9.5 (2.0, 27.5) 9.5 (2.0, 26.0) 
 Min, max (0, 60) (0, 66) (0, 66) 
 
Table 56: Descriptive PRWE statistics over time by randomised group and fracture 
displacement (as randomised) at baseline 
Time point Surgery Plaster cast Total 
Fracture displaced <1mm 
Pre-injury Mean (SD) 3.6 (12.3) 3.8 (12.8) 3.7 (12.5) 
 Median (IQR) 0.0 (0.0, 1.1) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
 Min, max (0, 85) (0, 90.5) (0, 90.5) 
Baseline (post-injury) Mean (SD) 73.3 (20.4) 73.3 (18.7) 73.3 (19.5) 
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 Median (IQR) 78.0 (69.0, 87.0) 76.3 (64.0, 87.0) 77.5 (65.9, 87.0) 
 Min, max (0, 98) (0, 100) (0, 100) 
6 weeks Mean (SD) 34.4 (21.1) 38.8 (21.3) 36.5 (21.2) 
 Median (IQR) 32.5 (18.0, 49.0) 38.0 (23.0, 54.5) 35.0 (19.5, 52.0) 
 Min, max (3, 82) (0, 100) (0, 100) 
12 weeks Mean (SD) 18.8 (17.7) 23.0 (18.9) 20.8 (18.3) 
 Median (IQR) 13.8 (5.8, 24.5) 18.8 (9.1, 30.8) 17.0 (6.8, 28.3) 
 Min, max (0, 73.3) (0, 90) (0, 90) 
26 weeks Mean (SD) 14.8 (16.8) 13.2 (16.3) 14.0 (16.5) 
 Median (IQR) 9.4 (3.5, 19.5) 8.3 (0.5, 16.0) 9.1 (2.0, 17.8) 
 Min, max (0, 84) (0, 77) (0, 84) 
52 weeks Mean (SD) 11.0 (17.0) 13.0 (19.4) 12.0 (18.2) 
 Median (IQR) 4.3 (0.0, 12.5) 4.0 (0.0, 18.0) 4.0 (0.0, 15.0) 
 Min, max (0, 85.5) (0, 88) (0, 88) 
Fracture displaced ≥1 mm and ≤2 mm 
Pre-injury Mean (SD) 2.4 (8.0) 3.3 (10.4) 2.8 (9.2) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
 Min, max (0, 64.7) (0, 76) (0, 76) 
Baseline (post-injury) Mean (SD) 74.7 (18.9) 73.1 (15.5) 73.9 (17.3) 
 Median (IQR) 79.5 (61.5, 90.0) 75.0 (62.9, 85.0) 76.8 (62.0, 87.5) 
 Min, max (0, 100) (34, 99) (0, 100) 
6 weeks Mean (SD) 37.7 (21.8) 38.7 (20.6) 38.2 (21.1) 
 Median (IQR) 34.5 (22.5, 51.5) 39.0 (19.5, 50.5) 36.0 (20.5, 51.0) 
 Min, max (4, 85.5) (4, 90.5) (4, 90.5) 
12 weeks Mean (SD) 23.4 (22.0) 30.5 (25.3) 26.7 (23.7) 
 Median (IQR) 16.3 (6.5, 38.5) 22.5 (8.0, 49.5) 18.0 (8.0, 45.0) 
 Min, max (0, 89.5) (0, 84.5) (0, 89.5) 
26 weeks Mean (SD) 16.9 (19.9) 18.0 (19.7) 17.4 (19.8) 
 Median (IQR) 8.2 (3.3, 23.5) 12.3 (4.0, 26.0) 10.5 (3.5, 25.5) 
 Min, max (0, 74) (0, 91.5) (0, 91.5) 
52 weeks Mean (SD) 12.0 (16.1) 15.8 (20.2) 13.9 (18.3) 
 Median (IQR) 4.0 (0.3, 16.3) 8.5 (1.0, 21.5) 6.5 (0.5, 18.5) 
 Min, max (0, 64) (0, 96) (0, 96) 
 
Table 57: Descriptive PRWE statistics over time by randomised group and fracture 
displacement (as recorded on Study Eligibility Form) at baseline 
Time point Surgery Plaster cast Total 
Fracture displaced <1mm 
Pre-injury Mean (SD) 3.6 (12.3) 3.2 (11.9) 3.4 (12.1) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
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 Min, max (0, 85) (0, 90.5) (0, 90.5) 
Baseline (post-injury) Mean (SD) 73.2 (20.1) 72.5 (18.8) 72.9 (19.4) 
 Median (IQR) 78.0 (68.5, 87.0) 76.0 (63.0, 87.0) 77.0 (64.5, 87.0) 
 Min, max (0, 98) (0, 100) (0, 100) 
6 weeks Mean (SD) 33.6 (20.7) 38.2 (21.5) 35.9 (21.2) 
 Median (IQR) 32.0 (18.0, 46.5) 36.0 (21.5, 54.5) 34.3 (18.8, 50.8) 
 Min, max (3, 82) (0, 100) (0, 100) 
12 weeks Mean (SD) 18.1 (16.9) 22.7 (19.4) 20.3 (18.3) 
 Median (IQR) 13.3 (5.5, 24.0) 18.3 (8.0, 31.0) 16.0 (6.3, 27.8) 
 Min, max (0, 73.3) (0, 90) (0, 90) 
26 weeks Mean (SD) 14.0 (15.1) 13.0 (16.0) 13.5 (15.5) 
 Median (IQR) 9.0 (3.5, 18.8) 8.5 (0.0, 16.0) 9.0 (2.0, 17.0) 
 Min, max (0, 60) (0, 77) (0, 77) 
52 weeks Mean (SD) 10.4 (15.9) 13.3 (19.5) 11.8 (17.8) 
 Median (IQR) 4.0 (0.0, 12.5) 4.0 (0.0, 18.5) 4.0 (0.0, 15.0) 
 Min, max (0, 85.5) (0, 88) (0, 88) 
Fracture displaced ≥1 mm and ≤2 mm 
Pre-injury Mean (SD) 2.4 (8.0) 4.2 (11.8) 3.3 (10.1) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 1.5) 0.0 (0.0, 1.3) 
 Min, max (0, 64.7) (0, 76) (0, 76) 
Baseline (post-injury) Mean (SD) 74.9 (19.3) 74.2 (14.9) 74.6 (17.2) 
 Median (IQR) 79.5 (61.5, 90.0) 76.3 (65.0, 85.5) 78.5 (63.0, 88.0) 
 Min, max (0, 100) (34, 99) (0, 100) 
6 weeks Mean (SD) 39.1 (22.1) 39.7 (20.2) 39.4 (21.1) 
 Median (IQR) 35.0 (22.5, 53.5) 39.5 (25.0, 50.5) 38.4 (23.3, 51.8) 
 Min, max (4, 85.5) (4, 90.5) (4, 90.5) 
12 weeks Mean (SD) 24.6 (22.6) 31.1 (24.6) 27.6 (23.7) 
 Median (IQR) 16.8 (6.8, 38.8) 23.0 (11.5, 48.5) 18.5 (9.5, 45.4) 
 Min, max (0, 89.5) (0, 84.5) (0, 89.5) 
26 weeks Mean (SD) 18.4 (22.0) 18.4 (20.1) 18.4 (21.0) 
 Median (IQR) 9.3 (3.3, 24.5) 12.0 (5.0, 26.0) 10.5 (3.5, 25.5) 
 Min, max (0, 84) (0, 91.5) (0, 91.5) 
52 weeks Mean (SD) 13.0 (17.6) 15.5 (20.2) 14.2 (18.9) 
 Median (IQR) 4.3 (0.5, 17.5) 8.8 (1.0, 21.0) 7.3 (0.5, 18.5) 
 Min, max (0, 72.5) (0, 96) (0, 96) 
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Table 58: Baseline characteristics of trial participants according to whether or not they 
had surgical screw penetration likely to cause cartilage damage (surgery group only), 
and whether surgery was required for non-union (plaster cast group only) 
Characteristic 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Gender, n (%)     
Male 65 (87.8) 58 (85.3) 14 (73.7) 164 (84.1) 
Female 9 (12.2) 10 (14.7) 5 (26.3) 31 (15.9) 
Age (years)     
N 74 68 19 195 
Mean (SD) 33.1 (13.6) 33.2 (13.4) 29.8 (10.3) 33.3 (12.4) 
Median (min, max) 30 (16, 69) 30 (16, 80) 26 (18, 51) 29 (16, 76) 
Ethnicity, n (%)     
White 69 (93.2) 64 (94.1) 13 (68.4) 177 (90.8) 
Black 0 (0.0) 0 (0.0) 2 (10.5) 2 (1.0) 
Asian 2 (2.7) 3 (4.4) 2 (10.5) 8 (4.1) 
Other 3 (4.1) 1 (1.5) 2 (10.5) 8 (4.1) 
Education, n (%)     
No formal qualifications 6 (8.1) 3 (4.4) 0 (0.0) 27 (13.8) 
Some qualifications/no 
degree 47 (63.5) 53 (77.9) 17 (89.5) 109 (55.9) 
Degree or higher 21 (28.4) 12 (17.6) 2 (10.5) 59 (30.3) 
Employment status, n (%)     
Part-time 6 (8.1) 7 (10.3) 2 (10.5) 16 (8.2) 
Full-time 52 (70.3) 39 (57.4) 9 (47.4) 110 (56.4) 
Self-employed 5 (6.8) 6 (8.8) 2 (10.5) 32 (16.4) 
Student 5 (6.8) 6 (8.8) 4 (21.1) 15 (7.7) 
Retired 4 (5.4) 3 (4.4) 0 (0.0) 5 (2.6) 
Looking after family/home 0 (0.0) 0 (0.0) 1 (5.3) 5 (2.6) 
Not employed but seeking 
work 1 (1.4) 2 (2.9) 0 (0.0) 5 (2.6) 
Other 0 (0.0) 5 (7.4) 1 (5.3) 7 (3.6) 
Missing 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Type of employment, n (%)     
Unskilled manual 6 (8.1) 8 (11.8) 4 (21.1) 19 (9.7) 
Skilled manual 22 (29.7) 17 (25.0) 6 (31.6) 51 (26.2) 
Unskilled non-manual 3 (4.1) 11 (16.2) 1 (5.3) 11 (5.6) 
Skilled non-manual 17 (23) 7 (10.3) 2 (10.5) 43 (22.1) 
Professional 9 (12.2) 8 (11.8) 1 (5.3) 18 (9.2) 
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Characteristic 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Other 9 (12.2) 6 (8.8) 1 (5.3) 29 (14.9) 
Missing 8 (10.8) 11 (16.2) 4 (21.1) 24 (12.3) 
Current smoker, n (%)     
Yes 21 (28.4) 22 (32.4) 6 (31.6) 48 (24.6) 
No 52 (70.3) 46 (67.6) 13 (68.4) 146 (74.9) 
Missing 1 (1.4) 0 (0.0) 0 (0.0) 1 (0.5) 
If Yes:     
How many cigarettes     
Median (min, max) 10 (1, 20) 9 (2, 20) 10 (1, 12) 10 (1, 30) 
For how many years     
Median (min, max) 10 (2, 50) 10 (4, 36) 20 (1, 30) 10 (1, 36) 
Past smoker, n (%)     
Yes 38 (51.4) 37 (54.4) 11 (57.9) 94 (48.2) 
No 32 (43.2) 27 (39.7) 7 (36.8) 92 (47.2) 
Missing  4 (5.4) 4 (5.9) 1 (5.3) 9 (4.6) 
Diabetes, n (%)     
Yes 2 (2.7) 3 (4.4) 0 (0.0) 4 (2.1) 
No 71 (95.9) 65 (95.6) 19 (100.0) 191 (97.9) 
Missing 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Steroid use, n (%)     
Yes 3 (4.1) 1 (1.5) 1 (5.3) 3 (1.5) 
No 70 (94.6) 67 (98.5) 18 (94.7) 192 (98.5) 
Missing  1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 
a allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters 
 
Table 59: Baseline fracture details of trial participants according to whether or not they 
had surgical screw penetration likely to cause cartilage damage (surgery group only), 
and whether surgery was required for non-union (plaster cast group only) 
Characteristic 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Time since injury (days)a     
N 74 68 19 195 
Mean (SD) 5.1 (3.2) 4.6 (3.0) 6.8 (3.5) 5.2 (3.3) 
Median (min, max) 4 (1, 14) 4 (1, 13) 6 (1, 14) 4 (0, 14) 
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Characteristic 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Affected wrist, n (%)     
Left 37 (50.0) 34 (50.0) 11 (57.9) 103 (52.8) 
Right 37 (50.0) 34 (50.0) 8 (42.1) 92 (47.2) 
Hand dominance, n (%)     
Yes 34 (45.9) 32 (47.1) 8 (42.1) 85 (43.6) 
No  40 (54.1) 36 (52.9) 11 (57.9) 110 (56.4) 
Displacement (eligibility), n 
(%)     
No displacement 39 (52.7) 42 (61.8) 8 (42.1) 123 (63.1) 
Displacement 35 (47.3) 26 (38.2) 11 (57.9) 72 (36.9) 
Displacement 
(randomisation), n (%)     
No displacement 40 (54.1) 41 (60.3) 8 (42.1) 119 (61.0) 
Displacement 34 (45.9) 27 (39.7) 11 (57.9) 76 (39.0) 
Radiographsb, n (%)     
Elongated scaphoid view 71 (95.9) 65 (95.6) 19 (100.0) 185 (94.9) 
Posterior-anterior view 74 (100.0) 66 (97.1) 19 (100.0) 193 (99.0) 
Semi 45° supine 54 (73.0) 45 (66.2) 15 (78.9) 146 (74.9) 
Lateral 74 (100.0) 68 (100.0) 19 (100.0) 192 (98.5) 
Semi 45° prone 70 (94.6) 57 (83.8) 15 (78.9) 176 (90.3) 
Previous wrist problems on 
same side, n (%)     
Yes 12 (16.2) 18 (26.5) 6 (31.6) 38 (19.5) 
No 62 (83.8) 49 (72.1) 12 (63.2) 157 (80.5) 
Missing 0 (0.0) 1 (1.5) 1 (5.3) 0 (0.0) 
If Yes, what injury, n (%)     
Previous fracture 5 (41.7) 10 (55.6) 3 (50.0) 24 (63.2) 
Arthritis 1 (8.3) 0 (0.0) 0 (0.0) 1 (2.6) 
Ligament, tendon or nerve 
injury 4 (33.3) 4 (22.2) 0 (0.0) 8 (21.1) 
Other 1 (8.3) 3 (16.7) 3 (50.0) 5 (13.2) 
Missing 1 (8.3) 1 (5.6) 0 (0.0) 0 (0.0) 
Injury mechanism, n (%)     
Fall – standing 9 (12.2) 9 (13.2) 2 (10.5) 26 (13.3) 
Fall – walking 6 (8.1) 7 (10.3) 0 (0.0) 23 (11.8) 
Fall – running 11 (14.9) 18 (26.5) 1 (5.3) 35 (17.9) 
Fall – from height   10 (13.5) 10 (14.7) 4 (21.1) 29 (14.9) 
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Characteristic 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Fall – from moving object 19 (25.7) 11 (16.2) 1 (5.3) 30 (15.4) 
Hit on palm of hand – object 
striking palm 4 (5.4) 3 (4.4) 3 (15.8) 12 (6.2) 
Hit on palm of hand – handle 
whipping back 3 (4.1) 3 (4.4) 3 (15.8) 8 (4.1) 
Hit on palm of hand – other 
sudden extension 5 (6.8) 3 (4.4) 0 (0.0) 7 (3.6) 
Punched something 1 (1.4) 1 (1.5) 1 (5.3) 11 (5.6) 
Road traffic accident 5 (6.8) 1 (1.5) 1 (5.3) 7 (3.6) 
Other 1 (1.4) 2 (2.9) 3 (15.8) 7 (3.6) 
Place of injuryb, n (%)     
Sport 31 (41.9) 32 (47.1) 7 (36.8) 68 (34.9) 
Home 6 (8.1) 10 (14.7) 2 (10.5) 40 (20.5) 
Work 7 (9.5) 4 (5.9) 1 (5.3) 17 (8.7) 
Road Traffic Accident 12 (16.2) 5 (7.4) 3 (15.8) 30 (15.4) 
Public place 18 (24.3) 16 (23.5) 5 (26.3) 42 (21.5) 
Other  0 (0.0) 1 (1.5) 0 (0.0) 0 (0.0) 
Missing  1 (1.4) 1 (1.5) 1 (5.3) 1 (0.5) 
Treatment preference, n 
(%)     
Surgery 31 (41.9) 25 (36.8) 10 (52.6) 85 (43.6) 
No surgery 7 (9.5) 2 (2.9) 1 (5.3) 18 (9.2) 
No preference 36 (48.6) 41 (60.3) 8 (42.1) 91 (46.7) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 
a allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters 
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Table 60: PRWE total and subscale scores for the surgery group stratified by whether participants had a complication caused by their 
surgical screw; and for the plaster cast group over time stratified by whether participants had to have surgery due to non-union 
PRWE 
Surgery (n=142)a Plaster cast (n=214)b 
No surgical 
screw 
complication 
(n=74) 
Surgical screw 
complication 
(n=68) 
Required 
surgery 
(n=19) 
No surgery 
required 
(n=195) 
Baseline (pre-injury)     
Pain subscale Mean (SD) 3.5 (9.9) 1.9 (4.6) 1.7 (4.7) 2.3 (6.3) 
 Median (IQR) 0.0 (0.0, 2.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 
 Min, max (0, 50) (0, 24) (0, 16.3) (0, 39) 
Function subscale Mean (SD) 2.0 (8.2) 0.6 (2.6) 1.3 (4.4) 0.9 (4.6) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 
 Min, max (0, 43) (0, 18) (0, 18.5) (0, 41.1) 
Total Mean (SD) 5.5 (16.9) 2.5 (6.7) 3.0 (9.0) 3.1 (10.2) 
 Median (IQR) 0.0 (0.0, 2.5) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 
 Min, max (0, 85) (0, 42) (0, 34.8) (0, 80.1) 
Baseline (post-injury)     
Pain subscale Mean (SD) 34.9 (11.4) 33.8 (11.7) 36.1 (8.2) 34.0 (9.8) 
 Median (IQR) 39.5 (30.0, 43.0) 36.0 (28.0, 43.0) 39.0 (30.0, 43.0) 35.0 (28.0, 42.0) 
 Min, max (0, 50) (0, 50) (21, 46.25) (0, 50) 
Function subscale Mean (SD) 38.7 (10.9) 38.2 (11.3) 38.0 (11.2) 38.6 (10.0) 
 Median (IQR) 41.5 (32.5, 47.0) 41.3 (33.3, 46.5) 42.0 (32.0, 46.5) 40.3 (33.5, 46.0) 
 Min, max (0, 50) (0, 50) (8.5, 49) (0, 50) 
Total Mean (SD) 73.8 (21.2) 72.0 (21.2) 74.1 (16.1) 73.0 (17.5) 
 Median (IQR) 79.5 (69.0, 89.0) 77.0 (59.5, 87.4) 76.6 (58.0, 86.5) 75.5 (63.8, 86.3) 
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 Min, max (0, 98) (0, 100) (48.5, 94.5) (0, 100) 
6 weeks     
Pain subscale Mean (SD) 18.0 (10.1) 19.1 (10.9) 20.2 (13.1) 18.1 (10.2) 
 Median (IQR) 17.0 (10.0, 25.0) 19.0 (10.5, 27.0) 18.0 (10.0, 22.0) 17.0 (10.0, 26.0) 
 Min, max (3, 39) (0, 44) (6, 48) (0, 47) 
Function subscale Mean (SD) 17.1 (13.4) 16.2 (12.2) 23.0 (16.2) 19.9 (11.8) 
 Median (IQR) 15.0 (4.3, 25.8) 12.5 (7.0, 22.5) 19.5 (9.0, 31.0) 19.0 (10.0, 26.5) 
 Min, max (0, 44) (0, 47) (4, 50) (0, 46.5) 
Total Mean (SD) 35.1 (21.5) 35.2 (21.2) 43.1 (26.8) 38.2 (19.8) 
 Median (IQR) 33.3 (17.5, 52.3) 32.0 (19.5, 46.5) 42.5 (19.0, 53.0) 38.0 (23.0, 51.5) 
 Min, max (4, 77) (3, 85.5) (11, 98) (0, 90.5) 
12 weeks     
Pain subscale Mean (SD) 11.4 (10.3) 13.7 (10.6) 21.9 (13.0) 13.9 (10.8) 
 Median (IQR) 8.0 (3.0, 17.0) 10.0 (6.0, 20.0) 22.5 (14.0, 34.0) 11.0 (5.0, 19.0) 
 Min, max (0, 41) (0, 45) (0, 41) (0, 47) 
Function subscale Mean (SD) 6.7 (8.4) 8.7 (9.9) 23.0 (13.3) 10.1 (10.7) 
 Median (IQR) 4.0 (0.5, 10.0) 4.8 (1.5, 12.0) 25.5 (12.3, 31.0) 6.5 (2.0, 15.0) 
 Min, max (0, 34.5) (0, 44.5) (0, 46.5) (0, 45) 
Total Mean (SD) 17.8 (18.0) 22.6 (20.1) 45.0 (24.5) 24.0 (20.6) 
 Median (IQR) 13.5 (4.0, 26.0) 15.8 (8.0, 36.8) 50.5 (26.3, 64.8) 18.3 (8.3, 31.0) 
 Min, max (0, 71.5) (0, 89.5) (0, 75.5) (0, 90) 
26 weeks     
Pain subscale Mean (SD) 9.2 (10.0) 10.7 (10.1) 18.3 (10.1) 9.3 (9.7) 
 Median (IQR) 5.0 (2.0, 13.0) 8.0 (4.0, 15.0) 16.0 (11.0, 23.0) 7.0 (1.0, 12.0) 
 Min, max (0, 43) (0, 39) (6, 44) (0, 44) 
Function subscale Mean (SD) 3.8 (7.2) 5.7 (8.0) 14.7 (13.4) 4.6 (7.7) 
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 Median (IQR) 1.0 (0.0, 3.5) 2.0 (0.5, 7.5) 12.0 (4.0, 23.0) 1.5 (0.0, 5.0) 
 Min, max (0, 41) (0, 35) (1.5, 47.5) (0, 40) 
Total Mean (SD) 13.1 (16.7) 16.4 (17.7) 33.0 (22.3) 13.6 (16.5) 
 Median (IQR) 6.3 (2.0, 15.5) 9.5 (4.0, 20.5) 32.0 (15.0, 40.0) 9.8 (1.0, 17.0) 
 Min, max (0, 84) (0, 74) (9, 91.5) (0, 83) 
52 weeks     
Pain subscale Mean (SD) 6.1 (8.9) 7.2 (8.5) 16.6 (16.0) 8.5 (10.5) 
 Median (IQR) 3.0 (0.0, 9.0) 4.0 (1.0, 10.0) 10.0 (4.0, 28.0) 4.0 (0.0, 13.0) 
 Min, max (0, 42) (0, 37) (0, 48) (0, 47.5) 
Function subscale Mean (SD) 2.8 (6.9) 3.6 (5.7) 12.5 (16.7) 4.2 (7.5) 
 Median (IQR) 0.5 (0.0, 3.0) 1.0 (0.0, 4.5) 4.0 (0.5, 16.5) 0.5 (0.0, 4.5) 
 Min, max (0, 43.5) (0, 26) (0, 48) (0, 33) 
Total Mean (SD) 8.9 (15.0) 10.8 (13.9) 29.1 (32.4) 12.8 (17.4) 
 Median (IQR) 3.8 (0.0, 11.3) 5.0 (1.0, 14.5) 14.0 (4.5, 47.5) 4.5 (0.0, 17.8) 
 Min, max (0, 85.5) (0, 58) (1, 96) (0, 76.5) 
a allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters 
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Table 61: Baseline characteristics of trial participants according to whether or not they had a CT scan taken within 2 weeks of injury, 
and for the surgery group whether their surgery was conducted within two weeks of presentation at A&E 
Characteristic 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
(n=)
Gender, n (%)     
  Male 342 (83.0) 21 (77.8) 156 (85.7) 24 (64.9) 
  Female 70 (17.0) 6 (22.2) 26 (14.3) 13 (35.1) 
Age (years)     
 n 412 27 182 37 
 Mean (SD) 32.9 (12.8) 32.3 (11.4) 32.2 (12.9) 36.2 (14.2) 
 Median (min, max) 29 (16, 80) 30 (17, 59) 27 (16, 80) 31 (17, 61) 
Ethnicity, n (%)     
  White 377 (91.5) 23 (85.2) 171 (94.0) 34 (91.9) 
  Black 3 (0.7) 2 (7.4) 0 (0.0) 0 (0.0) 
  Asian 16 (3.9) 1 (3.7) 6 (3.3) 1 (2.7) 
  Other 15 (3.6) 0 (0.0) 5 (2.7) 0 (0.0) 
  Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4) 
Education, n (%)     
  No formal qualifications 49 (11.9) 2 (7.4) 17 (9.3) 7 (18.9) 
  Some qualifications/no degree 263 (63.8) 17 (63.0) 126 (69.2) 25 (67.6) 
  Degree or higher 98 (23.8) 7 (25.9) 38 (20.9) 3 (8.1) 
  Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4) 
Employment status, n (%)     
  Part-time 34 (8.3) 4 (14.8) 15 (8.2) 5 (13.5) 
  Full-time 237 (57.5) 10 (37.0) 108 (59.3) 19 (51.4) 
  Self-employed 50 (12.1) 7 (25.9) 16 (8.8) 5 (13.5) 
  Student 37 (9.0) 4 (14.8) 18 (9.9) 2 (5.4) 
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  Retired 12 (2.9) 0 (0.0) 7 (3.8) 0 (0.0) 
  Looking after family/home 7 (1.7) 0 (0.0) 1 (0.5) 0 (0.0) 
  Not employed but seeking work 14 (3.4) 0 (0.0) 7 (3.8) 2 (5.4) 
  Other 19 (4.6) 1 (3.7) 9 (4.9) 2 (5.4) 
  Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4) 
Type of employment, n (%)     
  Unskilled manual 45 (10.9) 3 (11.1) 21 (11.5) 4 (10.8) 
  Skilled manual 115 (27.9) 8 (29.6) 54 (29.7) 9 (24.3) 
  Unskilled non-manual 29 (7.0) 2 (7.4) 15 (8.2) 4 (10.8) 
  Skilled non-manual 76 (18.4) 3 (11.1) 29 (15.9) 4 (10.8) 
  Professional 37 (9.0) 2 (7.4) 18 (9.9) 2 (5.4) 
  Other 44 (10.7) 5 (18.5) 14 (7.7) 5 (13.5) 
  Missing 66 (16.0) 4 (14.8) 31 (17.0) 9 (24.3) 
Current smoker, n (%)     
  Yes 120 (29.1) 9 (33.3) 56 (30.8) 17 (45.9) 
  No 289 (70.1) 17 (63) 125 (68.7) 18 (48.6) 
  Missing 3 (0.7) 1 (3.7) 1 (0.5) 2 (5.4) 
If yes:     
How many cigarettes     
  Median (min, max) 10 (1, 40) 10 (1, 25) 10 (1, 20) 10 (1, 40) 
For how many years     
  Median (min, max) 10 (1, 50) 6 (1, 30) 10 (2, 50) 10 (1, 44) 
Past smoker, n (%)     
  Yes 209 (50.7) 16 (59.3) 95 (52.2) 21 (56.8) 
  No 177 (43.0) 9 (33.3) 76 (41.8) 9 (24.3) 
  Missing  26 (6.3) 2 (7.4) 11 (6.0) 7 (18.9) 
Diabetes, n (%)     
  Yes 11 (2.7) 0 (0.0) 5 (2.7) 2 (5.4) 
  No 399 (96.8) 26 (96.3) 176 (96.7) 33 (89.2) 
  Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4) 
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Steroid use, n (%)     
  Yes 9 (2.2) 1 (3.7) 5 (2.7) 1 (2.7) 
  No 401 (97.3) 25 (92.6) 176 (96.7) 34 (91.9) 
  Missing  2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4) 
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Table 62: Baseline fracture details of trial participants according to whether or not they had a CT scan taken within 2 weeks of injury, 
and for the surgery group whether their surgery was conducted within two weeks of presentation at A&E 
Characteristic 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
Time since injury (days)a     
N 412 27 182 37 
Mean (SD) 5.2 (3.2) 5.3 (3.3) 4.8 (3.0) 6.3 (3.5) 
Median (min, max) 5 (0, 14) 5 (1, 14) 4 (1, 13) 6 (1, 14) 
Affected wrist, n (%)     
Left 221 (53.6) 12 (44.4) 98 (53.8) 17 (45.9) 
Right 191 (46.4) 15 (55.6) 84 (46.2) 20 (54.1) 
Hand dominance, n (%)     
Yes 184 (44.7) 11 (40.7) 85 (46.7) 15 (40.5) 
No  227 (55.1) 15 (55.6) 97 (53.3) 20 (54.1) 
Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4) 
Displacement (eligibility), n 
(%)     
No displacement 253 (61.4) 16 (59.3) 111 (61.0) 24 (64.9) 
Displacement 159 (38.6) 11 (40.7) 71 (39.0) 13 (35.1) 
Displacement 
(randomisation), n (%)     
No displacement 247 (60.0) 14 (51.9) 109 (59.9) 22 (59.5) 
Displacement 165 (40.0) 13 (48.1) 73 (40.1) 15 (40.5) 
Radiographsb, n (%)     
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Characteristic 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
Elongated scaphoid view 392 (95.1) 27 (100.0) 173 (95.1) 36 (97.3) 
Posterior-anterior view 406 (98.5) 27 (100.0) 181 (99.5) 34 (91.9) 
Semi 45° supine 305 (74.0) 20 (74.1) 132 (72.5) 27 (73.0) 
Lateral 408 (99.0) 27 (100.0) 182 (100.0) 36 (97.3) 
Semi 45° prone 370 (89.8) 24 (88.9) 164 (90.1) 34 (91.9) 
Previous wrist problems on 
same side, n (%)     
Yes 81 (19.7) 7 (25.9) 36 (19.8) 7 (18.9) 
No 328 (79.6) 18 (66.7) 145 (79.7) 28 (75.7) 
Missing 3 (0.7) 2 (7.4) 1 (0.5) 2 (5.4) 
If Yes, what injury, n (%)     
Previous fracture 47 (58) 4 (57.1) 21 (58.3) 2 (28.6) 
Arthritis 3 (3.7) 0 (0) 1 (2.8) 1 (14.3) 
Ligament, tendon or nerve 
injury 17 (21) 1 (14.3) 9 (25.0) 1 (14.3) 
Other 13 (16) 1 (14.3) 4 (11.1) 2 (28.6) 
Missing 1 (1.2) 1 (14.3) 1 (2.8) 1 (14.3) 
Injury mechanism, n (%)     
Fall – standing 53 (12.9) 4 (14.8) 21 (11.5) 7 (18.9) 
Fall – walking 45 (10.9) 3 (11.1) 18 (9.9) 6 (16.2) 
Fall – running 74 (18.0) 4 (14.8) 37 (20.3) 3 (8.1) 
Fall – from height   60 (14.6) 2 (7.4) 25 (13.7) 3 (8.1) 
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Characteristic 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
Fall – from moving object 69 (16.7) 4 (14.8) 40 (22.0) 2 (5.4) 
Hit on palm of hand – object 
striking palm 30 (7.3) 1 (3.7) 9 (4.9) 7 (18.9) 
Hit on palm of hand – handle 
whipping back 20 (4.9) 0 (0.0) 9 (4.9) 0 (0.0) 
Hit on palm of hand – other 
sudden extension 16 (3.9) 3 (11.1) 8 (4.4) 3 (8.1) 
Punched something 15 (3.6) 1 (3.7) 4 (2.2) 0 (0.0) 
Road traffic accident 15 (3.6) 2 (7.4) 7 (3.8) 2 (5.4) 
Other 14 (3.4) 2 (7.4) 4 (2.2) 2 (5.4) 
Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4) 
Place of injuryb, n (%)     
Sport 156 (37.9) 10 (37.0) 77 (42.3) 11 (29.7) 
Home 64 (15.5) 6 (22.2) 20 (11.0) 7 (18.9) 
Work 38 (9.2) 2 (7.4) 14 (7.7) 8 (21.6) 
Road Traffic Accident 57 (13.8) 3 (11.1) 24 (13.2) 2 (5.4) 
Public place 93 (22.6) 4 (14.8) 43 (23.6) 6 (16.2) 
Other  3 (0.7) 0 (0.0) 3 (1.6) 0 (0.0) 
Missing  5 (1.2) 1 (3.7) 3 (1.6) 1 (2.7) 
Treatment preference, n 
(%)     
Surgery 180 (43.7) 14 (51.9) 75 (41.2) 18 (48.6) 
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Characteristic 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
No surgery 29 (7.0) 3 (11.1) 10 (5.5) 3 (8.1) 
No preference 200 (48.5) 9 (33.3) 96 (52.7) 14 (37.8) 
Missing 3 (0.7) 1 (3.7) 1 (0.5) 2 (5.4) 
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Table 63: PRWE total and subscale scores according to whether or not participants had a CT scan taken within 2 weeks of injury, and 
for the surgery group whether their surgery was conducted within two weeks of presentation at A&E 
PRWE 
All (n=439) Surgery (n=219) 
CT ≤2wks after 
injury  
(n=412) 
CT >2wks after 
injury  
(n=27) 
Surgery ≤2wks 
after A&E 
presentation  
(n=182) 
Surgery >2wks 
after A&E 
presentation  
(n=37) 
Baseline (pre-injury)     
Pain subscale Mean (SD) 2.3 (6.6) 3.2 (9.3) 2.2 (6.6) 2.2 (6.3) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 
 Min, max (0, 50) (0, 35) (0, 50) (0, 32.5) 
Function subscale Mean (SD) 1.0 (5.1) 2.4 (9.0) 0.9 (5.0) 1.3 (5.8) 
 Median (IQR) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 
 Min, max (0, 49.5) (0, 41) (0, 43) (0, 32.2) 
Total Mean (SD) 3.2 (10.9) 5.7 (17.9) 3.1 (10.7) 3.4 (11.8) 
 Median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 
 Min, max (0, 90.5) (0, 76) (0, 85) (0, 64.7) 
Baseline (post-injury)     
Pain subscale Mean (SD) 34.5 (10.2) 33.9 (10.8) 34.3 (11.1) 36.7 (8.8) 
 Median (IQR) 36.0 (29.0, 42.0) 35.5 (25.0, 43.0) 36.0 (28.0, 42.0) 38.0 (31.0, 42.0) 
 Min, max (0, 50) (8.75, 47) (0, 50) (2, 50) 
Function subscale Mean (SD) 39.0 (10.3) 36.7 (9.4) 38.7 (10.9) 41.3 (7.6) 
 Median (IQR) 41.5 (33.5, 46.5) 40.0 (34.5, 42.5) 42.0 (33.0, 46.5) 41.0 (37.5, 48.5) 
 Min, max (0, 50) (15, 49) (0, 50) (20, 50) 
Total Mean (SD) 73.7 (18.6) 71.6 (18.2) 73.1 (20.5) 78.0 (14.7) 
 Median (IQR) 77.5 (64.0, 87.5) 75.5 (70.0, 85.0) 78.0 (62.0, 88.0) 79.0 (71.0, 87.5) 
 Min, max (0, 100) (35, 96) (0, 100) (22, 100) 
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6 weeks     
Pain subscale Mean (SD) 18.5 (10.6) 21.6 (9.3) 18.7 (10.3) 20.4 (12.1) 
 Median (IQR) 18.0 (10.0, 26.0) 21.0 (14.5, 28.5) 19.0 (10.0, 26.0) 18.0 (10.0, 33.0) 
 Min, max (0, 50) (6, 38) (0, 44) (2, 38) 
Function subscale Mean (SD) 18.3 (12.6) 22.5 (14.6) 16.2 (12.4) 21.1 (15.2) 
 Median (IQR) 16.5 (8.0, 26.5) 23.5 (14.5, 32.5) 13.0 (6.1, 25.0) 16.0 (9.5, 32.0) 
 Min, max (0, 50) (0, 46) (0, 44.5) (0, 47) 
Total Mean (SD) 36.8 (21.1) 45.4 (21.3) 34.9 (20.8) 41.5 (24.6) 
 Median (IQR) 35.0 (19.5, 51.3) 43.3 (33.0, 63.3) 33.5 (18.5, 48.5) 39.5 (19.5, 62.0) 
 Min, max (0, 100) (6, 84) (3, 85.5) (6, 82) 
12 weeks     
Pain subscale Mean (SD) 13.4 (10.9) 19.9 (13.3) 12.6 (10.9) 14.5 (11.6) 
 Median (IQR) 11.0 (5.0, 18.0) 23.0 (7.5, 31.5) 9.0 (4.0, 17.5) 12.5 (5.0, 18.0) 
 Min, max (0, 47) (0, 41) (0, 45) (0, 40) 
Function subscale Mean (SD) 9.1 (10.2) 17.8 (14.3) 7.7 (9.1) 9.7 (10.2) 
 Median (IQR) 5.5 (1.5, 12.0) 17.8 (5.0, 27.5) 4.3 (1.0, 11.0) 7.4 (1.5, 12.0) 
 Min, max (0, 45) (0, 46.5) (0, 44.5) (0, 34) 
Total Mean (SD) 22.5 (20.3) 37.8 (25.9) 20.2 (19.4) 24.2 (21.2) 
 Median (IQR) 17.0 (7.0, 30.0) 38.8 (11.5, 60.0) 14.1 (6.0, 26.8) 18.8 (8.0, 28.5) 
 Min, max (0, 90) (0, 78.5) (0, 89.5) (0, 73.3) 
26 weeks     
Pain subscale Mean (SD) 10.0 (10.3) 15.1 (9.8) 10.1 (10.4) 12.9 (12.4) 
 Median (IQR) 7.0 (2.0, 13.0) 13.0 (7.0, 23.0) 7.0 (3.0, 15.0) 8.0 (2.0, 24.0) 
 Min, max (0, 44) (0, 35) (0, 43) (0, 36) 
Function subscale Mean (SD) 5.3 (8.5) 7.5 (8.4) 5.0 (8.0) 7.9 (10.5) 
 Median (IQR) 1.5 (0.0, 5.6) 4.4 (1.5, 10.5) 1.5 (0.3, 5.3) 4.0 (0.0, 13.0) 
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 Min, max (0, 47.5) (0, 24) (0, 41) (0, 41) 
Total Mean (SD) 15.1 (18.0) 21.0 (15.6) 15.2 (17.9) 19.4 (19.8) 
 Median (IQR) 9.5 (2.5, 18.5) 15.5 (11.5, 36.5) 9.0 (3.5, 19.0) 12.0 (2.0, 37.5) 
 Min, max (0, 91.5) (0, 45) (0, 84) (0, 55.5) 
52 weeks     
Pain subscale Mean (SD) 8.1 (10.4) 14.2 (14.0) 7.5 (9.9) 9.1 (11.4) 
 Median (IQR) 4.0 (0.0, 11.0) 14.0 (2.0, 20.0) 4.0 (0.0, 10.0) 3.0 (0.0, 17.5) 
 Min, max (0, 47.5) (0, 48) (0, 42) (0, 37) 
Function subscale Mean (SD) 4.0 (7.6) 9.8 (13.4) 3.5 (6.9) 5.3 (8.8) 
 Median (IQR) 0.5 (0.0, 4.0) 4.0 (0.0, 14.5) 1.0 (0.0, 3.5) 0.5 (0.0, 10.3) 
 Min, max (0, 44) (0, 48) (0, 43.5) (0, 31) 
Total Mean (SD) 12.1 (17.5) 24.0 (27.0) 11.0 (16.1) 14.4 (19.7) 
 Median (IQR) 4.0 (0.0, 15.0) 17.5 (2.0, 32.5) 4.0 (0.5, 13.5) 4.3 (0.0, 27.8) 
 Min, max (0, 88) (0, 96) (0, 85.5) (0, 60) 
 
Table 64: Participant responses to questions relating to written advice about home exercises to perform to care for their wrist, asked on week 12 
questionnaire 
Returned 12 week 
questionnaire 
Surgery 
(n=182) 
Plaster cast 
(n=167) 
Total 
(n=349) 
How useful did you find the written advice about home exercises for your hand and wrist?, n (%) 
Very useful 59 (32.4) 38 (22.8) 97 (27.8) 
Quite useful 92 (50.6) 85 (50.9) 177 (50.7) 
Not very useful at all 15 (8.2) 21 (12.6) 36 (10.3) 
Not at all useful 10 (5.5) 11 (6.6) 21 (6.0) 
Missing 6 (3.3) 12 (7.2) 18 (5.2) 
Have you done any of these home exercises?, n (%) 
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Yes 151 (83.0) 136 (81.4) 287 (82.2) 
No 25 (13.7) 23 (13.8) 48 (13.8) 
Missing 6 (3.3) 8 (4.8) 14 (4.0) 
If ‘Yes’ on how many days over the past 12 weeks have you done these exercises? 
Mean (SD) 41.8 (28.5) 44.7 (28.6) 43.1 (28.5) 
Median (min, max) 35 (2, 137) 41 (1,  168) 38 (1, 168) 
Would you have preferred to have a formal referral to physiotherapy for your wrist injury?,n (%) 
Yes 67 (36.8) 56 (33.5) 123 (35.2) 
No 102 (56.0) 98 (58.7) 200 (57.3) 
Missing 13 (7.1) 13 (7.8) 26 (7.5) 
 
Table 65: Participant responses to questions relating to the current state of their wrist, and treatment preference, asked on 52-week questionnaire 
Returned 12 month 
questionnaire 
Surgery 
(n=186) 
Plaster cast 
(n=178) 
Total 
(n=364) 
Compared with one year ago how is your wrist now?, n (%) 
Much better now 149 (80.1) 139 (78.1) 288 (79.1) 
Slightly better now 17 (9.1) 17 (9.6) 34 (9.3) 
About the same now 9 (4.8) 11 (6.2) 20 (5.5) 
Slightly worse now 5 (2.7) 4 (2.3) 9 (2.5) 
Much worse now 1 (0.5) 3 (1.7) 4 (1.1) 
Missing 5 (2.7) 4 (2.3) 9 (2.5) 
Based upon your experiences of the treatment that you received as part of this trial, if you injured your 
wrist today to the same extent as you did one year ago, which treatment would you prefer?, n (%) 
No preference 36 (19.4) 68 (38.2) 104 (28.6) 
Surgery 137 (73.7) 59 (33.2) 196 (53.9) 
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Not surgery 8 (4.3) 48 (27.0) 56 (15.4) 
Missing 5 (2.7) 3 (1.7) 8 (2.2) 
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Figure 14: Unadjusted mean PRWE scores (with 95% CIs) over time by randomised 
group and patient treatment preference at baseline (a) No preference (b) Preference for 
surgery and (c) Preference for no surgery 
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(b) 
 
Figure 15: Unadjusted mean PRWE scores (with 95% CIs) over time by randomised 
group and fracture displacement (as randomised) at baseline (a) < 1 mm and (b) ≥1 mm 
and ≤2 mm 
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(b) 
 
Figure 16: Unadjusted mean PRWE scores (with 95% CIs) over time by randomised 
group and fracture displacement (as recorded on Study Eligibility Form) at baseline (a) 
< 1 mm and (b) ≥1 mm and ≤2 mm 
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(b) 
 
Figure 17: Adjusted mean PRWE subscale scores (with 95% CIs) over time by 
randomised group (a) pain and (b) function 
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(b) 
 
Figure 18: Adjusted mean SF-12 component subscale scores (with 95% CIs) over time 
by randomised group (a) MCS and (b) PCS 
 
 
Figure 19: Adjusted mean grip strength (with 95% CIs) over time by randomised group 
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Appendix 4: Software output for primary analysis model 
 
 LR test vs. linear model: chi2(9) = 589.70                Prob > chi2 = 0.0000
                                                                              
                cov(e26,e52)     253.1665   23.24352        207.61    298.7229
                cov(e12,e52)      228.317   24.05816      181.1638    275.4701
                cov(e12,e26)     273.1248   26.02855      222.1097    324.1398
                 cov(e6,e52)     180.8446   23.73652      134.3219    227.3673
                 cov(e6,e26)     204.2326   25.65127       153.957    254.5081
                 cov(e6,e12)     285.6388   28.50836      229.7634    341.5141
                    var(e52)     342.5324   25.92882       295.303    397.3154
                    var(e26)     342.8587   27.64151      292.7458      401.55
                    var(e12)     429.3117   33.16045      368.9989    499.4826
                     var(e6)     439.5566   34.14463      377.4798     511.842
Residual: Unstructured        
                                                                              
participan~d:        (empty)  
                                                                              
  Random-effects Parameters      Estimate   Std. Err.     [95% Conf. Interval]
                                                                              
                                                                                       
                _cons     33.85504   2.862057    11.83   0.000     28.24551    39.46457
                       
Surgical fixation#52      2.247439   2.212047     1.02   0.310    -2.088092    6.582971
Surgical fixation#26      3.997146   2.148946     1.86   0.063    -.2147109    8.209004
Surgical fixation#12     -1.154507   1.922734    -0.60   0.548    -4.922997    2.613983
      allocation#time  
                       
                  52     -25.92022   1.585252   -16.35   0.000    -29.02726   -22.81318
                  26     -23.35383   1.540652   -15.16   0.000    -26.37345   -20.33421
                  12     -13.31875   1.385872    -9.61   0.000    -16.03501   -10.60249
                 time  
                       
   Surgical fixation     -4.345097   2.191697    -1.98   0.047    -8.640744   -.0494512
           allocation  
                       
                  No     -2.688593   1.677597    -1.60   0.109    -5.976623    .5994366
            injarm_M0  
                       
        Displacement      2.875526   1.693336     1.70   0.089    -.4433527    6.194404
 fracturedisplacement  
                       
                  age     .1913108   .0643396     2.97   0.003     .0652074    .3174142
                                                                                       
              prwesum        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                       
Log restricted-likelihood = -5584.6207          Prob > chi2       =     0.0000
                                                Wald chi2(10)     =     545.12
                                                              max =          4
                                                              avg =        3.3
                                                              min =          1
                                                Obs per group:
Group variable: participantid                   Number of groups  =        406
Mixed-effects REML regression                   Number of obs     =      1,345
Computing standard errors:
Iteration 6:   log restricted-likelihood = -5584.6207  
Iteration 5:   log restricted-likelihood = -5584.6207  
Iteration 4:   log restricted-likelihood = -5584.6234  
Iteration 3:   log restricted-likelihood = -5585.4815  
Iteration 2:   log restricted-likelihood = -5611.4274  
Iteration 1:   log restricted-likelihood = -5632.2982  
Iteration 0:   log restricted-likelihood =  -5879.473  (not concave)
Performing gradient-based optimization: 
Obtaining starting values by EM: 
>  residuals(unstructured, t(time)) reml 
. mixed prwesum age i.fracturedisplacement i.injarm_M0 i.allocation##i.time || part:, noconstant
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Appendix 5: Analysis of the agreement between raters on the imaging 
 
Introduction 
This report describes the agreement study that was conducted to validate the radiology 
assessments that were fed into the trial analysis. All X-rays and CT scans were assessed 
independently by three raters and where there was disagreement, the three met to discuss the 
assessment and a consensus was reached. This study looks at the agreement at the first stage, 
that is prior to the consensus meeting. 
 
Methods 
The assessments of the three raters were compared in pairs, i.e. A with B, A with C and B 
with C. When a categorical assessment was required, the measure of agreement was taken to 
be the percentage of X-rays or CT scans on which the two raters gave exactly the same grade. 
It was decided that 50% agreement was acceptable and that 80% or greater agreement was 
good. Percentage agreement is reported together with a 95% confidence interval. 
When a continuous assessment was required, the measure of agreement was taken to be the 
95% limits of agreement and the data were displayed as a Bland-Altman plot. The limits of 
agreement depend on the standard deviation of the differences between the two raters and an 
acceptable agreement was defined as a standard deviation that was less that 25% the range of 
the scale. A standard deviation that was less than 10% of the range was considered good. The 
range was taken to be the difference between the largest and smallest measurements made by 
either of the two raters. 
Fracture 
X-ray at Baseline 
Rater A vs B 
                                               
            Rater B                            
  Rater A   Clear   Seen Just No (Missing) All 
  Clear     180      72  10   0  50        312 
  Seen       21      33  27   4  16        101 
  Just        1       3  15   0   6         25 
  No          0       0   0   0   0          0 
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  (Missing)   0       0   0   0   0          0 
  All       202     108  52   4  72        438 
 
Both raters graded 366 X-rays with 62.3% agreement, 95%CI (57.3, 67.3). 
Agreement was classified as acceptable. 
 
Rater A vs C 
                                               
            Rater C                            
  Rater A   Clear   Seen Just No (Missing) All 
  Clear     277     26    5    0 4         312 
  Seen       59     29   10    2 1         101 
  Just        5      6    6    8 0          25 
  No          0      0    0    0 0           0 
  (Missing)   0      0    0    0 0           0 
  All       341     61   21   10 5         438 
 
Both raters graded 433 X-rays with 72.1% agreement, 95%CI (67.8, 76.3). 
Agreement was classified as acceptable. 
 
Rater B vs C 
                                               
            Rater C                            
  Rater B   Clear   Seen Just No (Missing) All 
  Clear     188     13    1    0 0         202 
  Seen       84     18    5    1 0         108 
  Just       18     15   10    8 1          52 
  No          2      2    0    0 0           4 
  (Missing)  49     13    5    1 4          72 
  All       341     61   21   10 5         438 
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Both raters graded 365 X-rays with 59.2% agreement, 95%CI (54.1, 64.2). 
Agreement was classified as acceptable. 
 
CT at Baseline 
Rater A vs B 
                                               
            Rater B                            
  Rater A   Clear   Seen Just No (Missing) All 
  Clear     142      39   6   0  45        232 
  Seen       27      45  34   1  22        129 
  Just        2      17  31   6  12         68 
  No          0       0   1   0   1          2 
  (Missing)   0       0   0   0   0          0 
  All       171     101  72   7  80        431 
Both raters graded 351 CT scans with 62.1% agreement, 95%CI (57, 67.2). 
Agreement was classified as acceptable. 
 
Rater A vs C 
                                             
            Rater C                            
  Rater A   Clear   Seen Just No (Missing) All 
  Clear     227      5    0   0  0         232 
  Seen       84     25   18   1  1         129 
  Just       20     12   29   7  0          68 
  No          0      1    0   1  0           2 
  (Missing)   0      0    0   0  0           0 
  All       331     43   47   9  1         431 
 
Both raters graded 430 CT scans with 65.6% agreement, 95%CI (61.1, 70.1). 
Agreement was classified as acceptable. 
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Rater B vs C                                               
            Rater C                            
  Rater B   Clear   Seen Just No (Missing) All 
  Clear     168      3    0   0  0         171 
  Seen       73     20    8   0  0         101 
  Just       26     13   26   6  1          72 
  No          0      1    5   1  0           7 
  (Missing)  64      6    8   2  0          80 
  All       331     43   47   9  1         431 
 
Both raters graded 350 CT scans with 61.4% agreement, 95%CI (56.3, 66.5). 
Agreement was classified as acceptable. 
 
Displacement at Baseline 
The Bland-Altman plots of displacement show the difference in the measurement between 
two raters against their average measurement. Horizontal lines show the average difference 
(solid) and the 95% limits of agreement (dashed). 
 
Gap in X-ray 
Rater A vs B 
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95% limits of agreement (-0.88mm, 0.5mm). 
The standard deviation of the differences was 0.35 which is 11% of the range of 3.2. 
Agreement was classified as acceptable. 
 
Rater A vs C 
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95% limits of agreement (-0.82mm, 0.7mm) 
The standard deviation of the differences was 0.39 which is 12.2% of the range of 3.2. 
Agreement was classified as acceptable. 
 
Rater B vs C 
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95% limits of agreement (-0.68mm, 0.95mm) 
The standard deviation of the differences was 0.42 which is 9.7% of the range of 4.3. 
Agreement was classified as good. 
 
Step in X-ray 
Rater A vs B 
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95% limits of agreement (-0.8mm, 0.69mm) 
The standard deviation of the differences was 0.38 which is 6.7% of the range of 5.7. 
Agreement was classified as good. 
 
Rater A vs C 
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95% limits of agreement (-0.8mm, 0.82mm) 
The standard deviation of the differences was 0.41 which is 7.2% of the range of 5.7. 
Agreement was classified as good. 
 
Rater B vs C 
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95% limits of agreement (-0.75mm, 0.89mm) 
The standard deviation of the differences was 0.42 which is 13.5% of the range of 3.1. 
Agreement was classified as acceptable. 
 
Gap in CT scan: Coronal plane 
Rater A vs B 
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95% limits of agreement (-0.72mm, 0.7mm) 
The standard deviation of the differences was 0.36 which is 11.3% of the range of 3.2. 
Agreement was classified as acceptable. 
 
Rater A vs C 
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95% limits of agreement (-0.64mm, 0.69mm) 
The standard deviation of the differences was 0.34 which is 10.6% of the range of 3.2. 
Agreement was classified as acceptable. 
 
Rater B vs C 
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95% limits of agreement (-0.62mm, 0.68mm) 
The standard deviation of the differences was 0.33 which is 9.2% of the range of 3.6. 
Agreement was classified as good. 
 
Gap in CT scan: Sagittal plane 
Rater A vs B 
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95% limits of agreement (-0.89mm, 0.84mm) 
The standard deviation of the differences was 0.44 which is 7.9% of the range of 5.6. 
Agreement was classified as good. 
 
Rater A vs C 
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95% limits of agreement (-1.04mm, 1mm) 
The standard deviation of the differences was 0.52 which is 9.3% of the range of 5.6. 
Agreement was classified as good. 
 
Rater B vs C 
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95% limits of agreement (-0.96mm, 0.98mm) 
The standard deviation of the differences was 0.49 which is 9.9% of the range of 5. 
Agreement was classified as good. 
Step in CT scan: Coronal plane 
 
Rater A vs B 
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95% limits of agreement (-0.55mm, 0.61mm) 
The standard deviation of the differences was 0.29 which is 13.4% of the range of 2.2. 
Agreement was classified as acceptable. 
 
Rater A vs C 
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95% limits of agreement (-0.46mm, 0.57mm) 
The standard deviation of the differences was 0.26 which is 11.9% of the range of 2.2. 
Agreement was classified as acceptable. 
 
Rater B vs C 
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95% limits of agreement (-0.55mm, 0.61mm) 
The standard deviation of the differences was 0.3 which is 19.7% of the range of 1.5. 
Agreement was classified as acceptable. 
 
Step in CT scan: Sagittal plane 
Rater A vs B 
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95% limits of agreement (-0.71mm, 0.82mm) 
The standard deviation of the differences was 0.39 which is 13% of the range of 3. 
Agreement was classified as acceptable. 
 
Rater A vs C 
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95% limits of agreement (-0.67mm, 0.73mm) 
The standard deviation of the differences was 0.36 which is 11.9% of the range of 3. 
Agreement was classified as acceptable. 
 
Rater B vs C 
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95% limits of agreement (-0.84mm, 0.79mm) 
The standard deviation of the differences was 0.41 which is 12.6% of the range of 3.3. 
Agreement was classified as acceptable. 
 
Union by X-ray at 52 weeks 
Rater A vs B                                                                          
              Rater B                                                      
Rater A  United  Almost Partial Probably not Not united (Missing) All 
 United       186     46      1      0             0         0         233 
 Almost         2     13      1      0             0         0          16 
 Partial        7     12      4      1             3         0          27 
 Probably not   0      2      3      2             2         0          10 
 Not united     0      0      1      1            10         0          12 
 (Missing)      0      0      0      0             0         0           0 
 All          195     73     10      4            15         0         299 
Both raters graded 297 X-rays with 72.4% agreement, 95%CI (67.3, 77.5). 
Agreement was classified as acceptable. 
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Rater A vs C                                                                         
              Rater C                                                      
 Rater A      United  Almost Partial Probably not Not united (Missing) All 
 United       224      6      0      0            0          3         233 
 Almost        14      2      0      0            0          0          16 
 Partial       13     13      1      0            0          0          27 
 Probably not   2      1      7      0            0          0          10 
 Not united     0      0     11      1            0          0          12 
 (Missing)      0      0      0      0            0          0           0 
 All          253     22     19      1            0          4         299 
 
Both raters graded 295 X-rays with 76.9% agreement, 95%CI (72.1, 81.8). 
Agreement was classified as acceptable. 
 
Rater B vs C                                                                           
              Rater C                                                      
 Rater B      United  Almost Partial Probably not Not united (Missing) All 
 United       188      5      0      0            0          2         195 
 Almost        62      9      1      0            0          1          73 
 Partial        2      4      4      0            0          0          10 
 Probably not   0      1      3      0            0          0           4 
 Not united     0      3     11      1            0          0          15 
 (Missing)      0      0      0      0            0          0           0 
 All          253     22     19      1            0          4         299 
Both raters graded 294 X-rays with 68.4% agreement, 95%CI (63.1, 73.7). 
Agreement was classified as acceptable. 
 
Percent Union estimated from CT at 52 weeks 
Rater A vs B 
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95% limits of agreement (-20.21%, 13.01%) 
The standard deviation of the differences was 8.47 which is 8.5% of the range of 100. 
Agreement was classified as good. 
Rater A vs C 
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95% limits of agreement (-27.15%, 18.7%) 
The standard deviation of the differences was 11.7 which is 11.7% of the range of 100. 
Agreement was classified as acceptable. 
 
Rater B vs C 
 
95% limits of agreement (-18.67%, 17.43%) 
The standard deviation of the differences was 9.21 which is 9.2% of the range of 100. 
Agreement was classified as good. 
 
X-ray Union at 52weeks: summary 
A vs B 
                                                      
             Rater B                                  
  Rater A    United  Partial Not united (Missing) All 
  United     247      2       0         0         249 
  Partial     19      4       4         0          27 
  Not united   2      4      15         0          22 
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  (Missing)    0      0       0         0           0 
  All        268     10      19         0         299 
 
Both raters graded 297 CT scans with 89.6% agreement, 95%CI (86.1, 93). 
Agreement was classified as good. 
 
A vs C 
                                                      
             Rater C                                  
  Rater A    United  Partial Not united (Missing) All 
  United     246      0      0          3         249 
  Partial     26      1      0          0          27 
  Not united   3     18      1          0          22 
  (Missing)    0      0      0          0           0 
  All        275     19      1          4         299 
 
Both raters graded 295 CT scans with 84.1% agreement, 95%CI (79.9, 88.2). 
Agreement was classified as good. 
 
B vs C 
                                                      
             Rater C                                  
  Rater B    United  Partial Not united (Missing) All 
  United     264      1      0          3         268 
  Partial      6      4      0          0          10 
  Not united   4     14      1          0          19 
  (Missing)    0      0      0          0           0 
  All        275     19      1          4         299 
 
Both raters graded 294 CT scans with 91.5% agreement, 95%CI (88.3, 94.7). 
Agreement was classified as good. 
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X-ray Union at 52weeks: views 
A vs B 
                                                      
             Rater B                                  
  Rater A    United  Partial Not united (Missing) All 
  United     179     27       0         0         206 
  Partial     32     34       4         0          70 
  Not united   0      7      14         0          22 
  (Missing)    0      0       0         0           0 
  All        211     68      18         0         299 
 
Both raters graded 297 CT scans with 76.4% agreement, 95%CI (71.6, 81.3). 
Agreement was classified as acceptable. 
 
A vs C 
                                                      
             Rater C                                  
  Rater A    United  Partial Not united (Missing) All 
  United     203      0      0          3         206 
  Partial     63      7      0          0          70 
  Not united   3     18      1          0          22 
  (Missing)    0      0      0          0           0 
  All        270     25      1          3         299 
 
Both raters graded 295 CT scans with 71.5% agreement, 95%CI (66.4, 76.7). 
Agreement was classified as acceptable. 
 
B vs C                                               
             Rater C                                  
  Rater B    United  Partial Not united (Missing) All 
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  United     208      1      0          2         211 
  Partial     57     10      0          1          68 
  Not united   3     14      1          0          18 
  (Missing)    0      0      0          0           0 
  All        270     25      1          3         299 
 
Both raters graded 294 CT scans with 74.5% agreement, 95%CI (69.5, 79.5). 
Agreement was classified as acceptable. 
 
CT Union at 52weeks: MPR 
A vs B 
                                                      
             Rater B                                  
  Rater A    United  Partial Not united (Missing) All 
  United     161      1      0          0         162 
  Partial     86     32      1          0         119 
  Not united   0      3      8          0          11 
  (Missing)    0      0      0          0           0 
  All        247     36      9          0         292 
 
Both raters graded 292 CT scans with 68.8% agreement, 95%CI (63.5, 74.1). 
Agreement was classified as acceptable. 
 
A vs C 
                                                      
             Rater C                                  
  Rater A    United  Partial Not united (Missing) All 
  United     155      6       0         1         162 
  Partial     60     56       2         1         119 
  Not united   0      1       9         1          11 
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  (Missing)    0      0       0         0           0 
  All        215     63      11         3         292 
 
Both raters graded 289 CT scans with 76.1% agreement, 95%CI (71.2, 81). 
Agreement was classified as acceptable. 
 
B vs C 
                                                      
             Rater C                                  
  Rater B    United  Partial Not united (Missing) All 
  United     209     36       0         2         247 
  Partial      6     27       3         0          36 
  Not united   0      0       8         1           9 
  (Missing)    0      0       0         0           0 
  All        215     63      11         3         292 
 
Both raters graded 289 CT scans with 84.4% agreement, 95%CI (80.2, 88.6). 
Agreement was classified as good. 
 
CT Union at 52weeks: Estimated 
 
A vs B 
                                            
             Rater B                        
  Rater A    United  Partial Not united All 
  United     259      4       0         263 
  Partial      8      7       0          15 
  Not united   0      2      12          14 
  All        267     13      12         292 
 
Both raters graded 292 CT scans with 95.2% agreement, 95%CI (92.8, 97.7). 
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Agreement was classified as good. 
 
A vs C 
                                            
             Rater C                        
  Rater A    United  Partial Not united All 
  United     259      3      1          263 
  Partial     12      3      0           15 
  Not united   1      5      8           14 
  All        272     11      9          292 
 
Both raters graded 292 CT scans with 92.5% agreement, 95%CI (89.4, 95.5). 
Agreement was classified as good. 
 
B vs C 
                                            
             Rater C                        
  Rater B    United  Partial Not united All 
  United     264      3      0          267 
  Partial      8      4      1           13 
  Not united   0      4      8           12 
  All        272     11      9          292 
 
Both raters graded 292 CT scans with 94.5% agreement, 95%CI (91.9, 97.1). 
Agreement was classified as good. 
 
CT Union at 52weeks: Calculated 
 
A vs B                                            
             Rater B                        
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  Rater A    United  Partial Not united All 
  United     247      1      0          248 
  Partial     23      9      0           32 
  Not united   0      5      7           12 
  All        270     15      7          292 
 
Both raters graded 292 CT scans with 90.1% agreement, 95%CI (86.6, 93.5). 
Agreement was classified as good. 
 
A vs C                                            
             Rater C                        
  Rater A    United  Partial Not united All 
  United     246      2      0          248 
  Partial     21     10      1           32 
  Not united   0      4      8           12 
  All        267     16      9          292 
 
Both raters graded 292 CT scans with 90.4% agreement, 95%CI (87, 93.8). 
Agreement was classified as good. 
 
B vs C                                            
             Rater C                        
  Rater B    United  Partial Not united All 
  United     265      4      1          270 
  Partial      2     12      1           15 
  Not united   0      0      7            7 
  All        267     16      9          292 
 
Both raters graded 292 CT scans with 97.3% agreement, 95%CI (95.4, 99.1). 
Agreement was classified as good. 
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Discussion 
Agreement was either acceptable or good on all scales.  
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Appendix 6: Health Economics 
 
Section 1: Impact of lost employment and unpaid activities 
 
In addition to consideration of costs to the NHS and PSS and quality of life to the patients, 
this within trial analysis reports the impact of treatment allocation on days of lost 
employment and unpaid activities.  As part of the questionnaires patients were asked to 
report, if they were in paid employment, how many days over the period covered by the 
questionnaire they have missed as a result of their wrist injury, and how many days of unpaid 
activity they lost.  While such outcomes are not conventionally incorporated into an 
economic evaluation in a UK setting93 it can be helpful to inform decision makers who 
choose to take a broad definition of benefit, beyond patient quality of life and costs to the 
NHS, or patients who may choose to have the surgical procedure done through private 
healthcare provision to reduce the number of days of work lost.  Brief summary statistics are 
reported for the four relevant time periods, stratified by treatment allocation.   
 
Results 
Impact of lost employment  
The summary statistics of the patient reported days of lost employment are reported in Table 
35.  Primarily the table shows that the majority of patients experienced some days of lost 
employment in the first six weeks of the analysis period (with only 21.6% and 31.3% 
reporting no lost days over that period for surgery and cast respectively), but from 12 weeks 
onwards most were back to fulltime work (with medians of zero for all other periods).  There 
did, however, remain a number of patients who were forced to continue missing work as a 
result of their wrist, characterised by the persistent mean number of days lost despite close to 
90% reporting no lost days.  A very few cases of patients having to miss work for most of if 
not all the period covered by the questionnaire were reported. 
 
Over the entire within trial period for the compete case analysis surgical patients reported 
having lost a smaller mean number of days (16.62 compared to 17.57 respectively) but a 
larger median (9.5 compared to 5) and with fewer reporting no days of work lost (13.7% to 
28.6%).  Using the sum of the means for each time period, a larger difference is observed 
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between the two groups, with a mean lost days of employment of 17.30 and 21.69 reported, 
suggesting a biasing impact of the inconsistent level of missing data.  
 
This distribution is best explained by the invasive nature of the surgery necessitating at least 
some days off work in more patients but the large impact of a few extreme cases where 
patients were absent from work for the majority of the year. These outliers appear to be more 
evident in the plaster cast arm, with 10 patients reporting more than 50 days off work, 
compared to 6 in the surgical arm.  However, the high rate of missing data may be having a 
large biasing effect. 
 
These findings appear inconsistent with other studies focussing on the impact of scaphoid 
fracture on fixation176, 177 which have found much larger differences in days of work lost, 
favouring surgery, however, the source of this difference is not clear. 
 
Using estimates of the average weekly earnings from the Office for National Statistics 
(£512)178 allows us to crudely estimate the average societal impact of these lost days of 
employment of £1,702 per person for the surgical arm and £1,799 for the cast arm, a 
difference of £97 per person.  However, it is important to note that without an estimate of the 
number of days of work a person would lose if no treatment was available it is not possible to 
interpret these results beyond their comparative value. 
 
Impact on days of unpaid activity 
Similar to the last section, Table 66 reports the impact of treatment allocation on lost unpaid 
activity (e.g. household chores, shopping, helping others) for reasons related to the wrist 
injury and subsequent treatment. 
 
Table 66: Summary statistics for days of lost unpaid activity reported since last 
questionnaire 
Questionnaire 
period   
Treatment 
allocation 
Number of 
responses 
Mean Median 
(95% 
percentile) 
Percentage 
reporting 0 
days 
6 weeks Surgery 167 12.41 10 (40) 28.1% 
Cast 162 10.13 6 (35) 35.8% 
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12 weeks Surgery 163 2.21 0 (18) 83.4% 
Cast 151 5.03 0 (35) 66.9% 
26 weeks Surgery 150 1.77 0 (14) 89.3% 
Cast 140 3.51 0 (25) 85.7% 
52 weeks Surgery 169 1.08 0 (5) 91.7% 
Cast 163 2.73 0 (4) 91.4% 
Total Surgery 118 16.15 11 (54) 21.2% 
Cast 103 15.90 8 (52) 26.2% 
 
The table shows a larger impact on lost unpaid activity of surgery than casting for the 6 
weeks after randomisation, with larger mean and median values, and fewer patients reporting 
no days lost.  However, for all time points after this, patients allocated to the surgical arm 
report a smaller impact on unpaid activities.  As was seen in the responses to lost days of 
employment the results are highly skewed, with the majority of responders reporting no 
impact on unpaid activity after 6 weeks but a very small number continuing to report a large 
number of lost days throughout the trial period. 
 
 
Section 2: Systematic review of previous cost-effectiveness studies 
 
This Appendix details the literature review that was conducted to determine whether previous 
economic evaluations had sufficiently determined the cost-effectiveness of surgical fixation 
versus plaster cast immobilisation for treatment of bi-cortical, minimally displaced fractures 
of the scaphoid waist in adults.  A secondary aim of the search was to determine if previous 
mathematical models could be adapted to estimate the long-term cost-effectiveness of the 
population, and thus remove the need to construct a de novo mathematical model. 
Our strategy (detailed below) did not specify the form of treatment required, whether the 
evaluation considered the diagnosis or treatment of the fracture, or the extent of displacement 
of the fracture.  The strategy was submitted to Ovid Medline in April 2017,[12] with all 
published, in process and other non-indexed citations in any language between 1946 and 
April 2017 allowed.  The review was conducted by a single reviewer. 
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Systematic search strategy 
Search conducted using Ovid Mediline through the University of York library, 04/04/2017 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) <1946 to Present> 
1. Fracture Fixation/ (17279) 
2. Fracturers, Bone/ (59494) 
3. Orthopedic Fixation Devices/ (4975) 
4. 1 or 2 or 3 (75839) 
5. Scaphoid Bone/ (1850) 
6. Wrist Joint/ (8976) 
7. Wrist Injuries/ (5824) 
8. 5 or 6 or 7 (14701) 
9. Cost-Benefit Analysis/ (70573) 
10. 4 or 8 or 9 (24) 
 
In addition to the strategy submitted to Medline (above) a search of the grey literature was 
conducted.  The search consisted of an iterative investigations of the literature identified 
using an internet search engine (Google Scholar), coupled with a targeted search of the 
National Institute for Health and Care Excellence’s (NICE) website to explore any economic 
evaluations behind current best practice guidance. 
The Medline search yielded 24 hits, 16 of which were deemed relevant upon review of their 
titles, only 3 of which were relevant after consideration of their abstracts43, 179, 180. The search 
of the grey literature only identified one fully relevant article from the NICE website and 
none from the internet search engine exploration.  Consistent with the search strategy the 
relevance of the studies was defined by the existence of some form of economic evaluation at 
any point of the diagnostic or treatment pathway of a fracture of the wrist region. No further 
limits on the type of injury or point of care were placed to ensure all studies considering the 
cast immobilisation vs surgical fixation question were included.  As a result, some of the 
studies deemed relevant considered the pre-treatment decision of how different diagnostic 
strategies compared, but as these implicitly included the consequences of the treatment used 
they were deemed relevant.   
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The four studies identified43, 90, 179, 180 were reviewed using the Drummond Checklist for 
assessing the quality of economic evaluations,103 the results of which are available later in 
this Appendix. 
Of the four studies, two considered the cost-effectiveness of different diagnosis strategies for 
suspected scaphoid fractures.90, 180 Karl et al.180 explored the relative cost effectiveness of 
three strategies: empiric cast immobilisation for all patients followed by follow-up 
radiographs, immediate CT scan, and immediate MRI, in a population of patients deemed to 
have a possible scaphoid fracture after physical examination, but with a negative initial 
radiograph.  The authors concluded that initial advanced imaging dominated empiric casting.   
Similarly, the economic evaluation that accompanied NG3890  primarily focussed on the cost 
effectiveness of imaging suspected scaphoid fractures rather than the appropriate treatment 
pathway, but contains valuable insights into the pathway.  This analysis considered a slightly 
earlier problem than Karl et al., being prior to initial investigation.  As a result the decision 
problem considered whether MRI or CT scans should be used as the first line diagnostic tool, 
and thus a broader population than Karl et al. by considering all those with suspected 
scaphoid fractures rather those with indeterminate initial radiology findings.  The analysis 
included the possibility of patients having either cast immobilisation and/or surgical fixation, 
but these were considered to be accepted best practice depending on displacement and union, 
and as such no analysis of their respective cost-effectiveness was conducted.  The evaluation 
concluded that the use of immediate MRI was the most cost-effective approach, dominating 
all other strategies except immediate CT scans. 
As both Karl and NICE NG38 90, 180  focussed on the cost-effectiveness of the diagnostic 
strategies prior to confirmed diagnosis, and considered the treatment options to be fixed 
decisions, they are not directly applicable to the SWIFFT trial evaluation. 
The study by Hannemann et al. 179  considered the cost-effectiveness of pulsed 
electromagnetic fields in the treatment of acute undisplaced scaphoid fractures, compared to 
standard cast immobilisation.  While relevant to the SWIFFT evaluation as an evaluation of 
treatment options in scaphoid fractures, Hannemann et al. consider a less severe population 
than SWIFFT, including patients with tuberosity fractures.  Additionally, the study does not 
conduct a long-term mathematical model, instead being limited to a within trial analysis over 
52 weeks of follow up. 
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Finally, Davis et al.43 conducted an evaluation of the cost-effectiveness of open reduction and 
internal fixation surgery versus cast immobilisation for acute non-displaced scaphoid 
fractures.  As a result, the study is relevant to this evaluation.  The study is structured around 
a decision tree model which estimates the probability of a patient experiencing one of six 
possible outcomes after treatment with cast immobilisation (no complications, non-union, and 
delayed union, each with a normal and arthritis variant), and seven for surgical fixation (the 
same as the cast arm but with the addition of a risk of infection).  The model estimates the 
cost per QALY gained of each treatment by combining the short term cost and health related 
quality of life of the different treatment outcomes with long-term estimates of the health 
related quality of life implications of each outcome, no long-term costs appear to be 
considered despite the existence of a long-term arthritis outcome.    
As reflected in the review of the Davis study presented in the table later in this Appendix 
there are a number of areas of the model that were difficult to fully assess.  The decision tree 
and related characterisation of the different possible post-treatment outcomes are good, 
considering the potential for non and delayed union, infection, misplaced screws, and 
arthritis.  However, our review of the article raised a number of factors that limit the 
transferability of the model to the SWIFFT trial analysis.  These factors included the lack of 
long-term cost associated with arthritis, a lack of clarity regarding which patients were 
associated with which resource use, the use of an unvalidated time trade off questionnaire 
completed by 50 medical students who had not experienced the fracture, a lack of clarity as to 
how the durations and probabilities that informed the model were derived from the literature, 
and the lack of correlation between non-union and the probability of arthritis.  Furthermore, 
the lack of definition of non-displacement by Davis et al. makes the transferability of the 
model to the SWIFFT trial population difficult to determine.   
Therefore, we determined that in addition to the planned within trial economic evaluation of 
the SWIFFT trial a de novo mathematical model was required to investigate the long-term 
cost effectiveness of surgical fixation compared to cast immobilisation.  The de novo model 
is expected to draw from the Davis study, but this will be determined by the results of a series 
of targeted parameter specific literature reviews. 
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Drummond checklist review  
Table 67: Drummond checklist103 review of previous economic evaluations identified in the literature review (systematic and grey 
search) 
Study 1. Was a well 
defined 
question posed 
in an 
answerable 
form? 
2. Was a 
comprehensive 
description of 
the competing 
alternatives 
given? 
3. Was the 
effectiveness 
of the 
programmes or 
services 
established? 
4. Were all 
important & 
relevant costs 
& 
consequences 
for each 
alternative 
identified? 
5. Were costs 
& 
consequences 
measured 
accurately in 
appropriate 
physical units? 
6. Were costs 
& 
consequences 
valued 
credibly? 
7. Were costs 
& 
consequences 
adjusted for 
differential 
timing? 
8. Was an 
incremental 
analysis of 
costs & 
consequences 
of alternatives 
performed? 
9. Was 
allowance 
made for 
uncertainty in 
the estimates 
of costs & 
consequences? 
10. Did the 
presentation & 
discussion of 
results include 
all issues of 
concern to 
users? 
Davis 2006 117 Yes, a clear 
focus from 
both a direct 
and indirect 
perspective  
Yes, all options 
are considered, 
no explicit ‘do 
nothing’ but 
perhaps not 
appropriate. 
Limited detail 
on surgical 
option 
Yes, had to 
rely on limited 
RCT data. 
Based on a 
systematic 
review but 
simple 
averages taken 
Partial, short 
term direct and 
indirect costs 
were well 
handled but it 
is not clear 
how/if long-
term costs of 
arthritis is 
modelled 
Partial, not 
very clear as 
based on tariff 
payments so no 
clear 
breakdown. 
Outcomes in 
appropriate 
units 
Partial, costs 
valued credibly 
but hard to test 
without trial 
and tariff 
details. 
Outcomes 
questionable as 
based on 50 
medical 
students rather 
than patients 
Unclear, No 
statement on 
discounting but 
the results 
would suggest 
it was applied. 
Yes Yes, through 
one and two 
way scenario 
analysis with 
some 
conceptualisati
on for values 
chosen. 
No clear 
definition of 
non-displaced. 
Good 
consideration 
of the role of 
non-arthritis 
adverse events 
Karl 2015 181 Yes, clear 
outline of three 
different 
options, and 
the aim and 
hypothesis of 
the study and 
patients 
Yes, 
alternatives 
well defined. 
Not clear if all 
options are 
considered as 
possible repeat 
rests not 
Yes, through 
limited meta-
analysis, but 
only focus on 
diagnostic 
effectiveness, 
little on 
Yes, appear to 
be sufficiently 
identified 
(given 
limitations of 
treatment 
modelling) 
Yes, appear 
appropriate 
Partial, based 
on limited 
evidence in the 
literature 
which is 
averaged.  
Questionable 
approach to 
Partial, 
literature 
estimates 
adjusted to 
2014 USD. 
Not clear if 
discounting is 
applied, scale 
Yes Yes, one and 
two way 
scenario 
analysis. 
Yes, with 
exception of 
those raised 
elsewhere 
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included or 
discussed 
treatment post 
test 
cost of surgery. 
Utility based 
on Davis so 
same 
limitations. 
of results 
would suggest 
not. 
Hannemann 
2015 182 
Yes, clear 
outline of aims 
of analysis, 
although 
description of 
evaluation in 
abstract is a 
little 
misleading as 
study is just 
within trial 
report 
Yes, good 
description 
although not 
clear if surgery 
would have 
been an option 
Yes, using 
linked trial 
evidence only 
Yes, identified 
as part of trial 
Yes, costs and 
health 
outcomes well 
reported 
Yes, costs from 
hospital and 
Dutch 
Guidelines and 
QoL from trial 
EQ5D. Some 
credible 
societal costs 
N/A, only 1 
year timeline 
but could argue 
should have 
been included 
Yes Yes, PSA 
presented but 
no scenario 
analysis  
The study has 
limited scope 
as is only a 
within 1 year 
trial report 
with limited 
evaluation  
NICE NG38 
2016 90 
Yes, clearly 
defined but a 
little unclear as 
to how the 
overall 
analysis links 
to the NICE 
Guidance so 
hard to 
comment on 
ability to 
answer 
primary aim 
Yes, very well 
described and 
motivated, no 
‘do nothing’ 
but as 
emergency 
medicine 
perhaps not 
reasonable 
option 
Partial, the 
effectiveness 
of the 
diagnosis was 
well 
established but 
not the 
subsequent 
treatments 
(cast or 
surgical 
interventions) 
Partial, short 
term costs 
were well 
considered but 
long-term costs 
and the 
consequences 
of different 
treatment 
options were 
not, however it 
is hard to 
determine if 
this had an 
impact on the 
results 
Yes, costs and 
consequences 
were measured 
appropriately 
Yes, based on 
a good 
literature 
search, and 
where no 
literature was 
available, 
reasonable 
assumptions.  
Yes, all costs 
occurred in the 
first year but 
future QALYs 
were 
discounted 
appropriately. 
Yes Yes, through 
scenario 
analyses 
Overall a good 
piece given the 
limitations of 
the evidence, 
but concerns 
around the 
failure to 
justify the 
simplistic 
approach to 
modelling the 
treatment 
options. 
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Drummond checklist review  
 Age of 
population 
at injury 
Male to 
female 
ratio 
Characteristics of 
original injury 
OA definition Definition of union Surgical 
intervention type 
Definition of 
symptoms 
This analysis, 
as defined by 
the SWIFFT 
trial 
(N=439) 
Mean 33 
(range 16 
to 80) 
84% Unequivocal, bi-
cortical, minimally 
displaced fracture 
(<2mm) of the 
scaphoid, presenting 
within two weeks of 
injury 
Defined within trial 
period by radiography 
and CT scan 
 
Disappearance of the 
fracture line on 
radiographs and 
complete bridging on 
CT scans from those 
taken at baseline 
As per surgical 
preference (open or 
percutaneous fixation 
with standard CE 
marked headless 
compression screw) 
Reported in terms of 
EQ-5D 
Lindström 
and Nyström 
(1990) 104 
(n=229) 
Range 15 
to 76 years  
83.8% Scaphoid fractures, 
fractures of the 
scaphoid tuberosity 
were excluded 
One or more 
observations of: 
reduced joint space,  
osteophytes, or 
sclerosis of joint 
margins 
N/A, only considers 
‘healed fractures’ (not 
defined) 
N/A, only cast 
patients 
Patient reported 
weakness of grip, 
pain related to wrist 
motion and at rest, 
and impaired range of 
motion. 
Saeden109 
(n=61) 
29 +- 13 
years for 
surgical 
group 
37 +- 20 
years cast 
group  
84% 
surgical 
73% cast 
Acute fractures of the 
scaphoid visible at 
first radiological 
examination. 
Fractures of the 
scaphoid tuberosity 
were excluded. 
narrowing of the joint 
or reactive changes 
around it compared 
with the uninjured 
side 
radiological identified 
but not defined  
Open fixation using 
Herbert screw 
Symptoms reported 
as score out of 10 
across 9 questions 
including pain at 
different times, wrist 
movement and 
manual work 
Lindström 
and Nyström 
(1992) 
102(n=33) 
Mean 27.9, 
range 15 to 
52 years 
72.7% Scaphoid fractures, 
fractures of the 
scaphoid tuberosity 
were excluded 
One or more of: 
reduced joint space,  
osteophytes, or 
sclerosis of joint 
margins 
Not defined N/A as all untreated 
patients 
Patient reported pain, 
stiffness, and 
weakness 
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Ruby 101 
(n=56) 
Mean 32, 
range 18 to 
85 years 
89.2% Scaphoid fractures At least presence of 
joint narrowing, 
severity determined 
by osteophytes and 
intraosseous cysts 
Not defined N/A as all untreated 
patients 
Patient reported pain 
in the wrist 
Moritomo 107 
(n=33) 
Mean 26.3, 
range at 
review of 
all patients 
13 to 70 
84.5% Limited details given 
other than fracture of 
the scaphoid.  
N/A 
 
Not defined N/A, no treatment 
details reported 
Symptomatic 
population defined as 
seeking help for 
injury 
Vender 111 
(n=64) 
Median 22 86% Scaphoid fractures Radial styloid 
pointing, 
radioscaphoid 
narrowing, and 
midcarpal joint 
narrowing 
Displacement of the 
fragment cortices 
greater than 1 mrn. 
N/A, excluded any 
patients who had 
previous operations 
Patients who 
presented with 
clinical concerns 
related to the injured 
wrist 
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Section 3: Probability of developing OA  
 
In the extrapolated model the probability of OA was modelled for all treatment arms as being 
an exponential decay towards a limiting value with the limiting value characterised as a beta 
distribution for the PSA.  The functional form of the exponential function is: 𝑦 = 𝑦∞ + 𝑎 × 𝑒−𝑡𝜏  
Where 𝑦∞ is the limiting value, a is the constant, and 𝜏 is the time constant.  
This formula is fitted to the evidence from Lindström and Nyström that at year 1 2.6% of 
patients had radiological OA, and at year 7 5.6% had radiological OA.104  Figure 20 shows 
the goodness of fit of the fitted function to the observed data, with the bounds showing the 
95% confidence interval taking account of the uncertainty of the time limiting value. 
 
 
Figure 20: Goodness of fit of the exponential decay to the observed data 
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Section 4: Probability of developing SNAC 
To estimate the probability of non-union patients developing SNAC we conducted a survival 
analysis to the patient level data reported in Moritomo.107 The results of the survival analysis 
are reported below reporting the AIC and BIC of the seven regressions explored alongside the 
graphical goodness of fit of the Weibull, which was selected due to having the lowest AIC 
and BIC. 
 
 
 AIC BIC 
exp 25.12107 26.11681 
weibull 22.51636 24.50783 
gomp 22.79423 24.7857 
loglogistic 24.14154 26.133 
lognormal 23.19027 25.18174 
gamma 24.33022 27.31742 
Figure 21: AIC and BIC estimates for the survival regressions fitted to the Moritomo patient 
level data 
 
 
Figure 22: Weibull and Kaplan-Meier of the SNAC survival analysis 
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Section 5: Extrapolated model scenario analyses 
In order to develop the mathematical model into the form presented above a number of 
simplifying assumptions and interpretations of the available evidence were necessary, as is 
true of all mathematical models.99  While the assumptions made in the base-case analysis are 
considered to be the most reasonable given the evidence available it is important to test the 
impact of different approaches on the results of the analysis.  The following scenarios have 
been constructed to conduct these tests, as far as possible other sources of evidence are used 
to inform the scenarios, however, often the uncertainty is driven not by contradictory sources 
but by a complete lack of evidence: 
 
Scenario 1, Definition of non-union at 1 year 
In the base case analysis we assume that the definition of non-union informative to the 
extrapolated model from the previous Chapter includes only those patients who are classified 
as having a non-union at 52 weeks, therefore all other diagnoses (union, almost full union, 
partial union, and slight union) are categorised as union for the sake of the model.  If only this 
“pure” non-union definition is used there is one non-union in the surgical arm and four in the 
plaster cast arm (three of which we define as having surgical intervention at a later time).  If a 
broader definition is used to include the slight unions then this increases to four in the 
surgical arm and nine in the plaster cast arm.  The base-case assumption was made due to 
clinical guidance that there is no evidence to suggest that slight unions behave as non-unions, 
however there is uncertainty around this.  Therefore, this scenario explores the sensitivity of 
the model to this assumption by only considering the “pure” non-unions as informative to the 
extrapolated model. 
 
Scenario 2, no surgical treatment for those who fail to achieve union with cast 
Our base-case analysis assumes that the three patients who failed to achieve union with cast 
fixation alone by 52 weeks in the cast plus surgery arm of the trial (i.e. did have an identified 
or suspected non-union after cast immobilisation but were not treated surgically) can be 
assumed to receive surgical intervention at a later time point.  This scenario explores this 
assumption by assuming that these patients did not receive surgical intervention at a later 
date, and therefore are long-term non-unions. 
Scenario 3, probability of non-union after secondary surgery 
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The base-case analysis uses evidence from the SWIFFT trial to estimate the probability of 
non-union for patients who underwent surgery after cast immobilisation (one patient of 17 
who received surgery).  This scenario explores the impact of this assumption by using an 
estimate from Filan and Herbert183 to estimate the probability of non-union after secondary 
surgery (0.195, 95% CI 0.145 to 0.249).   
 
Scenario 4, treatment specific adverse events   
The base-case analysis assumed that the choice of treatment only impact the probability of 
achieving union, and not the subsequent risks of adverse event development.  The base-case 
uses the large study by Lindström and Nyström104 to inform the three parameters: the 
probability of having long-term non-OA adverse events, the probability of developing OA, 
and the probability that this OA is symptomatic.  The major limitations of this approach are 
that the Lindström and Nyström104 study solely considered patients treated with cast 
immobilisation. As observed by Saeden109 the act of conducting surgery may result in the 
development of OA that may not have occurred with conservative treatment alone, and may 
be associated with a greater level of non-OA adverse events due to the invasive nature of 
surgery. 
 
This scenario explores this assumption by using less robust, treatment specific estimates of 
adverse event rates from the literature.  The primary source of evidence is Saeden,109 a small 
(n=62) randomised study of cast versus Herbert screw fixation for acute scaphoid fracture.  
The small nature of this study, as well as the age of the surgical procedure (patients were 
randomised between 1984 and 1886), were the primary reasons for it being discounted as the 
primary source of the base-case analysis.  Furthermore, there were concerns that the results of 
Saeden were inconsistent with clinical expectations, as it suggests a higher overall rate of 
adverse events in the cast immobilisation group.  The use of this study changes the estimates 
reported in Table 29 in Chapter 4 to those reported in the condensed Table 68Error! 
Reference source not found. below, with the base-case estimates reported in the second line 
of each row.  Estimates of the probability of developing SNAC post non-union remain 
unchanged from the base-case.  
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Table 68: Scenario 4 parameter values (shaded values report the base-case parameter 
estimates) 
Parameter Base case value 
(95% CI) 
Distribution Source 
2.a. Long-term element of the model – Union Markov 
Probability of having long-term adverse symptoms that are not OA related 
Cast immobilisation 0.188 (0.043 to 
0.405) 
0.048 (0.024 to 
0.079) 
Beta (alpha-3, beta-13) 
(alpha-11, beta-218) 
Saeden109 
Lindström and 
Nyström 104 
Surgery as last 
treatment 
0.087 (0.011 to 
0.228) 
Assumed same as 
cast 
Beta (alpha-2, beta-21) 
 
Saeden  
 
 
Probability of developing OA  
Cast immobilisation Limiting value – 
0.308 
Time constant – 1.5 
CI – 0.123 to 0.527 
 
 
Limiting value – 
0.056 
Time constant – 1.5 
CI – 0.035 to 0.087 
Exponential decay 
towards a limiting 
value, with limiting 
value characterised as a 
beta distribution 
Saeden (only 
including 
scaphotrapezial 
joints) 
 
 
 
 
 
Lindström and 
Nyström  
Surgery as initial 
treatment 
Limiting value – 
0.609 
Time constant – 1.5 
CI – 0.440 to 0.776 
Exponential decay 
towards a limiting 
value, with limiting 
Saeden  
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Assumed same as 
cast 
value characterised as a 
beta distribution 
Probability that developed OA is symptomatic 
Cast 0.750 (0.292 to 
0.992) 
0.992 (0.918 to 1.00) 
Beta (alpha-3, beta-1) 
 (alpha-11.9, beta-0.1) 
Saeden 
Lindström and 
Nyström 
Surgery 0.214 (0.050 to 
0.454) 
Assumed same as 
cast 
Beta (alpha-3, beta-11) Saeden 
 
Scenario 5, additional risk of OA development post non-union surgery  
The base-case analysis assumes that there is no additional risk of developing OA as a result 
of multiple lines of treatment.  This assumption implies that, in the case of surgery for non-
union after cast immobilisation, there is no increase in the future risk of developing OA.  
However, Saeden109 argues that surgery which opens the scaphotrapezial joint may result in 
the development of OA, but members of the trial TMG argue that surgery may in fact have a 
delaying effect on the progression of OA.  This scenario will explore the sensitivity of the 
result to this assumption by assuming that patients undergoing surgery as a secondary 
treatment are firstly twice as likely to develop OA at any point than if surgery had been 
conducted as the primary treatment, and secondly if they are half as likely.  
 
Scenario 6, non-OA permanent adverse event quality of life 
The base-case model assumes that the HRQoL for non-OA permanent adverse event is the 
same as for OA, due to a lack of evidence. This scenarios tests the impact of this assumption 
by testing two extreme cases: 
a. The HRQoL decrement for non-OA permanent adverse event is 50% less than 
for OA (mean decrement 0.065, CI 0.045 to 0.085) such that they have a 
greater quality of life than OA sufferers. 
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b. The HRQoL decrement for non-OA permanent adverse event is 50% greater 
that for OA (mean decrement 0.195, CI 0.175 to 0.215), such that they have a 
lesser quality of life than OA sufferers. 
 
A third sub-scenario is additionally considered which attempts to separately model the role of 
rare but extremely impactful surgery related adverse events such as fusion, Chondrolysis, and 
infection.  While previous analyses includes non-OA related AEs that are the same for both 
treatments (the base-case) and different (scenario 1), and the quality of decrement applied is 
lifelong (-0.130 each year) it is possible that this underestimates the impact of a small number 
of high impact and lifelong AEs that can occur after surgery.  In the SWIFFT trial one patient 
was identified as having wrist fusion and reported a quality of life for the within trial period 
0.31 less than the surgical arm average.  This scenario explicitly incorporates this quality of 
life decrement occurring in 0.5% (roughly 1 in 219) of surgical patients for the rest of their 
lives.  
 
Scenario 7, proportion of untreated patients who have union 
The base-case analysis assumes that all patients in the untreated arm experience non-union, 
an assumption necessitated by the reality that it is impossible to estimate the rate in this 
treatment group. While in reality we know little about the prognosis and natural history of 
such a patient population, including whether any patients who did choose to not receive 
treatment would seek treatment later if symptoms persisted, we believe that the base case 
modelled provides a very important role in demonstrating the value of some form of active 
treatment.  This scenario explores the sensitivity of the result to the assumption that all no 
treatment options result in non-union by using a threshold analysis to estimate the probability 
that the injury fails to unite without intervention at which point the no-treatment arm becomes 
the most-cost-effective treatment approach.  This scenario can be used if future evidence 
emerges to reflect the validity of the base case assumption and therefore merits of active 
treatment. 
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Scenario 8, probability of SNAC post non-union 
To explore the sensitivity of the model to changes in the probability of SNAC occurring at 
any time point after a non-union this scenario doubles and halves the base-case annual 
probabilities. 
 
Scenario 9, proportion of patients who reject surgery post cast immobilization 
In the base-case analysis the estimated probability of patients having surgery after a 
confirmed non-union after initial cast immobilisation is taken directly from the SWIFFT trial, 
with 4 of 18 patients did not have surgery.  This scenario explores the sensitivity of the model 
to this parameter through a threshold analysis, identifying the rate at which patients would 
have to accept surgery after confirmed non-union after cast immobilisation for cast plus 
surgery to be the most cost-effective treatment. 
 
Scenario 10, cost of first line surgical fixation 
The base-case analysis estimates a cost per first line surgical fixation of £1,632 as informed 
by the relevant reference cost.94  However, the trial TMG highlighted that this reference cost 
was widely considered to be a large underestimate of the true cost to the hospital of providing 
this procedure.  Attempts were made to use data collected during the trial to conduct a bottom 
up costing of the procedure, but insufficient unit costs of the components and large variation 
in the level of reporting made it impossible to derive a meaningful estimate.  This scenario 
therefore estimates the impact on the estimated result if the cost of surgical fixation were 
doubled to £3,264.   
 
Scenario 11, No difference in quality of life in first year 
The base-case analysis assumes a quality of life difference of 0.02 in favour of the surgical 
treatment arm in the first year of the model.  This scenario explores the impact of 
incorporating the difference in baseline quality of life between the two arms by setting the 
quality of life of the two arms as the same (set to the cast value of 0.812).  
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Scenario 12, No quality of life decrement of non-union without SNAC 
The base-case analysis assumes the quality of life decrement for patients with long-term non-
union but no SNAC is the same as that used for OA (a decrement of 0.130).  This scenario 
tests this assumption by assuming that non-union patients without SNAC have no quality of 
life decrement, experiencing the same quality of life as the general population.  
 
 
Scenario Analyses Results 
 
A number of scenarios were conducted to explore some of the elements of uncertainty not 
well captured by the PSA, as discussed in the main report and above.  In this section the 
results presented of the different scenario analyses are reduced to reporting the NHB at a 
cost-effectiveness threshold of £20,000/QALY which gives a precise overview of which 
treatment option is the most cost-effective.  The full list of NHB across the scenarios are 
reported in Table 69. 
 
Table 69: Results of the scenario analyses, NHB at threshold of £20,000/QALY 
Scenario Surgery Cast plus 
surgery 
Cast only  No treatment 
Base-case 
Deterministic 
19.00 19.02 18.69 14.70 
Scenario 1  
Definition of non-
union at 1 year 
18.99 19.02 18.58 14.69 
Scenario 2 
No surgical 
treatment for those 
who fail to achieve 
union with cast 
19.00 18.98 18.70 14.69 
Scenario 3 
Probability of non-
union after 
secondary surgery 
18.98 18.99 18.69 14.69 
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Scenario 4 
Treatment specific 
adverse events 
from Saeden 
18.71 18.40 18.06 14.69 
Scenario 5a 
Double risk of OA 
development post 
non-union surgery 
19.00 19.03 18.70 14.69 
Scenario 5b 
Half risk of OA 
development post 
non-union surgery 
19.01 19.04 18.68 14.69 
Scenario 6a 
50% less non-OA 
permanent adverse 
events QoL 
decrement 
19.07 19.11 18.75 14.69 
Scenario 6b 
50% greater non-
OA permanent 
adverse events QoL 
decrement 
18.87 18.90 18.56 14.69 
Scenario 6c 
Explicit inclusion 
of additional fusion 
rate 
18.97 19.04 18.68 14.69 
Scenario 7 
Proportion of 
untreated patients 
who have union 
Would require 95.5% of untreated patients to achieve union for it 
to be the most cost-effective strategy 
 
Scenario 8a 
Double annual 
probability of 
19.00 19.03 18.65 14.27 
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SNAC post non-
union 
Scenario 8b 
Half annual 
probability of 
SNAC post non-
union 
19.01 19.04 18.75 15.17 
Scenario 9 
Proportion of 
patients who reject 
surgery post cast 
confirmed non-
union 
If the proportion of patients having surgery after confirmed non-
union after cast immobilisation reduces from 0.948 to 0.852 
primary surgery becomes cost-effective.  
Scenario 10 
Doubling of cost of 
first line surgical 
fixation 
18.92 19.04 18.68 14.72 
Scenario 11 
No difference in 
QoL in first year 
18.98 19.03 18.68 14.69 
Scenario 12 
No QoL decrement 
for non-union no 
SNAC patients 
19.00 19.03 18.81 16.01 
 
Table 69 shows that the cost-effectiveness results are sensitive to a number of key 
assumptions, while the headline result does not change in many of them, the incremental 
difference in NHB reduces in many.  While scenario 4 is striking in that it results is a large 
change in the NHB and resultant decision, the small scale of the Saeden study which informs 
this scenario results in very large levels of uncertainty.  Furthermore, it could be argued that 
the population used to inform this scenario from Saeden are not indicative of those 
considered here, with the cast population indicative of a more severe sub-set. 
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Scenarios 1 and 2 highlight the sensitivity of the model to the assumptions regarding the 
definition of slight union patients as union or non-union, and whether the three patients who 
are non-union at 52 weeks in the cast arm but have not received surgery can be assumed to be 
offered surgery at some point (as in the base case) or will remain non-unions (as in the 
scenario).  These show the key finding of the analysis that if initial cast immobilisation is 
unsuccessful but surgical intervention is offered soon after it is highly likely to be cost-
effective, as has avoided the high upfront cost implications of conducting surgery on all 
patients, but still avoids a high rate of long-term non-union and the adverse event risks of 
conducting a lot of surgical interventions.  
 
Scenario 4 shows that the use of Saeden109 to inform an estimate of treatment specific adverse 
events has a dramatic impact on the cost-effectiveness result.  This result was flagged by the 
clinical advisors of this section as being contrary to clinical expectations as surgical 
intervention would be expected to be associated with a greater level of adverse events than 
cast immobilisation.  However, as Saeden found a higher proportion of symptomatic adverse 
in the cast arm the model results responds accordingly.  It is likely that the Saeden estimate 
suffers from small numbers and that the quality of life of those reporting symptoms in the 
surgical group is less than the cast group.  However, given the evidence available it has not 
been possible to incorporate such factors without resorting to speculation.  The results of this 
scenario justify the assumption of treatment independent adverse events made in the base 
case and highlight the need for further research into the nature of long-term adverse events in 
this clinical area. 
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Section 6: Within Trial Analysis Results 
Summary statistics - costs 
This section briefly considers the values observed in terms of costs to the NHS and PSS prior 
to imputation for missing values.  These results provide a helpful overview of the results as 
reported by patients and prior to any assumptions being made about the nature of the missing 
data.  The crude summary statistics and frequency histograms are reported in Table 70 and 
Figure 23.   
 
As would be expected these compete case results show high levels of costs at the earlier stage 
of the trial, while patients are receiving treatment (p<0.001).  With the exception of the first 
six weeks, when surgical patients will be having surgical related reviews, the time related 
costs are similar, as are imaging costs.  While some surgical interventions did take place in 
the plaster cast arm (24 surgeries), resulting in a mean cost of £319, surgery costs are much 
greater in the surgery arm of the trials as would be expected.   
 
In contrast, the average cost resulting from cast immobilisation is actually larger in the 
surgical arm.  We believe this to be because many patients had casts fitted and re-fitted 
routinely after surgery to inspect healing, whereas the majority of patients randomised to cast 
immobilisation required fewer re-fittings.   Overall, the average costs in the surgical arm were 
found to be statistically significantly greater than in the plaster cast arm, both in terms of the 
total costs for patients with complete data across all of the cost variables as well as the sum of 
the average costs, both reported in Table 70. 
 
Table 70: Within trial cost summary statistics, complete case 
 
Variable  Surgery mean (n, SE) Plaster cast mean (n, SE) 
6 weeks £311 (168, 21.38) £233 (169, 19.09) 
12 weeks £125 (165, 13.60) £118 (162, 13.29) 
26 weeks £78 (153, 13.27) £86 (140, 14.36) 
52 weeks £51 (174, 11.15) £90 (163, 28.03) 
Imaging £42 (169, 4.72) £43 (170, 4.92) 
Surgery (no missing data) £1,516 (219, 59.27) £319 (220, 65.10) 
Casting (no missing data) £17 (219, 0.73) £13 (220, 0.45) 
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Total costs, complete case £2,350 (83, 94.72) £727 (65, 117.81) 
Sum of average costs £2,140 £901 
 
 
Figure 23: Histograms of patient interaction costs, complete case 
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Summary statistics - quality of life 
This section briefly reports the within trial analysis results for the quality of life and cost 
estimates as complete case, i.e. prior to any imputation for missing data.  The results are 
reported in Table 71 and Figure 24.   
 
These crude analyses show that patients in both treatment strategies reported a bi-modal, 
highly skewed quality of life scores, with a high proportion reporting a perfect quality of life 
score of one, which increased as time since injury.  However, there were also a small number 
of patients reporting very low quality of life score, including a proportion of negative scores 
throughout the follow up period, indicative of some patients experiencing very poor 
outcomes.  This distribution is typical of such injuries where initial injury and treatment 
related impacts on quality of life reduce over time but some patients continue to experience 
adverse event related impacts.  In addition, the average scores in the high 0.8 range are 
indicative of a ‘normal’ population of the age of the patients.113 
 
While Figure 24 shows a similar spread of scores throughout the within trial period the mean 
results presented in Table 71 do appear to show that the plaster cast arm are have lower 
quality of life at all time points.  The complete case average quality of life over the year (i.e. 
adjusted for the length represented by each questionnaire as given in the methods section) 
shows a slightly greater score for the surgical patients, alongside a smaller standard error.  
However, this difference may be the result of differences in the baseline score, which was 
0.0287 higher in the surgical than the plaster cast arm. 
 
Table 71: Quality of Life summary statistics, unadjusted mean complete case 
Variable  Surgery mean (n, SE) Plaster cast mean (n, SE) 
Baseline 0.6260 (214, 0.0194) 0.5973 (219, 0.0201) 
6 weeks 0.7522 (174, 0.0174) 0.7005 (179, 0.0181) 
12 weeks 0.8290 (180, 0.0138) 0.7898 (164, 0.0173) 
26 weeks 0.8361 (161, 0.0177) 0.8505 (146, 0.0183) 
52 weeks 0.8820 (182, 0.0123) 0.8551 (176, 0.0176) 
Average QoL, complete case  0.8317 (134, 0.0131) 0.8140 (119, 0.0159) 
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Figure 24: Complete case quality of life scores by time and treatment 
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Missing data results 
Missing data was found to occur across the patient reported questionnaires related to quality 
of life and resource use at levels reported in Table 72. Overall the level of missing data was 
low but occurred at a greater level in the plaster cast arm, most likely due to a lower 
frequency of interaction and patient buy in with the treatment, potentially due to the 
perceived importance of the injury if cast immobilisation is deemed sufficient rather than the 
injury requiring surgical fixation.   
 
Table 72: Missing data observed in patient reported questionnaires 
 Surgical fixation (n=219) Plaster cast (n=220) 
QoL score baseline 5 (2.3%) 1 (0.5%) 
QoL score 6 weeks 45 (20.5%) 41 (18.6%) 
QoL score 12 weeks 39 (17.8%) 56 (25.5%) 
QoL score 26 weeks 58 (26.5%) 74 (33.6%) 
QoL score 52 weeks 37 (16.9%) 44 (20.0%) 
Cost 6 weeks 51 (23.3%) 51 (23.2%) 
Cost 12 weeks  54 (24.7%) 58 (26.4%) 
Cost 26 weeks 66 (30.1%) 80 (36.4%) 
Cost 52 weeks 45 (20.5%) 57 (25.9%) 
Imaging 50 (22.8%) 50 (22.7%) 
 
Missing data was found to be non-monotonic and patients who were missing in one period 
were not necessarily missing in the next.  Logistic regression in the quality of life and cost 
variables found many of the variables to be correlated with previously observed values, 
which, using the Faria96 framework led to the assumption that the data was missing at random 
(MAR).  As a result, in the multiple imputation framework missingness is assumed to depend 
on all other missing variables and baseline covariates, specifically gender, whether the 
injured arm was the patient’s dominant, treatment allocation, and age.  The variables selected 
are consistent with those used in the previous Chapter and the regression analyses presented 
in the next section.  The imputation is run 36 times consistent with the largest proportion of 
missing data observed (36.0% in costs at 26 weeks in the plaster cast arm).96 
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Section 7: Extended model results 
 
The figures below gives a scatter plot of the cost-effectiveness results first including all four 
treatment options and then only including the two SWIFFT trial options. 
 
 
 
Figure 25: Scatter plot of the cost-effectiveness results for the 4 treatment options 
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The additional table below provides some of the clinical estimates of the model at three time 
points.  The estimates allow this model to be validated as additional evidence emerges, 
specifically the five year SWIFFT update. 
Table 73: Clinical estimates of the model at three time points 
Time 
point 
Percentage of initial population who have 
union with OA and are alive 
Percentage of initial population who 
have SNAC and are alive 
No 
treatment 
Cast 
only 
Cast + 
surgery 
Surgery No 
treatment 
Cast 
only 
Cast + 
surgery 
Surgery 
1 N/A 2.36% 2.58% 2.59% 0.69% 0.06% 0.00% 0.00% 
5 N/A  4.66% 5.08% 5.11% 11.34% 1.02% 0.10% 0.04% 
10 N/A 4.79% 5.23% 5.25% 33.53% 3.01% 0.31% 0.13% 
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Section 8: CHEERS Checklist 
 
Table 74: CHEERS checklist 
 
Section/item 
Item 
No Recommendation 
Reported on page 
No 
Title and abstract 
Title 1 Identify the study as an economic 
evaluation or use more specific terms 
such as “cost-effectiveness analysis”, and 
describe the interventions compared. 
Page 113 
Abstract 2 Provide a structured summary of 
objectives, perspective, setting, methods 
(including study design and inputs), 
results (including base case and 
uncertainty analyses), and conclusions. 
Page 3 to 4  
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the 
broader context for the study. 
Page 28 
Present the study question and its 
relevance for health policy or practice 
decisions. 
Page 28 to 32 
Methods 
Target population 
and subgroups 
4 Describe characteristics of the base case 
population and subgroups analysed, 
including why they were chosen. 
Page 113 and 124 
Setting and location 5 State relevant aspects of the system(s) in 
which the decision(s) need(s) to be made. 
Page 113 
Study perspective 6 Describe the perspective of the study and 
relate this to the costs being evaluated. 
Page 113 and 121 
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Section/item 
Item 
No Recommendation 
Reported on page 
No 
Comparators 7 Describe the interventions or strategies 
being compared and state why they were 
chosen. 
Page 125 
Time horizon 8 State the time horizon(s) over which 
costs and consequences are being 
evaluated and say why appropriate. 
Page 124 
Discount rate 9 Report the choice of discount rate(s) used 
for costs and outcomes and say why 
appropriate. 
Page 124 
Choice of health 
outcomes 
10 Describe what outcomes were used as the 
measure(s) of benefit in the evaluation 
and their relevance for the type of 
analysis performed. 
Page 113 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe 
fully the design features of the single 
effectiveness study and why the single 
study was a sufficient source of clinical 
effectiveness data. 
Page 4 and 
elsewhere in report 
11b Synthesis-based estimates: Describe fully 
the methods used for identification of 
included studies and synthesis of clinical 
effectiveness data. 
Page 113  
Measurement and 
valuation of 
preference based 
outcomes 
12 If applicable, describe the population and 
methods used to elicit preferences for 
outcomes. 
N/A 
Estimating resources 
and costs 
13a Single study-based economic evaluation: 
Describe approaches used to estimate 
resource use associated with the 
alternative interventions. Describe 
Page 113 to 121 
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Section/item 
Item 
No Recommendation 
Reported on page 
No 
primary or secondary research methods 
for valuing each resource item in terms of 
its unit cost. Describe any adjustments 
made to approximate to opportunity 
costs. 
13b Model-based economic evaluation:  
Describe approaches and data sources 
used to estimate resource use associated 
with model health states. Describe 
primary or secondary research methods 
for valuing each resource item in terms of 
its unit cost. Describe any adjustments 
made to approximate to opportunity 
costs. 
Page 131 to 145 
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource 
quantities and unit costs. Describe 
methods for adjusting estimated unit 
costs to the year of reported costs if 
necessary. Describe methods for 
converting costs into a common currency 
base and the exchange rate. 
Page 124 
Choice of model 15 Describe and give reasons for the specific 
type of decision-analytical model used. 
Providing a figure to show model 
structure is strongly recommended. 
Page 127 to 131 
Assumptions 16 Describe all structural or other 
assumptions underpinning the decision-
analytical model. 
Page 127 to 131 
Analytical methods 17 Describe all analytical methods 
supporting the evaluation. This could 
Page 120 and 128 to 
131 
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Section/item 
Item 
No Recommendation 
Reported on page 
No 
include methods for dealing with skewed, 
missing, or censored data; extrapolation 
methods; methods for pooling data; 
approaches to validate or make 
adjustments (such as half cycle 
corrections) to a model; and methods for 
handling population heterogeneity and 
uncertainty. 
Results 
Study parameters 18 Report the values, ranges, references, 
and, if used, probability distributions for 
all parameters. Report reasons or sources 
for distributions used to represent 
uncertainty where appropriate. Providing 
a table to show the input values is 
strongly recommended. 
Page 118 to 119, 
135 to 137, 140 to 
141, and 142 to 143 
Incremental costs 
and outcomes 
19 For each intervention, report mean values 
for the main categories of estimated costs 
and outcomes of interest, as well as mean 
differences between the comparator 
groups. If applicable, report incremental 
cost-effectiveness ratios. 
Page 151 to 153, 
and 157 
Characterising 
uncertainty 
20a Single study-based economic evaluation: 
Describe the effects of sampling 
uncertainty for the estimated incremental 
cost and incremental effectiveness 
parameters, together with the impact of 
methodological assumptions (such as 
discount rate, study perspective). 
Page 153 
20b Model-based economic evaluation:  Page 157 to 165 
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Section/item 
Item 
No Recommendation 
Reported on page 
No 
Describe the effects on the results of 
uncertainty for all input parameters, and 
uncertainty related to the structure of the 
model and assumptions. 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, 
outcomes, or cost-effectiveness that can 
be explained by variations between 
subgroups of patients with different 
baseline characteristics or other observed 
variability in effects that are not reducible 
by more information. 
N/A 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and 
describe how they support the 
conclusions reached. Discuss limitations 
and the generalisability of the findings 
and how the findings fit with current 
knowledge. 
Page 165 to 167 
Other 
Source of funding 23 Describe how the study was funded and 
the role of the funder in the identification, 
design, conduct, and reporting of the 
analysis. Describe other non-monetary 
sources of support. 
Page 4 
Conflicts of interest 24 Describe any potential for conflict of 
interest of study contributors in 
accordance with journal policy. In the 
absence of a journal policy, we 
recommend authors comply with 
Page 2 
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Section/item 
Item 
No Recommendation 
Reported on page 
No 
International Committee of Medical 
Journal Editors recommendations. 
 
